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Multigenerational Effects of Abnormal Folate Metabolism on Embryo 
Growth and Development 
Katerina Menelaou 
It has been known for decades that maternal folate deficiency impairs fetal development. 
However, the molecular mechanism of folate metabolism remains unclear. To explore this, 
we study a mouse model of abnormal folate metabolism whereby the gene Mtrr was mutated 
causing a knockdown effect. MTRR is a key enzyme required for the progression of folate 
and methionine metabolism, which are important for DNA synthesis and cellular 
methylation. The Mtrrgt mutation disrupts folate metabolism, alters global and locus-specific 
DNA methylation, and causes a wide spectrum of developmental phenotypes including 
growth defects and congenital malformations. Remarkably, the Mtrrgt mouse line is a model 
of transgenerational epigenetic inheritance since the congenital malformations persist at least 
up to four wildtype generations after an Mtrr+/gt maternal grandparent. In contrast, the growth 
phenotypes only appear until the F2 generation and have been attributed to an atypical uterine 
environment in the wildtype F1 generation as determined by a blastocyst transfer experiment. 
This thesis aims to examine how the Mtrrgt mutation influences uterine biology and 
fetoplacental growth. First, the effects of intrinsic and parental Mtrr deficiency on uterine 
structure and function at estrus and decidualisation at gestational day (GD) 6.5 were 
determined. We found that a paternal Mtrrgt allele was sufficient to alter the cellular structure 
of the uterine epithelium and outer myometrium at estrus. Furthermore, decidualisation was 
abnormal at GD6.5 based on mRNA expression analysis of key decidual markers. Next, to 
determine how an atypical uterine environment caused by the Mtrrgt mutation might 
influence fetoplacental growth, an unbiased transcriptome analysis of placentas at embryonic 
day (E)10.5 with specific growth phenotypes and from specific Mtrrgt pedigrees was 
completed. The Mtrrgt/gt mutation altered the placental transcriptome in a phenotype-specific 
manner. Genes involved in embryo growth and placental transport were differentially 
expressed between Mtrrgt/gt and C57Bl/6 placentas. This result suggests that intrinsic Mtrr 
deficiency affects the placental transcriptome and potentially fetal growth. However, 
transcriptomes of C57Bl/6 placentas and placentas of wildtype conceptuses derived from an 
Mtrr+/gt maternal grandfather were similar. This suggests that the F1 uterine phenotype 
caused by abnormal folate metabolism in F0 does not affect the placental transcriptome of the 
F2 generation at E10.5. Simultaneously, RNA-seq was performed on F2 Mtrr+/+ placentas 
after blastocyst transfer to determine whether programming effects of the F1 maternal 
environment become apparent in the F2 offspring after a normal uterine environment was 
provided. While fetal growth enhancement in transferred F2 conceptuses was more frequent 
in these litters, only six genes were upregulated in placentas of transferred growth enhanced, 
but not phenotypically normal F2 Mtrr+/+ compared to transferred C57Bl/6 conceptuses. One 
remarkable finding was that the blastocyst transfer procedure affected placental gene 
expression and development, indicating a potential influence of blastocyst transfer, as part of 
assisted reproductive technology procedures in humans, on fetoplacental growth. Overall, 
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these results indicate that while the Mtrrgt mutation in mice is sufficient to impair the uterine 
structure and function in their wildtype daughters, this does not substantially alter the 
placental transcriptome of their wildtype grandprogeny. However, Mtrr deficiency in the 
placenta cells themselves alters the transcriptome. In summary, abnormal folate metabolism 
caused by the Mtrrgt mutation affects the uterine environment, which potentially affects 
placental development. Normal folate metabolism is required to establish a normal maternal-






Στους γονείς μου, Μενέλαο και Έλενα, 
και την αδερφή μου, Άντρεα, 





I am grateful to my supervisor, Dr. Erica Watson, who gave me the opportunity to work in 
her lab, believed in me, and advised me during this journey. Also, my co-supervisor Prof. 
William Colledge, for all his advice, support and discussions during my PhD. 
A big thank you to the people in the CTR, especially Maria, who has been an awesome friend 
and has supported me throughout, Jorge, and Stephen. To Nuala and Emma, for their 
kindness and support. To Simon, for sharing his expertise with me. To Colleen Geary-Joo 
from the University of Calgary for performing the embryo transfer experiments. To Gina, for 
performing the bisulfite pyrosequencing and helping me with the mouse breeding at the 
beginning of my PhD, and to Russell, Malwina and Xiaohui for analysing my RNA-
sequencing data. 
I am deeply thankful to Newnham College and Leventis Foundation for their financial 
support. 
My time in Cambridge wouldn’t be the same without the people in Newnham, who made it 
feel like home. Especially the girls in Whitstead, the girls in W3, and the tutors, especially 
Dr. Kate Fleet, who were there for me throughout my PhD. 
Last but not least, I would like to thank my family: my parents and my sister for supporting 




Table of contents 
Declaration form ....................................................................................................................... II 
Abstract .................................................................................................................................... III 
Dedication ................................................................................................................................. V 
Acknowledgements .................................................................................................................. VI 
Table of contents .................................................................................................................... VII 
List of tables ............................................................................................................................. XI 
List of figures ......................................................................................................................... XII 
List of abbreviations ............................................................................................................. XIV 
 
Chapter 1: Introduction 
1.1 Fetal growth restriction (FGR) .................................................................................... 2 
1.1.1 Definition of FGR ................................................................................................ 2 
1.1.2 Aetiology of FGR ................................................................................................ 3 
1.1.3 Examples of causes of FGR in humans and mice ................................................ 3 
1.1.4 Long-term effects of FGR .................................................................................... 4 
1.1.5 Further studies are required on the causes of FGR .............................................. 6 
1.2 The mouse reproductive tract ...................................................................................... 7 
1.2.1 The non-pregnant mouse uterus and oviducts ..................................................... 7 
1.2.2 The estrous cycle in mice ..................................................................................... 8 
1.2.2.1 Estrous cycle vs menstrual cycle .................................................................. 8 
1.2.2.2 Hormonal regulation of the estrous cycle ................................................... 10 
1.2.2.3 Changes in the ovaries ................................................................................ 12 
1.2.2.4 Changes in the uterus .................................................................................. 13 
1.2.2.5 Abnormal cyclicity and infertility .............................................................. 15 
1.2.3 From estrous cycle to pregnancy in mice .......................................................... 17 
1.2.3.1 The estrous cycle after mating and maintenance of corpus luteum and 
progesterone .................................................................................................................. 17 
1.2.3.2 Changes in the uterus after fertilisation ...................................................... 18 
1.2.3.3 Decidualisation after implantation .............................................................. 19 
1.2.3.4 Gene expression during estrous cycle affects decidualisation .................... 21 
1.2.3.5 Factors that regulate decidualisation .......................................................... 22 
1.2.3.6 Factors that regulate angiogenesis .............................................................. 24 
1.2.4 Endometrial causes of FGR ............................................................................... 24 
1.3 Mouse placenta development and function ............................................................... 26 
1.3.1 Structure and function of the mature mouse placenta ........................................ 27 
1.3.2 Mouse placenta development ............................................................................. 28 
1.3.3 Maternal components of the mouse placenta ..................................................... 29 
1.3.4 Poor placenta development and function can lead to FGR ................................ 31 
1.4 Folate metabolism and reproductive health .............................................................. 33 
1.4.1 Role of folate in uterine health and pregnancy in humans and mice ................. 34 
1.4.2 Bioavailability and metabolism of folate ........................................................... 36 
1.4.3 The molecular function of folate........................................................................ 37 
1.4.4 Folate transport and metabolism-related mutations in mice and humans that 
affect development and uterine health ............................................................................. 42 
1.4.5 Folate supplementation, uterine health, and pregnancy in humans and mice .... 43 
VIII 
 
1.4.6 What is missing from the field? ......................................................................... 45 
1.5 Multigenerational effects of folate metabolism on development .............................. 45 
1.5.1 Maternal effects of folate metabolism on development ..................................... 45 
1.5.2 Mtrrgt mouse model of abnormal folate metabolism .......................................... 47 
1.5.2.1 FGR in the Mtrrgt mouse model .................................................................. 47 
1.5.2.2 Epigenetic instability in the Mtrrgt mouse model ....................................... 51 
1.5.2.3 The growth phenotypes in F2 generation are due to an atypical uterine 
environment of the F1 females ..................................................................................... 52 
1.6 Hypothesis and Aims ................................................................................................ 52 
 
Chapter 2: Methods 
2.1 Ethical approval......................................................................................................... 55 
2.2 Mouse pedigrees and diet .......................................................................................... 55 
2.3 Blastocyst transfer ..................................................................................................... 56 
2.3.1 Collecting blastocysts ........................................................................................ 56 
2.3.2 Oviduct transfer ................................................................................................. 56 
2.3.3 Dissection of transferred conceptuses ................................................................ 57 
2.4 Genotyping ................................................................................................................ 57 
2.5 Phenotypic analysis of developmental phenotypes at E10.5 ..................................... 58 
2.6 Uterine tissue collection and processing ................................................................... 59 
2.6.1 Estrus stage (non-pregnant) uteri ....................................................................... 59 
2.6.2 Uteri during early pregnancy (GD6.5) ............................................................... 60 
2.6.3 Tissue processing ............................................................................................... 60 
2.7 H&E staining and immunohistochemistry ................................................................ 60 
2.8 RNA extraction and DNAse treatment...................................................................... 61 
2.9 DNA/RNA extraction ................................................................................................ 62 
2.10 RNA-sequencing ................................................................................................... 62 
2.11 RNA-sequencing data analysis .............................................................................. 62 
2.12 Gene ontology analysis .......................................................................................... 63 
2.13 RT-qPCR analysis of gene expression .................................................................. 64 
2.13.1 Primer design ..................................................................................................... 64 
2.13.2 Reverse transcription ......................................................................................... 64 
2.13.3 Real time qPCR.................................................................................................. 64 
2.14 Bisulfite pyrosequencing ....................................................................................... 65 
2.15 Statistical analysis.................................................................................................. 65 
 
Chapter 3: The effects of abnormal folate metabolism on the uterus during estrus 
3.1 Introduction ............................................................................................................... 73 
3.2 Results ....................................................................................................................... 75 
3.2.1 Estrous cycle duration is unaffected by an intrinsic or paternal Mtrrgt allele .... 75 
3.2.2 Analysis of expression of Mtrr mRNA and protein in the estrus-staged uterus 77 
3.2.3 Analysis of folate-related proteins in Mtrr uteri at estrus .................................. 80 
3.2.4 Decreased mRNA expression of DNA methylation machinery enzymes in uteri 
at estrus from Mtrr pedigrees ........................................................................................... 81 
IX 
 
3.2.5 Intrinsic and parental Mtrrgt allele causes abnormal uterine morphology at 
estrus 82 
3.2.6 Cell density in outer myometrium is increased by parental Mtrr deficiency .... 87 
3.2.7 Analysis of genetic markers of uterine cells in the Mtrrgt mouse line ............... 94 
3.2.8 Altered cell polarity in uterine lumen epithelium of Mtrr mice at estrus .......... 96 
3.2.9 Decreased levels of progesterone receptor mRNA and protein in the Mtrr uteri .. 
 …………………………………………………………………………………99 
3.3 Discussion ............................................................................................................... 101 
 
Chapter 4: The effects of abnormal folate metabolism on decidualisation 
4.1 Introduction ............................................................................................................. 107 
4.2 Results ..................................................................................................................... 108 
4.2.1 The Mtrrgt mutation does not affect the litter size at GD6.5 ............................ 108 
4.2.2 Abnormal folate metabolism does not affect implantation site weight at GD6.5
 ………………………………………………………………………………..110 
4.2.3 Analysis of MTRR gene and protein expression in decidua at GD6.5 ............ 110 
4.2.4 Abnormal folate metabolism in males potentially affects the decidualisation 
reaction of their wildtype daughters at GD6.5 ............................................................... 112 
4.2.5 Analysis of decidual marker expression in implantation sites at GD6.5 ......... 115 
4.2.6 Analysis of growth restriction at E6.5 ............................................................. 118 
4.3 Discussion ............................................................................................................... 119 
 
Chapter 5: The effects of intrinsic abnormal folate metabolism on the placental 
transcriptome at E10.5 
5.1 Introduction ............................................................................................................. 124 
5.2 Results ..................................................................................................................... 124 
5.2.1 RNA quality control ......................................................................................... 125 
5.2.2 Quality control of RNA sequencing data ......................................................... 126 
5.2.3 Sample RNA largely clusters based on their experimental group ................... 127 
5.2.4 The Mtrrgt/gt placentas are transcriptionally variable ....................................... 128 
5.2.5 Improving the stringency of the Mtrrgt/gt RNA-sequencing dataset ................. 135 
5.2.6 The DEGs in the Mtrr locus............................................................................. 143 
5.2.7 Gene ontology analysis of the DEGs ............................................................... 143 
5.2.8 DEGs that are involved in placental function and embryo growth .................. 146 
5.2.9 Altered CpG methylation as a predicted mechanism for gene misexpression in 
Mtrrgt/gt placentas............................................................................................................ 149 
5.2.10 Predicted changes in histone modifications as a mechanism for placental gene 
misexpression ................................................................................................................. 153 
5.2.11 Analysis of the placental transcriptome in F2 Mtrr+/+ conceptuses at E10.5 .. 154 






Chapter 6: The effects of blastocyst transfer on the placental transcriptome at E10.5 
6.1 Introduction ............................................................................................................. 162 
6.2 Results ..................................................................................................................... 164 
6.2.1 Maternal grandpaternal abnormal folate metabolism affects the placental 
transcriptome in a growth phenotype-dependent manner .............................................. 164 
6.2.2 Blastocyst transfer leads to possible increase in placental efficiency at E10.5166 
6.2.3 Transferred conceptuses have a different placental transcriptome than non-
transferred ...................................................................................................................... 177 
6.2.4 Comparison of DEGs between placentas of non-transferred and transferred 
conceptuses at E10.5 ...................................................................................................... 183 
6.2.5 DEGs caused by the embryo transfer protocol ................................................ 184 
6.2.5.1 All major placental cell types are represented by DEGs in transferred 
C57Bl/6 placentas ....................................................................................................... 185 
6.2.5.2 DEG are involved in placental development and function ....................... 186 
6.2.5.3 Dysregulation of DNA methylation by blastocyst transfer is unlikely to be 
the primary mechanism of transcriptional disruption ................................................. 191 
6.2.5.4 Some DEGs cluster in the genome implying common transcriptional 
regulation    ................................................................................................................. 196 
6.2.6 DEGs as a result of developmental programming of F2 Mtrr+/+ conceptuses 199 
6.2.6.1 F2 Mtrr+/+ conceptuses respond differently to the blastocyst transfer into a 
BDF1 uterus at E3.0 compared to C57Bl/6 conceptuses ............................................ 199 
6.2.6.2 Genes involved in transport are misexpressed after transfer of blastocysts 
into the recipient uterine environment ........................................................................ 203 
6.2.6.3 The uterine environment of the recipient female might cause changes in 
epigenetic regulation of gene expression .................................................................... 204 
6.2.6.4 The abnormal uterine environment affects genes implicated in growth, 
placental phenotypes, and/or embryonic lethality at midgestation ............................. 206 
6.3 Discussion ............................................................................................................... 208 
 
Chapter 7: Discussion and future directions 
7.1 Summary ................................................................................................................. 217 
7.2 Developmental programming in the Mtrrgt model .................................................. 218 
7.2.1 Abnormal uterine morphology and function in Mtrrgt/gt and F1 Mtrr+/+ mice . 219 
7.2.2 Abnormal placental transcriptome in Mtrrgt/gt and F2 Mtrr+/+ mice ................ 222 
7.2.3 Associations between abnormal uterine and placental phenotypes ................. 224 
7.2.4 The blastocyst transfer process affects feto-placental growth, suggesting ART 
might affect the adult health of ART-born children ...................................................... 226 
7.3 Sexual dimorphism in the Mtrrgt model .................................................................. 228 
7.4 MTRR polymorphisms in the human population..................................................... 229 
7.5 Further analysis of placental phenotype and function in the Mtrrgt model ............. 230 
7.6 Future directions ...................................................................................................... 232 
 
Bibliography .......................................................................................................................... 233 
Appendix A ............................................................................................................................ 316 
Appendix B ............................................................................................................................ 324 
XI 
 
B1.1 Introduction ............................................................................................................... 324 
B1.2 Methods ..................................................................................................................... 326 
B1.3 Results ....................................................................................................................... 326 
B1.4 Discussion ................................................................................................................. 328 
Appendix C ............................................................................................................................ 331 
 
 
List of tables 
1.1 Changes in mouse reproductive organs during the estrous cycle. ..................................... 14 
1.2 Phenotypic frequencies in litters from Mtrr+/gt intercrosses compared to C57Bl/6 crosses. 
……………………………………………………………………………………………......49 
1.3 Phenotypic frequencies caused by Mtrr+/gt maternal grandmothers of grandfathers at 
E10.5 compared to C57Bl/6 controls. ……………………………………………………….50 
2.1 Primer sequences used for RT-qPCR for analysis of gene expression. ............................. 66 
2.2 Bisulfide pyrosequencing primers. .................................................................................... 71 
5.1 The number of misexpressed placental genes at E10.5. .................................................. 129 
5.2 Number of DEGs per Mtrr genotype and phenotype. ...................................................... 133 
5.3 Number of DEGs in Mtrrgt/gt placentas at E10.5 per Mtrr genotype and phenotype. ...... 140 
5.4 DEGs with transport function in phenotypically normal Mtrrgt/gt placentas at E10.5...... 144 
5.5 DEGs with transport function in growth restricted Mtrrgt/gt placentas at E10.5. ............. 145 
5.6 DEGs in phenotypically normal Mtrrgt/gt placentas related to placental function. ........... 147 
5.7 DEGs in placentas of growth restricted Mtrrgt/gt related to placental phenotypes. .......... 148 
5.8 DEGs in Mtrrgt/gt placentas with known regulation by DNA methylation ....................... 151 
6.1 Chromosomal location and placental expression of DEGs.............................................. 166 
6.2 Relationship between C57Bl/6 embryos transferred at E3.5 into recipient female and 
embryonic phenotype at E10.5. ............................................................................................. 169 
6.3 Relationship between F2 Mtrr+/+ embryos transferred at E3.5 into recipient female and 
embryonic phenotype at E10.5. ............................................................................................. 170 
6.4 Phenotypic comparison of C57Bl/6 control conceptuses and C57Bl/6 transfer conceptuses 
at E10.5. ................................................................................................................................. 171 
6.5 Phenotypic comparison of non-transferred F2 Mtrr+/+ conceptuses and transferred Mtrr+/+ 
conceptuses at E10.5. ............................................................................................................. 175 
6.6 Number of DEGs in transferred placentas per genotype and phenotype. ........................ 180 
6.7 DEGs implicated in growth, placental phenotypes, and/or embryonic lethality at 
midgestation. .......................................................................................................................... 188 
6.8 DEGs encoding proteins with transporter activity. .......................................................... 189 
6.9 DEG with known regulation by DNA methylation ......................................................... 193 
6.10 DEGs with transport activity in placentas of transferred F2 Mtrr+/+ conceptuses. ....... 204 
6.11 Genes whose expression is epigenetically regulated by DNA methylation and were 
differentially expressed in F2 Mtrr+/+ but not C57Bl/6 conceptuses at E10.5 after blastocyst 
transfer. .................................................................................................................................. 205 
6.12 DEGs implicated in growth, placental phenotypes, and/or embryonic lethality at 





List of figures 
1.1 Schematic cross section of the sexually mature mouse uterus. ........................................... 7 
1.2 The levels of hypothalamic, pituitary, and ovarian hormones during the estrous cycle. ... 11 
1.3 Schematic of an implantation site at E6.5. ......................................................................... 21 
1.4 Mouse placenta development. ............................................................................................ 28 
1.5 Folate and methionine metabolism. ................................................................................... 37 
2.1 Schematic diagrams of robust genetic pedigrees established to address the role of 
abnormal folate metabolism on uterine and placental structure and function. ........................ 57 
2.2 Cells of vaginal smears at each stage of the estrous cycle in adult mice. .......................... 59 
3.1 The Mtrrgt mutation does not affect estrous cyclicity. ....................................................... 76 
3.2 Mtrr transcript and MTRR protein expression in the mouse uterus at estrus. ................... 79 
3.3 Analysis of folate-related and DNA methylation machinery gene expression in the mouse 
uterus at estrus.......................................................................................................................... 81 
3.4 Histological analysis of Mtrr uteri at estrus. ...................................................................... 84 
3.5 Histological analysis of F1 Mtrr uteri at estrus. ................................................................ 86 
3.6 Decreased cell density in the outer myometrium of Mtrr uteri at estrus. .......................... 88 
3.7 Analysis of cell proliferation and apoptosis in the uterine tissue of littermate females from 
Mtrr+/gt intercrosses at estrus. .................................................................................................. 91 
3.8 Analysis of cell proliferation and apoptosis in the uterine tissue of F1 females at estrus. 93 
3.9 Marker expression in the uterine tissues of Mtrr mice at estrus. ....................................... 96 
3.10 Misexpression of pan-cadherin protein in the uterus of Mtrr mice at estrus. .................. 98 
3.11 Expression of progesterone receptor in Mtrr uteri at estrus. ......................................... 100 
4.1 Litter statistics of GD6.5 dissections after Mtrr females were mated with C57Bl/6 males.
................................................................................................................................................ 109 
4.2 Mtrr transcript and protein expression in whole implantation sites at GD6.5. ................ 112 
4.3 Analysis of decidual morphology in implantation sites at E6.5. ..................................... 114 
4.4 Relative mRNA expression of decidualisation markers in GD6.5 implantation sites. .... 117 
4.5 Analysis of growth restriction at E6.5. ............................................................................ 119 
5.1 RNA sample quality control. ........................................................................................... 125 
5.2 RNA sequencing data quality control. ............................................................................. 126 
5.3 PCA plot of sequenced placenta samples. ....................................................................... 128 
5.4 Degree of differential gene expression in Mtrrgt/gt placentas at E10.5 depends on growth 
phenotype. .............................................................................................................................. 130 
5.5 Validation of RNA-sequencing data by RT-qPCR analysis. ........................................... 131 
5.6 Data quality control for the second round of RNA sequencing. ...................................... 133 
5.7 Bioinformatic analysis of data from the second RNA sequencing experiment. .............. 134 
5.8 Principal component analysis plots used to exclude outliers. .......................................... 137 
5.9 Bioinformatic analysis of the RNA sequencing data from placentas of C57Bl/6, and 
phenotypically normal (PN) and growth restricted (GR) Mtrrgt/gt conceptuses. .................... 138 
5.10 Validation by RT-qPCR analysis of downregulated genes identified by RNA-
sequencing.............................................................................................................................. 141 
5.11 Validation by RT-qPCR analysis of up-regulated genes identified by RNA-sequencing.
................................................................................................................................................ 142 
5.12 Gene expression correlation between the RNA-sequencing data and the qPCR results. 
………………………………………………………………………………………………142 
5.13 The percentage of DEGs in Mtrrgt/gt placentas that were associated with CpG repeats. 149 
5.14 Frequency of histone modifications associated with genes that were misexpressed in 
Mtrrgt/gt placentas.................................................................................................................... 154 
XIII 
 
5.15 Bioinformatic analysis of the RNA sequencing data from placentas of C57Bl/6 and F2 
Mtrr+/+ conceptuses. ............................................................................................................... 156 
6.1 Bioinformatic analysis of the RNA sequencing data from C57Bl/6, and placentas of F2 
Mtrr+/+ conceptuses after blastocyst transfer. ........................................................................ 165 
6.2 Blastocyst transfer results in small placentas with a potential for increased efficiency at 
E10.5. ..................................................................................................................................... 172 
6.3 Blastocyst transfer into the normal BDF1 environment results in bigger embryos and 
placentas with a potential for increased efficiency at E10.5. ................................................. 176 
6.4 Bioinformatic analysis of the RNA sequencing data to compare placental transcriptome of 
non-transferred and transferred conceptuses. ........................................................................ 178 
6.5 Validation of RNA-sequencing data by RT-qPCR analysis of downregulated genes. .... 181 
6.6 Validation of RNA-sequencing data by RT-qPCR analysis of upregulated and non-
differentially expressed genes. ............................................................................................... 182 
6.7 Gene expression correlation between the RNA-sequencing data and the qPCR results. 183 
6.8 Comparisons between the DEGs of controls and transferred conceptuses. ..................... 184 
6.9 Spatial analysis of differentially expressed genes identified in placentas of transferred 
conceptuses. ........................................................................................................................... 186 
6.10 Functional analysis of differentially expressed genes identified in placentas of 
transferred conceptuses. ......................................................................................................... 187 
6.11 Unlikely that blastocyst transfer directly alters placental gene expression via CpG 
methylation. ........................................................................................................................... 195 
6.12 Clustering of differentially expressed genes in the genome suggests shared regulatory 
regions. ................................................................................................................................... 198 
6.13 Gene ontology analysis of the DEGs in transferred C57Bl/6 but not F2 Mtrr+/+ 
placentas. ................................................................................................................................ 200 








List of abbreviations 
AP  anterior posterior 
ART  assisted reproductive technologies 
BDF1  F1 resulting from crossing C57BL/6J (B6) female and DBA/2J (D2) male 
BSA  bovine serum albumin 
DD  developmentally delayed 
DEG  differentially expressed gene 
DV  dorsal ventral 
E  embryonic day 
E2  estradiol 
EPC  ectoplacental cone 
ES  embryonic stem cell 
ExE  extraembryonic ectoderm 
FC  fold change 
FEV  fetal endothelial vascular cells 
FGR  fetal growth restriction 
FSH  follicle stimulating hormone 
GD  gestational day 
GE  growth enhanced 
GR  growth restricted 
GnRH  gonadotrophin-releasing hormone 
gt  gene trap 
ICM  inner cell mass 
ICSI  intracytoplasmic sperm injection 
IGF1  insulin-like growth factor 1 
IRS  insulin receptor substrate 
IVF  in vitro fertilisation 
LH  luteinising hormone 
MA  log-intensity ratio (M), log-intensity average (A) 
MTRR  methionine synthase reductase 
NTD  neural tube defects 
P4  progesterone 
PC  principal component 
PCA   principal component analysis 
PCOS  polycystic ovary syndrome 
PDZ  primary decidual zone 
PN  phenotypically normal 
PBS  phosphate-buffered saline 
qPCR  quantitative polymerase chain reaction 
RIN  RNA integrity number 
S-AdoMet S-adenosylmethionine 
SAR  spiral artery remodelling 
SD  severe defects 
SDZ  secondary decidual zone 
SpT  spongiotrophoblast 
TB  trophoblast 
TE  trophectoderm 
TGC  trophoblast giant cell 
XV 
 
THF  tetrahydrofolate 
TS  trophoblast stem cell 












1.1 Fetal growth restriction (FGR) 
1.1.1 Definition of FGR 
Fetal growth restriction (FGR) is defined as the failure of the fetus to reach its full growth 
potential, as predetermined by its genome (Figueras & Gardosi 2011; Gardosi et al. 1992). 
Embryo growth is determined by measuring the crown-rump length using ultrasound. FGR 
affects 10-15% of human pregnancies (Suhag & Berghella 2013). According to the World 
Health Organisation (Kiserud et al. 2017), FGR is strongly associated with perinatal 
morbidity, including perinatal asphyxia, hypothermia, and hypoglycaemia. FGR can also lead 
to mortality in 50% of pre-term fetuses, and 20% of full-term fetuses (Gardosi et al. 2013). 
Full term FGR fetuses are at a higher risk of developing cardiovascular diseases (Menendez-
Castro, Rascher & Hartner 2018), and metabolic syndrome (Ma & Hardy 2012; Neitzke, 
Harder & Plagemann 2011; Valsamakis et al. 2006), and having abnormal neural 
development (Baschat 2014; Demicheva & Crispi 2014; Sehgal, Crispi & Boode 2017) in 
adult life. 
There are two types of FGR (Sharma, Shastri & Sharma 2016). Symmetrical FGR is early-
onset and it is usually caused by a genetic disorder, or an infection intrinsic to the fetus. All 
of the fetal organs, including the brain are equally affected, and the fetal weight, length, and 
head circumference are reduced. Asymmetrical FGR is late-onset and may be caused by 
various factors, including utero-placental insufficiency, maternal undernutrition, hypoxia, 
stress, or advanced maternal age. It is characterised by unaffected brain growth, at the 
expense of the rest of the fetal organs (Sharma, Shastri & Sharma 2016). In this case, there is 
decreased fetal weight, but normal fetal length (Krishna & Bhalerao 2011). Fetuses with 
symmetrical FGR have a higher incidence of brain dysfunction and neurodevelopmental 
impairment than those with asymmetrical FGR (Hartkopf et al. 2018). The 70-80% of FGR 
cases are asymmetrical, while the rest (20-30%) are symmetrical. Fetuses with asymmetrical 
FGR have better prognosis than those with symmetrical FGR (Sharma, Shastri & Sharma 
2016), as they are able to catch-up on growth postnatally (Wollmann 1998), and the brain is 




1.1.2 Aetiology of FGR 
The aetiology of growth restriction was discovered using animal models (Haugaard & Bauer 
2001; Morrison 2008), but also from examination of human placentas from pregnancies 
complicated with FGR (Redline & Pappin 1995; Roberts & Post 2008; Scifres & Nelson 
2009). In FGR, fetal growth is impaired by maternal, fetal, and/or placental factors (Grivell, 
Dodd & Robinson 2009). Factors arising from the mother and her environment include 
nutrition (Ceesay et al. 1997; Christian 2003; Haider & Bhutta 2017; Kramer & Kakuma 
2003), congenital uterine anomalies (Chan et al. 2011), age (Joseph et al. 2005), fertility 
treatment (Schieve et al. 2007), smoking (Andres & Day 2000), or medical conditions during 
pregnancy, such as hypertension (Brown et al. 2000). Fetal factors include chromosomal 
disorders (Reisman 1970) and twin pregnancies (Fox et al. 2011). Finally, fetal growth is 
dependent on a functional placenta. The placenta is responsible for delivery of oxygen and 
nutrients to the fetus, as well as removal of waste products such as carbon dioxide and urea 
(Gude et al. 2004). FGR is associated with abnormalities in embryo implantation and 
placental development. The most common cause of FGR is small placental size or abnormal 
vascular development of either the trophoblast or the decidua, leading to uteroplacental 
insufficiency (Barry, Rozance & Anthony 2008; Grivell, Dodd & Robinson 2009; Roberts & 
Post 2008). This will be further discussed in Sections 1.2.4 and 1.3.4. Altogether, these 
studies show that the cause of FGR lies in maternal, fetal, and/or placental factors. 
 
1.1.3 Examples of causes of FGR in humans and mice 
FGR is a multifactorial condition, and is associated, amongst others, with maternal 
malnutrition, and placental hormone signalling. For instance, from October 1944 until May 
1945, Amsterdam experienced a famine, due to decreased food shipments from farm towns, 
widely known as the Dutch famine (Banning 1946). Pregnant women were consuming low-
nutritional status food, leading to decreased birthweight of in utero exposed infants (Lumey 
1992). Additionally, placentas from pregnancies complicated with FGR have increased 
insulin-like growth factor 1 (IGF-1) receptor expression and impaired insulin receptor 
substrate 2 (IRS-2) signalling (Laviola et al. 2005), highlighting the significance of placental 
hormone signalling on embryo growth. 
To better understand the causes of FGR in humans, mice are often used as models. This is 
because mice are small in size, easy to maintain, and inexpensive to house. Additionally, their 
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genomes are similar enough to humans, and can be easily manipulated (Emes et al. 2003; 
Swanson & David 2015). Their gestation lasts around 21 days, which reduces the time and 
expenses (Swanson & David 2015). Examples of FGR in mice include Erk3-/- mice born from 
Erk3+/- intercrosses. ERK3 (extracellular signal-regulated kinase 3) is a protein kinase that is 
important for the regulation of cell growth and differentiation. Erk3-/- mice die between 
postnatal days 2-5, mainly from severe respiratory distress (Klinger et al. 2009). Respiratory 
distress is a severe consequence of FGR (Rosenberg 2008), and severe reduction of visceral 
organ growth. Erk3-/- and Erk3+/- had decreased birthweight compared to their Erk3+/+ 
littermates, suggesting the loss of a single Erk+ allele in mice causes growth restriction 
(Klinger et al. 2009). In addition, eNOS-/- mice had reduced fetal weight and abdominal 
circumference compared to eNOS+/+, due to decreased placental system A transport and 
placenta hypoxia at E17.5 characterised by increased superoxide levels. Endothelial nitric 
oxide synthase (eNOS) is required for the synthesis of the cellular signalling molecule nitric 
oxide, which regulates vasodilation. This suggests that the growth restriction observed in this 
model is due to uteroplacental hypoxia (Kusinski et al. 2012). Finally, unilateral ovariectomy 
in mice leads to production of a litter of 13 pups in one uterine horn. This results in decreased 
placental blood flow among the fetuses, leading to FGR in the middle fetuses (Coe et al. 
2008). Altogether, these studies provide examples of causes of FGR in mice and highlight the 
significance of using mouse models to study FGR in the human population. 
 
1.1.4 Long-term effects of FGR 
Exposure of fetuses to adverse intrauterine conditions that cause FGR, has long-term effects 
on the adult health, particularly affecting the cardiovascular, renal, and metabolic function 
(Demicheva & Crispi 2014; Sharma, Shastri & Sharma 2016). The Developmental Origins of 
Health and Disease hypothesis (DOHaD) was first described in 1990 (Barker et al. 1990), and 
highlights the potential effects of exposure to an abnormal uterine environment on 
development and health later in life. Epidemiological studies have shown that an individual 
who is exposed to different environmental cues as an embryo is more susceptible to develop 
diseases later in life (Hanson & Gluckman 2014; Jirtle & Skinner 2007). Under adverse 
intrauterine conditions, such as intrauterine malnutrition due to maternal malnutrition or 
obesity, the placenta is able to adapt its function to ensure optimal fetal growth (Tarrade et al. 
2015). The “Thrifty Hypothesis”, proposed in 1992 (Hales & Barker 2001, 2013) suggests 
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that the fetus compensates for maternal nutritional deficiency, or nutrient deprivation by 
altering its tissue sensitivity, physiology and metabolism. For instance, maternal 
undernutrition leads to metabolic changes, blood flow redistribution, and alteration of the 
fetal and placental hormone production, in order to ensure optimal embryo growth (Fowden 
1995; Osmond & Barker 2000). More specifically, in asymmetrical FGR, it assures optimal 
growth of the brain, which is a key organ, at the expense of organs such as the pancreas, 
leading to abnormal pancreatic function later in life. Impaired function of the pancreatic β-
cells in the islets of Langerhans, predispose the individual to type II diabetes (Hales & Barker 
2001). The fetus expects that the postnatal environment will be similar to the intrauterine one, 
therefore these adaptations made in fetal life, will ensure optimal health in the postnatal life. 
However, this is not the case, when there is different nutrient supply in the postnatal 
environment, compared to the intrauterine environment. The process by which these 
adaptations happen is called fetal programming. Exposure in the suboptimal intrauterine 
environment leads to growth restriction and low birth weight, and ultimately catch-up growth 
during postnatal life (Gicquel, El-Osta & Le Bouc 2008). Low birth weight has been 
associated with hypertension, glucose intolerance, insulin resistance, hyperlipidaemia, 
obesity, and reproductive disorders in the adult life (Barker et al. 1990, 1993; Barker 1997; 
Hales & Barker 2013). Adults who were in utero exposed to the Dutch famine developed 
metabolic syndrome and cardiovascular disease (Ravelli et al. 1999; de Rooij et al. 2006). 
Men who were exposed in utero to the famine, developed hypertension related to a large 
placental surface due to large placental breadth and a round-shaped surface, suggesting 
hypertension was due to compensatory expansion of the placental surface. In contrast, the 
relationship between placental size and hypertension was similar in females exposed in utero 
to the Dutch famine, and those who were not (van Abeelen et al. 2011). Additionally, peri-
adolescent children who were born small for gestational age have higher systolic blood 
pressure and lower glomerular filtration rate, which indicate systolic hypertension and renal 
dysfunction, respectively (Chan et al. 2010). In addition, these children had higher 
augmentation index and higher insulin serum levels two hours after glucose load, suggesting 
arterial stiffness and abnormal metabolism, respectively (Chan et al. 2010). FGR caused by 
exposure to a hypoxic (11.5% O2) environment during GD15.0-GD21.0 leads to increased 
cardiac susceptibility of rats to ischaemia/reperfusion injury, and a mismatch between 
glycolysis and glucose oxidation in the myocardium, leading to proton accumulation, 
suggesting decreased cardiac efficiency during reperfusion (Rueda-Clausen et al. 2011). FGR 
babies can experience catch-up growth, especially if they have asymmetrical FGR (Crume et 
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al. 2014). These children have normal body mass index at one year of age. However, in 
adolescence, they have higher waist circumference, higher insulin levels, insulin resistance, 
and lower adiponectin levels, indicating metabolic dysfunction (Crume et al. 2014). Type II 
diabetes mellitus is another metabolic long-term effect of FGR, associated with insulin 
resistance (Simmons, Templeton & Gertz 2001; Vuguin et al. 2004) and abnormal pancreatic 
islet development and β-cell function (Boehmer, Limesand & Rozance 2017) . Altogether, 
these studies show the long-term effects of FGR originating from exposure to an abnormal 
uterine environment, supporting the theory of fetal programming. 
The long-term effects of FGR have also been demonstrated in mice. For instance, litters born 
to mothers fed a low-protein diet during pregnancy had lower mean birth weight than 
controls. However, male offspring had normal weight at 8 weeks of age, but were obese at 32 
weeks of age, exhibiting increased adiposity and glucose intolerance. In contrast, female 
offspring were growth restricted from birth until at least 32 weeks of age, showing a sex-
specific effect of dietary protein restriction in the growth of offspring (Bhasin et al. 2009). 
When pregnant females lacking the low-density lipoprotein receptor (Ldlr) were fed a high 
fat diet to develop hypercholesterolemia, their offspring also developed FGR characterised by 
decreased birth weight, and decreased weight and length at 90 days of age compared to Ldlr-/- 
females fed a normal diet. The progeny of high fat-diet Ldlr-/- females also had decreased 
gonadal fat pad weight to body weight ratio, and bigger atherosclerotic lesions than the 
progeny of normal-diet Ldlr-/- females (Bhasin et al. 2009). In the studies that assess the long-
term effects of either low-protein diet or Ldlr deficiency, the mothers had also decreased 
circulating amino acid levels, possibly resulting in reduced fetal amino acid levels, leading to 
abnormal metabolic programming of the fetus (Bhasin et al. 2009). Altogether, these studies 
show the long-term effects of FGR in mice. 
 
1.1.5 Further studies are required on the causes of FGR 
Early diagnosis and prevention of FGR can prevent the long-term effects in adulthood, and in 
future generations. Current guidelines to prevent FGR include discouraging smoking during 
pregnancy and encouraging an optimal maternal nutrition before and during pregnancy, and 
administration of low-dose aspirin (McCowan, Figueras & Anderson 2018). Smoking during 
pregnancy can cause chronic gestational hypoxia (Longo 1976), which accelerates ovarian 
aging and lowers ovarian reserve in the in utero-exposed rats (Aiken et al. 2019). However, 
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little is known about the effects of maternal malnutrition, such as vitamin deficiencies, on the 
uterine environment and placental health. Ultimately, abnormal uterine and placental 
development or function can affect fetal growth. More research is required to assess the 
specific mechanisms of maternal malnutrition, for instance vitamin deficiencies, on FGR. 
 
1.2 The mouse reproductive tract 
In the previous section we discussed the aetiology and long-term effects of FGR. However, to 
further understand how the uterine environment prevents the embryo from reaching its full 
growth potential during development, we need to look at the uterine structure and function 
both during the estrous cycle, and during pregnancy. 
 
1.2.1 The non-pregnant mouse uterus and oviducts 
The female mouse has a duplex uterus, consisting of two uterine horns (Figure 1.1A). These 
are long, tubular structures, each of them terminating cranially to the oviduct. The oviducts 
are 1.8cm long, narrow tubular structures, and at the end of each there is an ovary (Rendi et 
al. 2012). Caudally, the uterine horns connect to the cervix (Figure 1.1A). The cervix is 
duplex, as there are two cervical canals, one for each uterine horn, and therefore conceptuses 
are not able to move between the uterine horns (Pang et al. 2014). 
 
Figure 1.1 Schematic cross section of the sexually mature mouse uterus. 
(A) Overview of the female mouse reproductive tract. (B) The sexually mature mouse uterus. 
OM: outer myometrium, IM: inner myometrium, ES: endometrial stroma, LE: lumen 




The uterus is composed of two layers of myometrial tissue, the outer myometrium and the 
inner myometrium (Figure 1.1B), which are composed of longitudinal and circular 
myometrial cells, respectively (Brody & Cunha 1989). The endometrial stroma contains 
stromal cells, luminal epithelium, and endometrial glands. The glands are formed by post-
natal day 15, when the uterus reaches its mature sexual stage (Teixeira, Rueda & Pru 2008). 
The endometrial glands are surrounded by the glandular epithelial cells (Figure 1.1B). The 
uterus contains a lumen, surrounded by luminal epithelial cells (Figure 1.1B; Teixeira, Rueda 
and Pru, 2008). On the other hand, the oviducts can be split up into five parts: the 
intramuscular portion, that is located in the uterine wall; the isthmus, which is the narrowest 
part; the ampulla, which is the central region of the tube; the infundibulum, which is the 
open, funnel-shaped part that is close to the ovary; and finally, the fimbriated end. The 
fimbriated end contains finger-like structures that help movement of the ovulated oocyte into 
the oviducts during estrus (Rendi et al. 2012). The appearance of the uterine structures 
changes over the course of the estrous cycle (Pang et al. 2014), as will be described in the 
next section.  
 
1.2.2 The estrous cycle in mice 
The uterus is essential for mammalian reproduction. A functioning uterus is important for the 
fertility and health of women, but also for the health of their offspring (Spencer et al. 2005). 
Abnormal uterine development during fetal life can lead to infertility, or affect embryonic 
development of future generations (Spencer et al. 2005). Postnatally, the mouse uterus 
undergoes two developmental processes, both of which are driven by steroid hormones 
produced by the ovary. The first developmental process occurs in the absence of conception 
and is known as the estrous cycle (Green 1966). The second developmental process occurs 
during pregnancy and is known as decidualisation. 
 
1.2.2.1 Estrous cycle vs menstrual cycle 
The estrous cycle in mice is the equivalent of the menstrual cycle in humans. The main 
functions of the estrous and menstrual cycles are the maturation and release of oocytes from 
the ovaries and the establishment and maintenance of the endometrial lining necessary for 
embryo implantation (Sato, Nasu & Tsuchitani 2016). Female mice reach sexual maturity at 5 
weeks of age (Silver 1995). Proper function of the hypothalamic-pituitary-ovarian axis is 
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essential for normal reproductive function in both mice and humans. The menstrual cycle 
occurs in humans and non-human, anthropoid primates, such as monkeys, and apes, and lasts 
for an average of 28 days. The estrous cycle occurs in non-primates, such as rodents, dogs, 
and cows (Sato, Nasu & Tsuchitani 2016). The duration of the estrous cycle varies between 
species. For example, it lasts for 18-24 days in cattle, and an average of five days in mice. 
The short duration of the estrous cycle in mice, makes them a good model to study the 
hypothalamic-pituitary-ovarian axis function, and the changes in the uterus that occur during 
the cycle (Caligioni 2009). In humans, the menstrual cycle consists of two phases (Hawkins 
& Matzuk 2008). The proliferative phase is characterised by an increase in serum estrogen 
concentration leading to rapid proliferation of the endometrium. Levels of follicle stimulating 
hormone (FSH) also increase, leading to ovarian follicle maturation. Ovulation, which is the 
release of the mature oocyte into the oviduct occurs on day 14 of the cycle, following the 
luteinising hormone (LH) surge (Hawkins & Matzuk 2008). The ruptured follicle transforms 
into a progesterone-producing corpus luteum. The next phase of the menstrual cycle, the 
secretory phase, is characterised by increased progesterone and estrogen, that stimulate 
further proliferation of the endometrium, so that it can accept the potential blastocyst. If no 
implantation occurs, the new cycle starts with menses, which is the discharge of the 
endometrial lining from the uterus, and lasts for five days. On day six, the proliferative phase 
is repeated (Hawkins & Matzuk 2008). 
In contrast to the menstrual cycle, the estrous cycle in mice consists of four phases: proestrus, 
estrus, metestrus, and diestrus (Caligioni, 2009; Figure 1.2) and lasts on average five days, 
unless it is interrupted by pregnancy. The four stages of the estrous cycle in mice can be 
determined by vaginal smears, as the combination of cell types present in the vaginal 
epithelium at each stage is unique (Caligioni 2009; Gonzalez 2016). Mice are poly-estrous 
mammals, since if embryo implantation does not occur, a new estrous cycle is initiated. The 
estrous cycle was first studied in 1922 (Allen 1922). The effects of FSH, LH, estrogen, and 
progesterone, are similar in mice and humans, and will be further explained in the next 
sections. In mice, ovulation occurs during the estrus stage. If implantation does not occur, the 
endometrium is reabsorbed, instead of discharged, and this is the main disadvantage of the 
use of mice to study women’s reproductive health. The first rodent species known to 
menstruate, the spiny mouse, was discovered in 2016 (Bellofiore et al. 2016), and therefore 
can be used in the future instead of the commonly used laboratory mouse to assess the 
mechanisms of endometrial shedding and proliferation. 
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1.2.2.2 Hormonal regulation of the estrous cycle 
The periodicity of the estrous cycle is dependent on the hypothalamic-pituitary-ovarian axis 
and on a cascade of events originating from gonadotrophin releasing hormone (GnRH) 
neurons (Miller & Takahashi 2014). GnRH is released in a pulsatile manner (Tsutsumi & 
Webster 2009) from GnRH neurons in the hypothalamus (Figure 1.2). GnRH binds the 
GnRH receptors in the anterior pituitary gland to stimulate secretion of the gonadotropic 
hormones FSH and LH (Rispoli & Nett 2005). FSH binds to its receptors on the granulosa 
cells of the developing follicles (George, Dille & Heckert 2011) and stimulates maturation of 
the ovarian follicle (Rimon-Dahari et al. 2016). LH binds to its receptors on theca cells of the 
pre-ovulatory follicles (Zhang et al. 2001) and stimulates ovulation (Miller & Takahashi 
2014). The developing and matured follicles in the ovary produce estradiol (E2), while the 
ruptured follicles, known as corpus lutea, produce progesterone (P4). 
On the afternoon of the preovulatory proestrus stage, which lasts around 13 hours (Table 1.1), 
the hypothalamic GnRH pulsatile frequency and expression of GnRH receptors in the anterior 
pituitary increase (Miller and Takahashi, 2014; Figure 1.2). This leads to an increased 
production of FSH, stimulating ovarian follicle maturation (Rimon-Dahari et al. 2016). As 
oocyte maturation occurs in proestrus, E2 levels increase, providing a positive feedback loop 
for more GnRH release from the hypothalamus (Herbison 2008) and subsequently more FSH 
and LH release from the anterior pituitary. As E2 levels peak, the LH surge occurs, and mice 
enter the estrus stage (Czieselsky et al. 2016). The LH surge induces ovulation. High E2 
levels prevent dopamine secretion by the hypothalamus (Cramer, Parker & Porter 1979), 
which in turn increases prolactin secretion by the anterior pituitary (Ben-Jonathan & Hnasko 
2001). After ovulation, E2 production decreases. The ruptured follicles are transformed into 
corpus lutea (Bachelot & Binart 2005). P4 produced by the corpus lutea provides a negative 
feedback signal for GnRH secretion, therefore inhibiting further GnRH secretion by the 
hypothalamus. Prolactin, which is induced by mating, is required for maintenance of the 
corpus luteum (Stocco 2012). Maintenance of the corpus luteum causes further reduction in 
E2 and further increase of P4, therefore inhibiting GnRH secretion by the hypothalamus 
(Bashour & Wray 2012). This suppresses further E2 production, releasing dopamine from 
suppression. Metestrus is the stage following estrus. Dopamine levels increase in metestrus, 
due to decreased E2 production. Increased dopamine levels suppress prolactin (Ben-Jonathan 
& Hnasko 2001) leading to regression of the corpus luteum (Port et al. 2000) and a decrease 
in P4 production. As a result, GnRH is released from inhibition by P4. The females enter 
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diestrus while an increase of hypothalamic GnRH stimulates FSH and LH secretion, initiating 
the development of further follicles, and therefore preparing them for maturation during the 
following cycles (Wood et al. 2007). The follicle-derived E2 provides a positive feedback 
signal for GnRH secretion and the females re-enter the proestrus stage. Overall, the 
hypothalamic-pituitary-ovarian axis regulates a cascade of events that are essential for the 
periodicity of the estrous cycle, and therefore female fertility. These hormonal changes result 
in the maturation and release of oocytes, and the preparation and maintenance of the 
endometrium for blastocyst implantation and pregnancy. 
 
Figure 1.2 The levels of hypothalamic, pituitary, and ovarian hormones during the 
estrous cycle. 








1.2.2.3 Changes in the ovaries 
The hormonal changes during the estrous cycle guide the events taking place in the ovary, 
which include follicle development and maturation, and ovulation. The female mouse, as 
other mammalian species like humans and dogs, is born with a predetermined number of 
oocytes. By 5 weeks of age, when mice reach their sexual maturity (Buckland et al. 1981), 
each ovary has 10,000 oocytes (Nagy, Vintersten & Behringer 2003). FSH binds to FSH 
receptors on granulosa cells of the developing follicles, leading to gradual development and 
maturation of the oocytes, a process known as folliculogenesis (Rimon-Dahari et al. 2016). 
Follicle development occurs mostly during diestrus. Primordial follicles, which contain the 
primary oocytes, mature into primary follicles. Oocytes are arrested at prophase I of the first 
meiotic division at this stage. During proestrus, when GnRH and therefore FSH increase 
further, the follicles mature. The primary follicles mature into preantral (early Graafian) 
follicles. Completion of meiosis I occurs in response to further increase in FSH leading to the 
formation of the antral, also known as Graafian follicles, ready for ovulation. The secondary 
oocyte then arrests in metaphase of meiosis II, which will resume after fertilisation. E2 
produced by the preantral and antral follicles provides a positive feedback signal, inducing 
more GnRH secretion, and subsequently more FSH secretion to induce follicle maturation 
(Green, 1966; Figure 1.2). E2 secretion peaks at the Graafian follicle stage (100-200pg/ml 
blood), causing a peak in GnRH production through a positive feedback loop (Figure 1.2). A 
peak in GnRH secretion induces the LH surge, leading to the rupture of the Graafian follicle 
and the release of the mature oocyte (ovulation; Amleh and Dean, 2002). 
Mice are spontaneous ovulators, and ovulation occurs in estrus (Table 1.1; Green, 1966). 
During ovulation, 6-16 oocytes are released into the oviduct. The ruptured follicles transform 
into progesterone-producing corpus lutea (Rimon-Dahari et al. 2016). The oocytes are fertile 
for 8-12 hours after ovulation in the mouse reproductive tract and the peak fertility rate is 
achieved in the morning of the estrus stage, which lasts around 15 hours (Table 1.1). In 
metestrus, the corpus lutea regress, leading to decreased P4 levels, which then cause an 
increase in GnRH and subsequently FSH secretion, to induce development of new follicles. 
The events taking place in the ovary, are therefore regulated by hypothalamic, pituitary, and 




1.2.2.4 Changes in the uterus 
The ovarian hormones E2 and P4 influence the preparation of the endometrium for blastocyst 
implantation. The endometrium proliferates, and the endometrial cells and blood vessels 
reach maximum proliferation capacity in diestrus (Green 1966), as a result of increasing E2 
levels produced by the developing follicles. In diestrus the uterus appears thin and elongated 
(Bachelot & Binart 2005) and the uterine lumen is collapsed (Wood et al. 2007). Next, E2 
produced by the developing follicles in proestrus induces further proliferation of the 
endometrium, therefore increases the uterine width. The endometrium is undulating, with 
projections of endometrial tissue into the lumen (Bertolin & Murphy 2014; Wood et al. 
2007). The epithelial cells undergo active mitosis, and there are few leukocytes present. 
Increased E2 levels in proestrus also reduce endometrial stromal cell apoptosis (Wood et al. 
2007). During estrus, the E2 levels drop, therefore endometrial proliferation stops. In 
proestrus and estrus, the uterus is thick and swollen, due to increased secretions by the 
endometrial glands. Endometrial stroma cell proliferation is correlated with increasing E2 
levels during proestrus and estrus. At estrus, there is increased extracellular fluid throughout 
the endometrium, which starts decreasing in late estrus. Additionally, P4 levels increase, due 
to the formation of the corpus luteum, inducing the secretory activity of the oviducts and the 
endometrium to nurture the ovulated oocyte (Green 1966; Miller & Takahashi 2014; Wood et 
al. 2007). P4 is required for the preparation of the endometrium for pregnancy, and its 
maintenance during gestation (Bachelot & Binart 2005). Finally, during metestrus, a decrease 
in P4 and low levels of E2 lead to resorption of the endometrium (Caligioni 2009). The 
endometrial oedema decreases significantly, while stromal cell apoptosis peaks, resulting in a 
thinner endometrium. Overall, the remodelling of the endometrium during the estrous cycle, 
that aims to prepare it for blastocyst implantation and maintenance of pregnancy, is guided by 
the ovarian hormones, produced in a regulated manner, as a response to the pituitary 
hormones FSH and LH. 
Ovarian hormone levels also influence other uterine structures, such as endometrial glands 
and luminal epithelia. Proliferation of the glandular epithelium peaks at proestrus and 
metestrus. It negatively correlates with E2 levels, but it is independent of P4 levels. Increased 
E2 levels in proestrus reduce the frequency of luminal and glandular epithelial cell apoptosis 
(Wood et al. 2007). Although E2 negatively correlates with proliferation of glandular 
epithelia cells, it positively correlates with proliferation of stromal cells. On the other hand, 
apoptosis of luminal epithelial cells and stromal cells peaks at metestrus and it is inversely  
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Table 1.1 Changes in mouse reproductive organs during the estrous cycle. 
Estrous cycle 
stage 
Proestrus Estrus Metestrus Diestrus 
Duration (hrs) 13 15 13 56 
Vaginal smear N±C C L±C±N L 
Hormone levels Increased GnRH 
pulsatility 
am: Increased E2 
pm: LH surge 
Low P4 
am: Elevated E2 
pm: Drop in E2 
Very low LH and 
FSH 




Very low LH 
and FSH 
Low P4 
Initial increase of 
GnRH, FSH, LH, 
and E2  
Vaginal 
epithelium 
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layer is lost. The 
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cells. There are 12 










appear in the 
outer layers. 
Few layers of 
nucleated cells. 
Many leukocytes 
appear in the outer 
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secretory activity 





































Distension of the 
upper part of the 
oviduct. Active 







in the oviduct. 




Rapid growth of 
follicle at the end of 
diestrus. 
N: nucleated epithelial cells, C: cornified squamous epithelial cells, L: leukocytes, E2: 
estradiol, LH: luteinising hormone, FSH: follicle stimulating hormone, am: morning, pm: 




correlated with E2 levels. P4 levels are inversely correlated with stromal cell apoptosis only 
(Wood et al. 2007). The luminal epithelium appears rough and uneven at metestrus, and 
smooth in the other stages of the estrous cycle (Wood et al. 2007). This might be a result of 
increased apoptosis of luminal epithelial cells in metestrus. Little is known about the 
morphology of the cells in the different uterine structures, such as myometrium, or lumen 
epithelium. However, E2 and P4 levels do not influence the myometrial thickness (Wood et 
al. 2007). Overall, the ovarian hormone levels during the estrous cycle affect not only the 
structure of the endometrium, but also the glandular and luminal epithelia. These changes aim 
to create a receptive environment following ovulation and prepare the uterus for blastocyst 
implantation. 
 
1.2.2.5 Abnormal cyclicity and infertility 
Abnormal estrous or menstrual cycles are associated with infertility. Anovulatory disorders 
caused by hypothalamic-pituitary-ovarian axis dysfunction are a leading cause of infertility 
(Mikhael, Punjala-Patel & Gavrilova-Jordan 2019). These disorders are classified into three 
groups, by the World Health Organisation. Group I, which accounts for 10% of ovulation 
disorders, involves hypogonadotropic hypogonadism resulting from hypothalamic failure. In 
this case, the ovaries are functionally competent, but there is no GnRH and subsequently no 
FSH or LH produced, therefore the ovaries fail to function (Jindal & Jindal 2015). Group II, 
which accounts for 85% of ovulation disorders, involves the polycystic ovary syndrome 
(PCOS), and abnormal body mass index, resulting from dysfunction of the hypothalamic-
pituitary-ovarian axis. PCOS is characterised by excess androgen production by the ovaries 
or the adrenal glands. Additionally, it causes anovulation due to arrested follicular 
development, increasing the risk of infertility (Macut 2009). Group III involves ovarian 
failure, leading to oocyte depletion, resulting from premature ovarian insufficiency caused by 
genetic or iatrogenic factors (Mikhael, Punjala-Patel & Gavrilova-Jordan 2019). Additionally, 
E2 and P4 produced during the menstrual cycle are essential for endometrial proliferation and 
induction of endometrial receptivity following ovulation, respectively (Paulson 2011). For 
instance, abnormal expression of endometrial E2 or P4 receptors during the menstrual cycle 
can lead to decreased proliferation and receptivity of the endometrium, and ultimately 
implantation failure (Fung et al. 2018; Garcia et al. 1988; Lessey et al. 1988). Moreover, E2 
upregulates endometrial Mucin 1 (Muc1) expression in mice, while P4 antagonises the action 
of E2. Muc1 expression is reduced during the window in implantation and its loss is 
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considered a prerequisite for a receptive endometrium (Dharmaraj, Gendler & Carson 2009). 
A polymorphism in the variable number tandem repeat of MUC1 resulted in a protein with 
significantly less O-glycosylation sites, which might possibly be associated with implantation 
failure (Horne et al. 2001). Therefore, the regulation of MUC1 expression by P4 is essential 
for endometrial receptivity. Abnormal cyclicity and abnormal production of E2 and P4 can 
therefore impair endometrial receptivity, leading to implantation failure (Hashimoto et al. 
2017). Altogether, these data show that abnormal function of either the hypothalamus, the 
pituitary, or the ovaries, can lead to anovulation or abnormal endometrial receptivity, and 
therefore infertility. 
Like humans, abnormal function of the hypothalamic-pituitary-ovarian axis can cause 
anovulation, abnormal folliculogenesis, and infertility in animals. In female mice, testicular 
orphan receptor 4 (TR4) induces LH receptor gene expression. Tr4-/- mice have prolonged 
diestrus stages, smaller ovaries, fewer corpora lutea, intensive granulosa cell apoptosis, and 
impaired folliculogenesis (Chen et al. 2008). Although not assessed, it was hypothesised that 
reduced LH receptor expression on theca cells leads to reduced E2 and P4 levels (Chen et al. 
2008). Additionally, deficiency of Complement-3 (C3) in mice, which is important for 
immune responses, leads to an extended estrous cycle and higher resorption rates at E14.5, as 
a result of decreased spongiotrophoblast and labyrinth areas of the placenta (Chow et al. 
2009). Similarly, in horses, anovulation leads to infertility (Mccue & Act 1998). It occurs 
because of insufficient pituitary FSH and LH, leading to inadequate development and 
maturation of the follicles, or insufficient E2 production from the follicles, not able to trigger 
the LH surge to induce ovulation. The anovulatory follicles persist in the ovaries and result in 
abnormal estrus behaviour and prolonged inter-ovulatory intervals. Bitches undergo an 
anestrous 2-10-month period where the reproductive tract undergoes uterine regeneration and 
endocrine preparation, before entering the next estrus phase. Shortened anestrus leads to 
shorter interestrus interval, resulting in difficulties in breeding (Wanke, Loza & Rebuelto 
2006). Prolonged estrus in bitches leads to prolonged exposure of the ovaries to estrogen, 
leading to ovarian cysts and ovarian tumors (Blendinger 2007). Additionally, hormonal 
changes during the estrous cycle regulate Muc1 expression. Muc1 levels peak at proestrus and 
estrus in response to E2 (Braga & Gendler 1993). Muc1 levels decrease in metestrus and 
diestrus, and the authors suggests that this might be in response to P4 (Braga & Gendler 
1993). Muc1 is important for endometrial receptivity, and decreased MUC1 is a marker of 
endometrial receptivity in women with recurrent implantation failure (Wu et al. 2018). 
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Therefore, abnormal cyclicity and abnormal changes in hormone levels during estrus can 
impair Muc1 expression, leading to decreased endometrial receptivity and ultimately 
implantation failure. Altogether, these studies show how abnormal cyclicity impairs fertility, 
by affecting either ovulation, or endometrial receptivity. 
 
1.2.3 From estrous cycle to pregnancy in mice 
Mating of mice usually occurs in the early morning of the estrus stage, when the females are 
more likely to be receptive to males (Byers et al. 2012). Copulation is identified by the 
presence of a copulatory plug the next morning, which is considered to be embryonic day (E) 
0.5. The formation of the copulatory plug prevents the female from mating with other males, 
but it does not guarantee pregnancy (Sutter et al. 2015). During a successful mating, the 
sperm travels through the uterus to the ampulla part of the oviducts, where fertilisation occurs 
(Deb, Reese & Paria 2006). The fertilised eggs are released from meiotic arrest, completing 
the second meiotic division (MacLennan et al. 2015), forming the zygote. The zygote 
undergoes mitotic divisions, to reach the cleavage stages to form the morula, and ultimately, 
the blastocyst, by E3.5 (Li, Zheng & Dean 2010). 
 
1.2.3.1 The estrous cycle after mating and maintenance of corpus luteum and 
progesterone  
After mating at the estrus stage, the ruptured follicle is transformed into the corpus luteum 
(see Section 1.2.2) and the estrous cycle is interrupted. Cervical stimulation during mating 
inhibits dopamine secretion, therefore increasing pituitary prolactin levels (Poletini et al. 
2010). Prolactin is released in a pulsatile manner (Helena et al. 2009). In rodents, prolactin is 
essential for the maintenance of the corpus luteum for the first 8-9 days of pregnancy, until 
the placenta takes over P4 production (Bachelot & Binart 2007; Risk & Gibori 2001; Stocco 
2012). Maintenance of the corpus luteum results in high P4 levels, which inhibit GnRH 
secretion by the hypothalamus. Low levels of GnRH and E2 prevent the development of 
further follicles and maintain low FSH and LH levels. These hormonal changes block further 
follicle development, ovulation and cyclicity, so that pregnancy can be maintained. After 
E8.5 mouse placental lactogens 1 and 2 produced by the trophoblast giant cells to maintain 
the corpus luteum (Malassiné, Frendo & Evain-Brion 2003). The corpus luteum is not 
affected by a hypophysectomy (removal of the hypophysis) after E10.5, since it is maintained 
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by placental lactogens. If sterile copulation occurs, i.e. mating with a vasectomised male and 
therefore fertilisation does not occur, the mice enter a pseudopregnant state, where the 
metestrus stage is prolonged by 10-13 days. The corpus luteum in mice is responsible for P4 
secretion throughout gestation (Risk & Gibori 2001). From E7.5 the corpus luteum starts 
increasing its size, reaching its maximal diameter on E12.5 (Greenwald & Rothchild 1968). 
The P4 produced by the corpus luteum is therefore key for blocking estrous cyclicity and 
initiating a successful pregnancy. 
 
1.2.3.2 Changes in the uterus after fertilisation 
Embryo implantation and development depend upon the different cell types present in the 
uterus that undergo dynamic changes at the peri-implantation and post-implantation stages 
(Jeong et al. 2010). The formation of the corpus luteum and the peak in P4 and E2 lead to 
optimal uterine receptivity between E3.5 and E4.5 (Wang & Dey 2006). This is mediated by 
MUC1, which is expressed by the apical surface of the uterine epithelial cells (Surveyor et al. 
1995). High levels of MUC1 prevents embryo implantation, and therefore its loss contributes 
to the acquirement of a receptive uterine state (Surveyor et al. 1995). E2 stimulates Muc1 
expression, while P4 antagonises the stimulatory effects of E2 on Muc1 expression (Surveyor 
et al. 1995). A successful pregnancy relies on the interaction between the implanting 
blastocyst and the receptive endometrium (Aplin & Ruane 2017). At the peri-implantation 
period, the apical plasma membrane of the uterine epithelial cells flatten, by losing their 
microvilli (Cha et al. 2014). The blastocysts are only able to attach when the apical surface of 
the cells is flattened (Murphy 2004). The uterine horns elongate before and during 
implantation (Finn 1968). This is important because embryo spacing in the uterine horns 
relies on the simultaneous elongation of the outer myometrial layer and contraction of the 
inner myometrial layer (Chen et al. 2011; Yoshinaga 2013). Endometrial stroma oedema is 
observed due to reabsorption of the intraluminal uterine fluid, leading to closure of the 
uterine lumen (Huet-Hudson & Dey 1990). This facilitates interactions between the uterine 
epithelium and the blastocyst, necessary for implantation (Chen et al. 2013). Studies in 
human in vitro fertilisation have highlighted the importance of synchronising blastocyst 
development with the endometrial environment, to prevent implantation failure (Valdes, 
Schutt & Simon 2017). If implantation occurs beyond the window of implantation, there is 
increased risk of spontaneous abortion (Wilcox, Baird & Weinberg 1999), or peri-
implantation pregnancy loss (Norwitz, Schust & Fisher 2001). Uterine gland secretions are 
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also important for successful implantation. For instance, leukemia inhibitory factor (LIF), 
which is expressed by the uterine glands, is essential for embryo implantation (Stewart et al. 
1992). Implantation failure was observed in Lif-/- females. However, the blastocysts of Lif-/- 
females that were transferred to a wildtype pseudopregnant female could implant and develop 
to term (Stewart et al. 1992). Other mice lacking functional uterine glands show defects in 
blastocyst implantation, which could be a result of the absence of LIF (Dunlap et al. 2011; 
Filant & Spencer 2013; Jeong et al. 2010). In mice, embryo implantation consists of three 
steps: (a) apposition, where the mural trophectoderm of the blastocyst contacts the epithelial 
cells at the antimesometrial side of the uterus, which is the side opposite the mesometrial 
blood vessels (Daikoku et al. 2011), (b) attachment, where the trophoblast cells of the 
blastocyst attach to the receptive endometrium, and (c) invasion, where the trophoblast cells 
cross the endometrial epithelial basement membrane to reach the endometrial stroma (Dey et 
al. 2004; Ruane et al. 2017). At E5.5, the lumen epithelial cells that are near the blastocyst 
undergo apoptosis (Filant & Spencer 2014; Joswig et al. 2003). Altogether, these studies 
show the changes that happen in the uterus after fertilisation and are essential for embryo 
implantation and development. However, one of the most important uterine changes is the 
process of decidualisation, which will be discussed next. 
 
1.2.3.3 Decidualisation after implantation 
The interaction of the implanting embryo with the uterine luminal epithelium stimulates 
decidualisation (Favaro, Abrahamsohn & Zorn 2014). Decidualisation is required for 
successful blastocyst implantation (Lee & Demayo 2004) and involves morphogenetic, 
biochemical, and vascular changes in the pregnant uterus, that are driven by activation of E2 
and P4 receptors. More specifically, decidualisation involves: (a) transdifferentiation of 
endometrial stromal cells into decidual cells, (b) extracellular matrix remodelling of the 
endometrial stroma, (c) production of molecules important for maternal-fetal interactions, (d) 
maternal angiogenesis essential for nutrient supply to the embryo, and (e) influx of uterine 
natural killer (uNK) cells with immunoregulatory and vasculogenetic roles (Favaro, 
Abrahamsohn & Zorn 2014). This process is therefore essential to provide an optimal 
intrauterine environment for embryo development. 
As a transient tissue, the murine decidua begins to form at E4.5 from the antimesometrial 
pole and it only occurs in the implantation sites (Lim & Wang 2010). The decidual cells 
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undergo extensive proliferation and differentiation between E4.5 and E7.5 and become 
polyploid (Sroga, Ma & Das 2012). It is speculated that the cells’ polyploid status ensures 
that they have a limited lifespan (Das 2009), although the mechanism is unknown. The 
limited lifespan of the decidual cells, however, is essential for decidual regression. Failure of 
decidual regression can lead to reduced trophoblast invasion and abnormal labyrinth 
development (Lague et al. 2010). Decidualised stromal cells produce growth factors and 
cytokines to support growth of the developing embryo (Ramathal et al., 2010). 
Decidualisation leads to the formation of a thicker endometrial wall (Fraser et al. 2015). 
During decidualisation, increased endometrial vascular permeability necessary for nutrient 
supply to the embryo is also prominent. 
The decidual cells at the antimesometrial pole form the avascular and epithelioid primary 
decidual zone (PDZ; Figure 1.3). The stromal cells proximal to the PDZ proliferate, undergo 
subsequent apoptosis, and disappear by E7.5. At E6.5, the trophectoderm-derived 
ectoplacental cone penetrates the mesometrial decidua, which is enriched with maternal blood 
vessels (Lim & Wang 2010). The stromal cells next to the PDZ continue to proliferate and 
differentiate into polyploid decidual cells to form the secondary decidual zone (SDZ; Figure 
1.3), which is fully developed by E6.5 (F. Gao et al. 2015; Tan et al. 2002). The SDZ 
contains polyploid decidual cells that are found in lateral and antimesometrial decidual zones. 
Mitochondrial activity is critical for the development of decidual cell polyploidy. Polyploid 
cells express genes associated with mitochondrial function, as shown by microarray analysis 
of polyploid and non-polyploid decidual cells and inhibition of mitochondrial activity 
attenuates decidual cell polyploidy (Ma et al. 2011).  In contrast, a non-polyploid decidual 
zone forms after proliferation and differentiation of mesometrial stromal cells by E7.5 (F. 
Gao et al. 2015). The cells in the SDZ eventually also undergo apoptosis, a process known as 
decidual regression, allowing the implantation chamber to enlarge and support growth of the 
developing embryo (Tan et al. 2002). Inadequate decidual regression due to decreased 
apoptosis can lead to an abnormally thick decidual layer, obstructing trophoblast invasion, 




Figure 1.3 Schematic of an implantation site at E6.5. 
am: antimesometrial region, m: mesometrial region, myo: myometrium, PDZ: primary 
decidual zone, SDZ: secondary decidual zone; Reproduced from Douglas et al. (2014). 
 
1.2.3.4 Gene expression during estrous cycle affects decidualisation 
Estrous cyclicity is regulated by the hypothalamic-pituitary-ovarian axis. However, the 
molecular mechanisms, such as transcription factors that regulate the events that take place 
during the cycle, are not well understood. The estrous cycle is driven by gene regulatory 
networks, and genes are specifically expressed at each stage of the cycle (Lee et al. 2005; Tan 
et al. 2003; Yip et al. 2013). Transcriptome analysis revealed that the Wingless-related 
integration site (WNT) signalling pathway was activated in estrus compared to proestrus (Yip 
et al. 2013). WNT signalling is important for proper decidualisation (Sonderegger, 
Pollheimer & Knöfler 2010). Additionally, proteinases and protease inhibitors, that regulate 
the uterine extracellular architecture, are differentially expressed between proestrus and 
estrus. For instance, Serpine2 is upregulated in estrus (Yip et al. 2013), is expressed by the 
luminal and glandular epithelial cells and is involved in uterine tissue remodelling (Chern et 
al. 2010). The Hedgehog pathway is also activated in estrus compared to proestrus, as genes 
involved such as Smo, Bmp4, Bmp6, Wnt2 and Wnt7a were upregulated during estrus (Yip et 
al. 2013). The hedgehog pathway is activated in response to P4 signalling in luminal and 
glandular epithelial cells (Simon et al. 2009), and is essential for implantation (Harman et al. 
2011). Overall, these data suggest that molecular events that occur in parallel with E2 action 
on endometrial proliferation, ensure that the endometrium expresses the receptors and 
molecules necessary to accept the blastocyst and maintain a successful pregnancy. 
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1.2.3.5 Factors that regulate decidualisation 
Extracellular matrix remodelling is essential during decidualisation. Differentiation of 
endometrial stroma cells into decidual cells, intense cell growth, and formation of 
intercellular junctions lead to decreased extracellular spaces in the endometrium (Favaro, 
Abrahamsohn & Zorn 2014). As a result, remodelling of the endometrial extracellular matrix 
occurs (Abrahamsohn & Zorn 1993). During extracellular matrix remodelling, collagen fibres 
become thicker. Collagen types I, III, and V have specific expression patterns. Collagen I is 
expressed in the non-decidualised endometrial stroma of the inter-implantation sites. 
Collagens III and V are found in the basement membrane of the uterine glands of the inter-
implantation sites and they appear in the decidua after E6.5 (Favaro, Abrahamsohn & Zorn 
2014). Extracellular matrix remodelling is also essential for further placenta development and 
will be discussed in Section 1.3.3. 
Decidualisation is regulated by transcription factors (Lim & Wang 2010). During normal 
decidualisation, Hoxa10 and Cyclin-D3 regulate FoxM1 transcription and nuclear 
translocation, respectively. FOXM1 is a transcription factor that is essential for mitosis in the 
mesometrial decidual zone, leading to formation of diploid cells (Gao et al. 2015). FOXM1 
also causes endoreduplication of the cells in the lateral and anti-mesometrial secondary 
decidual zone, leading to polyploid cell formation. Loss of uterine FoxM1 leads to arrest of 
the cell cycle prior to mitosis by downregulation of the mitotic regulators Ccnb1, Cdc25b, 
and Cenpf (Gao et al. 2015). This leads to increased formation of polyploid cells leading to 
increased secondary decidual zone, and decreased numbers of diploid cells leading to smaller 
mesometrial area. Changes in regional decidualisation, for instance in the size of the different 
decidual areas, impairs pregnancy progression, and leads to pregnancy loss during 
decidualisation (Gao et al. 2015). Therefore, proper regulation of FoxM1 leads to proper 
regional decidualisation, and ultimately proper embryo growth. Additionally, Prl8a2 is 
expressed in the anti-mesometrial decidua of mouse and rat (Orwig, Dai, et al. 1997; Orwig, 
Ishimura, et al. 1997; Orwig, Rasmussen & Soares 1997; Rasmussen et al. 1996, 1997; Roby 
et al. 1993) and inhibits activation of endometrial stress pathways in decidual cells (Alam, 
Konno & Soares 2015). Bmp2 is also used as a marker of decidualisation. Conditional 
ablation of Bmp2 in the uterus does not affect implantation, but the uterine stroma fails to 
differentiate into decidual cells, therefore decidualisation fails (Lee et al. 2007). Treatment of 
E4.5 pregnant uteri with progesterone receptor (PR) antagonist led to significant 
downregulation of Bmp2 at E5.5, suggesting Bmp2 is a downstream target of PR signalling 
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(Li et al. 2007). In addition, stromal cell differentiation was induced in a primary culture of 
undifferentiated stromal cells derived from pregnant mice after addition of recombinant 
Bmp2 (Li et al. 2007). Addition of BMP2-specific siRNA in the cell culture prevented the 
differentiation process. Wnt4 is a downstream target of BMP2 signalling. Addition of BMP2 
in the cell culture led to an increase in WNT4 expression and induced stromal cell 
differentiation (Li et al. 2007), suggesting that BMP2 and WNT4 mediate P4-induced stromal 
cell differentiation. NR2F2 is a transcription factor whose role in implantation and 
decidualisation is well established (Wetendorf & DeMayo 2012). NR2F2 is highly expressed 
in uterine stroma cells and it is known to activate Bmp2 transcription (Kurihara et al. 2007). 
Nr2f2+/- females display reduced fecundity, abnormal estrous cyclicity, delayed puberty, 
reduced decidualisation as indicated by wet weights of the uterine horns, and postnatal 
growth retardation compared to wildtype littermates (Takamoto et al. 2005). Ihh is also found 
downstream of PGR and activates Nr2f2. Conditional ablation of Ihh in PGR-positive uterine 
cells leads to attachment failure. In addition, when the uterine horns of these Ihh-/- females 
were traumatized by a needle scratch in order to induce artificial decidualisation, they failed 
to undergo decidualisation (Lee et al. 2006). HOXA10, another transcription factor, is highly 
expressed in the decidualising uterine stroma cells (Das 2010) and it regulates the 
responsiveness of uterine stromal cells to P4 during implantation and decidualisation (Lim et 
al. 1999). Hoxa10 mutant females exhibit failure of implantation and resorption of embryos 
in the early postimplantation period (Benson et al. 1996). HAND2 is another transcription 
factor that is regulated by P4 during decidualisation (Okada et al. 2014). Hand2 is expressed 
by the endometrial stromal cells prior to implantation, but it peaks in the uterus during 
decidualisation and its expression is regulated by P4 (Huyen & Bany 2011). SiRNA- 
mediated reduction of Hand2 mRNA leads to defective decidualisation and decreased 
expression of decidual markers (Huyen & Bany 2011). Pharmacological inhibition of Notch1 
led to impaired artificial induction of decidualisation, as indicated by a decreased uterine wet 
weight ratio of the decidual horn to the control horn in mice with pharmacological 
intervention compared to controls (Afshar et al. 2011). Altogether, these studies show that 
activation of Pgr and its downstream targets, such as Bmp2, Nr2f2, and Wnt4 is essential for 




1.2.3.6 Factors that regulate angiogenesis 
Uterine angiogenesis also occurs in the pregnant uterus during decidualisation. Angiogenesis 
involves the formation of new blood vessels from pre-existing ones to facilitate perfusion of 
the implantation site by the maternal blood (Adamson et al. 2002). Decidual cells are 
important for maternal blood vessel formation in the uterus (Fraser et al. 2015). For instance, 
decidual NK cells control vessel stability by inducing expression of the adhesion molecule 
Icam1 in the endothelial cells (Fraser et al. 2015). The angiogenic factor VEGF and its 
receptors, VEGFR1 and VEGFR2, encoded by Flt-1 and Flk-1, respectively, expressed by 
uterine endothelial cells are required for uterine angiogenesis (Matsumoto et al. 2002). Mice 
administered with a FLT1 blocking antibody during the pre-implantation and peri-
implantation period showed decreased decidual vascular density. However, embryo 
implantation and pregnancy progression were not affected (Douglas et al. 2014). In addition, 
cyclooxygenases are the key enzymes for prostaglandin biosynthesis. Prostaglandins regulate 
angiogenesis during implantation and decidualisation (Finetti et al. 2008; Lim, Gupta, et al. 
1999). For instance, Cox2-/- mice exhibited impaired implantation and attenuation of uterine 
angiogenesis due to defective VEGF signalling (Matsumoto et al. 2002). Transfer of the 
embryos in a P4-treated Cox2-/- pseudopregnant recipient led to embryo attachment, but 
abnormal decidualisation was characterised by decreased vascular permeability. Aberrant 
expression of PECAM-1, which is expressed early during vascular development, was 
observed in Cox2-/- recipients resulting in reduced mesometrial decidual area. Finally, cell-
cell communications are important for decidual cell function, such as production of 
angiogenic factors, as determined by conditional mutants of the gap junction protein 
Connexin 43 (Cx43; Laws et al. 2008). 
 
1.2.4 Endometrial causes of FGR 
Fetuses developing in a structurally abnormal uterus develop deformations (Miller, Dunn & 
Smith 1979), although there is little evidence linking abnormal uterine development and 
structure to FGR. There is also little evidence linking the estrous cycle to FGR. For instance, 
P4 and E2 levels affect collagen. Collagen type-IV is found on the basement membrane of 
luminal and glandular epithelial cells. At estrus, collagen type-IV is lost from the luminal 
cells but it is at similar levels in glandular cells compared to other stages of the cycle. P4 and 
E2 levels inversely correlate with the degradation of collagen type-IV from the basement 
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membrane of luminal and glandular epithelia cells, respectively (Wood et al. 2007). Although 
not shown, it has been suggested that inefficient degradation of collagen type-IV in response 
to P4 and E2 can lead to occlusion of blood vessels and possibly interfere with 
vascularisation (Rahima & Soderwall 1977). In turn, abnormal uteroplacental vascularisation 
can lead to FGR (Noguchi et al. 2009). The little evidence linking the estrous cycle to FGR 
could be because disruption of the estrous cycle can impair the preparation of the uterus for 
implantation, and therefore lead to implantation defects. However, there is some evidence 
that links endometrial function to FGR. As mentioned in the previous section, abnormal gene 
expression during the estrous cycle can affect uterine decidualisation during early pregnancy. 
Disrupted decidualisation can impair the blood flow and oxygen and nutrient transport to the 
developing fetus, leading to abnormal embryo growth (Wang & Dey 2006). For example, 
delayed implantation occurred as a result of maternal deletion of the homeobox gene Msx1, 
lysophosphatidic acid receptor 3 (Lpar3), prostaglandin synthase 2 (Ptgs2), or phospholipase 
A2 (Pla2g4a), leading to defective post-implantation development and retarded fetoplacental 
growth (Daikoku et al. 2011; Song et al. 2002; Ye et al. 2005). Similarly, disruption of 
decidualisation due to deletion of genes involved in decidualisation, such as Bmpr2, results in 
FGR at E9.5-E10.5 due to defective decidual cell proliferation, impaired decidual 
vascularisation, and ultimately abnormal nutrient transport (Nagashima et al. 2013). Decidual 
cell apoptosis is essential for trophoblast invasion. Deletion of Pten from the myometrial and 
stromal/decidual cells resulted in decreased apoptosis and subsequent decreased decidual 
regression. As a result, the decidual layer was abnormally thick, leading to defective 
trophoblast invasion and delayed spiral artery remodelling (SAR; see Section 1.3). This was 
frequently associated with FGR, possibly due to decreased nutrient supply to the embryo 
(Lague et al. 2010). Similarly, Mmp9 deficiency led to abnormal trophoblast differentiation 
and invasion and ultimately FGR in mice (Plaks et al. 2013). Additionally, CX43, which is 
encoded by Gja1, is expressed in the decidual cells and is required for the transdifferentiation 
of stromal cells into decidual cells, and for angiogenesis. A dominant mutation of Gja1 in the 
mother leads to abnormal decidual angiogenesis and increased expression of angiogenic 
factors, such as Vegfa, Flt1, Kdr, and Fgf2. This resulted in disorganised and dilated maternal 
blood spaces in the decidua, and ultimately decreased surface area available for exchange of 
nutrients, gas and waste products. As a result, the fetal weight at E17.5 was reduced, 
indicating FGR (Winterhager et al. 2013). A uterine Nodal knockout in the mothers led to 
malformation of the decidual basalis and abnormal placentation, characterised by larger 
decidual zone at E8.5, increased TGC expansion at E10.5, FGR at E15.5-E16.5, and fetal loss 
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by E17.5 (Park et al. 2012). Additionally, uterine Lk5 knockout in the mothers led to fewer 
and smaller implantation sites, uterine haemorrhage, unclosed uterine lumen, and shallow 
trophoblast invasion at GD8.5. At E9.5, the antimesometrial decidual area appeared thicker, 
possibly limiting fetal growth. At E10.5, the labyrinth layer was smaller, the TGC were 
expanded, and FGR was observed (Peng et al. 2015). Moreover, maternal floor infarction and 
massive chronic intervillositis are pathological diagnoses involving excessive fibrin 
deposition and are associated with FGR. In both cases, mononuclear or giant cells from the 
maternal circulation infiltrate the villi, leading to villous vascular occlusion, therefore 
preventing proper vascular development and function (Roberts & Post 2008). Tissues from 
pregnancies complicated with fetal growth restriction are characterised by defective 
myometrial SAR, including decreased muscle disruption, increased number of extravillous-
cytotrophoblast surrounding the decidual and myometrial vessels and less fibrinoid 
deposition in the decidual myometrial vessels (Lyall, Robson & Bulmer 2013). Finally, fetal 
thrombotic vasculopathy characterised by fetal vascular obstructive lesions cause villous 
infarction and leads to FGR (Roberts & Post 2008). Altogether, these studies show that 
abnormal endometrial function, such as abnormal endometrial gene expression and abnormal 
decidualisation and angiogenesis can cause FGR. 
 
1.3 Mouse placenta development and function  
The placenta is a highly specialised organ. It is responsible not only for anchoring the 
developing embryo on the maternal endometrium, therefore preventing its rejection by the 
maternal immune system, but also for the transport of nutrients, gases, and waste products 
between the maternal and fetal circulations. The placenta functions to support embryo growth 
and development (Cross, Simmons & Watson 2003). In the previous section we talked about 
the maternal tissues of the mouse placenta and discussed the endometrial causes of FGR. 
However, the placenta is a chimeric organ, consisting of both maternal and fetal tissues. 
Therefore, in this section we will give an overview of placental development and discuss the 
interactions between the maternal and fetal components of the placenta. Additionally, we will 




1.3.1 Structure and function of the mature mouse placenta 
The mouse is a good model organism to study placentation in humans. The invasive and 
endocrine trophoblast is called the extravillous cytotrophoblast in humans, which is 
analogous to the trophoblast giant cells and glycogen trophoblast cells in mice (Silva & 
Serakides 2016). In both species, the trophoblast is invasive and non-proliferative, with 
mononuclear polyploid cells. In addition, the transport and barrier trophoblast, known as 
chorionic villi and labyrinth in humans and mice respectively, is haemochorial, since the 
chorion is in direct contact with the maternal blood. Both the chorionic villi in humans, and 
the labyrinth in mice, have a syncytiotrophoblast layer that is formed by cell fusion. 
Syncytiotrophoblast cells are therefore polyploid in both species (Cross et al. 2003). 
The mature mouse placenta (E14.5) is divided into histologically distinct areas: the maternal 
decidua, that derives from the proliferation and differentiation of endometrial stroma cells, 
the junctional zone, and the labyrinth (Figure 1.4; John 2013; Watson & Cross 2005). The 
maternal decidua contains the spiral artery-associated TGCs, that derive from the 
ectoplacental cone. The maternal decidua is in direct contact with a layer of parietal 
trophoblast giant cells (p-TGCs). P-TGCs derive from the ectoplacental cone and surround 
the lacunae, which are large lakes of blood that lead to the uterine veins (Rai & Cross 2014). 
The next compartment of the placenta is the junctional zone, which contains four 
ectoplacental cone (EPC)-derived cell types: the spongiotrophoblast cells, the glycogen cells, 
the canal TGCs, and the channel TGCs. The spongiotrophoblast cells have an endocrine 
function and secrete the placental prolactins and pregnancy-specific glycoproteins. These 
proteins are essential for protecting the developing fetus from being attacked by the maternal 
immune system, and to remodel the blood vessels of the placenta and the maternal decidua 
(Kammerer & Zimmermann 2010; Wu et al. 2008). The glycogen trophoblast cells store 
glycogen, that is catabolised to glucose upon activation of glucagon receptors (Coan, Conroy 
& Burton 2006). The glucose is then released into the maternal bloodstream, and then 
transported to the fetus through glucose transporters (Hay 2006). Glycogen trophoblast cell 
number increases from E12.5 to E16.5 by 80-fold, while it decreases by E18.5 (Coan, Conroy 
& Burton 2006). The maternal blood travels through pipe-like structures formed by canal 
TGCs to the bottom of the labyrinth, while the deoxygenated blood is removed from the 
labyrinth by channel TGCs that form small channels (Rai & Cross 2014). 
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Finally, the labyrinth is the area of the placenta where maternal and fetal circulations come 
into close proximity to exchange nutrients, gases, and waste products. The labyrinth contains 
fetal endothelial cells derived from the allantois, as well as trophoblast cells derived from the 
chorion, which include two types of syncytiotrophoblast cells (SynT-I and SynT-II), and 
sinusoidal TGCs (sTGC; Maltepe, Bakardjiev & Fisher 2010; Simmons & Cross 2005). The 
sTGCs are in direct contact with the maternal blood. The SynT-I cells are found between the 
sTGCs and the SynT-II, while the SynT-II cells are the ones closest to the fetal endothelial 
cells. These three types of trophoblast cells form a trilaminar structure. The efficiency of 
nutrient and gas exchange largely depends on the thickness of this trilaminar structure, as 
well as the density of transporter proteins, and degree of branching (Sandovici et al. 2012). 
 
Figure 1.4 Mouse placenta development. 
The development of the trophoblast lineage begins at E3.5. The chorioallantoic attachment is 
established by E8.5, and the mature placenta is formed by E14.5. Image by Erica D. Watson. 
 
1.3.2 Mouse placenta development 
The extraembryonic lineages in mice are established at E3.5, when the first differentiation 
step occurs to create the blastocyst (Cross, Werb & Fisher 1994). The blastocyst consists of a 
fluid-filled cavity, called the blastocoele, a compacted inner cell mass (ICM) composed of 
irregular, non-polarised cells, and an outer cell layer, called the trophectoderm (Figure 1.4). 
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The trophectoderm which is in direct contact with the ICM is called the polar trophectoderm, 
while the part of it that is on the opposite side, is called the mural trophectoderm. The 
trophectoderm is formed of polarised epithelial cells with apical microvilli (Cross, Werb & 
Fisher 1994). 
During embryo implantation (E4.5) the mural trophectoderm differentiates into primary 
trophoblast giant cells, which are analogous to the extravillous cytotrophoblast cells in 
humans (Rossant & Cross 2001). These are polyploid cells, since they undergo 
endoreduplication, by replicating their genome, without undergoing cell division. The polar 
trophectoderm gives rise to the extraembryonic ectoderm (ExE) and the EPC (Rossant & 
Cross 2001). The ExE contributes to the chorion, that will form the labyrinth, while the EPC 
differentiates into the secondary parietal and the spiral artery TGCs, and cells forming the 
junctional zone, including spongiotrophoblast, glycogen cells, canal TGCs, and channel 
TGCs. (Tunster et al. 2016). The ICM, on the other hand, gives rise to extraembryonic 
mesoderm that differentiates into the chorionic mesoderm and allantois. Chorioallantoic 
attachment occurs at E8.5 (Figure 1.4) and is essential for labyrinth formation. At E9.0, 
branching morphogenesis initiates, which aims to form dense villi across the chorion, at the 
chorioallantoic interface. Villi are the structures responsible for the exchange of nutrient, gas, 
and waste products between the maternal and fetal circulations (Cross, Simmons & Watson 
2003). Branching morphogenesis causes the labyrinth layer to expand (Cross et al. 2006). By 
E10.5, angiogenesis takes place in the chorionic villi (Rossant & Cross 2001). The primary 
villi undergo a second round of branching and elongation, forming the mature labyrinth by 
E14.5. Simultaneously, the trophoblast cells undergo differentiation to form the sTGC, SynT-
I, and SynT-II, which separate the fetal capillaries from the maternal blood sinuses (Simmons 
& Cross 2005). Ultimately, the mature placenta is formed at E14.5. 
 
1.3.3 Maternal components of the mouse placenta 
As mentioned in Sections 1.2.3 and 1.3.1, the mouse uterus undergoes decidualisation during 
early pregnancy, and the decidua is one of the maternal components of the mature mouse 
placenta. The spiral arteries are the other main maternal component of the placenta. The 
spiral arteries are lined by endothelial cells and converge into the maternal canals. The 
maternal canals are lined by canal TGCs. Exchange of nutrient, gas, and waste products 
between the fetus and the mother occurs in the maternal sinusoids in the labyrinth, which are 
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lined by sinusoidal TGCs (Rennie et al. 2014). During SAR, the invading trophoblast cells 
induce apoptosis of the endothelial cells, and ultimately replace them in the spiral arteries 
(Ashton et al. 2005). Spiral arteries remodel between E6.5-E7.5 and undergo outward 
hypertrophic SAR, when their lumen widens, and their muscular wall thickens between E7.5 
and E10.5. During E8.5-E9.5, they undergo outward hypotrophic SAR when their lumen 
widens, but the muscular wall gets thinner (Charalambous, Elia & Georgiades 2012; Osol & 
Mandala 2009). This remodelling of the spiral arteries leads to the formation of dilated, 
inelastic tubes with decreased vascular resistance, that lack maternal vasomotor control. SAR 
is essential for establishing normal maternal blood flow and therefore normal embryo growth. 
Interactions between the maternal and fetal components of the placenta are essential for 
normal placentation. For example, trophoblast invasion is a prominent feature of placenta 
development (Anin, Vince & Quenby 2004) and occurs in two waves. The first wave of 
invasion is endovascular and perivascular and occurs during implantation and early 
placentation. The trophoblast cells penetrate the mesometrium and replace the vascular 
endothelial cells in the spiral arteries, a process known as SAR. Vascular remodelling 
precedes trophoblast invasion, and SAR is reduced in the absence of trophoblasts (Whitley & 
Cartwright 2010). These trophoblast cells express TGC markers, such as Plf1. The second 
wave of invasion, the interstitial invasion, occurs after E13.5. Tpbpa+ glycogen trophoblast 
cells invade the decidua basalis (Adamson et al. 2002; Cross et al. 2002; Silva & Serakides 
2016). Successful trophoblast invasion requires degradation of the extracellular matrix and 
expression of adhesion molecules by the trophoblasts. The trophoblast secretes proteases that 
break down the decidual tissue to make space for the developing embryo (Aplin 2000). 
Metalloproteinases MMP2, MMP9, and MMP14 are highly expressed by the trophoblast cells 
at the fetal-maternal interface and are involved in the degradation of extracellular matrix 
(Lala & Graham 1990). Degradation of the extracellular matrix is required for successful 
trophoblast invasion into the decidua (Favaro, Abrahamsohn & Zorn 2014). However, 
expression of metalloproteinases ceases in the decidua. Instead, tissue inhibitor 
metalloproteinase (TIMP) 3 is expressed by decidual cells to prevent excessive extracellular 
matrix degradation and excessive trophoblast invasion (Moore & Crocker 2012). Alterations 
in decidual extracellular matrix remodelling have been associated with impaired 
decidualisation (White, Robb & Salamonsen 2004). Extensive or inadequate trophoblast 
invasion leads to maladaptation of uteroplacental arteries and ultimately altered 
uteroplacental blood flow, which is associated with FGR. Lactogen is also secreted by the 
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trophoblast and found in the maternal circulation (Aplin 2000). Altogether, these studies 
show the importance of the interactions between the maternal and fetal components of the 
placenta for normal placentation. 
 
1.3.4 Poor placenta development and function can lead to FGR 
The main function of the placenta is the exchange of nutrients, gases, and waste products 
between the maternal and fetal circulations (Watson & Cross 2005). Abnormal development 
and function of the placental labyrinth, such as abnormal development of the blood vessels 
necessary for this exchange, or abnormal transport across the maternal-fetal interface, can 
limit the nutrients that are being delivered to the developing fetus, leading to FGR (Scifres & 
Nelson 2009). In addition, the adaptive changes of the spiral arteries that happen during 
pregnancy ensure adequate blood supply to the developing fetus. Ablation of Tpbpa-positive 
cells, which would normally differentiate into the invasive trophoblast, impairs trophoblast 
invasion of the spiral arteries, leading to defective SAR (Hu & Cross 2011). Defective 
remodelling of the spiral arteries results in decreased uteroplacental blood flow, increased 
vascular resistance, and a subsequent decrease of blood flow to the placenta, causing 
impaired nutrient and oxygen transport to the embryo, which prevents aerobic fetal growth 
(Krishna & Bhalerao 2011; Swanson & David 2015). These features are often indicators of 
pre-eclampsia (Granger et al. 2002). Doppler ultrasound is a non-invasive method used to 
assess blood flow in uteroplacental circulation (Campbell et al. 1983), by measuring the 
resistance index and pulsatility index of the uterine arteries as indicators of impedance. High 
resistance and pulsatility indices are associated with FGR (Dugoff et al. 2005; van den Elzen 
et al. 1995; Harrington et al. 1997; Khanduri et al. 2017; Martin et al. 2001). 
Junctional zone defects that affect vascularisation can also cause FGR. For instance, a 
hypomorphic mutation of Ascl2 or a targeted ablation of Hrta1 lead to a smaller junctional 
zone with fewer spongiotrophoblast and glycogen cells, and FGR at E15.5 and E14.5, 
respectively (Hasan et al. 2015; Oh-McGinnis, Bogutz & Lefebvre 2011). Overexpression of 
Ascl2 also leads to a smaller junctional zone with reduced spongiotrophoblast numbers, but 
with more glycogen cells that mislocalise in the labyrinth (Tunster et al. 2016). Targeted 
ablation of Esx1 in embryonic stem cells leads to enlarged junctional zone with excessive 
numbers of glycogen cells and mislocalisation of spongiotrophoblast cells in the labyrinth. In 
addition, abnormal branching of the fetal blood vessels in the labyrinth was observed. These 
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placental defects were associated with FGR between E16.5 and E18.5 (Li & Behringer 1998). 
Phlda2 overexpression or targeted ablation led to smaller junctional zone with fewer 
glycogen cells, or enlarged junctional zone with increased glycogen cell numbers, 
respectively. Both overexpression and targeted ablation of Phlda2 led to FGR at E16.5 and 
E18.5, respectively (Tunster, Creeth & John 2016; Tunster, Tycko & John 2010). Altogether, 
these studies show that abnormalities in the development and function of the junctional zone 
can cause FGR. 
Labyrinth defects can also cause FGR. Deletion of a labyrinthine trophoblast-specific 
transcript of Igf2 (P0) led to placental growth restriction by E11.5. Mutant fetuses exhibited 
growth restriction after E15.5 and had decreased birth weight. This was a result of decreased 
passive permeability of the placenta, with a compensatory increase of active amino acid 
transport at the initial stages of pregnancy. During late pregnancy, compensation fails 
resulting in FGR (Constância et al. 2002; Sibley et al. 2004). Additionally, Pkba-/- mice 
exhibit FGR at E14.5 and have hypotrophic placentas with decreased vascular branching and 
decreased labyrinth area covered by blood vessels (Yang et al. 2003). Egfl7-/- conceptuses 
have reduced placental weights and develop fetal growth restriction, as a result of reduced 
fetal blood space in the labyrinth and reduced chorioallantoic branching morphogenesis. 
Genes involved in branching morphogenesis such as Gcm1, Syna, and Synb were also 
downregulated in Egfl7-/- placentas in E8.5 and E9.5 (Lacko et al. 2017). Moreover, genetic 
ablation of Plk2 or Rgcc results in small labyrinth and defective angiogenesis, leading to FGR 
in E14.5-E18.5 or E16.5, respectively (Cui, Guo & Chen 2013; Ma, Charron & Erikson 
2003). Finally, ablation of Synb leads to abnormal vascularisation of the labyrinth, enlarged 
maternal blood spaces with extremely thin walls, and FGR at E18.5 (Dupressoir et al. 2011). 
Placental overexpression of genes can also impair labyrinth development. For instance, 
overexpression of Flt1 causes altered trophoblast differentiation, small labyrinth, and loss of 
glycogen cells. In addition, decreased expression of fatty acid and cholesterol transporters 
CD36 and ABCA1, respectively, was observed. As a result, fetal weight was reduced at 
E18.5 (Kuhnel et al. 2017). Embryos overexpressing Pgf in T cells exhibited reduced 
angiogenesis of the placenta, causing placenta detachment from the uterus and pregnancy 
loss. However, when this defect was not severe enough to lead to pregnancy loss, the 
newborn litters were growth restricted (Kang et al. 2014). Altogether, these studies show that 
misexpression of genes involved in the development of the different placental structures can 
lead to abnormal placental morphology and function, ultimately causing FGR. 
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Abnormal placental development leading to abnormal expression and distribution of 
transporters, and prevention of direct contact of maternal and fetal blood (Brett et al. 2014) 
causes abnormal placental transport function, inadequate nutrient delivery to the embryo, and 
ultimately it impairs embryo growth and development (Bell & Ehrhardt 2002; Brett et al. 
2014; Desoye, Gauster & Wadsack 2011; Winterhager & Gellhaus 2017). Placental growth 
factor (PlGF), VEGF receptor, and kinase insert domain receptor were reduced in placentas 
from pregnancies complicated with FGR, in contrast to normal, or preeclamptic pregnancies 
(Alahakoon et al. 2018). Reduced expression of these angiogenic factors, might be the cause 
of loss of vasculature and villous architecture in the human placentas (Alahakoon et al. 2018). 
Altogether, these studies show that FGR can be caused by abnormal placenta development 
leading to inadequate blood flow to the embryo, or inadequate nutrient transport through 
defective transport systems. 
 
1.4 Folate metabolism and reproductive health 
In the previous sections we discussed how the maternal and fetal components of the placenta 
can affect fetal growth. Next, in this thesis we will focus on folate metabolism and the effects 
of abnormal folate metabolism on embryo growth and development. 
Abnormal folate metabolism has been associated with a variety of diseases, including cancer, 
Down’s syndrome (Bagley & Selhub 1998; James et al. 1999; Wang et al. 2008), neural tube 
defects (NTD), vascular diseases (reviewed by (Nazki, Sameer & Ganaie 2014)), and 
depression (Miller 2008). A clinical indicator of folate deficiency in humans in 
hyperhomocysteinemia (Blom & Smulders 2011). Hyperhomocysteinemia is caused by a 
decreased rate of conversion of homocysteine into methionine (see Section 1.4.2) and is a risk 
factor for cardiovascular diseases (Verhaar, Stroes & Rabelink 2002). Folate deficiency 
impairs the immune function, as it leads to decreased T-cell proliferation, cell cycle arrest in 
the S phase due to nucleotide imbalance, apoptosis and misincorporation of uracil into DNA 
(Courtemanche et al. 2004). Culture of primary human CD8+ T-lymphocytes in media that 
contained folate, thymidine or a nucleoside mixture, led to restored nucleotide and cell 
imbalances (Courtemanche et al. 2004). Hypomethylated DNA isolated from livers of 
methyl-deficient rats was shown to be more sensitive to DNA double strand breaks, 
especially in the tumour suppressor p53 gene (Pogribny et al. 1995), possibly leading to 
cancer development. All these diseases are seemingly unrelated. The molecular mechanism 
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of folate metabolism is not well understood, which is particularly surprising, given that we 
have known the importance of folate metabolism in health for decades. 
 
1.4.1 Role of folate in uterine health and pregnancy in humans and mice  
Hyperhomocysteinemia is an indicator of folate deficiency in humans (Blom & Smulders 
2011). Ovarian follicular fluid levels reflect systemic homocysteine levels (Ebisch et al. 
2006). High follicular fluid homocysteine levels are associated with endometriosis and 
decreased embryo quality on day 3 in in vitro fertilisation (IVF) cycles (Ebisch et al. 2006). 
Low levels of homocysteine in the follicular fluid are associated with better oocyte quality, 
and folate supplementation increases the percentage of mature oocytes (Szymanski & 
Kazdepka-Zieminska 2003). Rhesus monkeys have been used as models to study the role of 
folate deficiency on the function of the reproductive system. Folate-restricted diet led to the 
presence of atretic and cystic ovarian follicles lacking granulosa cells in the ovaries. As a 
result, these monkeys had low pre-ovulatory E2, and low mid-luteal P4 levels and 
experienced irregular menstrual cycles (Mohanty & Das 1982). Therefore, folate is important 
for oocyte development and regular menstrual cycles, by maintaining normal hormone levels. 
However, little is known about the role of folate on the uterine structure and function in mice. 
Folate has also a role in embryo and placenta development. For instance, if 
hyperhomocysteinemia, which is a clinical indicator of folate deficiency, occurs in the third 
trimester of human pregnancy, it predicts low birth weight (Takimoto et al. 2007), increased 
risk of hypertensive illness, and premature delivery (Lindblad et al. 2005), while in the 
second trimester does not increase the risk of FGR (Hogg et al. 2000). In addition, abnormal 
maternal and fetal plasma folate, vitamin B12, and homocysteine concentrations increase the 
risk of placenta abruption (Ray & Laskin 1999) and are associated with decreased placenta 
weight and birth weight, and increased risk of adverse pregnancy outcomes, such as pre-
eclampsia, small for gestational age babies (Bergen et al. 2012), and FGR (Jiang, Cao & 
Chen 2016; Lindblad et al. 2005; Muthayya et al. 2006; Sram et al. 2005). Placenta 
dysfunction, such as increased trophoblast proliferation and apoptosis, abnormal placental 
hormone levels, and reduced amino acid transport, has also been associated with abnormal 
microRNA expression in pregnant women with low folate status (Baker et al. 2017). Target 
genes of the misexpressed microRNAs include Myc, Vegfa, Cdkn1c, and Tp53, all of which 
have altered expression in pregnancies complicated with FGR (Heazell et al. 2011; 
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Novakovic et al. 2006; Rajaraman et al. 2010; Roh et al. 2005; Whitehead et al. 2013). 
Altogether, these studies show that abnormal levels of folate and homocysteine affect 
placenta development and function, and ultimately lead to impaired embryo growth. 
However, the molecular mechanism by which folate is important for embryo development, is 
not well understood. 
Additionally, nutritional folate deficiency inhibits placental mammalian target of 
rapamycin (mTOR) signalling pathway. mTOR is a serine/threonine kinase. It is activated by 
oxygen, ATP, glucose, amino acids, insulin, and growth factor signalling, and regulates 
protein translation (Bar-Peled & Sabatini 2014; Chen et al. 2011; Ito, Ruegg & Takeda 2018; 
Miniaci et al. 2015). Therefore, it controls cell growth and proliferation (Mori et al. 2014). 
mTOR also regulates placental amino acid transport activity (Roos et al. 2009). Folate 
deficiency in primary human trophoblast cells inhibits mTOR signalling, suggesting a link 
between folate levels and placental nutrient transport with potential consequence in fetal 
growth in humans (Rosario, Powell & Jansson 2017). Finally, maternal exposure to folic acid 
antagonists, such as drugs used to treat epilepsy and mood disorders (Lambie & Johnson 
1985), increased the risk of pre-eclampsia, placenta abruption, fetal growth restriction, and 
fetal death (Wen, Zhou, et al. 2008). Folic acid antagonists bind to the folic acid receptors 
and prevent their activation by folate. These studies show how molecular pathways 
downstream of folate are disrupted by folate deficiency or exposure to folic acid antagonists, 
and ultimately affect pregnancy. 
To better understand the effects of nutritional folate deficiency in humans, mouse models of 
folate deficiency are used. For instance, folate deficiency inhibits mTOR signalling not only 
in primary human trophoblast cells (Rosario, Powell & Jansson 2017), but also in mice, 
leading to decreased trophoblast plasma membrane amino acid transporter activity and 
growth restriction (Rosario et al. 2017). Additionally, mice fed a folate-deficient diet had 
poor reproductive outcomes when mated with control males. Specifically, increased 
resorption rates at GD12.5-15.5 and GD14.5 and decreased fetal weights and developmental 
delay at GD17.5 were observed (Burgoon et al. 2002). Folate-deficiency also caused reduced 
number of implantation sites and hypermethylation of decidualisation-specific genes Nrlh3 
and Nr5al (Geng et al. 2015), and abnormal decidual angiogenesis (Li et al. 2015). The latter 
causes uteroplacental insufficiency, leading to abnormal fetal growth (Krishna & Bhalerao 
2011; Swanson & David 2015). Altogether, these studies show that folate deficiency in mice 
affects implantation and decidualisation and leads to FGR. 
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1.4.2 Bioavailability and metabolism of folate 
Folate is a member of the vitamin B family (Mahmood 2014). In contrast to plants, mammals 
cannot synthesise folate de novo (Basset et al. 2002). An excellent source of naturally-
occurring folate are green leafy vegetables, beans, and dark green vegetables such as broccoli 
(Chan, Bailey & O’Connor 2013). During pregnancy, folate is transported from the mother to 
the fetus through the folate receptors on the placenta. Folate is absorbed in the small intestine 
(Milman 2012) and is biochemically inactive. It exists either as a monoglutamate, or as a 
polyglutamate, which hydrolyses into monoglutamate in the intestinal mucosa prior to 
transport. It is hydrophilic, and enters the cells either via folate-carriers, or receptors. Folate 
carriers include reduced folate carrier 1 (RFC1), also known as SLC19A1, and the proton-
coupled folate receptors (PCFT), also known as SLC46A1. Alternatively, folate enters the 
cells via endocytosis, via folate receptors expressed by the apical membrane of the small 
intestine, such as folate receptors (FOLR), also known as folate binding protein (Zhao, 
Matherly & Goldman 2009). Once absorbed, folate is delivered to the liver, where it is stored. 
Folate is also stored in red blood cells and kidney cells. Folate  is reduced to its main 
circulating form, 5-methyltetrahydrofolate (Smulders et al. 2006; Visentin et al. 2014), 
through biochemical reactions (Figure 1.5). 
Folate metabolism is important for DNA synthesis, amino acid synthesis, and the release of 
methyl groups for cellular methylation (Locasale 2013). Folate is converted into 
dihydrofolate, which is then converted into tetrahydrofolate (THF) by dihydrofolate reductase 
(DHFR). THF is then reversibly converted to 5,10-methylene THF by MTHFD. Mthfd codes 
for a protein with three enzymatic activities: methylenetetrahydrofolate 
dehydrogenase, methenyltetrahydrofolate cyclohydrolase and formate–tetrahydrofolate ligase 
(Neagos et al. 2010). This protein converts 5,10-methylene-THF into THF, creating two 
intermediate products: 5,10-methenyl-THF and 10-formyl-THF (Neagos et al. 2010). Next, 
5,10-methylene THF is irreversibly converted into 5-methyl-THF, which is the main form of 
circulating folate, by methylene tetrahydrofolate reductase (MTHFR; Figure 1.5; Ghandour et 
al. 2004; Hart et al. 2002). Methionine synthase reductase (MTRR) is a key enzyme for the 
progression of folate or methionine cycles, as it is essential for the activation of methionine 
synthase (MS) through the reductive methylation of its vitamin B12 cofactor (Kazuhiro 
Yamada et al. 2006) and links the folate and methionine metabolisms (Mahmood 2014; 
Shane & Stokstad 1985). 5-methyl-THF acts as a methyl donor for homocysteine 
methylation, a reaction that is catalysed by MS. Transfer of a methyl group from 5-methyl-
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THF to homocysteine leads to formation of methionine and THF. Methionine is then 
converted to S-adenosylmethionine (S-AdoMet), by methionine adenosyltransferase. S-
AdoMet is an important methyl donor for methylation of DNA, RNA, histones and other 
cellular components (Ghandour et al. 2002; Jacob et al. 1998; Locasale 2013). 
Methyltransferases transfer methyl groups from S-AdoMet to cellular substrates, producing 
S-adenosyl-homocysteine (AdoHcy), which is then converted into homocysteine by S-
adenosyl-homocysteine hydrolase. Abnormal folate metabolism or folate deficiency are 
usually associated with hyperhomocysteinemia due to the decreased rate of conversion of 
homocysteine into methionine, decreased availability of methyl groups for cellular 
methylation due to decreased S-AdoMet levels, and a methyl-trap due to the decreased rate of 
methyl group donation from 5-methyl-THF to homocysteine (Bailey et al. 2015; Blom & 
Smulders 2011; Cuskelly et al. 2001; Padmanabhan et al. 2013). 
 
Figure 1.5 Folate and methionine metabolism. 
The folate metabolism is required for release of methyl groups for cellular methylation, for 
the production of dTMP, essential for DNA synthesis, and for amino acid synthesis. dTMP: 
deoxythymidine monophosphate, dUMP: deoxyuridine monophosphate, DHF: dihydrofolate, 
THF: tetrahydrofolate, MTHFR: methylenetetrahydrofolate reductase, MTRR: methionine 





1.4.3 The molecular function of folate 
Folate metabolism is required for DNA replication, amino acid synthesis, and the release of 
methyl groups necessary for cellular methylation (Figure 1.5). Folate metabolism leads to 
production of dTMP, and therefore is required for DNA synthesis. Abnormal folate 
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metabolism prevents the formation of dTMP from dUMP. Decreased levels of dTMP cause 
misincorporation of dUMP, as an alternative to dTMP in the DNA. DNA that contains dUMP 
is prone to mutations. dUMP misincorporation activates the DNA repair mechanisms, causes 
DNA breaks, and decreases DNA stability (Blount et al. 1997; Reidy 1988; Wickramasinghe 
& Fida 1993). Genetic instability and accumulation of mutations trigger the cell-cycle 
checkpoints resulting in proliferation arrest, or cell death. However, if the checkpoints are 
defective due to mutations, uncontrolled cell proliferation occurs (Khanna & Jackson 2001), 
ultimately leading to cancer (Duthie & Hawdon 1998; Melnyk et al. 1999). Additionally, 
DNA is synthesised de novo during the S-phase of the cell cycle. Nucleotide demand for 
DNA synthesis is therefore increased during cell proliferation. As a result, abnormal DNA 
synthesis can affect cell proliferation (Crider et al. 2012). Abnormal cell proliferation might 
lead to cancer, or abnormal cell differentiation, leading to impaired organ development and 
function (Copp, Brook & Roberts 1988). Increased cell proliferation that requires extensive 
DNA replication occurs during embryo development, therefore the developing embryos are 
particularly sensitive to folate levels. 
Folate metabolism is also important for the synthesis of amino acids methionine, 
homocysteine, and cysteine. Methionine is an essential amino acid and therefore should be 
obtained from diet, although it is synthesised in the one-carbon cycle. On the other hand, 
homocysteine and cysteine are non-essential amino acids. Homocysteine derives from the 
metabolism of dietary methionine. Cystathionine-β-synthase catalyses the condensation of 
homocysteine and serine to form cystathionine. Then, cystathionine-γ-lyase is required for 
the hydrolysis of cystathionine to form cysteine, α-ketobutyrate, and ammonia. 
Additionally, folate metabolism results in the production of S-AdoMet, which acts as a 
methyl donor necessary for cellular methylation. Disruption of the folate cycle can result in 
decreased availability of methyl groups and therefore disruption of cellular methylation. 
Abnormal methylation of DNA and histones affects gene expression, a process known as 
epigenetic regulation (Jones & Takai 2001). Folate deficiency or abnormal folate metabolism 
causes global DNA hypomethylation (Davis & Uthus 2003; James et al. 2003; Piyathilake et 
al. 2000; Smith et al. 1995; Wang et al. 2012; Wasson et al. 2006), but also locus-specific 
dysregulation of DNA methylation, including DNA hypermethylation and hypomethylation 
(Charles, Johnson & Belshaw 2012; Jhaveri, Wagner & Trepel 2001; Padmanabhan et al. 
2013). For instance, periconceptional folate dietary restriction in sheep caused locus-specific 
DNA hypomethylation and hypermethylation in the offspring (Sinclair et al. 2007). 
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Abnormal folate metabolism due to a gene-trap mutation in the Mtrr gene (Mtrrgt) caused 
global DNA hypomethylation in livers of adult Mtrrgt/gt mice compared to C57Bl/6 controls 
(Padmanabhan et al. 2013). Global DNA hypomethylation and locus-specific dysregulation 
of DNA methylation associated with changes in gene expression were also observed in E10.5 
placentas but not embryos of phenotypically normal and growth restricted Mtrrgt/gt 
conceptuses (Padmanabhan et al. 2013). Folate deficiency is also associated with histone 
methylation. Histone demethylase LSD1 is a folate-binding protein (Luka et al. 2011). 
Histone modifications were measured by mass spectrometry in livers of mice fed a folate 
deficient diet. Increased levels of methylated lysine 4 of histone 3 were observed in folate 
deficient mice. It is speculated that increased histone methylation is due to decreased LSD1 
activity, as a result of folate deficiency (Garcia et al. 2016). Folate metabolism has therefore a 
role on DNA and histone methylation. Embryo development is regulated by epigenetic 
mechanisms (Gabory, Attig & Junien 2011; Gicquel, El-Osta & Le Bouc 2008; Shi & Wu 
2009) and epigenetic reprogramming (Hajkova 2011) occurs during embryo development. As 
a result, embryo development is particularly sensitive to changes in folate availability. 
Altogether, the folate cycle is important for synthesis of amino acids, synthesis of dTMP 
important for DNA replication, and release of methyl groups, important for methylation of 
cellular substances.  
The mechanisms by which folate affects specifically placental development and function 
remain unknown. Possible mechanisms include epigenetic regulation of placental 
development, regulation of trophoblast invasion, placental vascularisation, or placental 
transport activity. Placental development is regulated by epigenetic modifications (Fowden et 
al. 2011; Tunster, Jensen & John 2013). For instance, mice lacking the maternally expressed 
Phlda2 gene have placental overgrowth characterised by expansion of the spongiotrophoblast 
(Frank et al. 2002). Additionally, a two-fold increase in the expression of the imprinted 
Phlda2 gene decreases the junctional zone area and increases the glycogen stores. This is 
accompanied by FGR at E16.5 (Tunster, Tycko & John 2010). It is possible that the 
decreased availability of methyl groups caused by abnormal folate metabolism or folate 
deficiency, alter the methylation and expression of the imprinted genes in the placenta. 
Imprinted genes have a role in placenta development (Fowden et al. 2006; Fowden et al. 
2011), therefore their misexpression can impair placentation. Folate regulates trophoblast 
invasion and placental development in humans. Culture of placental explants in folate media 
increased extravillous trophoblast invasion, leading to increased secretion of MMP2, MMP3, 
40 
 
and MMP9 in a folate concentration-dependent manner (Williams et al. 2011). These 
metalloproteinases are required to remodel the extracellular matrix during trophoblast 
invasion (Cohen, Meisser & Bischof 2006). Balanced cell proliferation and apoptosis is 
essential for trophoblast invasion and normal placentation (Naicker et al. 2013) and folic acid 
affects these processes in vitro in a concentration-dependent manner (Williams et al. 2011). 
Culture of cytotrophoblast cells in folate-free medium increased cell apoptosis (Steegers-
Theunissen et al. 2000) and decreased placental system A amino acid transport function, by 
possibly regulating post-translational modifications of nutrient transporters (Baker 2015). 
Folic acid also increased the placental vascular density in vitro (Williams et al. 2011). Folate 
deficiency led to decreased cell viability and impaired invasion of the HT8-8/SVneo human 
extravillous trophoblast cell line, while folate supplementation increased its proliferation. 
Folate supplementation also reduced cellular viability of the villous trophoblast BeWo cell 
line (Ahmed et al. 2016). Altogether, these studies show that abnormal folate metabolism or 
folate deficiency affect trophoblast function, while folate supplementation rescues some of 
the effects. 
Folate deficiency also affects the decidualisation reaction, therefore impairing embryonic 
development. The mechanism by which folate affects the decidualisation reaction and 
therefore embryo development is still not well understood, however it is suggested that 
dysregulation of DNA methylation and associated changes in gene expression may play a 
role. The effects of folate deficiency and DNA methyltransferases (Dnmt) deficiencies on 
development are similar. DNMTs methylate cytosine to form 5-metylcytosine. DNMT1 is the 
maintenance DNA methyltransferase that adds methyl groups in CpG sites during mitosis 
(Estève et al. 2006). Dnmt1 knockout causes abnormal embryonic development and 
embryonic lethality in mice, therefore Dnmt1 is essential for viability (Li, Bestor & Jaenisch 
1992). Dnmt1p and Dnmt1o are sex-specific isoforms of Dnmt1, expressed in male germ cells 
and oocytes, respectively. Loss of Dnmt1o leads to abnormal imprinting during early 
development, and embryonic lethality in mice (Howell et al. 2001). Dnmt2 is required for the 
methylation of transfer RNA molecules (Goll et al. 2006). De novo methylation is catalysed 
by DNMT3a and DNMT3b, and their cofactor DNMT3L. Dnmt3a-/- causes postnatal lethality 
associated with growth restriction in mice. Dnmt3b-/- mouse embryos suffer from more severe 
FGR and also neural tube defects (NTD), therefore die in utero (Okano e al. 1999). Maternal 
Dnmt3l deficiency also causes NTD (Hata et al. 2002). Its loss also causes abnormal placenta 
development, such as failure of chorioallantoic attachment, absent labyrinth, and decreased 
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spongiotrophoblast layer. These abnormalities result from abnormal establishment of 
maternal imprints in the placenta (Arima et al. 2006). Altogether, these data highlight the 
similar effects of folate deficiency and DNMT deficiencies on embryonic development, 
suggesting that dysregulation of DNA methylation and the associated changes in gene 
expression can be a mechanism by which folate deficiency affects embryo development. 
DNMT1 and DNMT3A regulate DNA methylation in the mouse uterus. At GD3.5, DNMT1 
is expressed by the luminal and glandular epithelial and stromal cells. DNMT3A shows 
similar, but weaker and sporadic expression. At GD6.5, DNMT1 is expressed by the 
mesometrial and antimesometrial decidua (Gao et al. 2012), and as before, DNMT3A shows 
similar, but weaker expression. In the uterus between the implantation sites at GD6.5, 
DNMT1 expression is limited in the luminal and glandular epithelium and stroma cells (Gao 
et al. 2012). Intraperitoneal injections of 5-aza-dC to inhibit DNA methylation were 
performed either at pre-implantation (days 3 and 4), post-implantation (days 5-7), or peri-
implantation (days 3-7) period. Injections during the pre-implantation period did not affect 
the number of implantation sites, but reduced stromal cell proliferation at GD3.5 and GD4.5, 
without affecting Esr1 or Pgr mRNA expression, compared to the controls. This suggests that 
embryo implantation is not affected by inhibition of DNA methylation. However, post-
implantation and peri-implantation inhibition of DNA methylation caused a reduction in 
implantation site weight at GD7.5, without affecting the number of implantation sites. 
Defective decidualisation, abnormal expression of stromal cell differentiation and endothelial 
cell proliferation markers, and an increase in the number of degenerated embryos were also 
observed, the latter suggesting inhibition of uterine DNA methylation leads to pregnancy 
loss. Inhibition of DNA methylation also affected deciduoma development and aberrant gene 
methylation (Gao et al. 2012). DNA methylation is therefore essential for the decidualisation 
process and possibly embryo development. 
Hyperhomocysteinemia is a clinical indicator of folate deficiency in humans and is thought to 
be responsible for many folate deficiency-related disorders. For instance, low plasma folate 
and hyperhomocysteinemia increase the risk of coronary artery diseases, such as stable and 
unstable angina pectoris, and myocardial infarction (Ma et al. 2017) and other vascular 
diseases (Blom & Smulders 2011; Boushey et al. 1995; Graham et al. 1997; Lanska 2010; Li 
et al. 2016; McNulty et al. 2008; Ward 2001). Low methionine levels caused by folate 
deficiency cause fat accumulation in the liver, leading to impaired liver function (da Silva et 
al. 2014), impaired creatinine production in piglets (Robinson et al. 2016), and impaired 
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collagen formation important for skin and connective tissue formation in mice (Ables et al. 
2012). Hyperhomocysteinemia is toxic for the cells and has been associated with 
neurodegeneration (Currò et al. 2014). Folate food fortification programmes in the USA and 
folic supplementation decreases the risk of cardiovascular diseases and stroke (Antoniades et 
al. 2009; Li et al. 2016). Altogether, these studies highlight the consequences of folate 
deficiency-associated hyperhomocysteinemia on vascular health. 
 
1.4.4 Folate transport and metabolism-related mutations in mice and humans that 
affect development and uterine health 
The effects of folate in mouse and human health can be studied though mutations of genes 
that disrupt folate metabolism. Mutations in human genes have been associated with adverse 
developmental outcomes. Studies have shown that mutations of genes involved in folate 
transport and metabolism, such as RFC1, MTHFD1, MTHFR, and MTRR are linked to NTD 
in humans (Brody et al. 2002; Jiang et al. 2014; De Marco et al. 2006; Relton et al. 2004; 
Relton et al. 2004). Abnormal folate metabolism in humans caused by mutations in genes 
involved in folate metabolism such as MS, TS, and MTHFD1 is associated with recurrent 
pregnancy loss (Kim et al. 2013; Parle-McDermott et al. 2005). In addition, a mutation in the 
maternal or fetal MTR gene (A2756G) was associated with uteroplacental insufficiency, 
which was defined as preeclampsia, intrauterine growth restriction, placenta abruption, and 
gestational hypertension. Folate supplementation rescued the effects only of maternal MTR 
deficiency (Furness et al. 2008). Maternal MTHFD1 polymorphism (G1958A) was associated 
with FGR (Furness et al. 2008).  
However, the studies of the effects of folate metabolism in humans are limited, since we 
cannot manipulate the human genome. Therefore, the mouse is used as a model to assess the 
effects of abnormal folate metabolism on embryo development. Homozygous mutation of the 
folate carrier Rfc1 is embryonic lethal. Maternal folic acid supplementation during pregnancy 
prolongs the survival of the Rfc1-/- embryos until midgestation or E18.5, in a dose-dependent 
manner. However, Rfc1-/- embryos that survive until midgestation are developmentally 
delayed, and exhibit failed chorioallantoic attachment and congenital malformations 
compared to their Rfc1+/+ littermates. Rfc1-/- embryos that survive until E18.5 have congenital 
malformations (Waes et al. 2008). Folbp1-/- embryos derived from Folbp1+/- intercrosses 
exhibit developmental delay at E8.5 and E9.5, with decreased somite numbers, and have an 
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open neural tube at E9.5. They eventually die in utero before neural tube closure (Piedrahita 
et al. 1999). Mouse models used to study the role of folate in development and uterine and 
placental function showed that folate plays an important role in placentation (Ahmed et al. 
2016; Pickell et al. 2009; Steegers-Theunissen et al. 2000; Williams et al. 2011). For 
example, loss of RFC1 in mice leads to placental defects, such as failure of chorioallantoic 
fusion (Waes et al. 2008). Moreover, Mthfr+/+ and Mthfr+/- females were fed either a control, 
or a folate-deficient diet and mated with Mthfr+/- males (Pickell et al. 2009). At E10.5, 
embryonic lethality was increased in the folate-deficient mice compared to those fed a normal 
diet in both genotypic groups, while developmental delay, decreased embryonic weight, and 
decreased embryonic crown-rump length were caused by either maternal Mthfr or folate 
deficiencies (Pickell et al. 2009). Dietary folate deficiency alone caused decreased placenta 
weight, decreased total placental area, and decreased trophoblast invasion. Also, small and 
disorganised placental layers with fewer primary giant cells, and fewer spongiotrophoblast 
cells between the giant cell layer and the labyrinth were observed by cell-marker staining, 
and compacted labyrinth layer (Pickell et al. 2009). However, this study is flawed, since they 
used Mthfr+/- males, instead of control males, and therefore the results could be due to a 
paternal effect. In addition, targeted disruption of Ms in mice causes hyperhomocysteinemia 
and fetal lethality (Swanson, Liu & Baker 2001), while a gene-trap mutation in the Mtrr gene 
causes increased resorption, growth restriction, developmental delay, congenital heart 
defects, and cardiovascular malfunction in the progeny (Deng et al. 2008). Altogether, these 
studies show that mutations in genes involved in folate transport and metabolism cause 
developmental phenotypes in mice. 
 
1.4.5 Folate supplementation, uterine health, and pregnancy in humans and mice 
Folate is a water-soluble, naturally-occurring vitamin, while folic acid is the synthetic form 
used for dietary supplementation (Elkin & Higham 2000). In 1991, the Centers for Disease 
Control and Prevention (CDC) highlighted the importance of folate in pregnancy, by 
recommending folic acid supplementation, typically 4000μg/day (CDC 1991) for women 
whose previous pregnancies were affected by NTD. NTD is a group of congenital 
malformations caused by abnormal formation of neural tube (Detrait et al. 2005). It was 
suggested that women should take supplements during the periconceptual period and in early 
pregnancy. In 1992, U.S Public Health Service recommended folic acid supplementation of 
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400μg/day to all women who are at an age of having children (MMWR 1992). These 
recommendations were reinforced by the Institute of Medicine recommendations in 1998 
(IoM 1998) and the U.S. Preventive Services Task Force in 2009 (Task 2009). Folic acid 
supplementation can be achieved by either taking vitamin supplements, or by consuming 
products made with folic acid-fortified flour. The initial recommendation was based on 
evidence that folate supplementation can prevent NTD (Czeizel & Dudas 1992; MRC 1991). 
Folic acid supplementation improves uterine health. Periconceptional folic acid 
supplementation increases folate and decreases homocysteine levels in the ovarian follicular 
fluid, with the latter having a correlation with the follicle diameter. Follicle diameter is an 
indicator of oocyte maturation (Boxmeer et al. 2008). Dietary folate supplementation 
improved human reproductive health by increasing P4 levels during the luteal phase of the 
menstrual cycle in premenopausal women and decreasing anovulation rates (Gaskins et al. 
2012). 
Folic acid supplementation and addition of folic acid in flour, a process known as folic acid 
fortification, does not prevent only NTD (Bailey, Rampersaud & Kauwell 2003; Morris et al. 
2016; MRC 1991). In the early 1900s, it was found that folic acid supplementation cures 
megaloblastic anaemia in pregnant women (Hoffbrand 2001; Mitchell, Snell & Williams 
1941). It also decreased the risk of preeclampsia (Wen, Chen, et al. 2008), which is known to 
be associated with increased risk of FGR (Odegard et al. 2000). Folic acid and vitamin B6 
supplementation of women with hyperhomocysteinemia and a history of pregnancy 
complicated with FGR led to normal homocysteine levels, while it decreased the risk of FGR 
in future pregnancies (Leeda et al. 1998). 
The benefits of folic acid supplementation on embryo development have also been studied in 
rodents. Administration of 25mg/kg/day or 50mg/kg/day of folic acid in Rfc1+/- female mice 
prolonged the survival of Rfc1-/- embryos, which otherwise would die early post-implantation, 
until E9.5 or E18.5, respectively (Waes et al. 2008). Folic acid supplementation in rats during 
pregnancy prevented the protein restriction diet-associated elevated systolic blood pressure 
and reduced endothelial nitric oxide synthase mRNA levels in offspring (Torrens et al. 2006). 





1.4.6 What is missing from the field? 
Folate deficiency and abnormal folate metabolism have important implications on embryo 
growth and development. Therefore, normal folate levels and metabolism are essential for a 
successful and healthy pregnancy. However, little is known about the effects of folate 
deficiency or abnormal folate deficiency on the uterine structure and function during the 
receptive estrus stage, and therefore further studies are required to address this. 
 
1.5 Multigenerational effects of folate metabolism on development 
In the previous section we discussed the role of folate in uterine health. Previously, we also 
talked about the endometrial causes of FGR, as well as how poor placental development and 
function can cause FGR. In this section, we will discuss the effects of an abnormal uterine 
environment caused by abnormal folate metabolism on embryo growth and development. 
 
1.5.1 Maternal effects of folate metabolism on development 
Folate deficiency or abnormal folate metabolism in the mother can affect embryo 
development. Studies have shown an effect of folate deficiency on the peri-implantation 
uterine structure and function, as well as on the decidualisation reaction in mice, although the 
mechanism by which folate affects uterine function and therefore embryo development is not 
well understood. For instance, implantation sites at E4.5 derived from folate-deficient female 
mice showed decreased methylation and downregulation of estrogen receptor (Esr1) 
expression (Gao et al. 2012b). As the receptor of the ovarian hormone estrogen, Esr1 plays a 
role in the progression of the estrous cycle and endometrium proliferation (Wood et al. 2007). 
Misexpression of Esr1, can therefore impair embryo implantation. In contrast to the 
methylation levels of Esr1, the methylation status of Pgr and E-cadherin (Cdh1) was not 
affected by folate deficiency in the mother. As the receptor of the ovarian hormone P4, Pgr is 
essential for the maintenance of pregnancy (Wetendorf et al. 2017).  Cdh1 is essential for 
endometrial differentiation and gland development (Reardon et al. 2012). Therefore, since 
folate deficiency does not affect Pgr and Cdh1 methylation and embryo implantation occurs 
normally in mice, the folate deficiency-induced abnormalities in embryo growth and 
development are possibly due to events taking place after implantation (Gao et al. 2012b). 
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Maternal folate deficiency also impairs decidualisation. When decidualisation was artificially 
induced by intraluminal infusion of sesame oil, the deciduoma (tissue after induced 
decidualisation) in the folate-deficient mice was inelastic and softer compared to the control, 
as determined by assessment of the uterine gross anatomy, and expressed decreased levels of 
the decidualisation marker Bmp2. Folate deficiency also restrained decidualisation of 
endometrial stem cells in vitro (Geng et al. 2015). Finally, folate deficiency alters the DNA 
methylation patterns of genes related to decidualisation. For instance, higher CpG 
methylation levels were identified in the promoter region and the CpG islands in the decidual 
tissues of folate-deficient females compared to controls. Increased methylation levels were 
associated with downregulation of expression of decidualisation-related genes, such as 
Nr5a1, and Nr1h3. Folate deficiency therefore alters decidualisation in the pregnant folate-
deficient females (Geng et al. 2015). 
Folate is important for decidual angiogenesis, a process necessary to support embryo 
development (Winterhager et al. 2013). Folate deficiency in female mice mated with control 
males lead to restrained decidual angiogenesis, accompanied by abnormal vascular density 
and enlarged and elongated vascular sinus in implantation sites at E5.5, E6.5, and E7.5 (Li et 
al. 2015). Implantation sites also showed decreases in Vegfa, Vegfr2, Plgf, Pgr, and Esr1 
mRNA and protein expression. Pregnant females also had reduced serum P4, E2, LH, and 
prolactin (Li et al. 2015). Possible mechanisms for impaired angiogenesis could include the 
vasculotoxic effects of folate deficiency-induced hyperhomocysteinemia, and the hormonal 
imbalance, although further studies are required to solve this. 
Folate deficiency impairs the decidual regression process. Implantation sites from folate-
deficient mice at E6.5 and E7.5 have decreased Bax/Bcl2 mRNA and protein ratios. These 
genes are important to initiate the apoptotic process in the decidualised mesometrium (Dai, 
Moulton & Ogle 2000). In addition, folate-deficient mice do not exhibit a change in 
mitochondrial transmembrane potential, which is observed in control mice, suggesting that 
the decidual cell apoptosis is inhibited via the mitochondrial apoptosis pathway in folate-
deficient mice (Liao et al. 2015). 
Although not directly assessed, it is hypothesised that MTHFR mutation in combination with 
low folate intake can lead to hyperhomocysteinemia-associated decidual vasculopathy in 
humans (Kramer et al. 2001). Decidual vasculopathy is an incomplete or abnormal 
remodelling of the spiral arteries, leading in tissue necrosis (Stevens et al. 2012). It can cause 
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pre-eclampsia, FGR, or preterm birth (Kramer et al. 2001; Stevens et al. 2012). However, 
more studies in humans are required to assess the effects of folate deficiency and abnormal 
folate metabolism on the decidual reaction. Altogether, these studies highlight that folate 
deficiency impairs decidualisation, and might have a detrimental effect on embryo growth 
and development, although the exact mechanism remains unclear. 
 
1.5.2 Mtrrgt mouse model of abnormal folate metabolism 
To assess the effects of abnormal folate metabolism on embryo growth and development, the 
Mtrrgt mouse model was generated. The Mtrrgt mutation is hypomorphic, as Mtrr+/+ transcript 
and methionine synthase activity was found in liver, kidney, brain, and heart of Mtrrgt/gt mice 
tissues, although these levels were significantly decreased compared to Mtrr+/+ mice (Elmore 
et al. 2007). Complete loss of Mtrr activity causes embryonic lethality, however the 
hypomorphic Mtrrgt mutation leads to viable Mtrrgt/gt mice (Elmore et al. 2007). 
The Mtrrgt mutation leads to altered metabolic phenotype. Mtrrgt/gt mice had significantly 
higher plasma homocysteine levels compared to Mtrr+/gt and Mtrr+/+ mice (Elmore et al. 
2007; Padmanabhan et al. 2013), which correlate with previous studies showing that folate 
deficiency is associated with hyperhomocysteinemia (Bailey et al. 2015; Blom & Smulders 
2011; Cuskelly et al. 2001). Inversely, the levels of plasma methionine were significantly 
decreased in the Mtrrgt/gt compared to the Mtrr+/+ (Elmore et al. 2007). The levels of AdoMet 
and AdoHcy were significantly increased and reduced, respectively, in Mtrrgt/gt livers 
compared to Mtrr+/+, confirming a metabolic derangement caused by the Mtrrgt mutation 
(Elmore et al. 2007). 
 
1.5.2.1 FGR in the Mtrrgt mouse model 
Mtrrgt/gt embryos derived from Mtrrgt/gt parents have a wide spectrum of developmental 
phenotypes at midgestation (E10.5). These include growth defects, such as growth restriction 
and developmental delay, and congenital abnormalities, such as NTD (open neural tube in the 
cranial or spinal cord regions), heart defects (pericardial oedema, reversed heart looping and 
enlarged hearts), and abnormal placental development (eccentric chorioallantoic attachment 
and haemorrhage; Padmanabhan et al. 2013). C57Bl/6 mice were used as controls, since the 
Mtrrgt mouse line was created in a C57Bl/6 genetic background (Elmore et al. 2007). This 
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suggests the abnormal folate metabolism due to the Mtrrgt mutation affects embryo 
development by midgestation. 
Interestingly, Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt progeny of Mtrr+/gt intercrosses displayed similar 
developmental defects to the Mtrrgt/gt mice derived from Mtrrgt/gt parents. All the embryonic 
phenotypes were similarly affected, suggesting a parental Mtrrgt allele might be sufficient to 
cause the developmental defects (Table 1.2). However, litters derived from a C57Bl/6 mother 
and a Mtrr+/gt father were phenotypically normal, suggesting the developmental phenotypes 
are observed only through the maternal linage (Table 1.3; Padmanabhan et al. 2013). Mtrr+/+ 
conceptuses (F2) derived from a Mtrr+/+ mother (F1), and a Mtrr+/gt maternal grandparent 
(F0) had similar developmental phenotypes to those observed in Mtrr+/+, Mtrr+/gt, and 
Mtrrgt/gt progeny of Mtrr+/gt intercrosses, and in Mtrrgt/gt mice derived from Mtrrgt/gt parents. 
Additionally, growth enhancement was observed in F2 Mtrr+/+ embryos at E10.5. Notably, 
the developmental phenotypes were observed in a higher frequency in the Mtrrgt/gt 
conceptuses compared to the F2 Mtrr+/+ conceptuses at E10.5 (Table 1.3; Padmanabhan et al. 
2013). Developmental delay or significant frequencies of growth restriction at E10.5 did not 
persist past F2 generation. In contrast, the congenital abnormalities persisted in the Mtrr+/+ 
conceptuses from generations F2, F3, and F4 derived from an Mtrr+/gt maternal ancestor 
(Padmanabhan et al. 2013). This is important, since it suggests that the Mtrrgt model is a 
model of transgenerational epigenetic inheritance. However, the mechanism by which 
epigenetic factors are transmitted through the germline leading to congenital abnormalities, is 
still unknown. An embryo transfer experiment showed that the growth phenotypes but not the 
congenital malformations were due to an atypical uterine environment of the F1 generation 




















































































Data are presented as average number of conceptuses per litter ± SEM followed by the 




Table 1.3 Phenotypic frequencies caused by Mtrr+/gt maternal grandmothers of grandfathers at E10.5 compared to C57Bl/6 controls. 
 
       
No. of maternal grandmothersa, maternal 
grandfathersb, or fathersc 
3a,b 3c 7a 7a 3b 4b 7a, 3b 
No. of litters (No. of conceptuses) 10 (93) 10 (94) 10 (83) 14 (129) 10 (89) 10 (87) 21 (176) 













































































Data are presented as number of conceptuses per litter with a specific phenotype and average number of phenotypically affected conceptuses per 




1.5.2.2 Epigenetic instability in the Mtrrgt mouse model 
The Mtrrgt mutation causes epigenetic instability in adult tissues and placentas at E10.5, 
suggesting a possible mechanism for the developmental phenotypes (Padmanabhan et al. 
2013). Disruption of the folate cycle inhibits the transmission of methyl groups that are 
required by cellular methylation, such as methylation of DNA, RNA, and histones (Locasale 
2013). Global DNA hypomethylation was observed in non-pregnant uteri and livers of adult 
Mtrr+/gt and Mtrr+/+ mice, and livers of Mtrrgt/gt mice compared to C57Bl/6 controls. Global 
DNA methylation of adult Mtrrgt/gt uteri was trending downwards but did not reach 
significance. Interestingly, global DNA methylation in the brains remained unaltered 
(Padmanabhan et al. 2013), suggesting a sparing effect to protect brain development. 
Dysregulation of DNA methylation in the nonpregnant uteri could be associated with the 
observed developmental phenotypes. Global DNA hypomethylation was also observed in 
placentas at E10.5 but not embryos of normal and growth restricted Mtrrgt/gt and F2 Mtrr+/+ 
conceptuses, suggesting the placentas are more prone to epigenetic instability than the 
embryos in the Mtrrgt model (Padmanabhan et al. 2013). Dysregulation of locus-specific 
DNA methylation was also observed in placentas at E10.5, characterised by both DNA 
hypermethylation and DNA hypomethylation (Padmanabhan et al. 2013). The degree of CpG 
methylation change correlated to the severity of phenotype, indicating epigenetic instability 
in the Mtrrgt model. Changes in expression of genes involved in placental growth were 
associated with DNA methylation changes. The overall hypermethylation in the differentially 
methylated region of the genes was associated with downregulation of gene expression 
(Padmanabhan et al. 2013). It was hypothesised that DNA methylation dysregulation 
precedes any changes in gene expression because DNA methylation changes were not always 
associated with gene expression changes (Padmanabhan et al. 2013). The mechanism behind 
locus-specific hypermethylation in models of global DNA hypomethylation, remains 
unknown (Cho et al. 2010; Deng et al. 2006; Padmanabhan et al. 2013). In summary, the 
Mtrrgt mutation causes abnormal folate metabolism and limited availability of methyl groups 
necessary for DNA methylation. This leads to global DNA hypomethylation and locus-
specific dysregulation of DNA methylation in E10.5 placentas, causing misexpression of 
genes that are necessary for normal placental development, and developmental phenotypes 




1.5.2.3 The growth phenotypes in F2 generation are due to an atypical uterine 
environment of the F1 females 
As highlighted earlier, the Mtrrgt model is a model of transgenerational epigenetic 
inheritance, and the growth phenotypes do not persist past the F2 generation, suggesting they 
are associated with an abnormal uterine environment of the F1 generation. However, the 
mechanism is unknown. It is therefore possible that the mechanism of inheritance of the 
developmental phenotypes involves either inheritance of an epigenetic factor via the 
germline, or the uterine environment is implicated. In order to identify the mechanism, and 
assess the possibility that the maternal environment is responsible for the phenotypes, a 
blastocyst transfer experiment was performed (Padmanabhan et al. 2013). Briefly, an Mtrr+/+ 
female (F1) derived from one Mtrr+/gt parent (F0) was mated with a C57Bl/6 male. At E3.0, 
prior to embryo implantation, the Mtrr+/+ grandprogeny (F2) was transferred into a control 
E2.5 pseudopregnant B6D2F1 female, who has not been previously exposed to the Mtrrgt 
mutation. The embryos were dissected at E10.5 and scored for phenotypes. This 
developmental stage was selected since previous dissections were performed also at 
midgestation. C57Bl/6 embryos were also transferred and used as controls. This experiment 
revealed two distinct epigenetic mechanisms in the Mtrrgt model:  a) The growth defects were 
rescued after transfer of the embryos in a normal uterine environment, suggesting these are 
due to an atypical uterine environment of F1 Mtrr+/+ females, and b) the congenital 
abnormalities persisted even after blastocyst transfer, suggesting these are due to inheritance 
of epimutations through the germline (Padmanabhan et al. 2013). Remarkably, an increased 
frequency of growth enhancement was observed in the transferred embryos derived from an 
either maternal Mtrr+/gt grandparent (Padmanabhan et al. 2013). The mechanism by which the 
uterine environment of F1 Mtrr+/+ females metabolically programmes the growth of their 
embryos during the first three days of development, is still unknown. It is possible that 
abnormal folate metabolism in either parent affects the uterine development and function, 
decidualisation, placentation, and placental function in their wildtype daughters, leading to 
growth defects in their wildtype grandprogeny. 
 
1.6 Hypothesis and Aims 
Despite the number of studies in the literature showing an effect of folate deficiency and 
abnormal folate metabolism on embryo growth and development, little is known about the 
mechanism by which folate leads to growth defects and congenital abnormalities. The 
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blastocyst transfer experiment revealed that the growth phenotypes in F2 Mtrr+/+ conceptuses 
are due to an atypical uterine environment of F1 Mtrr+/+ females. In this thesis, I used 
specific genetic pedigrees of the Mtrrgt mouse model to examine the effects of abnormal 
folate metabolism on uterine development and fetoplacental growth. 
We hypothesise that the Mtrr deficiency affects the uterine structure and function at estrus, 
impairs the decidualisation reaction during pregnancy, and alters the placental transcriptome 
at midgestation, ultimately causing FGR. To test these hypotheses, specific aims were 
addressed, including: 
a. To assess the effects of intrinsic and paternal Mtrr deficiency on the uterine structure and 
function of Mtrrgt/gt and F1 Mtrr+/+ females (Chapter 3). 
b. To assess the effects of intrinsic and paternal Mtrr deficiency on decidualisation at 
GD6.5 (Chapter 4). 
c. Global DNA hypomethylation was observed in placentas, but not embryos at E10.5. 
Therefore, to assess the effects of intrinsic and maternal grandpaternal Mtrr deficiency 
on the placental transcriptome, we performed an unbiased RNA-sequencing experiment 
where we sequenced RNA from placentas of Mtrrgt/gt and F2 Mtrr+/+ conceptuses with 
growth phenotypes. C57Bl/6 placentas were used as control (Chapter 5). 
d. The RNA-sequencing experiment revealed that the blastocyst transfer experiment alone 
was sufficient to affect the placental transcriptome. Assisted reproductive technology 
(ART) in humans can have a big impact on the placental transcriptome of the mother, 
therefore possibly affecting their offspring’s embryonic development and adult health. 
To assess the effects of blastocyst transfer on the placental transcriptome at E10.5, we 
compared the transcriptomes of non-transferred and transferred C57Bl/6 placentas, and 














2.1 Ethical approval 
All experiments were performed according to the UK Government Home Office licensing 
procedures. This research was regulated under the Animals (Scientific Procedures) Act 1986 
Amendment Regulations 2012 following ethical review by the University of Cambridge 
Animal Welfare and Ethical Review Body (AWERB). The blastocyst transfer experiments 
were performed also in accordance with the Canadian Council on Animal Care and the 
University of Calgary Committee on Animal Care (protocol number M06109). 
 
2.2 Mouse pedigrees and diet 
The Mtrrgt mouse line was originally generated as previously described (Elmore et al. 2007; 
Padmanabhan et al. 2013). Briefly, the Mtrr gene-trap (gt) vector was randomly inserted into 
129/P2 embryonic stem (ES) cells. The ES cells were injected into C57Bl/6 blastocysts and 
then implanted into pseudopregnant females. The resulting males were tested for germline 
transmission of the Mtrrgt allele. Mice with germline transmission were backcrossed for eight 
generations into the C57Bl/6 genetic background (Elmore et al. 2007; Padmanabhan et al. 
2013). Therefore, C57Bl/6 mice (The Jackson Laboratory, Bar Harbor, USA) were used in all 
experiments as controls. C57Bl/6 mice were bred in house and maintained in separate cages 
from the Mtrrgt mouse line (Figure 2.1A). The following genetic pedigrees were used to 
determine the effects of abnormal folate metabolism on embryo growth and development 
(Figure 2.1). Mtrr+/gt intercrosses generated Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt offspring (Figure 
2.1B). Mtrrgt/gt mice were derived by mating Mtrrgt/gt females with Mtrrgt/gt males (Figure 
2.1C). The Mtrr+/gt paternal pedigree derived by mating an Mtrr+/gt male with a C57Bl/6 
female to generate Mtrr+/+ and Mtrr+/gt offspring (Figure 2.1D). The Mtrr+/gt maternal 
grandfather pedigree (Figure 2.1E) involved mating an Mtrr+/gt male (F0) and a C57Bl/6 
female (F0). Their Mtrr+/+ daughters (F1) were mated with C57Bl/6 males to generate the F2 
Mtrr+/+ mice. Mice were fed a normal breeding diet (Rodent no.3 breeding chow, Special 
Diet Services, Essex, UK) ad libitum from weaning onwards. Details of the dietary 




2.3 Blastocyst transfer 
The blastocyst transfer experiments were previously performed by Colleen Geary-Joo 
(University of Calgary) and Dr. Erica Watson as described in detail (Padmanabhan et al. 
2013). No hormones were used. 
2.3.1 Collecting blastocysts 
Pregnant females were euthanised by cervical dislocation followed by decapitation. The 
abdominal cavity was opened, and a cut was made between the ovary and the oviduct. The 
uterus was also cut close to the oviduct. The oviduct and the attached segment of the uterus 
were transferred in M2 medium (Sigma-Aldrich, Gillingham, UK). The blastocysts were 
flushed from the oviducts and uteri of F1 Mtrr+/+ females using a flushing needle and 0.1ml 
of M2 medium. C57Bl/6 blastocysts were also flushed and used as a control. The flushed 
blastocysts were cultured in KSOM media (Millipore, Etobicoke, ON, Canada) microdrops 
covered in mineral oil (Millipore, Etobicoke, ON, Canada) at 37°C for no more than 30 
minutes. This unavoidable culture period allowed for the surgical preparation of the recipient 
female. 
2.3.2 Oviduct transfer 
The blastocysts were transferred into B6D2F1 females (F1 hybrid females from C57Bl/6 x 
DBA/2 mating) 2.5 days after mating them with vasectomized C57Bl/6 males (i.e., 
gestational day [GD] 2.5 equivalent; Ueda et al. 2003). B6D2F1 mice have 50% genetic 
similarity to C57Bl/6 mice and were used because C57Bl/6 females are notoriously poor 
recipients for blastocyst transfer. Noon of the day that the copulatory plug was detected was 
considered embryonic (E) day 0.5. Pseudropregnant B6D2F1 females were weighed and 
anesthetised by intraperitoneal injection. The flushed blastocysts were transferred into M2 
media at room temperature. The transfer pipette was loaded with M2 media, then a small air 
bubble, then M2 media, and then a second small air bubble. The blastocysts were then loaded 
in the transfer pipette, followed by another air bubble. A small incision was made on the 
recipient’s female skin and the reproductive organs were exposed. Using the 
stereomicroscope, the infundibulum and the ampulla were located, and the loaded transfer 
pipette was inserted into the oviduct opening. The blastocysts were then transferred to the 
ampulla. The procedure was repeated for both oviducts. Blastocysts were transferred 
regardless of appearance and litters were never pooled (Figure 2.1G). C57Bl/6 embryos were 
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transferred into B6D2F1 recipients as a control (Figure 2.1F). The B6D2F1 females were 
then sutured and allowed to recover from the injected anaesthetic. 
2.3.3 Dissection of transferred conceptuses 
Transferred litters were dissected at E10.5, the timing of which corresponded to the staging of 
the recipient pseudopregnant females. Embryos and placentas from transferred conceptuses 
were dissected, scored for phenotypes, photographed, and stored at -80oC. 
 
Figure 2.1 Schematic diagrams of robust genetic pedigrees established to address the 
role of abnormal folate metabolism on uterine and placental structure and function. 
(A) C57Bl/6 control pedigree (B) Mtrr+/gt intercrosses (C) The Mtrrgt/gt pedigree (D) The 
Mtrr+/gt paternal pedigree (E) The Mtrr+/gt maternal grandfather pedigree was derived by 
mating a Mtrr+/gt male (F0) and a C57Bl/6 female. Then, their Mtrr+/+ (F1) daughter was 
mated with a C57Bl/6 male (F1) to get the Mtrr+/+ F2 mice. (F-G) Pedigrees illustrating a 
blastocyst transfer experiment that was previously performed (Padmanabhan et al. 2013) 
including those in which F2 blastocysts that were transferred into the oviducts of control 
BDF1 pseudopregnant females at GD2.5. Conceptuses were allowed to develop until E10.5 
when they were dissected and scored for phenotypes. (F) Control transfer experiment 
whereby C57Bl/6 blastocysts were transferred into the recipient female. (G) Blastocyst 
transfer experiment whereby F2 Mtrr+/+ blastocysts derived from an Mtrr+/gt maternal 
grandfather were transferred into the recipient female. Circle: female, square: male, blue 
outline: C57Bl/6, white-filled symbols with black outline: Mtrr+/+, semi-filled symbols: 
Mtrr+/gt, black-filled symbols: Mtrrgt/gt, red outline: BDF1. 
 
2.4 Genotyping 
DNA samples were obtained from yolk sacs or ear notches for PCR genotyping. Mtrr 
genotypes were confirmed using a three-primer PCR reaction (a: 
GAGATTGGGTCCCTCTTCCAC, b: CGACTTCCGGAGCGGATCTC, c: 
GCTGCGCTTCTGAATCCACAG), as previously described (Padmanabhan et al. 2013). Sex 
genotypes were determined using primers against Ube1 (F: 
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TGGTCTGGACCCAAACGCTGTCCACA, Ube1 R: 
GGCAGCAGCCATCACATAATCCAGATG) or Rmb31 (F: 
CACCTTAAGAACAAGCCAATACA, Rmb31 R: GGCTTGTCCTGAAAACATTTGG) as 
previously described (Chuma & Nakatsuji 2001; Tunster 2017). 
 
2.5 Phenotypic analysis of developmental phenotypes at E10.5 
Noon of the day that the vaginal plug was detected was considered E0.5. Pregnant mice were 
euthanised by cervical dislocation followed by decapitation at GD 10.5. Dissections were 
performed in 1x phosphate buffered saline (PBS). Each conceptus was individually scored for 
phenotypes as previously described (Padmanabhan et al. 2013, 2017; see below). Growth 
defects and congenital abnormalities were assessed. The conceptuses were photographed 
using a Zeiss SteReo Discovery V8 microscope with an AxioCam MRc5 camera and 
AxioVision 4.7.2 software (Carl Zeiss) before weighing and snap-freezing in liquid nitrogen 
for molecular analysis. 
Growth defects: Crown-rump lengths of the embryos were determined using the AxioVision 
4.7.2 software. Embryos with a crown-rump length that was less than or greater than two 
standard deviations from mean C57Bl/6 crown-rump length were considered growth 
restricted or growth enhanced, respectively. Embryonic somite staging was determined 
according to e-Mouse Atlas Project (http://www.emouseatlas.org) whereby 30-39 somite 
pairs were considered the normal range for E10.5. Embryos with less than 30 somite pairs 
were considered developmentally delayed. Embryos with growth defects, were otherwise 
phenotypically normal, i.e. did not display one or more congenital malformations 
(Padmanabhan et al. 2013, 2017). 
Severely affected conceptuses: The gross morphology of extraembryonic (yolk sac, 
chorioallantoic placenta, and amnion) and embryonic tissues were assessed. Congenital 
abnormalities included placental defects (e.g. placenta hemorrhage, off-centered 
chorioallantoic attachment), and embryonic defects (e.g. open neural tube, pericardial edema, 
reversed cardiac looping). Implantation sites with two or more embryos (i.e. twinning) were 




2.6 Uterine tissue collection and processing 
2.6.1 Estrus stage (non-pregnant) uteri 
The estrous cycle of post-pubertal female mice was monitored by examining vaginal smears 
as previously described (Caligioni 2009; McLean et al. 2012) so that uteri could be collected 
during the estrus stage. Vaginal cells were obtained by dipping the plug check tool into 1x 
PBS and inserting its tip into the vaginal opening of a manually restrained mouse. The 
vaginal smear was spread on a glass slide. Cells from each vaginal smear were stained for 5 
minutes with 50% Giemsa stain (48900, Fluka Chemika) and microscopically examined. 
Estrus stage is characterised by predominantly cornified epithelial cells (Figure 2.2B). This 
differs from the smears of mice in proestrus stage, which include mostly nucleated epithelial 
and some cornified epithelial cells (Figure 2.2A). During metestrus, some nucleated epithelial 
cells are present, as well as many leukocytes (Figure 2.2C), while in diestrus there are only 
leukocytes (Figure 2.2D; McLean et al. 2012). Females who went through three consecutive 
normal cycles (i.e., the proestrus was followed by the estrous; Caligioni 2009) were 
euthanised at noon of the day that the vaginal smears determined the presence of cornified 
epithelial cells indicating estrous stage. The uterus was removed, weighed, and dissected in 
1x PBS. One of the uterine horns was cut into three pieces using a sterile scalpel, snap frozen 
and stored at -80oC for molecular analysis. The other uterine horn was cut into three pieces 
and fixed overnight in 10% natural-buffered formalin (HT501128, Sigma-Aldrich) at 4oC for 
histological processing. 
 
Figure 2.2 Cells of vaginal smears at each stage of the estrous cycle in adult mice. 
(A) Proestrus stage, where nucleated epithelial and cornified squamous epithelial cells are 
present. (B) Estrus stage, where the majority of the cells are cornified squamous epithelia. (C) 
Metestrus stage, where some nucleated epithelial and cornified squamous epithelial cells are 
present, and a large leukocyte population is present. (D) Diestrus stage, where only 




2.6.2 Uteri during early pregnancy (GD6.5) 
Noon of the day that the vaginal plug was detected was considered GD0.5. The pregnant 
females were euthanised at GD6.5 and the uteri were removed. The number of implantation 
sites in each uterine horn was noted. The uterus was cut between each implantation site, 
which were then weighed. Then, half of the implantation sites were snap frozen in liquid 
nitrogen for molecular analysis and half of the implantation sites were processed for 
histology. Implantation sites from each uterine horn were represented in each experiment. 
 
2.6.3 Tissue processing 
The formalin-fixed tissue was washed three times in 1x PBS for 20 minutes and dehydrated 
in ascending concentrations of ethanol. The uterine tissues were stored in 100% ethanol at 
4oC until all the samples were collected and then washed twice in Histoclear (HS202, 
National Diagnostics). The tissue was embedded in paraffin using standard procedures. The 
tissue was sectioned to 5μm sections using a manual microtome (RM2235, Leica). 
 
2.7 H&E staining and immunohistochemistry 
Tissue sections were deparaffinized in xylene (IS8126, Thermo Fisher) and rehydrated in 
descending concentrations of ethanol. For hematoxylin and eosin (H&E) staining, standard 
staining procedures were used. For immunohistochemistry, endogenous peroxidase activity 
was quenched using 3% hydrogen peroxide (H/1750/15, Fisher Scientific). Antigen retrieval 
was performed by addition of trypsin (T7168-20TAB, Sigma Aldrich) for 10 minutes at room 
temperature. The sections were washed with 1x PBST (1xPBS with 20% Tween20) and 
blocked with 5% serum (D9663 Sigma Aldrich) in 1% bovine serum albumin (BSA; A4503, 
Sigma Aldrich) in PBS for one hour. Tissue was incubated overnight at 4oC using the 
following primary antibody dilutions in 5% serum, 1%BSA in 1x PBST: 1:100, rabbit anti-
Ki67 (ab15580, Abcam), 1:50, rabbit anti-caspase 3 (#9661, Cell Signalling Technologies), 
1:100, rabbit anti-progesterone receptor (ab63605, Abcam), 1:100, rabbit anti-pan cadherin 
(ab16505, Abcam), or 1:100 rabbit anti-MTRR (26994-1-AP, Proteintech Europe, 
Manchester, UK). The sections were washed in 1x PBST. Tissue was incubated for 1 hour at 
room temperature in donkey anti-rabbit (ab6802-1, Abcam) secondary antibody diluted 1:300 
in 5% serum, 1%BSA in 1x PBST. The immunoreactive signals were developed using a DAB 
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substrate kit (ab64238, Abcam). Slides were coverslip mounted using DPX mountant 
(360294, VWR). A Zeiss AxioImager A1 light microscope, Zeiss AxioCam MRc5 camera 
and AxioVision 4.7.1 acquisition software (Carl Zeiss) were used to obtain micrographs. 
Alternatively, the slides were scanned using NanoZoomer (Hamamatsu Photonics, UK) and 
the NDP Scan 2.5 software. Images were analysed using ImageJ software (Schneider, 
Rasband & Eliceiri 2012) and the ImageJ cell counter plugin. The histological analyses were 
performed blind to the treatment group. 
 
2.8 RNA extraction and DNAse treatment 
RNA was extracted from tissues using the Trizol method. Briefly, 1ml TRI Reagent (T9424, 
Sigma Aldrich) was added to the tissue in a Matrix D tube (6913-100, MP Biomedicals). The 
tissue samples were homogenised using the MagNa Lyser (Roche) homogenizer. The 
placenta samples were homogenised at 6000x speed for 20 seconds. The uterine tissues were 
cut into 2-3 pieces each and homogenised at 6500x for 25-30 seconds, four times with 
intervening rests on ice for 1 minute. The implantation sites at GD6.5 were homogenised at 
6000x for 30 seconds, four times with a 20 second rest in ice in between. Samples were left to 
stand for 5 minutes at room temperature and then transferred to Eppendorf tubes with 200μl 
chloroform. Each sample was shaken vigorously for 15 seconds and left to stand at room 
temperature for 15 minutes before being centrifuged at 12,000g for 15 minutes at 4oC.  The 
colourless upper phase that contains RNA was transferred in a fresh tube with 500μl 
isopropanol. Samples were centrifuged at 12,000g for 10 minutes at 4oC. The pellet was air-
dried, resuspended in 400 μl of ice-cold diethyl pyrocarbonate-treated water and 400μl of 4 
M lithium chloride. RNA was allowed to precipitate overnight at -20oC and then centrifuged 
at 20,000g for 30 minutes at 4oC. The pellet was washed in 500μl of 75% ethanol, 
centrifuged at 20,000g for 10 minutes at 4oC, air-dried and resuspended in 55μl of DEPC-
treated water. The quality and concentration of the extracted RNA were determined by 
NanoDrop and its integrity was determined in an RNA gel. RNA was stored at -80oC. The 
extracted RNA was treated with DNAse I (M0303S, New England Biolabs) and EDTA 
(R1021, Thermo Scientific) according to the manufacturer’s instructions. The DNAse-treated 




2.9 DNA/RNA extraction 
In order to extract both DNA and RNA from the same sample simultaneously, whole 
placentas at E10.5 were homogenized using lysing matrix D beads (MP Biomedicals, 
Carlsbad, CA, USA). Total RNA and genomic DNA were purified using the AllPrep 
DNA/RNA kit (QIAGEN, Manchester, UK) according to manufacturer’s instructions. All 
RNA extracts were treated with DNAseI, as previously described. 
 
2.10 RNA-sequencing 
RNA quality control, library preparation and sequencing were performed at the Cambridge 
Genomic Services, Department of Pathology, University of Cambridge as follows. The 
concentration of the samples was determined using UV absorption at 260nm with a 
spectrophotometer plate reader, the SpectroStar (BMG Labtech). The purity of the RNA was 
determined by the 260/280 and 260/230 ratios using the SpectroStar. The integrity was 
determined by the RNA Integrity Number (RIN), which was generated by the Agilent 
Tapestation Bioanalyzer. The sample libraries were prepared using the TruSeq stranded 
mRNA Library Preparation kit (RS-122-2101, Illumina), according to the manufacturer’s 
instructions. Quantitative RT-qPCR was performed to quantify the libraries (SY-930-1010, 
Illumina) according to the manufacturers’ instructions. The quality of each RNA library was 
determined by the RIN, which was generated by the Agilent Tapestation Bioanalyzer. Each 
RNA sample was barcoded individually using adaptor sequences, and the samples were 
pooled together for sequencing. Each sequencing run was performed in the NextSeq500 
sequencer (SY-415-9001DOC, Illumina) using the high output, 75 cycle kit, according to 
manufacturers’ instructions. A 1% PhiX library was prepared and used as a 
sequencing/calibration control. Sequencing was performed to reach an average of 20 million 
reads per sample, using 75bp single end reads. 
 
2.11 RNA-sequencing data analysis 
Bioinformatic analysis of the raw RNA-sequencing data was performed by Dr. Russell 
Hamilton, Dr. Malwina Prater, and Dr. Xiaohui Zhao. Quality control of Fastq files was 
performed using FastQC and fastq_screen. Sequences were trimmed with Trim Galore!, and 
aligned to GRCm38 mouse genome using STAR aligner (Dobin et al. 2013; Dobin & 
Gingeras 2015). Alignments were processed using custom ClusterFlow (v0.5dev) pipelines 
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and assessed using MultiQC (0.9.dev0; Ewels, Lundin & Max 2016). Gene quantification 
was determined with HTSeq-Counts (v0.6.1p1). Additional quality control was performed 
with rRNA and mtRNA counts script, feature counts (v 1.5.0-p2) and qualimap (v2.2). 
Principal component analysis and MA plots were created in R Studio. Differential gene 
expression was performed with DESeq2 package (v1.16.1, R v3.4.0). Read counts were 
normalised on the estimated size factors. Heat maps were generated with 'pheatmap' R 
package. The Venn diagrams were created with InteractiVenn (Heberle et al. 2015). The 
UpSetR tables were created with the UpSetR package (Conway, Lex & Gehlenborg 2017). 
The cnet plot was created using the ReactomePA R package. 
 
2.12 Gene ontology analysis 
Gene ontology was performed using DAVID (Huang, Lempicki & Sherman 2009; Huang, 
Sherman & Lempicki 2009) and Enrichr (Chen et al. 2013; Kuleshov et al. 2016). Analysis of 
placental expression of genes was determined using online databases. The databases included 
the Mouse Encode Project (http://www.mouseencode.org/; Davis et al. 2018; Dunham et al. 
2012; Yue et al. 2014) and the Mouse Cell Atlas (http://bis.zju.edu.cn/MCA/; Han et al. 
2018), which assess general RNA expression in C57Bl/6 placentas at term (E19.0) via 
transcriptome analyses, and the Human Protein Atlas (https://www.proteinatlas.org/; Uhlen et 
al. 2015), which assesses homolog protein expression in human placentas at term via 
immunohistochemistry. The list of 50 random genes was generated using the Random Gene 
Set Generator (www.molbiotools.com). Data were also obtained from Deciphering the 
Mechanisms of Developmental Disorders (https:/dmdd.org.uk), which is a programme funded 
by the Wellcome Trust (www.wellcome.ac.uk) with support from the Francis Crick Institute 
(www.crick.ac.uk) and is licensed under a Creative Commons Attribution license 
(https://creativecommons.org/licenses/by/4.0/legalcode). Other online databases used include  
the Mouse Genome Informatics (http://www.informatics.jax.org/; Bult et al. 2019), the 
Mouse ENCODE Consortium 2012 (Stamatoyannopoulos et al. 2012), and the UCSC 
Genome Browser (http://genome.ucsc.edu/) using mm9 mouse genome (Haeussler et al. 




2.13 RT-qPCR analysis of gene expression 
2.13.1 Primer design 
The gene accession numbers according to RefSeq (NR or NM) were found using the 
Universal Probe Library of Roche Life Science 
(https://lifescience.roche.com/en_gb/brands/universal-probe-library.html). Unless otherwise 
stated, the primers were designed using the NCBI primer design tool (Ye et al. 2012). Primer 
pairs were designed with a maximum amplicon size of 150 bp and an optimal melting 
temperature of 60oC (Ye et al. 2012). Primers were optimised according to Real-time PCR 
Application Guide (BioRad). For primer sequences, refer to Table 2.1. 
 
2.13.2 Reverse transcription 
The DNAse-treated RNA was incubated with random hexamer primers (S0142, Thermo 
Scientific) at 65oC for 5 minutes and then in ice for at least 2 minutes. Primed RNA was 
reverse transcribed using RevertAid H Minus Reverse Transcriptase (EP0452, Thermo 
Scientific), RiboLock RNAse inhibitor (EO0382, Thermo Scientific), and dNTPs 
(11969064001, Roche) according to the manufacturer’s instructions. The synthesized cDNA 
was stored at -20oC. For long term storage, cDNA was stored at -80oC. 
 
2.13.3 Real time qPCR 
Real-time qPCR amplification was performed to assess relative mRNA levels using SYBR 
Green (RT-SY2X-03+WOUN, Eurogentec) on Opticon 2 system (MJ Research). All primers 
listed below were optimised with the following protocol. The enzyme was activated at 95oC 
for 10 minutes and the cDNA was amplified for 40 cycles under the following conditions: 
denaturation at 95oC for 30 seconds, annealing at 60oC for 30 seconds, and extension at 72oC 
for 45 seconds. cDNA was diluted 1:5 to a final concentration of 5 ng/μl and 1μl was used 
per reaction. Transcript levels were normalised to Hprt or Polr2a (Solano et al. 2016). 
mRNA levels of the housekeeping gene were similar between groups. RNA levels were 
analysed using the ΔΔCt method (Livak & Schmittgen 2001). cDNA levels in C57Bl/6 
tissues were normalised to 1. Experiments were conducted with technical duplicates or 
triplicates and at least four biological replicates. 
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2.14 Bisulfite pyrosequencing 
Bisulfite pyrosequencing was performed by Dr. Gina Blake. Genomic DNA was bisulfite-
converted using the one-step method of the Imprint DNA Modification Kit (MOD50, Sigma), 
according to manufacturer’s instructions. Non-template controls were used to ensure absence 
of contamination. Pyrosequencing was used to quantify methylation at individual CpG sites, 
as previously described (Tost & Gut 2007). Pyrosequencing primers were designed using 
PyroMark Assay Design Software 2.0 (Qiagen). A PCR reaction was performed using 50ng 
of bisulfite-converted DNA as a template, together with 0.2 μM of each biotinylated primer 
and 0.25 units of HotStarTaq DNA polymerase (QIAGEN). Refer to Table 2.2 for primer 
sequences. During PCR the DNA was amplified for 40 cycles under the following conditions: 
denaturation at 95oC for 30 seconds, annealing at the annealing temperature (Table 2.2) for 
30 seconds, and extension at 72oC for 45 seconds. PCR products were purified using 
Strepdavidin Sepharose High Performance columns (Sigma Aldrich) and hybridised to the 
sequencing primer using a PyroMark Q96 Vacuum Prep Workstation (Qiagen). The mean 
CpG methylation was calculated using at least four biological replicates and two technical 
replicates. 
 
2.15 Statistical analysis 
Statistical analyses were performed using GraphPad Prism 6 software. Histology, 
immunohistochemistry, and RT-qPCR data of gene expression in the uteri were analysed 
using one-way ANOVA with Kruskal-Wallis correction where appropriate, since four groups 
were compared. The post-hoc Tukey’s test for multiple comparisons was used to determine 
which means differ from the rest. Two-way ANOVA with post-hoc Sidak’s test for multiple 
comparisons was used to compare the mean differences between transferred and non-
transferred conceptuses in a sex-dependent manner. RT-qPCR data of placental gene 
expression and bisulfite pyrosequencing were analysed using Mann-Whitney test, or 
independent t-test with Welch correction where appropriate, since two groups were 
compared. P values less than 0.05 were considered statistically significant. The nbinomTest 




Table 2.1 Primer sequences used for RT-qPCR for analysis of gene expression. 
Gene Forward primer* Reverse primer Conc. Reference 
2610020C07Rik GGAAGTTTTCTGACACATGCACA CAAGCCAAGATTGACCCCCT 100nM - 
Acta2 GTCCCAGACATCAGGGAGTAA TCGGATACTTCAGCGTCAGGA 100nM - 
Adamdec1 GAGGGCTTGAGAACAACCAGA GCCCCAGAAGATGCTTGGT 150nM - 
Aldh3a1 TCCTGCTCGAGATCTTCTCTTAC GGAGGTGCCACATGACTTTAGG 200nM (Nishiyama et 
al. 2015) 
Ang2 GAAAGGAAGCCCTTATGGACGA ATCTGAACCCTTTAGAGGCTCG 200nM - 
Ankra2 GGCATCTGTCTTATTTAAAGCTGAG CGTTTCCCCTGTGCTTGTTG 100nM - 
Anxa8 ACTCACCTGATGAGAGTGTTCG AAGTAGCTGTGGACGTTCCG 200nM - 
Atp2b2 AGTCGAGGAGACAGAGCTGA CTGGCATCTACATGGTCGGG 100nM - 
Bmp2 CCTGAAGCAGAGACCCACCC CTGGAAGTTCCTCCACGGCT 200nM (Woods et al. 
2017) 
Cadps CCCCCATCTCACAATTTTACGC TCAAAGAGGGAAGCGTGGTC 150nM - 
Calcoco2 GGCTGCTGTTCCTGGACTT TCAGTGAGGGTGTAATAGCACAT 100nM - 
Ccl1 GACATTCGGCGGTTGCTCTA GTAAGCATGCTCTTGCTGTCAAC 200nM - 
Cdh1 AACCCAAGGCACGTATCAGGG ACTGCTGGTCAGGATCGTTG 100nM - 
Ceacam14 GAGCTTGGAAACAGCACGAGA TTAAAAGGGAGACTGTGAGCAGGA 200nM - 
Clca3a1 ACCCCGAGGCAGAGTCTTT CACATTGGTGCCAGTGATCC 200nM - 
Cldn10 GGGCTGCTCTCTTCATCGG  GTAGCCCATTCTGGGTGTCT 200nM - 
Cldn11 TCCCCACCTGCCGAAAAATG ACGTAGCCTGGAAGGATGAGG 200nM - 
Crybg3 CCAATTGGAACCACTCGGGA GGTCAGGTCGGCACATTCTT 200nM - 
Ctla4 CCATGCCCGGATTCTGACTT GGACTTCTTTTCTTTAGCATCTTGC 200nM - 
Ctsm TTGGAAAGCTGTGCAGTGGA GCATGGCCAGGAAGATAGCA 150nM - 
Ctsq GGGTTTGCTGACATGACTGA  CCAAGTGCACGTTTCCAGAG 200nM - 
Dazl CTAGGCAGCCACCTCACGTA GAAGTTGTGGCAGACATGATGG 200nM - 
Dhtkd1 GTACCCTGCAGCTGTGTCAA TCTTTGCTTCAGCAGGGCAT 50nM - 
Dnmt1 CCTAGTTCCGTGGCTACGAGGAGAA TCTCTCTCCTCTGCAGCCGACTCA 150nM (Kowluru, Shan 
& Mishra 2016) 
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Dnmt3a CCGCCTCTTCTTTGAGTTCTAC AGATGTCCCTCTTGTCACTAACG 100nM (Ding et al. 
2012) 
Dnmt3b TTCAGTGACCAGTCCTCAGACACGAA TCAGAAGGCTGGAGACCTCCCTCTT 100nM (Anier et al. 
2010) 
Dusp4 GCCTGCTTAAAGGTGGCTATG GCCAGGGCCTTGGTTTTAGA 200nM - 
E130309F12Rik 
(Plppr1) 
CTCCCACGCAAGCGGAAT CAGAAACTGTCCAGGCTTTGG 100nM - 
EpCam TTGCTCCAAACTGGCGTCTA TCGTACAGCCCATCGTTGTT 200nM - 
Esr1 CACCAGATCCAAGGGAA CGGCGTTGAACTCGTAG 200nM (Li et al. 2017) 
Fbp2 ACAGAAAGACCACGGAGGATG TGTCCTGTGGAAAGAGCGAC 150nM - 
Folr1 GGCCCTGAGGACAATTTACA TCGGGGAACACTCATAGAGG 200nM (Kooistra, 
Trasler & Baltz 
2013) 
Foxa2 CGGCCAGCGAGTTAAAGTATG TTGCTCACGGAAGAGTAGCC 200nM - 
G530011O06Rik TTTAGGCACAGGCATCGGAA AGCATTTCGGTGAAGCAGGA 150nM - 
Gapdh CATGGCCTTCCGTGTTCCT GCGGCACGTCAGATCCA 200nM (Gillich et al. 
2012) 
Gbp2b TCCCTTAAACTTCAGGAACAGGA  GATCGAGGTGGAGGCATGTT 100nM - 
Gm773 TGGAAACTTAAGCCTGCATTTGT TGCTGTAAGTGTAGAGTGTGCT 150nM - 
Gm773 TGGAAACTTAAGCCTGCATTTGT TGCTGTAAGTGTAGAGTGTGCT 150nM - 
Hand2 CACCAGCTACATCGCCTACC TCTCATTCAGCTCTTTCTTCCTCT 150nM - 
Hhipl1 GCTGCACATGGGGTCATCTA CGGATGAACTTTTCCTTGGGC 200nM - 
Hoxa10 CACAGGCCACTTCGTGTTCTT TTGTCCGCAGCATCGTAGAG 200nM - 
Hprt CAGGCCAGACTTTGTTGGAT TTGCGCTCATCTTAGGCTTT 200nM (Rameix-Welti 
et al. 2014) 
Hsd3b6 CCAGGGAGCAATTCTTCAACCT TGACAGCTGCAGTGTGGATA 200nM - 
Il33 AACTCCAAGATTTCCCCGGC TTATGGTGAGGCCAGAACGG 200nM - 
Jchain AGCGACCATTCTTGCTGACA     TGTTCAAAGGGACAACAATTCGG 200nM - 
Klk9 GCTGGCCTCTTCTACCTCAC GACCCACAGGTACGGCTTTC 150nM - 
Klra7 CTCTCCAATGAGTGTAAAAGTGCAA AGCTTTGGGGGACCAGAGTA 100nM - 
68 
 
Klra8 TTCTTCTTGGAGCCTCTTAGGG AAAATATGTCCTGTGTCTCCACC 200nM - 
Klrb1c GAGTGTCTTAGTGCGAGTCTTAGT TTGTGGGCACTCTAAATTAACTGAA 200nM - 
Med12 TCCCCTACTGCTGCGATACT GAGCCAATCTCCGGGTACAG 200nM - 
Mndal AAGTGGAGGGGAGTGGACAA TTGGTGACCTTGATCTTGACGA 150nM - 
Mthfr AGCTTGAAGCCACCTGGACTGTAT AGACTAGCGTTGCTGGGTTTCAGA 100nM (Uthus & 
Brown-Borg 
2006) 
Mtrr (WT) CCTTCAGGAGAATGGCTACG GGACCAGATGTCCTGCAGAT 150nM - 
Mtrr (WT+gt) GGTTTTCCGCAGATCTTCAC CTGTGTCAGGTGGGTCTCCT 150nM (Padmanabhan 
et al. 2013) 
Myocd CCAACACCTTGCCCAGTTATC GGAGCTTGTGCTGCCAAAG 200nM - 
Myot CCCCCTCTGAGCTAAGGAAAC GGTTGCAGCAAGTCAGAAGC 150nM - 
Ndufa4l2 TAAAAAGACACCCTGGGCTCAT TGGGTTGTTCTTTCTGTCCCA 200nM - 
Nell1 ACCTAAATCGCACTTGCCCA TGACCAAGTCTCGTCTCTGC 200nM - 
Nkg7 CATGGCTTTTTCTGCAGCTCTC GCCTAGGTAGAAGGACCAGGA 150nM - 
Noct GCGTCCCCGAACAGTGAGTT AGGATCGATGGGCTCCAGAT 150nM - 
Nr2f2 GCCAGTACTGCCGCCTCAA CAAACTGCCCGTGGGTAGGC 200nM (Woods et al. 
2017) 
Pgr GCCTATACCGATCTCCCTG TTCCCTATGAGTGGCTTCTAC 200nM (Li et al. 2017) 
Pianp CACCAGGCATGCAGTAAAGG GAGCAGGTGGTAATACGGACA 100nM - 
Pilrb1 GAGTCTGACCAAGCCCAGTA TTGAGTGCTTGGGTCACGTT 150nM - 
Polr2a GAGTCCAGAACGAGTGCATGA ACAGGCAACACTGTGACAATC 100nM (Rakoczy et al. 
2017) 
Polr2a GAGTCCAGAACGAGTGCATGA ACAGGCAACACTGTGACAATC 100nM (Rakoczy et al. 
2017) 
Ppef1 CTAAGAAAGTGATAAAAGCCGCGT CATTTGGCCTTGCTCGTCAG 150nM - 
Prl3d1 CATTCCTGCGGAGCCTGAAA GGAGCCTACATTGTGGTGGA 200nM - 
Prl3d1 GGAGCCTACATTGTGGTGGA CATTCCTGCGGAGCCTGAAA 200nM - 
Prl7a2 ACTGCGCAAGACATATACAGTCA AATTGTGGCAGCAGGTGAGA 200nM - 
Psca CTGCATCCAGGTGCTGCT GCGCGATGTAAAGCAACTGT 200nM - 
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Psg25 GCAGGAGCTGAAGGTCTTTTCA TAGGTTAAGATGGAGGCTGTGA 200nM - 
Psg27 GGTTGACACCTCCCTTTCCC GGCTTGTGGATCTTTTGGCAG 200nM - 
Ptafr TGAGCTCCTCCTACAGGCAT TCGGAAAGAGCGTGTATCGAA 200nM - 
Ptgdr CCTGCCTTTAATTTATCGTGCGT GATGAAGATCCAGGGGTCCAC 200nM - 
Rem1 GCTGGGAGGTGTGTACGAG AGTACACGATGACGTAGGCG 200nM - 
Rfc1 GGGTGTGCTACGTGACCTTT ACGGAACTGATCACGGACTT 100nM (Kooistra, 
Trasler & Baltz 
2013) 
Rgs1 ATCGGCCAAGTCCAAAGACAT TTTTGACCTGTCTGGTTGGC 150nM - 
Rmrp AAGTCACTGTTAGCCCGCC      TGAGAATGAGCCCCGTGTG 200nM - 
RNAse2a AGACTGGGAAACATGGGTCTGG ATGCTGGATGTCAAACCACCG 200nM - 
Rpph1 CTGGGAAGGTCTGAGACTTGG CCAGTCTGCCCAAGCGTA 200nM - 
Serf2 CATGACCCGCGGTAACCAG CTGCATGATCTCCGAGTCCC 200nM - 
Sfrp5 TTCCCCCTGGACAACGACCT CGCTGTGCTCCATCTCACACT 200nM (Woods et al. 
2017) 
Slc2a2 TCCCTTGGTTCATGGTTGCT AGGAAGTCCGCAATGTACTGG 200nM - 
Slit3 CTCAAGACGCTGATGTTGCG GGCAGTTGCAGTTGAAAGGG 200nM - 
Star AGCTCTCTGCTTGGTTCTCAA TCCAGCCTTCCTGGTTGTTG 200nM - 
Stim1 AGGAGATTGTGTCGCCCTTG GGGTCAAATCCCTCTGAGATCC 200nM - 
Tet1 ACACAGTGGTGCTAATGCAG AGCATGAACGGGAGAATCGG 200nM (Stryjewska et 
al. 2017) 
Tet2 ACCTGGCTACTGTCATTGCTCC TGCAGTGACTCCTGAGAATGGC 50nM - 
Tet3 AGGCAGCTAAGCACCTCAG GGCCCCGTAAGATGACACAG 50nM (Hwang et al. 
2016) 
Tex13b AGATAGAACGCAAGGAGGCG     GGTGGCAAATCTTGCGTGTA 100nM - 
Tmem55a ATTCCTGTGGATGGAACTGAGG GATGGTGACATACGCACAGC 50nM - 
Tmprss11bnl GATGCTGGAGAACAACCCAGA TCCCACAGCGGTTGTTGATAA 200nM - 
Tmprss11e TGTTGGAGGGACACCAGTAGA TGGATGGGTCCTTGTGTGTTC 200nM - 




Tpbpb GAAGTGCAAGAGCAGAAGGATA GCTGACCAAAGAAGACTCTCAA 200nM - 
Tspan8 AGTCGGAGTTCAAGTGCTGT GGGTAAACGGAACTCCCCTG 200nM - 
Ugt2b34 AGGATGACTTTCATGGAGAGGG GAGTGTCGTGGGTCTTCCTAAT 200nM - 
Vimentin AACTGCACGATGAAGAGATCCA GCCACGCTTTCATACTGCTG 200nM - 
Wif1 CCCGATGTATGAACGGTGGT GGTGGTTGAGCAGTTTGCTTT 150nM - 
Zkscan3 CTGCGTTCGCGGTCTTTTAC GCAGAGTGTGAGTCCAAGGT 200nM - 
*All primers are listed in the 5’ to 3’ orientation. 
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Table 2.2 Bisulfite pyrosequencing primers. 
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Chapter 3: The effects of abnormal 










This chapter includes experiments that have been performed in collaboration. Dr. J. Rakoczy 
performed the immunohistochemical staining for MTRR expression on estrus-staged uteri 





The importance of folate has been well examined during pregnancy. However, the effects of 
abnormal folate metabolism on the structure and function of the non-pregnant uterus is not 
well established. Profound changes were observed in the reproductive organs of folate-
deficient rhesus monkeys compared to controls (Mohanty & Das 1982). For instance, more 
atresic and cystic ovarian follicles lacking granulosa cells were observed in the ovaries of 
folate-deficient monkeys. This impaired the ovarian hormone secretion, leading to irregular 
menstrual cycles and decreased serum E2 and P4 levels. Folate deficiency also caused 
abnormal proliferation and maturation, megaloblastosis and multinucleation in the cervico-
vaginal epithelium. Finally, decreased cell proliferation of the luminal epithelium of the 
uterus was observed in folate-deficient monkeys (Mohanty & Das 1982). In addition, folate 
supplementation did not affect the uterine horn weight of gilts, but information is not 
available for uterine histology (Matte, Girard & Tremblay 1993). The effects of folate 
supplementation and folate receptor 4 (Folr4) mutation on gene expression in the peri-
conceptional mouse uterus were assessed via microarray (Salbaum, Kruger & Kappen 2013). 
In the wildtype mice, folinic acid supplementation led to increased expression of genes 
involved in lipid metabolism, and decreased expression of genes involved in vasculature 
development. Folinic acid supplementation in the mice lacking Folr4 had more profound 
effects on gene expression, and it affected the immune system, mitochondrial, and ribosomal 
function. Folinic supplementation of Folr4-/- mice also increased histone methylation patterns, 
compared to non-supplemented Folr4-/- mice, suggesting a mechanism for differential gene 
expression. This suggested that periconceptional supplementation with folinic acid alters the 
uterine transcriptome (Salbaum, Kruger & Kappen 2013). No data are available for humans. 
Mouse reproductive success depends on estrous cyclicity, which is regulated by hypothalamic 
GnRH, pituitary LH and FSH, and ovarian E2 and P4 hormones. As mentioned in Section 
1.2.2, the estrous cycle lasts around five days and has four stages: proestrus, when oocyte 
maturation occurs; estrus, when ovulation occurs; metestrus, when the mature oocytes move 
through the oviducts into the uterus; and diestrus, when the unfertilised oocytes are 
eliminated (Table 1.1). The maturing follicles produce E2, and therefore E2 peaks at 
proestrus, when follicles reach the mature Graafian follicle stage. A peak in E2 induces the 
LH surge (Green 1966). E2 also induces epithelial and stromal cell proliferation in the uterus, 
therefore the uterus mitotic activity and uterine width peak at morning of the estrus stage 
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(Martin & Finn 1968; Tibbetts et al. 1998; Wood et al. 2007). Proestrus and estrus stages are 
characterised by increased endometrial gland secretions, leading to uterine distention (Green 
1966). The E2-producing ruptured follicle transforms into a P4-producing corpus luteum, and 
the female enters the metestrus stage, followed by diestrus. P4 secretion increases and binds 
to the progesterone receptor on the luminal and glandular epithelium of the uterus. Once the 
receptor is activated, a signalling cascade results that is important for preparing the uterus for 
potential implantation of blastocysts, for the secretory transformation of the uterine glands, 
and maintenance of pregnancy (Riesewijk 2003). 
The Mtrrgt/gt mutation causes growth defects including growth restriction and developmental 
delay in mice. Furthermore, these growth defects in addition to growth enhancement were 
observed in the wildtype grandprogeny (F2) of Mtrr+/gt mice (F0; Padmanabhan et al. 2013). 
Through a blastocyst transfer experiment, the Watson lab previously determined that these 
growth defects were associated with an abnormal uterine environment of the F1 Mtrr+/+ 
females (Padmanabhan et al. 2013), though the details of this abnormality remain unknown. 
The Mtrrgt mutation leads to global DNA hypomethylation in adult tissues, including the non-
pregnant Mtrr+/+ uteri, and increased plasma total homocysteine levels in the Mtrrgt/gt mice 
(Elmore et al. 2007; Padmanabhan et al. 2013), which may contribute to an atypical maternal 
environment. The mechanism by which the Mtrrgt allele in mice causes an atypical uterine 
environment in their wildtype daughters that gives rise to growth defects in their wildtype 
grandprogeny at midgestation is still unknown, but epigenetic mechanisms are possibly 
implicated. The aim of this chapter is to assess the effects of Mtrrgt mutation on the uterine 
structure and function during estrus. Here, we hypothesise that the Mtrrgt mutation affects the 
uterine structure and function at estrus, possibly leading to abnormal decidualisation during 
pregnancy and ultimately FGR. To test this, hypothesis we assessed the intrinsic effect of the 
Mtrrgt mutation by assessing Mtrr+/gt and Mtrrgt/gt females, and the parental effect of Mtrrgt 
mutation by assessing Mtrr+/+ females derived from either an Mtrr+/gt father or Mtrr+/gt 
parents. This will explore the characteristics of an atypical uterine environment as a cause for 





3.2.1 Estrous cycle duration is unaffected by an intrinsic or paternal Mtrrgt allele 
To examine the effects of abnormal folate metabolism on estrous cyclicity, we assessed the 
estrous cycles of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt post-pubertal female mice littermates derived 
from Mtrr+/gt intercrosses (Figure 2.1B) compared to C57Bl/6 control females (Figure 2.1A). 
We also assessed the paternal effect of Mtrrgt allele by assessing Mtrr+/+ and Mtrr+/gt females 
derived from an Mtrr+/gt father and C57Bl/6 mother (Figure 2.1D). Four mice were assessed 
per genotypic group. For each female, the estrous cycle was monitored daily for at least three 
cycles. This was done by generating vaginal smears at the same time each day. The cycling 
females were euthanised during the estrus stage, and uterine tissue was collected for 
histological and molecular analyses. The age of the females at the time of dissection averaged 
between 11-19 weeks. 
First, we assessed the length of the entire estrous cycle in days. One estrous cycle was 
determined as the days between two estrus stages with at least one intervening day in 
proestrus stage (i.e., estrus, proestrus, estrus; Caligioni 2009). No differences between 
C57Bl/6 (4.3 ± 0.6 days; mean ± SEM), Mtrr+/+ (3.6 ± 0.5 days), Mtrr+/gt (4.1 ± 0.9 days) or 
Mtrrgt/gt (4.3 ± 0.6 days, p=0.4) females were observed (Figure 3.1A). Next, we determined 
the length of each stage including proestrus, estrus and metestrus/diestrus stages in each 
genotypic group. Again, the duration of each stage in Mtrr+/+, Mtrr+/gt and Mtrrgt/gt females 
was similar to controls (Figure 3.1B-D). Furthermore, no difference in estrous cycle length 
was observed in F1 Mtrr+/+ females (4.4 ± 0.8 days) or F1 Mtrr+/gt females (3.9 ± 0.5 days) 
compared to C57Bl/6 controls (4.2 ± 0.2 days, p=0.4; Figure 3.1E). The duration of each 
stage of the estrous cycle was also similar in F1 Mtrr+/+ and F1 Mtrr+/gt females compared to 
C57Bl/6 females (Figure 3.1F-H). Therefore, neither an intrinsic nor a parental Mtrrgt allele 
affects the duration of the estrous cycle in mice. 
Next, uterine tissue was collected for histological and molecular analyses. First, one uterine 
horn from each mouse was weighed after dissection. No difference (p=0.1) in uterine weight 
was determined between C57Bl/6 (0.020 ± 0.008 g), Mtrr+/+ (0.04 ± 0.02 g), Mtrr+/gt (0.030 ± 
0.004 g) or Mtrrgt/gt (0.030 ± 0.007 g; Figure 3.1I). Furthermore, no difference (p=0.2) in the 




Figure 3.1 The Mtrrgt mutation does not affect estrous cyclicity. 
(A-H) Graphs depicting (A, E) the average duration of the whole estrous cycle, (B, F) the 
average duration of the proestrus stage, (C, G) the average duration of the estrus stage, and 
(D, H) the average duration of the metestrus/diestrus stages combined. Data are presented in 
mean ± SEM. (I-J) Graphs representing the average uterine horn weight per genotype. Data 
are presented in mean ± SEM. n=4-5 females per genotype. (K-V) Analysis of (K-M, Q-S) 
estrus stage-specific and (N-O, T-V) proestrus stage-specific gene expression in estrus stage 
uterine horns. n=4-5 females per genotype. Hprt was used as a housekeeping gene. Data are 
presented as fold change compared to C57Bl/6 controls (normalised to 1). Statistical analysis: 
one-way ANOVA, *p<0.05. 
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Mtrr+/gt females (0.030 ± 0.004 g) compared to C57Bl/6 controls (0.030 ± 0.008 g; Figure 
3.1J). One limitation of this analysis, is that we did not take into account the body weight to 
calculate the uterus:body weight ratio. Next, we determined whether genes that are normally 
expressed in either estrus stage or proestrus stage uteri were altered in estrus stage uteri from 
each pedigree via RT-qPCR analysis. Under normal conditions, the genes Wif1, Plppr1, and 
Cadps are highly expressed in estrus and lowly expressed in proestrus (Yip et al., 2013). We 
observed that Wif1 and Plppr1 mRNA expression was not statistically different between all 
Mtrr uterine groups compared to the C57Bl/6 controls (Figure 3.1K-L, Q-R), however Cadps 
mRNA expression was decreased (p=0.033) in the Mtrr+/gt uteri compared to C57Bl/6 (Figure 
3.1M). mRNA expression of all three genes was quite variable in some C57Bl/6 control uteri 
(Figure 3.1K-M), which might explain the lack of significance. Why expression levels were 
so variable in the controls is unclear, though it is possible that gene expression fluctuates 
even within the estrus stage. Increasing the sample size for each experimental group will 
make this result more robust. The expression of estrus-specific genes was similar in the F1 
Mtrr+/+ and F1 Mtrr+/gt compared to C57Bl/6 females (Figure 3.1Q-S). The expression of 
three proestrus-specific genes Tmprss11e, Trmpss11bnl, and Myot (Yip et al., 2013) was also 
similar in estrus-staged uteri from Mtrr and C57Bl/6 females (Figure 3.1N-P, T-V). 
Altogether, these data suggest that Mtrrgt mutation does not affect estrous cyclicity and that 
the hypothalamic-pituitary-ovarian axis is likely functioning properly. 
 
3.2.2 Analysis of expression of Mtrr mRNA and protein in the estrus-staged uterus 
The Watson lab previously showed that the Mtrrgt allele is a knockdown mutation since 
Mtrrgt/gt mice express wildtype Mtrr transcript (Elmore et al. 2007; Padmanabhan et al. 2013). 
However, the degree of Mtrr knockdown varies between tissue types (Elmore et al. 2007; 
Padmanabhan et al. 2013). Therefore, to confirm the level of wildtype Mtrr transcript 
expression in the uteri of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt female littermates compared to 
C57Bl/6 females, RT-qPCR analysis was performed. Wildtype Mtrr transcript was detected 
using primers that anneal downstream of the gene-trap insertion site in the Mtrr locus. As 
expected, there was no difference in wildtype Mtrr transcript levels between the Mtrr+/+ and 
the C57Bl/6 uteri (Figure 3.2A). This result suggests that a paramutation effect (Hollick 
2016) is not present in Mtrr+/+ uteri, confirming what was previously shown by 
Padmanabhan et al. (2013). Furthermore, the expression of the Mtrr wildtype transcript was 
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decreased to 43.0% and 13.1% of control levels in Mtrr+/gt and Mtrrgt/gt uteri, respectively 
(p<0.0001; Figure 3.2A), a result consistent with Mtrr genetic knockdown and previous 
observations (Padmanabhan et al. 2013). Next, we determined whether “total Mtrr” transcript 
levels, which contain both wildtype and mutant transcripts, were altered by the gene-trap 
insertion. Total Mtrr mRNA levels were determined using RT-qPCR primers that anneal 
upstream of the gene-trap insertion and can be used to indicate whether a mutant cell attempts 
to up-regulate Mtrr transcription in response to low MTRR protein expression. There was no 
difference in the expression of total Mtrr in Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri compared to 
the controls (Figure 3.2B). This result suggests that the Mtrr+/gt or Mtrrgt/gt uterine cells do 
not compensate for MTRR deficiency at a transcriptional level. 
A similar analysis was performed on the uteri of F1 Mtrr+/+ and F1 Mtrr+/gt females derived 
from an Mtrr+/gt father and a C57Bl/6 mother. The average Mtrr wildtype transcript levels in 
F1 Mtrr+/+ uteri (60.0% of control levels) and F1 Mtrr+/gt uteri (29.0% of control levels; 
p=0.005) were much lower than expected (100% and ~50-60% of control transcript levels, 
respectively; Figure 3.2C). While total Mtrr mRNA expression in F1 Mtrr+/+ uterine tissue 
was similar to controls, expression in F1 Mtrr+/gt uteri was 55% of control levels, which is 
much lower than expected (p=0.03; Figure 3.2D). Although it is unclear why F1 Mtrr+/gt uteri 
have reduced total Mtrr transcript expression, it is possible that Mtrr transcripts might be 
degraded due to a paramutation effect. This is interesting given that this result was specific to 
a paternal effect of Mtrr deficiency and not apparent in Mtrr+/+ females derived from Mtrr+/gt 
intercrosses. 
To explore this finding further, we sought to confirm the Mtrrgt genotype of the F1 uterine 
samples used in this analysis. A conventional PCR reaction was performed using a three-
primer reaction to determine the presence or absence of the gene-trap (Padmanabhan et al. 
2013) in DNA collected from ear notches of the females in question. On the electrophoresis 
gel, the PCR product at 272 bp indicated a wildtype allele and the band at 383 bp indicated a 
mutant allele (lanes 13-15, Figure 3.2E). Indeed, the DNA samples from the C57Bl/6 and F1 
Mtrr+/+ females displayed a single wildtype band at 272 bp on the DNA gel (lanes 1-4 and 5-
8 respectively, Figure 3.2E). As expected, DNA from F1 Mtrr+/gt females revealed two bands, 
a wildtype and mutant allele (lanes 9-12, Figure 3.2E). Therefore, the genotypes of the F1 
mice used in this analysis were confirmed. It remains unclear as to why Mtrr transcript levels 




Figure 3.2 Mtrr transcript and MTRR protein expression in the mouse uterus at estrus. 
(A-D) Graphs showing relative Mtrr mRNA expression. n=4-7 uteri per genotype. Data are 
presented as mean ± SEM. Statistical test: One way ANOVA, a p<0.05 when compared to b, 
**p<0.01. (E) Electrophoresis gel showing DNA bands at 272 bp (Mtrr wildtype transcript) 
and 383 bp (Mtrr gene-trapped transcript) to verify the Mtrr genotypes of F1 females 
assessed. Samples 1-4: C57Bl/6 females, 5-8: F1 Mtrr+/+ females, 9-12: F1 Mtrr+/gt females, 
13: Mtrr+/+ DNA, 14: Mtrr+/gt DNA, 15: Mtrrgt/gt DNA, 16: No template control. (F-G) 
Representative uterine sections from C57Bl/6, Mtrr+/+, Mtrr+/gt and Mtrrgt/gt females at estrus 
that were stained with an MTRR antibody (brown). DNA, purple. Boxed region in panel (F) 
represents higher magnification of the endometrium shown in panel (G). Red arrows in panel 
(G) indicate cells with no MTRR expression. (H) No primary antibody controls. Scale bars: 
(F) 100 μm, (G) 25 μm, (H) 15 μm. LE: lumen epithelium, GL: glands, EN: endometrium, 




Next, MTRR protein levels were assessed in the uterine tissues at estrus using histological 
methods to determine cellular localization of MTRR expression in C57Bl/6 uterus, and to 
determine whether MTRR protein expression correlates with Mtrr mRNA expression. 
Immunohistochemistry was performed (in collaboration with Dr J. Rakoczy) on histological 
sections of C57Bl/6, Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt uteri at estrus using an antibody against 
MTRR. Within C57Bl/6 uterine tissue, MTRR protein expression was detected in all the 
uterine structures, including outer and inner myometrial layers, endometrium, glandular 
epithelium, and lumen epithelium (Figure 3.2F, H). However, there were some stromal cells 
within the endometrium with undetectable MTRR expression (Figure 3.2G). Nuclear and 
cytoplasmic staining was apparent in all uterine cell types (Figure 3.2F). Qualitatively, 
MTRR protein levels in the Mtrr+/gt uterine sections were slightly less than those in the 
C57Bl/6 and Mtrr+/+ uteri (Figure 3.2F). There was also a clear decrease in MTRR protein 
levels in the Mtrrgt/gt uterine tissues compared to C57Bl/6 controls (Figure 3.2F). Overall, 
these data indicate that MTRR protein expression is widely expressed within the uterus at 
estrus and is substantially decreased but still detectable in Mtrrgt/gt tissue. 
  
3.2.3 Analysis of folate-related proteins in Mtrr uteri at estrus 
Next, we determined whether gene expression of folate receptors, carriers, or enzymes was 
altered in Mtrr+/gt and Mtrrgt/gt uterine tissues as a compensatory mechanism to Mtrr 
deficiency. We assessed the mRNA expression of genes that encode for folate transporters 
Folr1 and Rfc1, and folate metabolic enzyme, Mthfr in C57Bl6, Mtrr+/+, Mtrr+/gt and Mtrrgt/gt 
uteri and F1 Mtrr+/+ and F1 Mtrr+/gt uteri via RT-qPCR analysis. No difference in mRNA 
expression was apparent in all Mtrr genotypes compared to C57Bl/6 controls (Figure 3.3A, 
B). The exception was the expression of Rfc1 mRNA, which was decreased in the F1 Mtrr+/gt 
uteri (48% of C57Bl/6 expression, p=0.048; Figure 3.3B). While Rfc1 mRNA expression 
displayed a downward trend in F1 Mtrr+/+ females compared to the C57Bl/6, the result was 
not statistically significant (Figure 3.3B). It is unclear why F1 Mtrr+/gt females derived from 
an Mtrr+/gt father and not Mtrr+/gt females derived from Mtrr+/gt parents show changes in Rfc1 
mRNA expression, but it is possible that a maternal Mtrrgt allele is required to compensate for 
changes in Rfc1 mRNA caused by the paternal Mtrrgt allele. A future experiment should 
include assessment of protein expression of these key folate factors to determine whether 




Figure 3.3 Analysis of folate-related and DNA methylation machinery gene expression 
in the mouse uterus at estrus. 
Relative mRNA expression of (A-B) folate related genes including Folr1, Rfc1, and Mthfr 
and (C-F) DNA methylation machinery genes including (C-D) Dnmt1, Dnmt3a, Dnmt3b, and 
(E-F) Tet1, Tet2, and Tet3 in uteri at estrus stage from the following genotypes: (A, C, E) 
C57Bl/6, Mtrr+/+, Mtrr+/gt, Mtrrgt/gt, (B, D, F) C57Bl/6, F1 Mtrr+/+, and F1 Mtrr+/gt. Hprt was 
used as a housekeeping gene, n=4-7 females per genotype. Data are presented as mean ± 
SEM and as a fold change compared to C57Bl/6 controls (normalised to 1). Statistical test: 
One-way ANOVA, *p<0.05, **p<0.01. 
 
3.2.4 Decreased mRNA expression of DNA methylation machinery enzymes in 
uteri at estrus from Mtrr pedigrees 
It was previously shown that global DNA hypomethylation occurs in the uteri of Mtrr+/+, 
Mtrr+/gt, and Mtrrgt/gt mice (Padmanabhan et al. 2013). How changes in methyl group 
availability affect the expression of the DNA methylation machinery enzymes has not yet 
been determined in the Mtrrgt model. Therefore, we examined the mRNA expression of DNA 
methyltransferase (Dnmt) genes including Dnmt1, Dnmt3a, and Dnmt3b and genes that 
encode for ten-eleven-translocation (Tet) enzymes involved in the demethylation of DNA 
including Tet1, Tet2, and Tet3 in C57Bl/6, Mtrr+/+, Mtrr+/gt, Mtrrgt/gt, F1 Mtrr+/+ and F1 
Mtrr+/gt uterine tissues at estrus.  
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While there was no difference in Dnmt3a or Dnmt3b mRNA expression between C57Bl/6, 
Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri, Dnmt1 mRNA expression was decreased in the Mtrr+/gt 
and Mtrrgt/gt uteri (p=0.01), but not Mtrr+/+ uteri compared to C57Bl/6 controls (Figure 3.3C). 
Our data suggest that there might be an intrinsic effect of the Mtrrgt mutation on Dnmt1 
mRNA expression. Similarly, Dnmt1 mRNA expression was not altered in F1 Mtrr+/+ uteri 
and was decreased in the F1 Mtrr+/gt uteri (p=0.01; Figure 3.3D). However, in contrast to 
Mtrr+/gt females from Mtrr+/gt intercrosses, Dnmt3a (p=0.009) and Dnmt3b (p=0.028) mRNA 
expression in the F1 Mtrr+/gt uteri was reduced compared to the C57Bl/6 uteri (Figure 3.3E). 
DNMT protein expression levels should be determined to better understand the functional 
implications of this finding. 
In contrast to Dnmt expression, Tet1, Tet2, and Tet3 mRNA expression remained unaltered in 
Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri (Figure 3.3E). Interestingly, variation in the expression of 
these genes was observed mainly in the C57Bl/6 and Mtrr+/+ uteri. Although there was a 
decreasing trend in Tet1 mRNA levels in the F1 Mtrr+/+ and F1 Mtrr+/gt uteri, the result was 
not statistically significant (Figure 3.3F). In contrast, Tet2 mRNA was decreased in the F1 
Mtrr+/gt uteri (p=0.017), and Tet3 mRNA was decreased in both the F1 Mtrr+/+ and F1 
Mtrr+/gt uteri (p=0.0023) compared to C57Bl/6 (Figure 3.3F). Altogether, these data suggest 
that the expression of DNA methylation machinery was most dysregulated in the F1 Mtrr+/gt 
uteri. It is unclear why F1 Mtrr+/gt females derived from an Mtrr+/gt father and not Mtrr+/gt 
females derived from Mtrr+/gt parents show changes in DNA methylation machinery enzyme 
expression, but this result is consistent with the expression of Rfc1 mRNA. 
 
3.2.5 Intrinsic and parental Mtrrgt allele causes abnormal uterine morphology at 
estrus 
To determine whether an intrinsic or parental Mtrrgt allele(s) affects the uterine morphology 
at estrus, we performed H&E staining on histological sections of Mtrr+/+, Mtrr+/gt and 
Mtrrgt/gt uteri and compared them to C57Bl/6 control uteri (n = 4 females per group). First, 
the thickness of the uterine myometrium was assessed. Overall, only Mtrr+/gt females had a 
total myometrium thickness that was larger than controls (p=0.017; Figure 3.4A-B). 
Although myometrial thickness of Mtrrgt/gt uteri was also increased, the difference was not 
significant (Figure 3.4A-B). Total myometrial thickness in Mtrr+/+ was similar to C57Bl/6 
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(Figure 3.4). When the myometrium was broken down into inner and outer myometrium as 
determined by the presence of circular and longitudinal myometrial cells respectively (Brody 
& Cunha 1989), the outer myometrium was observed to be thicker in Mtrr+/+, Mtrr+/gt and 
Mtrrgt/gt uteri (p=0.0094) compared to C57Bl/6 controls (Figure 3.4A-B). On the other hand, 
the inner myometrium was thicker only in the Mtrr+/+ females (p=0.025; Figure 3.4A-B). 
Next, we observed that the overall thickness of the endometrial layer of each Mtrr genotypic 
group was on average similar to C57Bl/6 controls (Figure 3.4A, C). Additionally, the number 
and diameter of endometrial glands over the long and short axes was not affected by Mtrr 
deficiency (Figure 3.4A, D-F). The whole uterus diameter was not different in any of the 
Mtrr genotypes (Figure 3.4G). Thicker myometrium and normal whole uterus diameter in the 
Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri could suggest differences in the lumen size, although we 
found that the percentage of lumen area to the whole uterus area is similar between C57Bl/6, 
Mtrr+/+, and Mtrrgt/gt uteri, but higher in the Mtrr+/gt uteri (p=0.0004, Figure 3.4H). Increasing 
the sample size would improve the statistical power and give us more reliable results. 
Remarkably, we observed that the luminal epithelium was highly invaginated in the uteri of 
Mtrr+/+, Mtrr+/gt and Mtrrgt/gt females (Figure 3.4A). This was in contrast to the smooth 
luminal epithelium in the C57Bl/6 control uteri (Figure 3.4A). Since an abnormal uterine 
phenotype was observed in Mtrr+/+ females, these data suggest that the parental Mtrrgt allele 
is an important factor controlling gross uterine morphology. 
Next, to determine whether paternal Mtrr deficiency was sufficient to affect uterine structure 
at estrus, we performed a similar analysis on histological sections of F1 Mtrr+/+ and F1 
Mtrr+/gt uteri derived from an Mtrr+/gt father and a C57Bl/6 mother (Figure 2.1D) and 
compared them to C57Bl/6 control uteri (n = 4 females per group). Overall, F1 Mtrr+/+ and 
F1 Mtrr+/gt females had a total myometrium thickness that was larger than controls (p=0.01; 
Figure 3.5A-B). When the myometrium was broken down into inner and outer myometrium, 
the outer myometrium was observed to be thicker in F1 Mtrr+/+ and F1 Mtrr+/gt uteri 
(p=0.038) compared to C57Bl/6 controls (Figure 3.5A-B), which were similar to the 
increased myometrial thickness observed in the uteri of females derived from Mtrr+/gt 






Figure 3.4 Histological analysis of Mtrr uteri at estrus. 
(A) Representative histological sections of uteri from C57Bl/6, Mtrr+/+, Mtrr+/gt and Mtrrgt/gt 
females. Blue, nuclei; pink, cytoplasm. EN, endometrium; LE, lumen epithelium; IM, inner 
myometrium; OM, outer myometrium. Scale bars: whole uterus, 500 μm; endometrium, 
100μm; myometrium, 50μm; glands and lumen, 25μm. Red arrow shows invagination in the 
lumen epithelium. (B-E) Graphs quantifying (B) myometrium thickness, (C) endometrium 
thickness, (D) number of glands, (E-F) gland diameters along the (E) short axis and the (F) 
long axis, (G) whole uterus diameter, (H) percentage of lumen:uterus area. Data presented as 
mean ± SEM. n=4 females per genotype, One-way ANOVA. a p<0.05 when compared to b 
and c; b p<0.05 when compared to a and c; c p<0.05 when compared to a and b. 
 
 
unchanged (Figure 3.5A-B). Next, we observed that the overall thickness of the endometrial 
layer of F1 Mtrr+/+ and F1 Mtrr+/gt uteri was on average similar to C57Bl/6 controls (Figure 
3.5A, C) and the number and diameter of endometrial glands were unaffected (Figure 3.5A, 
D-E). Furthermore, the lumen epithelium was highly invaginated in F1 Mtrr+/+ and F1 
Mtrr+/gt uteri (Figure 3.5A), which was in contrast to the smooth luminal epithelium in the 
C57Bl/6 control uteri, and similar to the invaginations observed in the uteri of females 
derived from Mtrr+/gt intercrosses (Figure 3.4A). The whole uterus diameter or the 
lumen:uterus area were not different in each case (Figure 3.5F-G), even though the 
myometrium was thicker in the uteri of F1 Mtrr+/+ and F1 Mtrr+/gt females. Since we 
observed some variability in the quantification of the lumen:uterus area, increasing the 
sample size could give us more reliable results. Altogether, these data suggest that the 
paternal Mtrrgt allele is an important factor controlling gross uterine morphology since F1 
Mtrr+/+ uteri were affected in a similar manner to F1 Mtrr+/gt uteri. Since these uteri show 
similar phenotypes to females derived from Mtrr+/gt intercrosses, it will be important to 
explore a maternal Mtrr+/gt effect to determine whether Mtrr deficiency in a single parent is 
sufficient to affect the uterine morphology of their daughters, or if only a paternal Mtrrgt 







Figure 3.5 Histological analysis of F1 Mtrr uteri at estrus. 
(A) Representative histological sections of uteri from C57Bl/6, F1 Mtrr+/+ and F1 Mtrr+/gt 
females. Scale bars: whole uterus, 500 μm; endometrium, 100μm; myometrium, 50μm; 
glands and lumen, 25μm. Red arrow shows invagination in the lumen epithelium. LE, lumen 
epithelium; IM, inner myometrium; OM, outer myometrium; EN, endometrium. (B-E) 
Graphs quantifying (B) myometrium thickness, (C) endometrium thickness, (D) gland 
number, (E) gland diameter, (F) whole uterus diameter, (H) percentage of lumen:uterus area. 




3.2.6 Cell density in outer myometrium is increased by parental Mtrr deficiency 
The increased outer myometrial thickness observed in all Mtrr genotypes might be attributed 
to: a) increased cell size, and/or b) increased cell number caused by increased cell 
proliferation or decreased apoptosis. First, we analysed Mtrr+/+, Mtrr+/gt and Mtrrgt/gt, and F1 
Mtrr+/+ and F1 Mtrr+/gt uteri at estrus by counting the number of cells in specified areas to 
determine cell density. For this analysis, we assessed the uterine samples that were stained 
with H&E using ImageJ. When analysing all genotypes, there was no difference in the cell 
density in the endometrium or the inner myometrium compared to C57Bl/6 controls (Figure 
3.6A, C-D, F-G). However, the density of the cells in the outer myometrium was lower in all 
the Mtrr genotypes (p<0.019) compared to C57Bl/6 controls. More specifically, the cell 
density in the outer myometrium of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt, F1 Mtrr+/+ and F1 Mtrr+/gt 
uteri was 68.1%, 59.5%, 58.9%, 60.1%, and 63.6%, respectively of the cell density in the 
C57Bl/6 controls (Figure 3.6A, B, E). The cell nuclei in Mtrrgt/gt appear bigger than those in 
C57Bl/6, Mtrr+/+ and Mtrr+/gt uteri (Figure 3.6A). This result suggests that increased cell size 
and possibly an increase in the extracellular matrix space might be responsible for increased 
outer myometrial thickness in the Mtrrgt mouse model and that paternal Mtrr deficiency is 
sufficient to cause this phenotype. 
Next, we investigated whether changes in cell proliferation and/or cell apoptosis were 
associated with increased myometrial thickness. The uterine sections were immunostained 
with antibodies against Ki67 and Caspase3 protein to assess cell proliferation and cell 
apoptosis, respectively. No primary antibody controls are shown in Figure 3.2G and Figure 






Figure 3.6 Decreased cell density in the outer myometrium of Mtrr uteri at estrus. 
(A) Representative images of uterine histological sections from C57Bl/6, Mtrr+/+, Mtrr+/gt, 
Mtrrgt/gt, F1 Mtrr+/+ and F1 Mtrr+/gt females at estrus stained with hemotoxylin (blue). Outer 
myometrium, inner myometrium, and endometrium are shown. Scale bars: 25 μm. (B-G) 
Graphs depicting cell density in the outer myometrium (B, E), inner myometrium (C, F), and 
endometrium (D, G) in (B-D) Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri and (E-G) F1 Mtrr+/+ and F1 
Mtrr+/gt uteri compared to C57Bl/6 controls. Data are presented as mean ± SEM. n=4 females 
per genotype. Statistical test: One-way ANOVA, a p<0.05 when compared to b. 
 
and outer myometrial layers. Interestingly, there was an increased number of Ki67+ cells in 
the endometrium of Mtrr+/gt and Mtrrgt/gt females (p=0.0079) compared to C57Bl/6 controls 
(Figure 3.7A-B). This occurred even though the endometrial thickness was not different 
(Figure 3.4A, C). There was also an upward trend of Ki67+ cells in Mtrr+/+ endometrium, 
though the difference did not reach statistical significance (Figure 3.7B). In contrast, the 
number of Ki67+ cells in the inner and outer myometrial layers of Mtrr+/+, Mtrr+/gt and 
Mtrrgt/gt uteri was unaffected compared to controls (Figure 3.7A-B) indicating cell 
proliferation was not likely responsible for a thicker outer myometrial layer. Interestingly, we 
were not able to quantify the Ki67+ staining in the luminal or glandular epithelium of any 
uterine group assessed, since in all the genotypes we observed staining of the apical surface 
of all the glandular epithelial and luminal epithelial cells (Figure 3.8A).  
Additionally, there were no differences in the percentage of Ki67+ cells in all uterine 
structures assessed between C57Bl/6, F1 Mtrr+/+ and F1 Mtrr+/gt uteri (Figure 3.8A-B). 
Staining in Figure 3.8A is better than in Figure 3.7A, since the brown nuclei are more visible. 
Therefore, immunostaining of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri with Ki67 antibody should 
be repeated for more reliable results. Altogether, these data suggest that cell proliferation 
occurs at a normal rate in these uteri and is an unlikely cause for the increase in outer 
myometrial layer thickness. 
The number of Caspase3+ cells was also similar throughout the uteri of Mtrr+/+, Mtrr+/gt and 
Mtrrgt/gt females compared to the C57Bl/6 controls (Figure 3.7C-D). No primary antibody 
controls are shown in Figure 3.2G for each uterine structure. Furthermore, the percentage of 
Caspase3+ cells in the endometrium, uterine epithelial layer, and glandular cells was similar 
in F1 Mtrr+/+, F1 Mtrr+/gt and C57Bl/6 uteri (Figure 3.8C-D). While Caspase3 expression 
was undetectable in the inner myometrial layer, a decrease in the percentage of Caspase3+ 
cells was apparent in the outer myometrium only within F1 Mtrr+/+ uteri compared to 
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C57Bl/6 (p=0.02; Figure 3.8C-D). A high degree of variation within each genotype was 
observed in these graphs (Figure 3.7D). To alleviate this variation, more females should be 
assessed. This result in F1 Mtrr+/+ uteri correlates with the decreased cell density in the outer 
myometrium, but contradicts the increased myometrial thickness. Overall, these data indicate 
that increased myometrial thickness is caused by paternal Mtrr deficiency since females 
derived from Mtrr+/gt intercrosses or from Mtrr+/gt fathers displayed this phenotype regardless 
of the presence of an intrinsic Mtrrgt allele. Increased myometrial thickness is likely 
associated with increased cell size at the exclusion of changes in cell proliferation and cell 
apoptosis in all genotypes except F1 Mtrr+/+ uteri, which are characterised by decreased cell 








Figure 3.7 Analysis of cell proliferation and apoptosis in the uterine tissue of littermate 
females from Mtrr+/gt intercrosses at estrus. 
(A) Representative uterine histological sections stained with anti-Ki67 (brown) to assess cell 
proliferation in the myometrium and endometrium of uteri from C57Bl/6, Mtrr+/+, Mtrr+/gt, 
and Mtrrgt/gt females. Scale bars: 20 μm. Sections were counterstained with hemotoxylin 
(blue). (B) Quantification of the percentage of Ki67+ cells out of the total number of cells 
counted in a defined area of the endometrium, inner myometrium, and outer myometrium of 
C57Bl/6, Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt uteri at estrus. Data are presented as mean ± sem. 
N=4 females per genotype assessed. (C) Representative uterine histological sections stained 
with anti-CASP3 (brown) to assess apoptosis in the myometrium and endometrium of uteri 
from C57Bl/6, Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt females. Scale bars: 20μm. Sections were 
counterstained with hematoxylin (blue). (D) Quantification of the percentage of CASP3+ 
cells out of the total number of cells counted in a defined area of endometrium, outer 
myometrium, lumen epithelium, and glands of C57Bl/6, Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt uteri at 
estrus. LE, lumen epithelium; IM, inner myometrium; OM, outer myometrium; EN, 
endometrium; GL, glands. Red arrows point at positively stained cells. Data are presented as 
mean ± sem. Statistical test: One-way ANOVA. a p<0.05 when compared to b and c; b 







Figure 3.8 Analysis of cell proliferation and apoptosis in the uterine tissue of F1 females 
at estrus. 
(A) Representative uterine sections stained with anti-Ki67 (brown) to assess cell proliferation 
in the myometrium and endometrium of C57Bl/6, F1 Mtrr+/+ and F1 Mtrr+/gt uteri at estrus. 
Scale bars: 20 μm. Sections were counterstained with hemotoxylin (blue). (B) Quantification 
of the percentage of Ki67+ cells out of the total number of cells counted in a defined area in 
endometrium, inner myometrium, and outer myometrium of C57Bl/6, F1 Mtrr+/+ and F1 
Mtrr+/gt uteri. Data are presented as mean ± sem. N=4 females per genotype assessed. (C) 
Representative uterine sections stained with anti-CASP3 to assess cell apoptosis in the 
myometrium and endometrium of C57Bl/6, F1 Mtrr+/+ and F1 Mtrr+/gt uteri at estrus. Scale 
bars: 20 μm. Sections were counterstained with hemotoxylin (blue). (D) Quantification of the 
percentage of CASP3+ cells out of the total number of cells counted in a defined area in 
endometrium, outer myometrium, lumen epithelium, and glands of C57Bl/6, F1 Mtrr+/+ and 
F1 Mtrr+/gt uteri. LE, lumen epithelium; IM, inner myometrium; OM, outer myometrium; 
EN, endometrium; GL, glands. Red arrows point at positively stained cells. Data are 
presented as mean ± SEM. Statistical test: One-way ANOVA, *p<0.05. 
 
 
3.2.7 Analysis of genetic markers of uterine cells in the Mtrrgt mouse line 
Given that there is increased outer myometrial thickness associated with decreased cell 
density in the uteri of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt, and F1 Mtrr+/+ and F1 Mtrr+/gt females at 
estrus, we wanted to assess the molecular character of the myometrial cells. To do this, we 
assessed the expression of known uterine smooth muscle cell marker genes Myocd and Acta2 
via qPCR. Myocd and Acta2 are genes expressed by uterine smooth muscle cells (Gao, 
Bayless & Li 2014). Myocd is an E2-responsive gene (Kararigas, Nguyen & Jarry 2014) and 
encodes for a transcription factor necessary for differentiation of the smooth muscle cell 
lineage (Wang et al. 2003). Myocd is also a critical regulator of smooth muscle gene 
expression during postnatal development (Wang et al. 2003). Analysis of Myocd mRNA 
expression in C57Bl/6, Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri revealed a difference (p=0.03), 
although multiple comparison analysis revealed no significance. However, Myocd expression 
was reduced in Mtrr+/gt and Mtrrgt/gt uteri compared to C57Bl/6 controls (Figure 3.9A), and 
Myocd mRNA expression was reduced in F1 Mtrr+/gt uteri compared to controls (p=0.016, 
Figure 3.9F). F1 Mtrr+/+ females showed decreased levels of Myocd expression compared to 
controls, though this effect was not statistically significant (Figure 3.9F). Acta2 encodes for 
the major component of the contractile muscle (Perrin & Ervasti 2010). Acta2 mRNA 
expression was unaltered in Mtrr+/+, Mtrr+/gt and Mtrrgt/gt, and F1 Mtrr
+/+ and F1 Mtrr+/gt 
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uteri compared to controls (p=0.068; Figure 3.9B, G) and could suggest normal number of 
myometrial cells. Altogether, these data suggest that an intrinsic and, possibly paternal, Mtrrgt 
allele might affect the differentiation of the stem/progenitor myometrial cells that are present 
in the adult myometrium (Szotek et al. 2007), and thus contributing to the outer myometrial 
phenotype. To increase the robustness of this data, more uterine samples should be assessed. 
Next, we wanted to determine whether gene expression in other key uterine cell types was 
affected by the Mtrrgt mutation. By RT-qPCR, we assessed the expression of Epcam, Vim, 
and Foxa2 mRNA in the uteri of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt, and F1 Mtrr+/+ and F1 
Mtrr+/gt uteri compared to controls. Epcam encodes for a cell adhesion molecule that is 
expressed by the lumen epithelial cells (Deane et al. 2016). The gene Vim encodes for the 
intermediate filament vimentin and is a marker of uterine stromal cells within the endometrial 
layer (Clercq, Hennes & Vriens 2017). Foxa2 mRNA expression is important for uterine 
gland development and continues to be expressed within the glands during estrus (Chang et 
al. 2018; Kelleher et al. 2017). Overall, the mRNA expression of all these uterine markers 
assessed was not different in the uteri of Mtrr+/+, Mtrr+/gt and Mtrrgt/gt females compared to 
the controls (Figure 3.9C-E). There was also no difference in the mRNA expression of the 
uterine markers assessed in the uteri of F1 Mtrr+/+and Mtrr+/gt females compared to the 
controls (Figure 3.9H-J). Based on the marker genes selected, these data confirm our 
histological evidence that the endometrium and glands are normal in Mtrr uteri at estrus. The 




Figure 3.9 Marker expression in the uterine tissues of Mtrr mice at estrus. 
Relative mRNA expression of marker genes specific to myometrium (Myocd and Acta2), 
lumen epithelium (Epcam), stromal cells (Vimentin), and uterine glands (Foxa2) in (A-E) 
Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt uteri at estrus and (F-J) F1 Mtrr+/+ and F1 Mtrr+/gt uteri at 
estrus compared to C57Bl/6 controls. Transcript levels were normalised to Hprt RNA levels. 
Data are presented as fold change compared to C57Bl/6 controls (normalised to 1) and as the 
mean ± SEM. n=4-6 females per genotype assessed. Statistical test: One-way ANOVA 
*p<0.05. 
 
3.2.8 Altered cell polarity in uterine lumen epithelium of Mtrr mice at estrus 
To further characterise the hyper-invagination phenotype of the luminal epithelium of 
Mtrr+/+, Mtrr+/gt, Mtrrgt/gt, F1 Mtrr+/+, and F1 Mtrr+/gt uteri, we assessed higher magnification 
images of histological sections. The epithelial cells of the C57Bl/6 uteri appeared in a 
monolayer of polarised epithelium whereas in the Mtrr genotypes, the luminal epithelium 
was disorganised and, in some cases, 3-4 cells thick (Figure 3.10A, C). A schematic image 
was generated whereby the cell nuclei in the lumen epithelium were outlined to better show 
the disruption in cell organisation in the Mtrr uteri compared to the C57Bl/6 controls (Figure 
3.10A, C). Since the epithelial cells appeared disorganised, we immunostained uterine 
sections with a pan-cadherin antibody to mark cell-cell adhesion junctions that are important 
for establishing epithelial cell polarity (Desai et al. 2009; Reardon et al. 2012). Instead of 
appearing at the lateral and apical cell membranes of the uterine epithelium as in C57Bl/6 
uteri (Figure 3.10A), pan-cadherin expression was decreased, localised cytoplasmically and 
largely undetectable at the basolateral membranes of the luminal cells of Mtrr+/+, Mtrr+/gt and 
Mtrrgt/gt uterine sections (Figure 3.10A) and F1 Mtrr+/+ and F1 Mtrr+/gt uterine sections 
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(Figure 3.10C). Control sections stained only with the secondary antibody are shown in 
Figure 3.8A. A similar decrease in pan-cadherin expression was also apparent in the 
glandular epithelium of Mtrr+/gt and Mtrrgt/gt uterine sections (Figure 3.10A) and F1 Mtrr+/gt 
uterine sections (Figure 3.10C) compared to controls suggesting that cell polarity of glandular 
epithelium might also be affected by the Mtrrgt mutation. Next, to determine whether Mtrrgt 
mutation affects the transcription of the gene encoding for E-cadherin, we analysed Cdh1 
mRNA expression levels using qPCR in uteri at estrus. E-cadherin protein is an important 
component of adherens junctions and necessary for the establishment of cell polarity (Desai 
et al. 2009). Although variation was observed in the C57Bl/6 and Mtrr+/+ uteri, mean Cdh1 
mRNA expression was unaltered in all the Mtrr genotypes (Figures 3.10B, D). This result 
correlates with Epcam mRNA levels, which were unaltered (Figure 3.9C, H), and suggests 
that the transcription of cell adhesion molecules is not altered by Mtrr deficiency. Normal 
Cdh1 mRNA expression and decreased pan-cadherin protein staining suggests that either the 
protein is not translated at normal levels or cannot be properly localised to the cell membrane 




Figure 3.10 Misexpression of pan-cadherin protein in the uterus of Mtrr mice at estrus.  
(A, C) Representative uterine sections of females derived from (A) Mtrr+/gt intercrosses or 
(C) F1 females derived from an Mtrr+/gt father and a C57Bl/6 mother that were 
immunostained with an antibody against pan-Cadherin (brown). The lumen epithelium and 
glandular epithelium are shown. Scale bars: 25 μm.; Sections were counterstained with 
hemotoxylin (blue). Under each image of the lumen epithelium, a schematic drawing was 
produced to highlight the nuclear organization (black outline). (B, D) Relative mRNA 
expression of Cdh1 in the uteri of C57Bl/6, Mtrr+/+, Mtrr+/gt, Mtrrgt/gt  ̧F1 Mtrr+/+ and F1 
Mtrr+/gt females at estrus. Transcript levels were normalised to Hprt RNA levels. n=4-7 for 
female per genotype assessed. Data are presented as fold change compared to C57Bl/6 





3.2.9 Decreased levels of progesterone receptor mRNA and protein in the Mtrr 
uteri 
To explore whether disrupted cell polarity affects the function of the uterine lumen, we 
assessed progesterone receptor (Pgr) and estrogen receptor (Esr1) expression via RT-qPCR 
and immunohistochemistry in Mtrr+/+, Mtrr+/gt, Mtrrgt/gt, F1 Mtrr+/+, and F1 Mtrr+/gt uteri 
compared to C57Bl/6 controls at estrus. The expression of Esr1 mRNA was within the 
normal range in the uteri of all the Mtrr genotypes at estrus compared to the controls (Figure 
3.11A, D). On the other hand, while a downwards trend was observed in Mtrr+/+ and Mtrr+/gt 
uteri at estrus, Pgr mRNA expression was decreased in the Mtrrgt/gt uteri at estrus compared 
to the controls (p=0.035; Figure 3.11C). Pgr mRNA expression was also statistically reduced 
in the F1 Mtrr+/+ and F1 Mtrr+/gt uteri compared to the controls (p=0.01; Figure 3.11F). The 
decreased expression of Pgr mRNA was confirmed at the protein level using 
immunohistochemistry on histological sections (Figure 3.11B, E). Control sections with no 
primary antibody are shown in Figure 3.8A. Correspondingly, decreased expression intensity 
of the PGR protein in the glandular and luminal epithelia was apparent in Mtrr+/gt and 
Mtrrgt/gt uteri and similarly in the F1 Mtrr+/+ and F1 Mtrr+/gt uteri compared to controls 
(Figure 3.11B, E). The PGR antibody staining in the C57Bl/6 and Mtrr+/+ tissues appeared to 
be similar (Figure 3.11B). The decrease in Pgr mRNA and protein expression in uteri at the 
estrus stage suggests that the epithelial cells have not differentiated and/or organised well 
enough to establish proper polarity to express progesterone receptors and initiate 
progesterone signalling. 
Overall, these data suggest that altered luminal polarity caused by an intrinsic or paternal 






Figure 3.11 Expression of progesterone receptor in Mtrr uteri at estrus. 
(A, C-D, F) Relative mRNA expression of (A, D) Esr1, (C, F) Pgr in females derived from 
(A, C) Mtrr+/gt intercrosses or (D, F) F1 females derived from an Mtrr+/gt father compared to 
C57Bl/6 controls. Transcript levels were normalised to Hprt RNA levels. n=4-7 females per 
genotype assessed. Data are presented as mean ± SEM and as fold change compared to 
C57Bl/6 controls (normalised to 1). (B, E) Representative uterine sections of females derived 
from (B) Mtrr+/gt intercrosses or (E) F1 females derived from an Mtrr+/gt father. Sections were 
immunostained with anti-PGR (brown) and counterstained with hemotoxylin (blue). Scale 




Here, we first assessed the effects of intrinsic and paternal Mtrrgt mutation on uterine 
structure and function in non-pregnant females at estrus. We found that the paternal Mtrrgt 
mutation appears to be important for initiating uterine phenotypes including thicker outer 
myometrium due to increased cell size and decreased apoptosis, and abnormal cell polarity in 
the epithelium lining the uterine lumen. The latter result was associated with improper 
presentation of PGR on the uterine lumen epithelium. PGR expression was also decreased in 
the uterine gland epithelium. Estrous cyclicity was normal indicating that the function of the 
hypothalamic-pituitary-ovarian axis was likely unaltered by a paternal or intrinsic Mtrrgt 
mutation. Overall, this uterine phenotype caused by paternal Mtrr deficiency might prevent or 
delay normal blastocyst implantation or predict abnormal decidualisation during pregnancy. 
While the estrous cycle was determined to occur normally in the females of all Mtrrgt 
genotypes and pedigrees assessed, one drawback of our methodology was that the metestrus 
and diestrus stages were grouped together. This is because we determined estrous cyclicity by 
proestrus followed by estrus (Caligioni 2009) and did not initially pay attention to the other 
stages individually. The vaginal smears were stained with Giemsa stain but were not fixed, 
and therefore retrospectively reassessing the smears to identify the duration of metestrus and 
diestrus stages separately is not possible. Even though we observed normal estrous cyclicity, 
if we were to repeat this experiment, we would identify these stages separately. Furthermore, 
collection of uterine tissues at the proestrus, metestrus, and diestrus stages, would help us to 
identify the intrinsic and paternal effects of the Mtrrgt mutation on the uterine morphology in 
different estrus stages, and identify possible further discrepancies in the uterine cell 
differentiation in the Mtrr mouse model. 
Surprisingly, wildtype and total Mtrr transcripts were unexpectedly low in F1 Mtrr+/+ and F1 
Mtrr+/gt uteri at estrus compared to C57Bl/6 controls. A similar effect was not observed in 
Mtrr+/+, Mtrr+/gt and Mtrrgt/gt uteri in females derived from Mtrr+/gt intercrosses. This result 
indicates that paternal Mtrr deficiency might alter the expression of the Mtrr locus, even at 
the wildtype allele. Since the Mtrrgt mutation causes global hypomethylation of the cell, 
alterations in epigenetic regulation (e.g., DNA methylation or histone methylation) might 
occur at the Mtrr locus (among other loci) to suppress Mtrr gene expression. Indeed, mRNA 
expression of genes encoding for the DNA methylation machinery (e.g., Dnmt1, Dnmt3a, 
Dnmt3b, Tet2, Tet3) was decreased in the F1 Mtrr+/gt females, which might further disrupt 
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DNA methylation patterns. However, this epigenetic effect would need to be inherited by F1 
Mtrr+/+ females and the mechanism for inheritance of DNA methylation marks, if it exists, is 
not well understood. Our data also suggest a potential paramutation effect similar than 
observed in the kit mutant (Pilu 2011). In this case, the paramutagenic mutant allele (Kittm1Af) 
affected the transcription of the wildtype allele in heterozygous mice by causing the 
degradation of wildtype transcripts, leading to mice with white tails. When these 
heterozygous mice were crossed with wildtype mice with coloured tails, all the progeny, even 
the wildtype, had white tails. This suggests that the wildtype paramutated allele gained 
paramutagenic activity and reduced the expression of the other wildtype allele in Kit+/+ mice 
(Pilu 2011). The Watson lab previously showed that a direct paramutation effect was unlikely 
since F2 generation wildtype placentas and embryos from an Mtrr+/gt maternal grandparent 
showed normal levels of wildtype Mtrr transcript (Padmanabhan et al. 2013). However, this 
finding may not carry over to F1 Mtrr+/+ uterine tissue. This experiment should be repeated 
in new F1 Mtrr+/+ and F1 Mtrr+/gt uterine samples at estrus to rule out a paramutation effect. 
The uterine tissue morphology of estrus stage females derived from an Mtrr+/gt father was 
characterised by a highly invaginated and apolar luminal epithelium and increased thickness 
of the outer myometrial layer that was associated with decreased apoptosis and decreased cell 
density. The invaginations observed in the Mtrr lumen epithelium at estrus resemble those 
observed in control uteri at metestrus (Wood et al. 2007). This suggests that the 
morphological changes in the luminal epithelium of the Mtrr uteri over the course of the 
estrous cycle occur quicker than expected. To further assess this, histological analysis of Mtrr 
uteri from different stages of the estrous cycle is required. In addition, since the 
morphological changes in the uterus are driven by the ovarian hormones E2 and P4, 
assessment of plasma E2 and P4 at different stages of the estrous cycle is required. To further 
assess whether cell and nuclear size in the outer myometrium are related to a thicker outer 
myometrial layer, we could stain the histological sections with a cell membrane marker, such 
as anti-CD44 (Kennel et al. 1993) or CellMask stains that target the plasma membrane, which 
would allow us to visualise the cell boundaries and measure its size using software, such as 
ImageJ. An alternative hypothesis is that inappropriate cell adhesion may prevent normal 
myometrial structure causing the cells to appear larger. Further analysis is required. 
Constitutive activation of transforming growth factor beta receptor 1 (Tgfbr1) in the mouse 
uterus leads to increased myometrial thickness (Gao et al. 2015). Tgfbr1 is expressed in the 
myometrium (Gao, Li & Li 2014) and is required for myometrial development during the 
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early postnatal uterine development (Gao, Bayless & Li 2014). Analysis of Tgfbr1 mRNA 
expression would assess whether the increased myometrial thickness observed in our model 
is due to abnormal early postnatal uterine development.  
The uterine lumen epithelium of Mtrr females appeared abnormal. Specifically, we observed 
defects in the apicobasal polarity based on the mislocalisation of pan-cadherin antibody 
expression, and also defects in planar cell polarity based on the observation that the cells are 
not organised in a monolayer as in C57Bl/6, but in layers that are 2-3 cells thick. Apicobasal 
polarity refers to the different function of the apical and basal cell membranes. The apical 
membrane has a secretory function, expresses channels and transporters, and faces the lumen. 
The basal cell membrane contains mostly proteins involved in interactions with the 
extracellular matrix (Marcinkevicius, Fernandez-Gonzalez & Zallen 2009). This is different 
from planar cell polarity, which refers to how cells orientate within the plane of the epithelial 
tissue (Devenport 2014). The pan-cadherin antibody binds to all members of the cadherin 
superfamily including classical cadherins (such as E-cadherin, N-cadherin, P-cadherin), 
protocadherins, seven-pass transmembrane cadherins and desmosomal cadherins (Angst, 
Marcozzi & Magee 2001; Harmon, Desai & Green 2009; Nollet, Kools & Van Roy 2000). To 
confirm a polarity phenotype, analysis of the expression and cellular localisation of specific 
cadherins should take place as well as other proteins in adherent junction complexes that help 
generate a polarised cell layer. E-cadherin protein is expressed in the uterine epithelial cells 
also during early pregnancy, with higher expression at the apical membrane of the 
endometrium in the peri-implantation sites, compared to the inter-implantation sites (Jha et al. 
2006). mRNA expression of Cdh1, which encodes for E-cadherin, was unchanged in the F1 
uteri. Even if E-cadherin protein expression is normal, it is possible that its localisation is 
altered to prevent the establishment of cell polarity and abnormal organisation of the lumen 
epithelium cell layer. Cdh1 is important for uterine development and function. A conditional 
ablation of Cdh1 (Cdh1d/d) in the neonatal mouse uterus induced abnormal epithelial 
proliferation, excessive apoptosis, and abnormal stromal differentiation, with no apparent 
effects on the myometrium (Reardon et al. 2012). In addition, Cdh1d/d altered the expression 
of Wnt and Hox genes, that are involved in uterine development. Cdh1d/d mice had decreased 
expression of epithelial Wnt genes, Wnt receptors, and epithelial and stromal Hox genes, and 
were infertile due to defects in implantation and decidualisation (Reardon et al. 2012). 
Abnormal decidualisation can lead to FGR (see Section 1.2.4), which is one of the 
phenotypes observed in the Mtrrgt model (Padmanabhan et al. 2013). This suggests that 
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abnormal expression of CDH1 in the Mtrr mice can impair uterine function during 
pregnancy. 
Reduced expression of cadherins causes the cell junctions to loosen and reduces apicobasal 
polarity, which prevents the establishment of proper signalling pathways (Gradilla et al. 
2018). The decrease in Pgr mRNA and PGR protein expression at the estrus stage uteri of 
Mtrr females indicates that P4 signalling might be disrupted. However, it is unclear whether 
this is attributed to poor organisation of the uterine luminal cells or whether defective P4 
signalling has affected cellular organisation. After ovulation, P4 is produced by the corpus 
luteum and is essential to prepare the endometrium for implantation and maintenance of 
pregnancy (Goyeneche et al. 2003; Wang & Dey 2006; Wetendorf & DeMayo 2014). Pgr-/- 
females exhibit uterine epithelial hyperplasia and inflammation but display a normal 
endometrium and myometrium (Lydon et al. 1995; Mulac-Jericevic & Conneely 2004) 
suggesting that the increased myometrial thickness observed in the uteri of Mtrr females is 
independent of the decreased PGR expression. As a mitogen, P4 induces uterine stromal cell 
proliferation (Clarke & Sutherland 1990; Rider 2002). Exogenous administration of P4 also 
prolongs the window of receptivity up to day 6 (Song, Han & Lim 2007) suggesting that poor 
P4 signalling might reduce the blastocyst implantation window or prevent it from occurring. 
However, in the Mtrr model we observe normal litter sizes, suggesting that implantation is 
not altered (Padmanabhan et al. 2013). Further experiments are required to explore P4 
signalling in the Mtrr model, such as assessing the mRNA and protein expression of P4 
signalling target genes in the mouse uterus, such as Areg, Wnt4, Bmp2, Ihh, and Hoxa10. 
Stromal Esr1 activation has been shown to suppress expression of Pgr mRNA in the uterine 
epithelium (Mehta et al. 2016). However, in our Mtrr model, Esr1 mRNA was similarly 
expressed to the C57Bl/6 when the whole uterus was considered. These results might suggest 
that suppression of Pgr mRNA and protein expression is independent of the Esr1. Despite 
this, E2 levels might be increased in Mtrr females and causing increased estrogen signalling 
through the estrogen receptor. Ovariectomised mice treated with a high dose (24.0 g/kg) of 
the herb ginseng, which has an estrogenic effect, had increased lumen epithelial thickness 
including multiple cell layers (Xu et al. 2014), a phenotype similar to the Mtrr uteri. To 
examine this hypothesis, an ELISA experiment should be performed to measure blood 
estrogen levels in Mtrr females during proestrus and estrus. 
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Abnormal cell polarity in Mtrr uteri might alter cell-cell signalling and subsequent uterine 
function, such as decidualisation or receptivity to blastocysts. The effects of folate deficiency 
on blastocyst implantation are disputed since some studies find normal litter sizes at GD4.5 
(Gao et al. 2012b) and others find abnormal litter sizes after GD5.5 (Geng et al. 2015). The 
Mtrrgt model shows normal litter sizes at GD6.5 (see Chapter 4) and up to GD10.5 
(Padmanabhan et al. 2013), which supports the hypothesis that blastocysts implant at a 
normal frequency in mothers carrying one or two Mtrrgt alleles or had a father who was a 
carrier. Even though the frequency of blastocyst implantation was normal in the Mtrr model 
based on litter sizes at GD6.5, it is possible that there are implantation defects. We have 
observed the occurrence of twinning of wildtype conceptuses derived from an Mtrr mutant 
maternal grandparent, or from Mtrrgt/gt intercrosses (Padmanabhan et al. 2013). These 
conceptuses, which share an implantation site, are not identical given that they are different 
sexes, based on PCR genotyping of yolk sac tissue (E. Watson, unpublished). The cause is 
unclear; however, it is possible that improper signalling from the uterus to the embryo affects 
embryo spacing. It is unclear whether poor spacing is due to abnormalities in the blastocyst or 
uterine lining. Alternatively, the uterus might display late blastocyst receptivity to cause 
developmental delay or growth restriction in the embryo. More analysis is required to assess 
possible dysregulation of the window of implantation, by looking at the expression of 
receptivity markers such as Muc1, Lif, and Itgβ3 at the peri-implantation stage uterus (E3.5; 
Raheem 2018). Muc1 is an anti-adhesive expressed by the lumen epithelium. Increased levels 
of Muc1 prevent embryo attachment (Surveyor et al. 1995). Lif is secreted by the endometrial 
gland and stromal cells and binds its receptor on the luminal epithelium (Cullinan et al. 1996; 
Raheem 2018; Song & Lim 2006; Xu et al. 2012). Lif1 signals embryo implantation via an 
autocrine/paracrine manner (Cullinan et al. 1996). Itgβ3 is an adhesive molecule expressed 
both by the endometrium and the blastocyst (Raheem 2018). Altogether, these studies could 
suggest that either of these factors might be dysregulated in the Mtrrgt model, causing altered 
blastocyst spacing or delayed implantation. 
Overall, we showed that paternal abnormal folate metabolism alters uterine structure and 
function, in particular the cell polarity in the uterine lumen and the expression of 
progesterone receptor. Therefore, it will be important to assess how this affects 









Chapter 4: The effects of abnormal 
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Decidualisation, the differentiation of endometrial stromal cells into epithelioid cells, starts at 
GD4.5 at the antimesometrial zone. Differentiation of the stromal cells close to the primary 
decidual zone occurs by GD5.5, while the secondary decidual zone is fully developed by 
GD6.5 (Lim & Wang 2010; Figure 1.3). Growth factors and cytokines secreted by the 
decidualised cells are essential for embryo growth (Fraser et al. 2015; Lim & Wang 2010; 
Ramathal et al. 2010). In humans, the decidualised cells provide nutrients for the embryo 
until the placenta matures fully, regulate trophoblast invasion, sense and distinguish between 
high- and low-quality embryos, modulate the maternal immune system so it does not attack 
the semi-allogenic embryo, and provide the embryo with access to maternal vasculature (Cha, 
Sun & Dey 2012; Gellersen & Brosens 2014). 
Nutritional folate deficiency might affect the decidualisation process, since implantation sites 
of folate-deficient females showed hypomethylation and downregulation of Esr1 (Gao et al. 
2012a), hypermethylation of decidualisation-specific genes Nrlh3 and Nr5al, stunted decidual 
bulges (Geng et al. 2015) and abnormal decidual angiogenesis in mice (Li et al. 2015). 
Abnormal decidual vascularisation causes uteroplacental insufficiency, therefore impairing 
nutrient and oxygen transport, leading to abnormal fetal growth (Krishna & Bhalerao 2011; 
Swanson & David 2015). However, it is unknown whether abnormal folate metabolism has 
the same effects on decidualisation as nutritional folate deficiency. More specifically, the role 
of the Mtrrgt mutation in this process is unknown.  
In Chapter 3, we showed that structure and gene expression in the Mtrr uteri at estrus is 
altered. More specifically, uteri of Mtrr females have altered lumen epithelial organisation 
and polarity, and increased outer myometrial thickness. Progesterone signalling may be 
altered as indicated by low PGR expression in the uterine epithelial cells. In addition, we 
have observed the occurrence of twinning of conceptuses derived from either Mtrrgt/gt 
intercrosses, or an Mtrr+/gt maternal grandparent (Padmanabhan et al. 2013). Twinning is 
when two or more blastocysts implant into the uterus in close proximity so that their 
implantation sites merge into one single site. Approximately 5% and 25% of all severely 
affected conceptuses from Mtrrgt/gt and F1 Mtrr+/+ females, respectively, share an 
implantation site (Padmanabhan et al. 2013, 2017). While the cause is unclear, it is possible 
that the uteri of these females are unable to regulate blastocyst spacing at implantation or that 
the blastocysts, themselves, are unable to signal to one another to optimise spacing. 
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Altogether, these data might suggest that blastocyst receptivity and/or decidualisation 
potential might be affected by the Mtrrgt mutation compared to control uteri. We therefore 
hypothesise that the Mtrrgt mutation affects decidualisation, which consequently impairs 
embryonic growth. To explore this further, we assessed the effects of intrinsic and paternal 
Mtrrgt mutation on frequency of implantation, litter sizes, and decidualisation at GD6.5.  
 
4.2 Results 
4.2.1 The Mtrrgt mutation does not affect the litter size at GD6.5 
To assess the effects of the Mtrrgt mutation on the frequency of blastocyst implantation, we 
mated C57Bl/6 males with Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt females derived from Mtrr+/gt 
intercrosses and with F1 Mtrr+/+ and F1 Mtrr+/gt females derived from Mtrr+/gt fathers to 
assess the effects of intrinsic and paternal Mtrr deficiency on the litter size at GD6.5. This 
stage was chosen because it allowed for easy analysis of implantation sites a short time after 
implantation occurs (at GD4.5). C57Bl/6 implantation sites at GD6.5 were used as controls. 
Four litters were assessed per genotypic group. Mating with C57Bl/6 males was performed to 
eliminate any potential paternally-inherited effects of the Mtrrgt mutation on the decidual 
reaction as caused by the fetal genotype, sperm, or seminal fluid. All the vaginal plugs 
detected at GD0.5 resulted in pregnancies regardless of the female genotype suggesting the 
fertility is unlikely to be compromised by intrinsic or paternal Mtrrgt mutation. At GD6.5, we 
compared the overall litter sizes and found that compared to C57Bl/6 controls (8.5 ± 0.6 
implantation sites/litter), all Mtrr females displayed normal litter sizes (Figure 4.1A-C). 
However, Mtrrgt/gt (7.8 ± 1.7 implantation sites/litter) and Mtrr+/gt (10.3 ± 1.0 implantation 
sites/litter) females were different from each other (p=0.04). To increase the robustness of 
this result, sample sizes should be increased. Overall, the result indicated that implantation 
occurred at a normal rate regardless of the presence of the Mtrrgt allele in the mother. These 
data are supported by the observation of normal litter sizes at GD10.5 in litters from Mtrrgt/gt 





Figure 4.1 Litter statistics of GD6.5 dissections after Mtrr females were mated with 
C57Bl/6 males. 
(A-B) Graphs showing litter size at GD6.5 in (A) females derived from Mtrr+/gt intercrosses 
and (B) females derived from an Mtrr+/gt father compared to C57Bl/6 control matings. Data 
are presented as mean ± SEM. n=4 litters per female genotype. Statistical test: One-way 
ANOVA *p<0.05. (C) Representative images of pregnant uteri at GD6.5 from each mating. 
(D-E) Graphs depicting the weight of implantation sites derived from the indicated maternal 
genotype. n=4 litters per maternal genotype. Implantation sites from the same litter are colour 
matched. Data are presented as mean ± SEM. Statistical test: One-way ANOVA, a p<0.05 
when compared to b. (F) Graphs comparing the average weight of implantation sites/litter to 




4.2.2 Abnormal folate metabolism does not affect implantation site weight at 
GD6.5 
To explore whether the decidualisation reaction occurred normally, the weight of individual 
implantation sites at GD6.5 was assessed per Mtrr maternal genotype. At GD6.5, 
implantation sites are largely composed of maternal decidua. The fetoplacental component is 
very small at this stage and contributes little to the overall weight. Uteri were dissected at 
GD6.5 and scissors were used to cut between and close to each implantation site before 
weighing. No differences in average implantation site weight were detected between litters 
from Mtrr+/+, Mtrr+/gt, and Mtrrgt/gt females compared to C57Bl/6 control litters (Figure 
4.1D). However, the average weight of implantation sites from F1 Mtrr+/gt females was less 
than those from F1 Mtrr+/+ females or C57Bl/6 females (p=0.0001; Figure 4.1E). This result 
is difficult to resolve since the litters of Mtrr+/gt females from Mtrr+/gt intercrosses did not 
show a similar effect. It suggests a maternal Mtrrgt allele in the F0 generation might have a 
protective effect on decidualisation of their Mtrr+/gt daughter’s uterus. The different 
phenotype between F1 Mtrr+/+ and F1 Mtrr+/gt could be due to an additive effect of a paternal 
Mtrrgt allele and intrinsic Mtrrgt allele. The decrease in implantation site weight might be a 
result of abnormal decidualisation due to defects in progesterone signalling. Pgr expression 
will be assessed later. To determine whether litter size impacted the weight of each 
implantation site, we performed a linear regression analysis (Figure 4.1F). We found that 
there was no correlation between litter size and average implantation site weight within any 
of the Mtrr maternal genotypic groups at GD6.5. This suggests that even in case of intrinsic 
or parental abnormal folate metabolism, the litter size does not affect the implantation site 
weight at GD6.5. 
  
4.2.3 Analysis of MTRR gene and protein expression in decidua at GD6.5 
Similar to Chapter 3, we assessed wildtype and total Mtrr transcript expression in whole 
implantation sites at GD6.5 collected from matings of C57Bl/6 males with C57Bl/6, Mtrr+/+, 
Mtrr+/gt, Mtrrgt/gt, F1 Mtrr+/+ or F1 Mtrr+/gt females. The analysis was completed via RT-
qPCR. In matings of C57Bl/6 males with Mtrr+/gt females, we were unable to determine the 
genotype of the resulting offspring at GD6.5 (i.e., Mtrr+/+ or Mtrr+/gt). However, since the 
majority of each implantation site is composed of maternal decidua and uterus at this stage, 
the Mtrr genotypic contribution by the conceptus is unlikely to affect the result. Wildtype 
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Mtrr transcript expression in the decidua of Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt females was as 
expected (Figure 4.2A), since implantation sites of Mtrr+/+ females displayed wildtype Mtrr 
transcript levels that were 98% of C57Bl/6 levels whereas the implantation sites of Mtrr+/gt 
and Mtrrgt/gt females showed an appropriate reduction of expression (62.0% and 6.0% of 
control levels, respectively; Figure 4.2A). The expression of the Mtrr wildtype transcript was 
similar between implantation sites of F1 Mtrr+/+ and C57Bl/6 females and was decreased as 
expected to 62.0% of C57Bl/6 levels in the implantation sites of F1 Mtrr+/gt females (Figure 
4.2C). Also, as expected, there was no difference in total Mtrr transcript expression in 
implantation sites at GD6.5 between any of maternal genotype groups tested (Figure 4.2B, 
D).   
To determine the spatial pattern of MTRR protein expression in the decidua, 
immunohistochemistry on implantation sites from C57Bl/6 intercrosses at GD8.5 was 
performed (in collaboration with J. Rakoczy), since implantation sites at GD6.5 were not 
available at the time of this analysis. We observed widespread decidual expression of MTRR 
protein in the regressing primary decidual zone, the decidua basalis, and the lateral decidua 
(Figure 4.2E-G). The secondary decidual zone showed a distinct staining pattern for MTRR 
protein, whereby expression was restricted to the cells on the outer edge (Figure 4.2E, G). 
There was also widespread MTRR expression in fetally-derived tissue including the 
trophoblast giant cell layer, ectoplacental cone, chorion, yolk sac and embryo. In the future, 
immunohistochemistry for the MTRR protein should be performed in C57Bl/6 implantation 





Figure 4.2 Mtrr transcript and protein expression in whole implantation sites at GD6.5. 
(A-D) Relative mRNA expression of (A, C) wildtype Mtrr transcript and (B, D) total Mtrr 
transcript in implantation sites of females derived from Mtrr+/gt intercrosses (A-B) or from a 
Mtrr+/gt father (C-D). Data are presented as mean ± SEM. N=5-8 per genotype. Statistical 
test: One-way ANOVA *p<0.05, **p<0.01. (E-G) Representative sections of a C57Bl/6 
implantation site at GD8.5 stained with anti-MTRR (brown) and counterstained with 
hematoxylin (blue). Scale bars: (E) 1mm, (F) 50μm, (G) 100μm. Am: amnion, ys: yolk sac, 
DB: decidua basalis, LD: lateral decidua, myo: myometrium, TGC: trophoblast giant cells, 
Ch: chorion, EPC: ectoplacental cone, PDZ: primary decidual zone (dotted line), SDZ: 
secondary decidual zone. 
 
4.2.4 Abnormal folate metabolism in males potentially affects the decidualisation 
reaction of their wildtype daughters at GD6.5 
To test whether intrinsic Mtrr deficiency affects regional decidualisation after implantation, 
implantation sites (including surrounding uterus) of C57Bl/6, Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt 
females mated with C57Bl/6 males were dissected at GD6.5, and either embedded in paraffin 
for histological analysis or frozen for molecular analysis. Histological sections of 
implantations sites at GD6.5 were stained with H&E to assess gross morphology. First, 
decidual thickness in the antimesometrial and mesometrial regions and on the left and right 
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sides of the conceptus were measured. Three histological sections per each implantation site 
were assessed and 1-2 implantation sites from at least four litters were assessed per maternal 
genotype. All experiments were done without taking into account the fetal genotype. We did 
not observe any difference in the antimesometrial or mesometrial distances, or the left and 
right decidual zones in implantation sites of Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt females compared to 
C57Bl/6 controls (Figure 4.3A-B). Regional decidualisation was also assessed in 
implantation sites at GD6.5 of F1 Mtrr+/+ and F1 Mtrr+/gt females derived from an Mtrr+/gt 
father. We observed an increase in the antimesometrial (p=0.04) and mesometrial (p=0.03) 
distances in implantation sites at GD6.5 from F1 Mtrr+/+ females compared to C57Bl/6 
females (Figure 4.3A, C). No differences were apparent when measuring decidual zones on 
the left or right of the conceptus (Figure 4.3A, C). Next, we assessed cell density in the lateral 
decidua. While there was no difference in decidual cell density in implantation sites from 
Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt females compared to controls (p=0.1; Figure 4.3D-E), there was 
a decrease in cell density in the implantation sites of F1 Mtrr+/+and F1 Mtrr+/gt females 
compared to C57Bl/6 (p=0.017; Figure 4.3D, F). The latter result suggests that the decidual 
cells are bigger in response to the Mtrrgt allele in the F0 males. The cell density in the 
antimesometrial and mesometrial areas should also be assessed in the future. Furthermore, it 
will be important to examine the cell types that make up the decidua, such as uNK cells, 
macrophages, cytotoxic T cells, dendritic cells, and innate lymphoid cells via 
immunohistochemistry to see whether any cell population is altered in the Mtrr females. 
Overall, these data show that there may be a decidua phenotype in implantation sites in litters 







Figure 4.3 Analysis of decidual morphology in implantation sites at E6.5. 
(A) Representative histological sections of implantation sites at E6.5 stained with H&E. 
Conceptuses from litters of C57Bl/6, Mtrr+/+, Mtrr+/gt and Mtrrgt/gt females are shown. Also, 
conceptuses from F1 Mtrr+/+ and F1 Mtrr+/gt females derived from an Mtrr+/gt male are 
shown. All females were mated with C57Bl/6 male. The genotype of the conceptus was not 
taken into account. Scale bar: 1 mm. m: mesometrial decidua, am: anti-mesometrial decidua, 
r: right decidual zone, l: left decidual zone. (B-C) Quantification of the distances of each 
decidual region as denoted in the top panel in (A). Implantation sites of litters from females 
from (B) Mtrr+/gt intercrosses or (C) an Mtrr+/gt father were assessed. Data are presented as 
mean ± SEM. Two implantation sites were assessed per litter. N=4 litters per adult female 
genotype. (D) Representative images of lateral decidua stained with H&E. Maternal genotype 
shown. Scale bars: 50 μm. (E-F) Quantification of cell density in the lateral decidua of 
implantation sites whose mothers are derived (E) from Mtrr+/gt intercrosses or or (F) from an 
Mtrr+/gt male. Data are presented as mean ± SEM. n=4 implantation sites per maternal 
genotype. Statistical analysis: One-way ANOVA, *p<0.05. 
 
 
4.2.5 Analysis of decidual marker expression in implantation sites at GD6.5 
The process of decidualisation is dependent on progesterone receptor signalling (Large & 
DeMayo 2012). Since we have previously observed a decrease in progesterone receptor 
protein expression in the Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt uteri at estrus, we wanted to determine 
whether a similar finding occurred at GD6.5 with the potential to affect decidualisation 
during pregnancy. We assessed Pgr mRNA expression via RT-PCR in whole implantation 
sites at GD6.5 derived from mating C57Bl/6 males with C57Bl/6, Mtrr+/+, Mtrr+/gt, Mtrrgt/gt, 
F1 Mtrr+/+, or F1 Mtrr+/gt females. There was a decrease in Pgr mRNA expression in 
implantation sites of Mtrr+/gt and Mtrrgt/gt females compared to implantation sites of C57Bl/6 
females (p=0.0002; Figure 4.4A). No change in Pgr mRNA expression was observed in 
Mtrr+/+ females compared to the C57Bl/6 (Figure 4.4A). Furthermore, a decrease in Pgr 
mRNA expression was observed in implantation sites of F1 Mtrr+/gt females compared to 
C57Bl/6 females (p=0.003; Figure 4.4B). No change in Pgr mRNA expression was observed 
in F1 Mtrr+/+ females (Figure 4.4B). Altogether, these data suggest that intrinsic but not 
paternal abnormal folate metabolism affects Pgr mRNA expression at GD6.5. PGR protein 
expression in implantation sites at GD6.5 should be assessed in the future. 
To further assess molecular differences in the decidua of implantation sites at GD6.5 caused 
by the maternal Mtrr genotype, we assessed the expression of genes important for 
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decidualisation (e.g., Hoxa10, Hand2, Nrf2f, Bmp2, Sfrp5 and Cdh1) via qPCR analysis. 
HOXA10 is a regulator of progesterone responsiveness of uterine stromal cells, and therefore 
important during implantation and decidualisation (Lim, Ma, et al. 1999). Hand2 is also a 
gene that is regulated by progesterone during decidualisation (Okada et al. 2014). However, 
Hoxa10 and Hand2 mRNA expression did not change in implantation sites at GD6.5 derived 
from Mtrr+/+, Mtrr+/gt, or Mtrrgt/gt females (Figure 4.4C, D). These data are inconsistent with 
Pgr mRNA expression levels in Mtrr+/gt and Mtrrgt/gt implantation sites (Figure 4.4A), 
although PGR protein levels should be assessed to address this inconsistency. Interestingly, 
Hoxa10 mRNA expression was decreased in the implantation sites of F1 Mtrr+/gt mothers 
compared to those from either C57Bl/6 or F1 Mtrr+/+ females (p=0.0005; Figure 4.4I), a 
similar trend to Pgr mRNA expression in similar implantation sites (Figure 4.4B). Hand2 
expression was only slightly decreased in F1 Mtrr+/gt implantation sites but the result was not 
statistically significant (Figure 4.4J). The inconsistency of Hoxa10 and Hand2 expression in 
implantation sites at GD6.5 from Mtrr+/gt females derived from either two Mtrr+/gt parents or 
only an Mtrr+/gt father needs to be resolved.  
NR2F2 is a transcription factor that is highly expressed in uterine stroma cells and is 
important for decidualisation (Kurihara et al. 2007). It is known to activate Bmp2 
transcription (Wetendorf & DeMayo 2012). We observed a decrease in Nr2f2 and Bmp2 
mRNA expression specifically in implantation sites from Mtrr+/gt and Mtrrgt/gt females 
compared to C57Bl/6 controls (p=0.0012; Figure 4.4E-F). Bmp2 mRNA was lower in 
implantation sites from Mtrr+/+ females than controls (Figure 4.4F) even though Nr2f2 
expression did not change (Figure 4.4E). These data suggest that only an intrinsic Mtrrgt 
allele is sufficient to affect Nr2f2 expression and that another transcription factor beyond 
NR2F2 might regulate Bmp2 during decidualisation. In support of this finding, normal levels 
of Nr2f2 mRNA were found in implantation sites from F1 Mtrr+/+ and F1 Mtrr+/gt females 
(Figure 4.4K) despite decreased Bmp2 mRNA levels (Figure 4.4L). SFRP5 is an inhibitor of 
WNT signalling (Bovolenta et al. 2008; Stuckenholz et al. 2013) and is involved in stromal 
cell differentiation and decidualisation (Li et al. 2007). Expression of Sfrp5 mRNA was 
within the normal range in all of the Mtrr implantation sites assessed compared to the 
controls (Figure 4.4G, M). Lastly, CDH1, also known as E-cadherin, is a protein important 
for decidualisation (Reardon et al. 2012). While Cdh1 mRNA expression was unaltered in all 
Mtrr uteri during estrus (Chapter 3), we observed a decrease in Cdh1 mRNA expression at 





Figure 4.4 Relative mRNA expression of decidualisation markers in GD6.5 implantation 
sites. 
Graphs depicting relative mRNA expression of genes involved in decidualisation in 
implantation sites from mothers derived from either (A, C-H) Mtrr+/gt intercrosses or (B, I-N) 
from an Mtrr+/gt father. Polr2a mRNA was used as a housekeeping gene. n=5-7 implantation 
sites from each adult female genotype. Data are presented as fold change compared to 
C57Bl/6 controls (normalised to 1). Statistical test: One-way ANOVA, a p<0.05 when 





4.4H). A downward trend in Cdh1 mRNA expression was also observed in Mtrr+/+ uteri at 
GD6.5, though this did not reach statistical significance compared to C57Bl/6 uteri (Figure 
4.4N). Cdh1 mRNA expression was similar in C57Bl/6, F1 Mtrr+/+ and F1 Mtrr+/gt females at 
GD6.5, suggesting a combined effect of a maternal and an intrinsic Mtrrgt allele to disrupt its 
expression. 
In summary, even though histological sections did not show gross alterations in 
decidualisation at GD6.5, gene expression of decidualisation markers were disrupted by one 
or more intrinsic Mtrrgt allele. While Pgr mRNA expression is altered, this effect on 
decidualisation may in part be independent of progesterone signalling, since we observe 
normal Pgr mRNA expression, but abnormal expression of Bmp2 mRNA in Mtrr+/+ and F1 
Mtrr+/+ females. For instance, BMP2 is a downstream mediator of Egfr signalling and 
ablation of Egfr in mice results in defects in decidualisation (Large et al. 2014), and this is 
independent of Pgr signalling. The misexpression of some, but not all, decidual markers 
suggests that specific pathways important for proper decidualisation might be affected (e.g., 
BMP2 signalling). 
 
4.2.6 Analysis of growth restriction at E6.5 
Defective decidualisation is known to cause growth restriction (Plaisier 2011). We previously 
observed growth defects in embryos at E10.5 from the Mtrrgt mouse line that were shown to 
be associated with the uterine environment (Padmanabhan et al. 2013). While a specific 
uterine defect has not yet been identified, we wanted to determine whether the growth 
restriction phenotype in conceptuses associated with intrinsic or paternal Mtrrgt mutation 
appeared as early as E6.5. To do this, we assessed conceptuses in histological sections of 
implantation sites at GD6.5 obtained from mating C57Bl/6 males with Mtrr+/+, Mtrr+/gt, and 
Mtrrgt/gt females derived from Mtrr+/gt intercrosses or with F1 Mtrr+/+ and F1 Mtrr+/gt females 
derived from Mtrr+/gt fathers. The anterior-posterior (AP) and dorsal-ventral (DV) axis of 
each conceptus (n=1-2 conceptuses per litter, n=4 litters per genotype) was measured and the 
average lengths per litter were determined (Figure 4.5A, B). No differences in AP and DV 
axis lengths of the conceptuses were observed in the conceptuses derived from Mtrr+/+, 
Mtrr+/gt, or Mtrrgt/gt (Figure 4.5A), or from F1 Mtrr+/+ and F1 Mtrr+/gt mothers compared to 
C57Bl/6 implantation sites (Figure 4.5B). Of note, the genotype of the conceptus was not 
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taken into account in the litters derived from Mtrr+/gt females (e.g., Mtrr+/+ and Mtrr+/gt 
conceptuses result from these matings). Therefore, the size of implantation sites and 
conceptuses were largely unaffected by grandpaternal or maternal Mtrr genotype at E6.5. 
Overall, these data suggest that fetal growth restriction occurs after E6.5. Furthermore, other 
physiological differences in factors that comprise the ‘maternal environment’ might be 
disrupted by the Mtrrgt mutation to cause the growth defects in their offspring. For instance, 
folate has been associated with thyroid stimulating hormone (Lippi et al. 2008). Specifically, 
folic acid supplementation in adolescent rats led to suppression of thyroid hormone function 
(Sittig et al. 2012). Clinical hypothyroidism has been associated with FGR (Tong et al. 2016). 
 
Figure 4.5 Analysis of growth restriction at E6.5. 
(A-B) Graphs depicting the average lengths of the conceptuses in implantation sites of 
females derived from (A) Mtrr+/gt intercrosses or (B) Mtrr+/gt fathers. AP: anterior-posterior 
axis, DV: dorsal-ventral axis. Data are presented as mean ± SEM. n=4 implantation sites per 
maternal genotype. Statistical analysis: One-way ANOVA. 
 
4.3 Discussion 
We assessed the effects of intrinsic and paternal abnormal folate metabolism on gross 
decidual structure and expression of decidual markers at GD6.5. We did not observe any 
structural defects in the decidua, however the expression of some decidual markers was 
disrupted by an intrinsic or parental Mtrrgt mutation. This suggests that decidualisation could 
be affected after GD6.5. 
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Our study revealed that there is a decrease in Pgr mRNA in implantation sites of Mtrr 
females with one or two Mtrrgt alleles. Progesterone and its receptor regulate decidualisation 
by the activation of cascade reactions (Kurihara et al. 2007; Large & DeMayo 2012). 
Progesterone induces stromal cell differentiation (Li et al. 2007). Activation of PGR in the 
uterine epithelium induces activation of Ihh, which in turn activates Nr2f2 in the uterine 
stroma. Nr2f2 mRNA was decreased in females derived from Mtrr+/gt intercrosses with at 
least one Mtrrgt allele, which correlates with Pgr mRNA levels. Interestingly, even though 
Pgr mRNA was decreased in F1 Mtrr+/gt females, Nr2f2 levels were normal, suggesting a 
compensatory mechanism that restores Nr2f2 expression in females with an Mtrr+/gt father 
only. Nr2f2 activation leads to upregulation of Bmp2 and possibly Hand2 (Li et al. 2007; 
Okada et al. 2014). We observed decreased expression of Bmp2 and normal expression of 
Hand2 in all the Mtrr females assessed. This suggests that the Bmp2, but not Hand2 
signalling pathway is affected by abnormal Pgr mRNA expression. Interestingly though, 
wildtype females from both pedigrees had normal Pgr mRNA but decreased Bmp2 mRNA 
expression, suggesting dysregulation of Bmp2 expression by other factors, such as Egfr 
(Large et al. 2014) is possible. Analysis of PGR and BMP2 protein levels is required. PGR 
activation in the uterine stroma also activates Hoxa10 expression (Kurihara et al. 2007; Large 
& DeMayo 2012). Hoxa10 regulates progesterone responsiveness of uterine stromal cells, 
and therefore is important during implantation and decidualisation (Lim, Ma, et al. 1999). 
Hoxa10 mRNA expression was normal in all Mtrr females assessed, except F1 Mtrr+/gt 
females, compared to C57Bl/6 controls, suggesting an alternative mechanism of Hoxa10 
mRNA expression, independent of PGR signalling. In the case of F1 Mtrr+/gt decidua at 
GD6.5, decreased Hoxa10 mRNA expression might suggest that uterine stromal cells are less 
responsive to progesterone thus impairing decidualisation. In addition, Hoxa10 expression is 
known to be regulated by methylation (Wu et al. 2005). We observed global DNA 
hypomethylation in the adult non-pregnant uteri in Mtrr+/gt and Mtrrgt/gt females 
(Padmanabhan et al. 2013), suggesting that altered DNA methylation levels of Hoxa10 
promoter might alter gene expression. It is therefore possible that Hoxa10 is hypomethylated 
also in the pregnant uteri and decidual tissues. However, others showed that dietary folate 
deficiency did not affect Hoxa10 promoter methylation or mRNA expression levels in 
endometrial tissues of pseudopregnant mice (Long et al. 2012). 
Whether there is a link between Pgr mRNA and Cdh1 mRNA levels remains unclear, 
although some suggest that progesterone can induce the expression of Cdh1 during embryo 
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implantation (Jha et al. 2006). Additionally, neither Pgr nor Cdh1 mRNA expression at 
GD4.5 has been affected by a folate-deficient diet (Gao et al. 2012b). We observed decreased 
Cdh1 mRNA expression in Mtrr+/gt and Mtrrgt/gt females at GD6.5, which correlates with Pgr 
mRNA levels. However, we did not observe decreased Cdh1 expression in F1 Mtrr+/gt 
females, even though Pgr mRNA levels were decreased. Decreased expression of Cdh1 
mRNA in Mtrr+/gt and Mtrrgt/gt uteri can prevent the establishment of proper signalling 
pathways in the uterus (Gradilla et al. 2018). 
Folate deficiency was previously shown to decrease apoptosis of decidual cells at GD6.5, at 
the time of decidual regression initiation (Liao et al. 2015). This supports our finding of 
increased decidual size in the implantation sites of F1 Mtrr+/+ conceptuses at GD6.5, 
although analysis of apoptosis by immunohistochemistry using anti-Caspase 3 antibody is 
required. Further analysis is required to determine the distinct populations of cells in the 
maternal decidua and relate the decrease in cell density to their function. Staining the 
implantation sites with PAS and DBA (Chen et al. 2012) will determine the uterine natural 
killer (uNK) cell population. Uterine NK cells regulate SAR and trophoblast invasion, 
therefore have a role in placental function (Gaynor & Colucci 2017; Soares et al. 2014). The 
spiral arteries are high-resistance, low-flow vessels, and they are remodelled into low-
resistance, high-flow during SAR. During this process, uNK cells induce vascular smooth 
muscle cells apoptosis or migration, leading to decreased vessel contractility, and prime the 
vessel for remodelling (Cartwright et al. 2010). Failure to transform the spiral arteries leads to 
reduced capability of meeting the nutritional demands of the developing fetus, leading to 
FGR (Lyall, Robson & Bulmer 2013). In addition, flow cytometry could be performed to 
assess all the decidual cell populations, including uNK cells, macrophages, cytotoxic T cells, 
dendritic cells, Ptprc+ (CD45+), and innate lymphoid cells (Mori et al. 2016). SAR is 
dependent on uNK cells (Gaynor & Colucci 2017), therefore abnormal uterine cell 
populations might affect this process, ultimately causing FGR. 
Bmp2 mRNA expression, which is required for decidualisation, was reduced in uterine tissues 
at day 8 of pseudopregnancy in mice fed a folate-deficient diet where decidualisation was 
artificially induced, by intraluminal infusion of sesame oil, compared to normal-fed mice 
(Geng et al. 2015). Accordingly, a downregulation of Bmp2 mRNA expression was observed 
in implantation sites of all the Mtrr females compared to C57Bl/6. Bmp2 regulates the 
transformation of the endometrial stromal cells into epithelioid decidual cells (Lee et al. 
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2007), therefore decreased Bmp2 expression in the Mtrr uteri could indicate abnormal 
transformation of endometrial stromal cells. Abnormal transformation of stromal cells leads 
to impaired formation of the decidua tissue, and ultimately altered transfer of nutrients to the 
fetus causing FGR. However, in the Mtrrgt model we did not observe any gross 
morphological abnormalities in the decidua tissue, suggesting that Bmp2 likely affects the 
decidualisation reaction after GD6.5.  
Overall, we showed here that intrinsic and paternal abnormal folate metabolism affect the 
decidualisation reaction at the molecular level. Whether only one or both parents have 
abnormal folate metabolism is important, since a maternal Mtrrgt allele seems to have a 
protective effect on Hoxa10 expression, while a paternal Mtrrgt allele seems to have a 
protective effect on Cdh1 and Nr2f2 mRNA expression. One parental Mtrrgt allele is 
sufficient to alter Bmp2 expression, while an intrinsic Mtrrgt allele is sufficient to alter Pgr 
expression. It is possible, that even though embryo growth was normal at E6.5, the growth 
defects observed in the Mtrr model at E10.5 are due to abnormal decidualisation reaction as 
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The RNA sequencing was performed by the Cambridge Genomic Services, Department of 
Pathology. The bioinformatic analysis of the RNA sequencing was performed by Dr. 




We previously showed that the growth phenotypes observed in the F2 Mtrr+/+ conceptuses 
derived from an Mtrr+/gt  maternal grandparent are due to the abnormal uterine environment 
of their Mtrr+/+ mothers (Padmanabhan et al. 2013). Furthermore, global DNA 
hypomethylation and dysregulation of locus-specific DNA methylation were observed in 
placentas of Mtrrgt/gt and F2 Mtrr+/+ conceptuses at E10.5 (Padmanabhan et al. 2013). These 
changes were associated with gene misexpression. Interestingly, altered DNA methylation 
was only observed in placentas and not in the associated embryos, suggesting a placenta-
specific effect (Padmanabhan et al. 2013). Therefore, we wanted to determine the extent to 
which the Mtrrgt mutation alters the placental transcriptome in the Mtrrgt/gt conceptuses and in 
the F2 Mtrr+/+ grandprogeny derived from an Mtrr+/gt maternal grandfather. Furthermore, we 
aimed to determine whether providing a new uterine environment to the F2 Mtrr+/+ 




To examine the effects of intrinsic and ancestral abnormal folate metabolism on the placental 
transcriptome, RNA from placentas at E10.5 was sequenced. We also considered whether 
conceptuses with growth phenotypes caused by the Mtrrgt mutation had an altered placental 
transcriptome. To assess the effects of intrinsic abnormal folate metabolism on placental 
transcriptome, we extracted RNA from placental samples of phenotypically normal and 
growth restricted Mtrrgt/gt conceptuses (Figure 2.1C). To assess the effects of maternal 
grandpaternal Mtrrgt mutation on placental gene expression of their wildtype grandprogeny, 
RNA from placentas of phenotypically normal and growth enhanced F2Mtrr+/+ conceptuses 
derived from an Mtrr+/+ mother and an Mtrr+/gt maternal grandfather was analysed (Figure 
2.1E). In both experiments, RNA from normal C57Bl/6 placentas at E10.5 was used as a 
control. Finally, to understand whether transcriptional changes caused by ancestral Mtrr 
deficiency could be normalised, we assessed the placental transcriptome of phenotypically 
normal and growth enhanced F2 Mtrr+/+ conceptuses at E10.5 derived from an Mtrr+/gt 
maternal grandfather that were transferred into the uterus of a normal recipient female at E3.0 
(Padmanabhan et al. 2013; Figure 2.1G). The placentas of normal C57Bl/6 transferred 
conceptuses were used as control in this experiment (Figure 2.1F). All placentas analysed 
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were from male conceptuses to avoid any discrepancies in the transcriptome that might be 
due to sexual dimorphism (Clifton 2010; Gallou-Kabani et al. 2010). 
 
5.2.1 RNA quality control 
RNA was isolated from placental samples of male conceptuses at E10.5 of the pedigrees and 
growth phenotypes mentioned above and sequenced (initially n=4 placentas per category, 32 
samples in total). First, the integrity and overall quality of total RNA was performed by 
running the samples on an RNA gel (Figure 5.1A). Ribosomal RNA, which represents more 
than 80% of total RNA and is comprised of the 28S and 18S subunits, is represented by two 
bands on the RNA gel, and suggests good overall quality of the samples. The sample quality 
was excellent, with sample absorbance peaks around 260 nm (Figure 5.1B) and a minimum 
RNA integrity number of 8.2 (Figure 5.1C). A minimum RNA integrity number of 8.0 is 
considered sufficient and suitable for RNA sequencing. The RNA library preparation and 
sequencing were performed by the Cambridge Genomic Services, as described in Section 
2.10. 
 
Figure 5.1 RNA sample quality control. 
(A) A representative RNA gel, showing the 18S and 28S rRNA bands. (B) Absorbance 
spectrum of the RNA samples, showing a peak at 260mm. (C) RNA Integrity number (RIN) 
of all RNA samples sequenced. 
126 
 
5.2.2 Quality control of RNA sequencing data  
Before bioinformatics analysis of the RNA sequencing data, we performed a data quality 
control analysis using MultiQC (Ewels, Lundin & Max 2016; Figure 5.2). First, a FastQ 
Screen was performed to align the sequences to known genomes. In all samples, at least 85% 
of the sequences were aligned to the mouse genome, as expected. Less than 15% were 
aligned to multiple genomes, and the rest gave no hits (Figure 5.2A) suggesting a successful 
sequencing run. Next, the genomic origin of the sequenced reads was determined. Around 
65% of the reads were aligned to exonic sequences, 10% to intronic, and 25% to intergenic 
regions (Figure 5.2B). The presence of intronic sequences in the samples might be a result of 
unspliced mRNA. The Phred Score, which is a measure of the probability that a given base is 
called incorrectly by the sequencer and therefore, estimates the sequencing quality, was 
calculated. The Phred Score per base and read counts was above 30, suggesting that the 
individual sequence reads and mean sequencing were of good quality (Figure 5.2C-D). The 
percentage of the GC content per sequence was calculated and showed mean %GC content 
between 40% and 60%, which is the optimal GC content (Figure 5.2E). Finally, the base N 
content, which is the percentage of cases in which the sequencer was unable to call a base 
correctly, and therefore assigned an N base, was calculated to be less than 0.5%, suggesting 
sufficient confidence in more than 99.5% of the bases (Figure 5.2F). Therefore, the RNA 
sequencing data was of good quality, and we were confident to proceed to bioinformatic 
analysis.  
 
Figure 5.2 RNA sequencing data quality control. 
(A) Percentage of the RNA sequencing reads aligned to mouse and other genomes. (B) 
Percentage of reads aligned to exonic, intronic, and intergenic regions. (C) Phred score along 
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the RNA sequencing read (which is approximately 75bp long). (D) Phred score per read 
counts. (E) Percentage of the GC content in each read. (F) Percentage of an unknown base 
along the sequence read. 
 
5.2.3 Sample RNA largely clusters based on their experimental group 
To understand whether the samples clustered together based on their transcriptomes, we 
created a Principal Component Analysis (PCA) plot based on the 500 most variably 
expressed genes. The first principal component (PC1), which is on the x-axis, is the direction 
at which the samples show the highest variation, while the second principal component 
(PC2), which is on the y-axis, is the direction at which the samples show the second highest 
variation (Ringnér 2008). We observed that the blastocyst transfer experiment is the factor 
that caused the highest variation in gene expression. Placentas from non-transferred 
conceptuses clustered on the left-hand side of the PCA plot, while the placentas from 
transferred conceptuses clustered on the right-hand side (Figure 5.3). Therefore, the variation 
in the PC1 represents the blastocyst transfer process. In addition, we observed that the RNA 
samples clustered by growth phenotype. For instance, placentas of growth enhanced 
conceptuses clustered at the bottom of the PCA plot, both in the transferred and non-
transferred groups. The phenotypically normal conceptuses clustered in the middle of the 
plot, except for three Mtrrgt/gt placentas (black arrows in Figure 5.3) that clustered closer to 
the placentas of growth restricted Mtrrgt/gt conceptuses than to the phenotypically normal 
C57Bl/6 or F2 Mtrr+/+ non-transferred conceptuses. However, the placentas of growth 
restricted Mtrrgt/gt conceptuses cluster on the top of the PCA plot (Figure 5.3). One 
phenotypically normal F2 Mtrr+/+ transferred sample was an exception, since it clustered with 
the growth enhanced placentas (turquoise arrow in Figure 5.3). When considering the 
transferred samples, PC2 represents the growth phenotype. 
The remainder of this chapter will focus on the analysis of Mtrrgt/gt placentas. Further 
analyses of the F2 Mtrr+/+ placentas is presented and discussed in Chapter 6. We also 
identified that the embryo transfer procedure itself alters the placental transcriptome. 






Figure 5.3 PCA plot of sequenced placenta samples. 
Principal component analysis (PCA) based on the 500 most variable genes showing the 
clustering of whole male placentas according to their transcriptome. Green circle: C57Bl/6, 
yellow circle: F2 Mtrr+/+ (PN), blue triangle: F2 Mtrr+/+ (GE), black circle: Mtrrgt/gt (PN), 
pink square: Mtrrgt/gt (GR), purple circle: C57Bl/6 transferred, orange triangle: F2 Mtrr+/+ 
transferred (GE), blue circle: F2 Mtrr+/+ transferred (PN). Black arrows indicate the Mtrrgt/gt 
samples that are variable, turquoise arrow indicates the outlier Mtrr+/+ placenta. 
 
 
5.2.4 The Mtrrgt/gt placentas are transcriptionally variable 
Our analysis initially focused on Mtrrgt/gt placentas. The cut-off p-value to consider a gene as 
differentially expressed was p<0.05. Additionally, we set the cut-off fold change to two 
(log2foldchange=1; Table 5.1) to eliminate the genes that were differentially expressed with 
less than two folds in Mtrrgt/gt placentas. This is because the higher the fold change, the more 
likely it is that the differential expression is of biological significance. MA plots, a heatmap, 
and lists of differentially expressed genes (DEGs) were created (Figure 5.4). The MA plot 
129 
 
plots the log-intensity ratios (M) versus the log-intensity averages (A). The x-axis shows the 
normalised read counts, while the y-axis shows the log2fold-change. We identified only 10 
DEGs (i.e., four down-regulated genes, six up-regulated genes) in the placentas of 
phenotypically normal Mtrrgt/gt conceptuses compared to the C57Bl/6 control placentas 
(Figure 5.4A, Table 5.1). Mtrrgt/gt placentas from growth restricted conceptuses were 
appreciably more affected. We identified 38 DEGs (i.e. six downregulated genes, thirty-two 
upregulated genes) in the placentas of growth restricted Mtrrgt/gt conceptuses compared to the 
C57Bl/6 placentas (Figure 5.4B, Table 5.1). When the transcriptomes of placentas of 
phenotypically normal and growth restricted Mtrrgt/gt conceptuses were compared, 20 DEGs 
were identified (i.e. four downregulated genes, 16 upregulated genes (Figure 5.4C, Table 
5.1). Together, these data suggest that as the phenotype of Mtrrgt/gt conceptuses becomes 
worse, their transcriptome is altered to a greater degree. However, fewer DEGs were 
identified than expected. 
A heatmap representing fold change of gene expression shows that two Mtrrgt/gt placentas 
have a higher fold change of expression of four genes: Psca, Ang2, Adamdec1, and Ftl2-ps 
compared to the other placentas (Figure 5.4D). These Mtrrgt/gt placentas represent those that 
did not cluster with the others in the PCA plot (black arrows, Figure 5.3). In addition, there is 
no clear clustering of the samples based on their phenotype (dendrogram on left hand side, 
Figure 5.4D). 







PN: phenotypically normal, GR: growth restricted, FC: fold-change 
 
Comparison C57Bl/6 Vs Mtrrgt/gt 
(PN) 
C57Bl/6 Vs Mtrrgt/gt 
(GR) 






















1.5<fc<2 72 165 147 320 37 124 




Figure 5.4 Degree of differential gene expression in Mtrrgt/gt placentas at E10.5 depends 
on growth phenotype. 
(A-C) MA plots showing differential gene expression between (A) placentas of C57Bl/6 and 
phenotypically normal Mtrrgt/gt conceptuses, (B) placentas of C57Bl/6 and growth restricted 
Mtrrgt/gt conceptuses and (C) placentas of phenotypically normal and growth restricted 
Mtrrgt/gt conceptuses (D) Heatmap showing the 50 most variable genes in phenotypically 
normal (PN, dark green) and growth restricted (GR, purple) Mtrrgt/gt placentas compared to 
C57Bl/6 (light green) placentas at E10.5. Each column represents one gene. Each row 
represents an individual placenta. Degree of gene expression change: red, up-regulated; blue, 
down-regulated; yellow, no change. 
 
 
To validate the RNA sequencing experiment via RT-qPCR, we used placentas from 
phenotypically normal Mtrrgt/gt conceptuses and compared them to the C57Bl/6 controls. For 
each group, we used up to four placentas that were sequenced, in addition to up to eight new 
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placentas (Figure 5.5). Ten genes with at least 1.5-fold change in expression were validated. 
Considering that only C57Bl/6 and phenotypically normal Mtrrgt/gt samples were available for 
validation, and only ten genes were differentially expressed between them, we chose to also 
validate genes with at least 1.5-fold change, due to unavailability of specific primers for some 
of the genes with a 2-fold change. While all four downregulated genes in Mtrrgt/gt placentas 
validated (Figure 5.5A), none of the upregulated genes validated (Figure 5.5B). Polr2a was 
used as a reference gene, since its expression was shown to remain constant in the placenta 
throughout gestation (Solano et al. 2016). As expected, Mtrr gene expression was reduced in 
all Mtrrgt/gt placentas compared to C57Bl/6. Interestingly, Slit3 mRNA was downregulated in 
Mtrrgt/gt placentas, which contradicts the RNA sequencing data (p=0.02; Figure 5.5B). This 
might be due to the large variability in Slit3 mRNA expression in the C57Bl/6 placentas that 
underwent RNA-sequencing (Figure 5.5B). Furthermore, the expression of Anxa8 and Psca 
mRNA was higher in two of the sequenced Mtrrgt/gt samples as determined by RNA-
sequencing (Figure 5.4D) and RT-qPCR analysis (Figure 5.5B). Since the total validation 
success was only 40%, and we observed a high degree of variability in gene expression in the 




Figure 5.5 Validation of RNA-sequencing data by RT-qPCR analysis. 
Graphs show transcripts that were (A) downregulated and (B) upregulated in the placentas of 
phenotypically normal Mtrrgt/gt conceptuses (squares) compared to the C57Bl/6 (circles). 
Sequenced (hollow shapes) and non-sequenced (full shapes) samples were used. Data are 
presented as fold change compared to controls (normalised to 1). N=4-12 placental samples 
per genotype. The number below each graph represents the fold change (FC) observed in the 
RNA-sequencing experiment. Unpaired t tests with Welch correction or Mann-Whitney tests, 
where appropriate, were performed to independently compare Mtrrgt/gt placentas to control 
placentas. *P<0.05, **P<0.01. 
 
Therefore, the RNA sequencing experiment was repeated to increase the sample size. 
Placentas from phenotypically normal conceptuses (N=10 placentas) and growth restricted 
Mtrrgt/gt conceptuses (N=3 placentas) were considered. Considering that the abnormal uterine 
environment causes growth phenotypes (Padmanabhan et al. 2013), we have sequenced 
samples from thirteen different Mtrrgt/gt litters, representing thirteen different maternal 
environments. An additional four C57Bl/6 placentas were also sequenced. To correct for 
batch effects between sequencing runs, one placental sample per genotype and phenotype 
group was re-sequenced. 
After sequencing the new libraries, the data were combined with the sequencing data of the 
first experiment, giving us a total of eight C57Bl/6 placentas, fourteen placentas from 
phenotypically normal Mtrrgt/gt conceptuses, and seven placentas from growth restricted 
Mtrrgt/gt conceptuses. Data quality control showed that the data were of good quality (Figure 
5.6). Batch effects corrections were performed and a PCA plot was created excluding only 
one C57Bl/6 outlier (not shown; Figure 5.7A). When more placental samples were included, 
phenotypic clustering of Mtrrgt/gt placentas did not occur. However, both Mtrrgt/gt placental 
groups tended to cluster separately from C57Bl/6, with a few exceptions (Figure 5.7A). 
Initially, without excluding any samples, MA plots, heatmaps, and the lists of DEG were 
created. As before, the cut-off fold change for differential expression was two 




Figure 5.6 Data quality control for the second round of RNA sequencing. 
(A) Percentage of the RNA sequencing reads aligned to mouse and other genomes. (B) 
Percentage of reads aligned to exonic, intronic, and intergenic regions. (C) Phred score along 
the RNA sequencing read. (D) Phred score per read counts. (E) Percentage of the GC content 
in each read. (F) Percentage of an unknown base along the sequence read. 
 
 
Table 5.2 Number of DEGs per Mtrr genotype and phenotype. 


























2<fc<4 15 22 53 38 1 0 
4<fc<11 6 3 24 3 0 0 
Total 21 25 77 41 1 0 





Figure 5.7 Bioinformatic analysis of data from the second RNA sequencing experiment. 
(A) PCA plot based on the 500 most variable genes in the C57Bl/6 and Mtrrgt/gt samples. Blue 
circles: C57Bl/6 placentas; green squares: growth restricted (GR) Mtrrgt/gt placentas; gold 
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circles: phenotypically normal (PN) Mtrrgt/gt placentas. (B-D) MA plots showing differential 
gene expression between placentas of (B) C57Bl/6 and phenotypically normal Mtrrgt/gt 
conceptuses, (C) C57Bl/6 and growth restricted Mtrrgt/gt conceptuses and (D) phenotypically 
normal and growth restricted Mtrrgt/gt conceptuses. (E-F) Heatmaps showing differential gene 
expression between placentas of (E) C57Bl/6 and phenotypically normal Mtrrgt/gt 
conceptuses, and (F) C57Bl/6 and growth restricted Mtrrgt/gt conceptuses. Each column 
represents an individual placenta. Each row represents one gene. (G) Venn diagram 
comparing the DEG numbers between the three comparisons. 
 
In the dendrogram above each heatmap, a separation in clustering between the C57Bl/6 
controls and Mtrrgt/gt placentas was largely observed (Figure 5.7E-F). No heatmap was 
created to compare the placental transcriptome of phenotypically normal and growth 
restricted Mtrrgt/gt conceptuses, since only one gene was differentially expressed between the 
two groups. Interestingly, we identified 27 genes (Eps8l1, Slc5a4b, Dlx4, Fbp2, Ctsl, Adcy2, 
Noct, St8sia2, Iqcm, Mt3, Hephl1, Cdc14b, Mtrr, Gbp2b, Vat1l, Ube2ql1, Cbx7, Xlr3c, 
Khdc1a, Fbp1, Zfp429, Zfp456, Gm6673, Gm10251, Gm16907, Gm9522, and Gm43305) that 
were similarly differentially expressed between C57Bl/6 and Mtrrgt/gt placentas regardless of 
phenotype (Figure 5.7G). Altogether, these data suggest that the placental transcriptomes of 
phenotypically normal and growth restricted Mtrrgt/gt conceptuses are similar. 
 
5.2.5 Improving the stringency of the Mtrrgt/gt RNA-sequencing dataset 
Given that a few DEGs were identified when comparing the placental transcriptomes of 
phenotypically normal and growth restricted Mtrrgt/gt conceptuses, we assessed the PCA plots 
more closely. Using statistical methods (Conesa et al. 2016), we decided to exclude any 
potential outliers in order to obtain a more stringent dataset. First, a PCA plot was created 
using all of the samples sequenced (Figure 5.8A). Within this PCA plot, there was a clear 
C57Bl/6 outlier which was excluded from future analysis (blue dot in red circle; Figure 
5.8A). This sample was removed to avoid skewing the data. Further PCA plots were 
generated revealing seven Mtrrgt/gt outliers and an additional C57Bl/6 outlier (Figure 5.8B-C), 
which were excluded from the final data. Another PCA plot was created using the remaining 
samples (Figure 5.8B). Here, we observed that the placenta from the growth restricted 
Mtrrgt/gt conceptus shown as an orange dot in red circle clusters with the placentas of 
phenotypically normal conceptuses of the same pedigree. Even though the embryo is 
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characterised as growth restricted based on its crown-rump length, its placental weight was 
0.0645g, which was higher than the average placental weight of the phenotypically normal 
(0.04±0.008g) or the rest growth restricted conceptuses (0.04±0.001g). This could suggest 
that the placenta is trying to compensate for the restricted growth of the embryo. 
Additionally, the phenotypically normal Mtrrgt/gt sample shown as a purple dot in red circle 
clusters with the placentas of growth restricted conceptuses from the same pedigree. There 
were not any different features in this animal. However, these two samples were excluded 
from further analysis, to prevent skewing of the results. Another PCA plot was created 
(Figure 5.8C), showing that the placental sample from the growth restricted Mtrrgt/gt 
conceptus shown as an orange dot in red circle clusters with the phenotypically normal 
samples. Even though the placenta and embryo weights, as well as the embryo:placenta 
weight ratio was similar to the other samples of this phenotypic group, this sample was 
excluded from further analysis. The three phenotypically normal Mtrrgt/gt samples shown as 
purple dots in red circles were also outliers, based on their position on the PCA plot. Two of 
these samples were the same outliers identified in Section 5.2.4, and therefore were excluded 
from future analysis. The other phenotypically normal Mtrrgt/gt sample that was excluded had 
38 somite pairs. Although this is within the normal range for E10.5 conceptuses, this was 
higher than the rest of the conceptuses (33±2 somite pairs). The final PCA plot (Figure 5.8D), 
shows all the samples used to perform differential gene expression analysis (n=6 C57Bl/6 
placentas, n=9 phenotypically normal Mtrrgt/gt placentas, n=5 growth restricted Mtrrgt/gt 
placentas). 
After excluding the outliers mentioned above, MA plots, heatmaps, and the lists of DEGs 
were created. The cut-off fold change to consider a gene differentially expressed was two 
(log2foldchange=1). Table 5.3 shows the number of DEGs identified when comparing 
C57Bl/6 and Mtrrgt/gt placentas according to their fold change. The new MA plots show a 
larger number of DEGs when comparing C57Bl/6 placentas to Mtrrgt/gt placentas (Figure 
5.9A, Table 5.3). This included: 111 downregulated genes and 127 upregulated genes in the 
placentas of phenotypically normal Mtrrgt/gt conceptuses compared to C57Bl/6 placentas 
(Figure 5.9A, Table 5.3) and 153 downregulated genes and 126 upregulated genes in the 
placentas of growth restricted Mtrrgt/gt conceptuses compared to the C57Bl/6 placentas 
(Figure 5.9B, Table 5.3). Furthermore, we were more successful in identifying DEGs (23 
down-regulated genes, 21 up-regulated genes) when comparing the placentas of growth 
restricted Mtrrgt/gt conceptuses, to those of the phenotypically normal Mtrrgt/gt conceptuses 
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(Figure 5.9C, Table 5.3). The dendrograms above the heatmaps show a clear separation of the 
C57Bl/6 and phenotypically normal Mtrrgt/gt placentas (Figure 5.9D), and between the 
C57Bl/6 and growth restricted Mtrrgt/gt placentas (Figure 5.9E). However, the placentas of 
 
Figure 5.8 Principal component analysis plots used to exclude outliers. 
(A) PCA plot based on the 500 most variable genes showing all the C57Bl/6 and Mtrrgt/gt 
samples sequenced in two experiments. (B-D) Further PCA plots generated after removing 
outlier samples. Red lines indicate the samples removed; blue circles: C57Bl/6 placentas, 
purple circles: phenotypically normal (PN) Mtrrgt/gt placentas; orange circles: growth 







Figure 5.9 Bioinformatic analysis of the RNA sequencing data from placentas of 
C57Bl/6, and phenotypically normal (PN) and growth restricted (GR) Mtrrgt/gt 
conceptuses. 
(A-C) MA plots showing differential gene expression between placentas of (A) C57Bl/6 and 
phenotypically normal Mtrrgt/gt conceptuses, (B) C57Bl/6 and growth restricted Mtrrgt/gt 
conceptuses and (C) phenotypically normal and growth restricted Mtrrgt/gt conceptuses. (D-F) 
Heatmaps showing DEGs between placentas of (D) C57Bl/6 (light blue) and phenotypically 
normal Mtrrgt/gt (pink) conceptuses, (E) C57Bl/6 (pink) and growth restricted Mtrrgt/gt (light 
blue) conceptuses and (F) phenotypically normal (pink) and growth restricted (light blue) 
Mtrrgt/gt conceptuses. Each column represents an individual placenta. Each row represents one 






phenotypically normal Mtrrgt/gt conceptuses cluster with the Mtrrgt/gt placentas of growth 
restricted conceptuses (dendrogram above, Figure 5.9F). This, together with the fact that only 
44 DEGs were identified suggest that there is only a minor difference between the placental 
transcriptomes of the two growth phenotypes.  
Altogether, 109 DEGs were common between phenotypically normal and growth restricted 
Mtrrgt/gt when compared to C57Bl/6 placentas. This suggests that these genes are disrupted 
due to Mtrr deficiency and are not likely associated with a growth phenotype. In addition, 
one gene (Prl7a2) was common in all three comparisons (Figure 5.9G). 
 
Table 5.3 Number of DEGs in Mtrrgt/gt placentas at E10.5 per Mtrr genotype and 
phenotype. 


























2<fc<3 80 98 107 100 19 20 
3<fc<4 12 22 20 16 2 1 
4<fc<12 17 6 19 8 1 0 
fc>12 2 1 7 2 1 0 
Total 111 127 153 126 23 21 
PN: phenotypically normal, GR: growth restricted, FC: fold-change 
 
RT-qPCR was performed for validation of the new RNA-seq experiment. The list of DEGs 
identified in phenotypically normal Mtrrgt/gt placentas when compared to C57Bl/6 placentas 
was used for validation. Genes were selected for validation based on the fold change, and the 
specificity of the designed primers. Samples that were sequenced and new samples were 
used. The differential expression of eleven out of the 14 genes that were downregulated in the 
Mtrrgt/gt placentas and analysed, reached statistical significance (p<0.05; Figure 5.10), giving 
a rate of 78.6%. In contrast, the differential expression of none of the 10 genes that were 
upregulated in the Mtrrgt/gt placentas reached statistical significance (p>0.05; Figure 5.11). 
Some variability in gene expression was observed in placentas of both the C57Bl/6 and the 
Mtrrgt/gt conceptuses. Even so, the results from the RNA-sequencing experiment were deemed 
to be robust and reliable, following validation. Next, we performed gene expression 
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correlation analysis between the RNA sequencing data and the qPCR results (Figure 5.12). 
We observed a weak positive linear relationship between the expression of downregulated 
genes in the RNA-seq and qPCR experiments (r2=0.2543, p=0.0659; Figure 5.12A), and no 
relationship between the expression of upregulated genes (r2=0.0729, p=0.4506; Figure 
5.12B). It is important to note that the higher the read counts, the lower the variance. As a 
result, any differences in the expression of genes with higher read counts between C57Bl/6 
and Mtrrgt/gt placentas can be more reliably quantified. This suggests that the higher the read 
counts, the more reliable the RNA-seq data are. The genes used for validation are shown on 
the MA plot in Figure 5.9A. One possible reason that the differential expression of Rmrp and 
Tex13b did not reach statistical significance via qPCR is that low read counts of these genes 
were detected via RNA-seq. 
 
Figure 5.10 Validation by RT-qPCR analysis of downregulated genes identified by 
RNA-seq. 
Graphs show transcripts that were downregulated in the phenotypically normal Mtrrgt/gt 
placentas (squares) compared to the C57Bl/6 (circles). Sequenced (hollow shapes) and 
biologically independent (full shapes) samples were used. Data are presented as fold change 
(mean ± SEM) compared to controls (normalised to 1). N=5-12 placental samples per 
genotype. The number below each graph represents the fold change (FC) observed in the 
RNA-seq experiment. Unpaired t tests with Welch correction or Mann-Whitney tests where 
appropriate were performed to independently compare placentas of C57Bl/6 and Mtrrgt/gt 





Figure 5.11 Validation by RT-qPCR analysis of up-regulated genes identified by RNA-
sequencing. 
Graphs show transcripts that were upregulated in the phenotypically normal Mtrrgt/gt placentas 
(squares) compared to the C57Bl/6 (circles). Sequenced (hollow shapes) and biologically 
independent (full shapes) samples were used. Data are presented as fold change (mean ± 
SEM) compared to controls (normalised to 1). N=10-14 placental samples per genotype. The 
number below each graph represents the fold change (FC) observed in the RNA-sequencing 
experiment. Unpaired t tests with Welch correction or Mann-Whitney tests where appropriate 
were performed to independently compare placentas of C57Bl/6 and Mtrrgt/gt conceptuses. 
 
 
Figure 5.12 Gene expression correlation between the RNA-sequencing data and the 
qPCR results. 
Graphs show the correlation of expression between the RNA sequencing and qPCR data of 
genes that were (A) downregulated and (B) upregulated in Mtrrgt/gt placentas compared to 
C57Bl/6 placentas and used for qPCR validation. Linear regression and correlation analyses 
were performed, and the Pearson correlation coefficient was calculated. 
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5.2.6 The DEGs in the Mtrr locus 
The Mtrrgt mouse model was originally generated in a 129/P2 genetic background, and then 
backcrossed with C57Bl/6 mice for at least eight generations (Padmanabhan et al. 2013). 
However, using whole genome sequencing, the Watson lab identified a 20Mb region of 
129/P2 genetic sequence (chr13:60162000:70162000) around the Mtrr gene when the gene-
trap is present (G. Blake, X. Zhao, R. Hamilton, E. Watson, unpublished). Ten of the DEGs 
identified in Mtrrgt/gt placentas were found in this 20 Mb region: Zfp429, Ctsm, Tpbpb, Ctsq, 
4930525G20Rik, Tpbpa, Zfp456, Cts3, Gm16907, and Zfp457. Among these genes, Ctsm, 
Tpbpb, Ctsq, Tpbpa, and Cts3 have known expression in trophoblast cells. It is unclear 
whether the differences in genetic sequence around the Mtrr gene in Mtrrgt/gt conceptuses 
compared to C57Bl/6 controls affect gene regulation, or whether these genes are 
misexpressed because of a placental phenotype caused by Mtrr deficiency. None of the DEGs 
identified when comparing phenotypically normal and growth restricted Mtrrgt/gt conceptuses 
were within the Mtrr locus. It is unclear whether this is because of the similar genetic 
sequence around the Mtrr gene, or whether similar placental phenotypes caused by the Mtrr 
deficiency occur in both phenotypically normal and growth restricted Mtrrgt/gt conceptuses 
compared to C57Bl/6 conceptuses. 
 
5.2.7 Gene ontology analysis of the DEGs 
We performed gene ontology analysis of the DEGs to identify potential enriched biological 
processes, molecular functions, or mammalian phenotypes that are disrupted or arise in 
Mtrrgt/gt placentas. First, we performed gene ontology on the DEGs between placentas of 
C57Bl/6 and phenotypically normal Mtrrgt/gt conceptuses. Interestingly, not many pathways 
were identified. This might be due to the variability in gene expression between the Mtrrgt/gt 
placentas. In the Mtrrgt model, the availability of methyl groups for cellular methylation is 
limited. We hypothesise that DNA methylation changes occur stochastically in each 
individual, and therefore, the genes that are misexpressed vary. This interindividual 
variability might prevent gene expression from being statistically significant. 
Interestingly, enriched biological processes included transport function such as vitamin 
transport (p=0.0002) and fructose metabolism (p=0.003). Indeed, an important placental 
function necessary for proper embryo development, is nutrient transport (Bell & Ehrhardt 
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2002). We identified 16 genes that encode proteins with transport function in placentas of 
phenotypically normal Mtrrgt/gt conceptuses compared to C57Bl/6 (Table 5.4). Since many of 
these genes were upregulated, it is possible that the Mtrrgt/gt placenta is compensating to 
maintain fetal growth. We have previously showed that the embryo and placenta weights of 
phenotypically normal Mtrrgt/gt conceptuses are proportionally decreased at E10.5 compared 
to C57Bl/6 (Padmanabhan et al. 2017). Placental transport assays are required to further 
assess active placental transport in the Mtrrgt model. Additionally, there were no enriched 
terms related to placenta function or embryo growth. Finally, analysis of DEGs in 
phenotypically normal Mtrrgt/gt placentas suggested a cardiovascular system phenotype 
(p=0.046, Scarb1, Slc2a2) and abnormal vitamin homeostasis (p=0.035, Mtrr). Interestingly, 
the genes associated with the cardiovascular system phenotype are Scarb1 and Slc2a2, which 
also have transport activity. 
Table 5.4 DEGs with transport function in phenotypically normal Mtrrgt/gt compared to 
C57Bl/6 placentas at E10.5. 
Gene FC Function 
Rhd -2.34 Cation transmembrane transport 
Afm -2.31 Vitamin transport 
Nanos1 2.01 Regulation of Ca2+ transport 
Tnfaip8l3 2.02 Phospholipid transport 
Scn7a 2.03 Cation transmembrane transport 
Slc23a1 2.04 Carboxylic acid transport 
Slc16a5 2.25 Carboxylic acid transport 
Scarb1 2.26 Phospholipid transport 
Mt-tp 2.4 Phospholipid transport 
Mt3 2.53 Cation transmembrane transport 
Ttpa 2.66 Vitamin transport 
Slc5a9 2.9 Hexose transport 
Slc2a2 3.13 Hexose transport 
Hrc 3.27 Regulation of Ca2+ transport 
Atp2b2 4.33 Cation transmembrane transport 
Trmp2 8.24 Cation transmembrane transport 
 
Next, we identified enriched gene ontology terms related to the DEGs in growth restricted 
Mtrrgt/gt placentas at E10.5 compared to C57Bl/6 controls. Enriched biological processes 
include cAMP biosynthesis (p=0.001, Adcy3, Adcy2, Adcy5), regulation of VEGFR signalling 
(p=0.014, Flt1, Mt3), cholesterol metabolism (p=0.016, Cyp11a1, Fdx1, Dhcr7, Mt3), and 
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gluconeogenesis (p=0.02, Pkc1, Fbp1, Fbp2). Abnormal VEGFR signalling can affect 
decidual angiogenesis and vascular development of the placenta, leading to growth restriction 
(Douglas et al. 2014; Li et al. 2015). Interestingly, we identified enriched molecular function 
terms, such as BMP signalling (p=0.01, Bmp2, Bmp6), glucose transport (p=0.03, Ppbp, 
Slc2a5), and WNT-activated receptor activity (p=0.04, Sfrp4, Fzd3). BMP signalling is 
involved in decidualisation, and abnormal expression of Bmp2 and BMP signalling can lead 
to abnormal decidualisation and growth restriction (Lee et al. 2007). As mentioned in a 
previous chapter, we identified decreased expression of Bmp2 mRNA in implantation sites of 
Mtrrgt/gt females compared to C57Bl/6 controls at GD6.5. We also identified 16 genes that 
were misexpressed in placentas of growth restricted Mtrrgt/gt compared to C57Bl/6 
conceptuses (Table 5.5). In contrast to the placentas of phenotypically normal Mtrrgt/gt 
conceptuses, an equal number of these misexpressed transporter genes were up- and down-
regulated in the placentas of growth restricted Mtrrgt/gt conceptuses, which does not indicate 
functional compensation. 
Table 5.5 DEGs with transport function in growth restricted Mtrrgt/gt compared to 
C57Bl/6 placentas at E10.5. 
Gene FC Function 
Trpm1 -2.73 Calcium transport 
Slc1a1 -2.41 Dicarboxylic acid and amidic amino acid transport 
Slc26a7 -2.33 Dicarboxylic acid transport 
Afm -2.19 Vitamin transport 
Ppbp -2.17 Glucose transmembrane transport 
Trpc3 -2.13 Ion transport 
Kcnh2 -2.04 Regulation of cation transport 
Kcnj5 -2.02 Regulation of ion transport 
Slco2a1 2.14 Fatty acid transport 
Slc2a5 2.2 Glucose transmembrane transport 
Scarb1 2.74 Vitamin transport 
Slc16a5 2.97 Carboxylic acid transport 
Mt3 3.03 Ion transport 
Hrc 3.43 Regulation of cation transport 
Trpm5 3.78 Calcium transport 
Atp2b2 5.53 Calcium transport 
 
Finally, enriched mammalian phenotypes include delayed heart development (p=0.018, 
Bmp2, Actc1), abnormal chorion morphology (p=0.03, Bmp2, Dnmt3l), and increased 
trophectoderm apoptosis (p=0.04, Cdx2). These phenotypes might suggest abnormal 
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placental development and function, leading to growth restriction, and delayed organ 
development. 
 
5.2.8 DEGs that are involved in placental function and embryo growth 
We identified enriched gene ontology terms based on the DEGs between phenotypically 
normal and growth restricted Mtrrgt/gt conceptuses. Both sample groups have abnormal folate 
metabolism, therefore this analysis would highlight genes that are responsible for growth. 
Enriched biological function terms included purine metabolism (p=0.015, Nudt10), mRNA 
stabilisation (p=0.038, Dazl), and transport (p=0.02, Trpc3). Finally, an enriched mammalian 
phenotype was small allantois (p=0.02, Zic3). Given that we previously reported defects in 
chorioallantoic attachment in Mtrrgt/gt conceptuses (Padmanabhan et al. 2013), Zic3 will be a 
gene to explore in the future. Altogether, these data suggest that placentas of growth 
restricted Mtrrgt/gt conceptuses might have altered placental development compared to the 
placentas of phenotypically normal Mtrrgt/gt conceptuses. 
Comparing placentas of phenotypically normal Mtrrgt/gt conceptuses to C57Bl/6 placentas 
also revealed a few upregulated genes important for growth (Fosl1, Ctsl, Htra1, Rbp4, Ptx3; 
Table 5.6). For instance, Ctsl mRNA was upregulated in placentas of phenotypically normal 
Mtrrgt/gt conceptuses. Ctsl is expressed in trophoblast and endometrial glands, and as a 
lysosomal cysteine protease, it is thought to play an important role in implantation and 
placentation (Krueger et al. 2001; Song, Bazer & Spencer 2007; Varanou et al. 2006). Since 
Htra1 mutants are growth restricted as a result of aberrant vascularisation of the labyrinth 
(Hasan et al. 2015), it is possible that Mtrrgt/gt placentas attempt to increase Htra1 expression 
to prevent growth restriction. In humans, RBP4 is required for trophoblast cell proliferation 
and invasion (Li et al. 2018), while PTX3 expression is altered in pregnancies complicated 
with FGR (Cozzi et al. 2012). Altogether, this suggests that the placentas of phenotypically 
normal Mtrrgt/gt conceptuses compensate by upregulating the expression of genes that are 




Table 5.6 DEGs in phenotypically normal Mtrrgt/gt compared to C57Bl/6 placentas 
related to placental function. 
Gene 
(FC) 





Responsible for the 
development of trophoblast 
lineages and establishment 
of the maternal-fetal 
interface 
Knockdown of Fosl1 disrupted the 
expression of Mmp9, associated with the 
invasive-vascular remodelling trophoblast 
phenotype. Inhibition of Fosl1 expression 
using shRNA abrogated trophoblast 
invasion. 





involved in the initiation of 
protein degradation 
Ctsl regulates cellular invasiveness by 
promoting migration and basement 
membrane degradation, it is important for 
placental development. 
(Krueger et al. 
2001; 




Serine peptidase Mutants exhibit FGR and have small 
placentas due to smaller junctional zone 
and aberrant vascularisation in the 
labyrinth at midgestation. SAR is also 
impaired. 






proliferation and invasion 
RBP4 knockdown inhibits HTR8/SVneo 
cell proliferation and invasion and 
represses the expression of matrix 
metalloproteinases. 






activation, plays a role in 
angiogenesis and tissue 
remodelling 
Increased expression of PTX3 in 
pregnancies complicated with FGR 
indicates altered endothelial function due 
to excessive maternal inflammatory 
response to pregnancy. 
(Cozzi et al. 
2012) 
 
Three of these genes were also differentially expressed between placentas of growth 
restricted Mtrrgt/gt and C57Bl/6 conceptuses: Fosl1 (FC=2.34), Ctsl (FC=2.67), and Htra1 
(FC=2.89; Table 5.6). Six additional genes involved in placenta development, such as TGC 
differentiation and formation of labyrinth and spongiotrophoblast layers (i.e., Sox15, Vash2, 
Dnmt3l, Flt1, Rbm46, Cdx2) were downregulated in the placentas of growth restricted 
Mtrrgt/gt conceptuses compared to C57Bl/6 (Table 5.7). Altogether, these data suggest the 
potential for a causative or a compensatory mechanism in the placenta in response to 
abnormal folate metabolism. 
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Table 5.7 DEGs in placentas of growth restricted Mtrrgt/gt compared to C57Bl/6 related 
to placental phenotypes. 
Gene 
(FC) 







Sox15 mutants that lack the HAND1 binding 





Cadherin family of cell 
adhesion receptors 
Expressed in placental mesenchymal stem 
cells. Placental phenotype unknown. 
Dsc3-/- have preimplantation lethality.  







Vash2−/− mutants have thinner villi of the 
labyrinth and larger maternal lacunae and 








Knockout: defective labyrinth formation, 
reduced spongiotrophoblast layer, excess 
TGCs, insufficient attachment between the 
chorion and the EPC. 




Placental growth factor 
receptor 
Treatment of a trophoblast cell line with an 
FLT1 inhibitor leads to slow growth, inhibition 
of cell proliferation, decreased expression of 
cell cycle progression genes, and attenuated 
migration of trophoblast cells in vitro. In vivo, 
decreased number of cytotrophoblast cells 
were observed in pregnancies complicated 
with FGR. 




RNA-binding protein Knockdown of Rmb46 leads to downregulation 
of trophectoderm markers and upregulation of 
endoderm and mesoderm markers in ESCs. 
Rmb46 stabilises Cdx2 mRNA and regulates 
trophectoderm specification. 




Transcription factor Cdx2 is required for proper cell fate 
specification and differentiation of 
trophectoderm. Overexpression of Cdx2 in 
human TS cells enhanced cell invasion by 
increasing MMP9 and decreasing its inhibitor, 
TIMP1 expression. Also, gain of Cdx2 
function in ES cells induces differentiation 
into cells with trophoblast cell characteristics. 





et al. 2006) 
Bmp2 
(2.15) 
Decidualisation marker Bmp2 mutant females have defective 
decidualisation. 
(Lee et al. 





Interestingly, we did not identify any genes involved in developmental phenotypes that were 
differentially expressed between phenotypically normal and growth restricted Mtrrgt/gt, even 
though these two sample groups have different growth phenotypes. This suggests that the 
phenotypically normal Mtrrgt/gt conceptuses could potentially become growth restricted later 
during gestation. Overall, these data suggest that abnormal folate metabolism alters the 
expression of genes involved in trophoblast development and decidualisation. There are more 
DEGs associated with developmental phenotypes between growth restricted Mtrrgt/gt and 
C57Bl/6 conceptuses than between phenotypically normal Mtrrgt/gt and C57Bl/6 conceptuses, 
which correlates with the severity of the phenotype. The fact that the placentas of 
phenotypically normal Mtrrgt/gt conceptuses are affected, suggests that the associated embryo 
although phenotypically normal, might be molecularly and metabolically abnormal. 
 
5.2.9 Altered CpG methylation as a predicted mechanism for gene misexpression 
in Mtrrgt/gt placentas 
The Mtrrgt model is characterised by global DNA hypomethylation in the placentas, and 
dysregulation of CpG methylation at E10.5 (Padmanabhan et al. 2013). To examine the 
potential sensitivity of the DEGs to changes in CpG methylation, we evaluated whether the 
top 50 downregulated genes (FC<-2.34) and top 50 upregulated genes (FC>2.56) in Mtrrgt/gt 
placentas contained CpG repeats that were intragenic or proximal (within 20kb) to the gene 
(Figure 5.13 A-D). To do this, we used the UCSC Mouse Genome Browser to identify the 
location of CpG repeats with relation to the DEGs. As a control, 50 randomly selected genes 
were identified as a proxy of the genome and used in a similar analysis. This analysis did not 
determine whether the CpG repeats present were methylated, however it highlights the 




Figure 5.13 The percentage of DEGs in Mtrrgt/gt placentas that were associated with CpG 
repeats. 
The percentage of the top 50 down-regulated (blue lines) or up-regulated (pink lines) genes in 
placentas of (A-B) phenotypically normal Mtrrgt/gt conceptuses, or (C-D) growth restricted 
Mtrrgt/gt conceptuses at E10.5 that display CpG repeats localised (A,C) intragenically or (B,D) 
within 20 kb of the gene. The percentage of 50 randomly selected genes with similar features 
is indicated as a proxy for the genome (black lines). Data on the x-axis are presented as the 
cumulative number of differentially expressed genes (DEGs). Statistical analysis: Fisher’s 
exact test. *p<0.05, **p<0.01, ****p<0.001. Blue asterisks: significance between down-
regulated genes and the genome, red asterisks: significance between up-regulated genes and 
the genome, green asterisks: significance between down-regulated and up-regulated genes. 
 
When the DEGs in placentas of phenotypically normal Mtrrgt/gt conceptuses were considered, 
both up- and down-regulated gene sets were less likely to contain intragenic CpG repeats 
compared to the rest of the genome (21-30% of DEGs compared of 46% of genes genome-
wide; p<0.05, Fisher’s exact test; Figure 5.13A). Moreover, upregulated genes were less 
frequently associated with proximal CpG repeats (30% of DEGs compared to 42% of gene 
genome wide; p<0.05, Fisher’s exact test). Downregulated genes had similar frequencies of 
proximal CpG repeated (32% of DEG) both to upregulated DEGs and the genome (Figure 
5.13B). 
Mtrrgt/gt placentas from growth restricted conceptuses displayed a similar frequency of CpG 
repeats. In this case, both up- and down-regulated gene sets were less likely to contain 
intragenic CpG repeats (11.4-34% of DEGs compared of 46% of genes genome-wide; 
p<0.05, Fisher’s exact test; Figure 5.13C). Moreover, upregulated genes were less frequently 
associated with proximal CpG repeats (6.4% of DEGs compared to 42% of gene genome 
wide; p<0.05, Fisher’s exact test) compared to the rest of the genome. The higher the fold 
change, the less likely it was that the gene is associated with CpG repeats. Downregulated 
genes had similar frequencies of proximal CpG repeats (37.7% of DEG) to the genome but 
were less frequently associated with proximal CpG repeats compared to the upregulated 
genes (Figure 5.13D). Overall, these findings suggest that the DEGs are less likely to be cis 
regulated by CpG methylation compared to the genome at large. Therefore, it is suggested 
that epigenetic mechanisms other than CpG methylation, such as histone modification, or 
RNAi affect the expression of the DEGs. Alternatively, it is possible that CpG methylation of 
genes that regulate the expression of the DEGs occurs. 
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The analysis above assumes that the CpG repeats associated with the DEG directly regulate 
its expression. However, little is known about the functional implications of CpG methylation 
near specific genes in the genome. We were only able to identify 15 DEGs in Mtrrgt/gt 
placentas whose expression has been directly linked to changes in CpG methylation in other 
studies (Table 5.8). Based on these studies and our RNA-seq data, we predicted the change of 
CpG methylation at these locations in the Mtrrgt/gt placentas (Table 5.8). Four out of 15 
(26.7%) of the DEGs are hypothesised to be associated with hypermethylated CpGs that 
cause downregulation of gene expression. The remaining 11 DEGs (73.3%) are suspected to 
display an opposite trend: hypomethylated CpGs that cause upregulation of gene expression. 
Therefore, we predicted both hypermethylation and hypomethylation of specific CpG sites in 
response to Mtrr deficiency in the placenta. However, locus specific hypomethylation might 
occur more frequently than hypermethylation. 
 
Table 5.8 DEGs in Mtrrgt/gt placentas with known regulation by DNA methylation. 





DEGs in placentas of PN Mtrrgt/gt conceptuses 
Trpm2 
(-8.23) 
Cation channel DNA methylation 
of inner CpG island 
associated with 
reduced expression 




Circadian clock effector, 

















Hypo (Jin et al. 2016) 
Igfbpl1 
(3.79) 
Binds IGFs, either 
inhibit or stimulate the 
growth promoting effects 
of the IGFs 
Hypermethylation 
of intragenic CpG 
island is associated 
with decreased 
expression 




Protein kinase C-binding 
protein 
Hypermethylation 
in promoter or gene 
body is associated 












is associated with 
decreased 
expression 






which is involved in the 







Hypo (Samaiya et al. 
2011) 
DEGs in placentas of GR Mtrrgt/gt conceptuses 
Stk33 
(-3.66) 








Regulates cell growth and 
differentiation  
Demethylation leads 
to an increase in gene 
expression 


















Hypo (Hayakawa et 
al. 2012)  
Star 
(3.29) 
Steroid hormone synthesis 
enzyme 
CpG methylation of 
Pax6 binding motif 
in STAR promoter 
reduces the gene 
expression 




Binds IGFs, either inhibit or 
stimulate the growth promoting 
effects of the IGFs 
Hypermethylation of 
intragenic CpG 
island is associated 
with decreased 
expression 




Protein kinase C-binding protein Hypermethylation in 
promoter or gene 
body is associated 
with decreased 
expression 












Hypo (Chen et al. 
2011) 
 
5.2.10 Predicted changes in histone modifications as a mechanism for placental 
gene misexpression 
In general, genes that were upregulated in Mtrrgt/gt placentas were less likely to associate with 
CpG repeats suggesting that their regulation might not depend upon this epigenetic 
modification. Another epigenetic mechanism of gene regulation is histone modifications. 
Therefore, we explored histone modifications as a potential mechanism for differential gene 
expression in Mtrrgt/gt placentas. To do this, we used published ChIP-seq data set that shows 
localised genomic enrichment for H3K4 monomethylation (me1) and H3K27 acetylation (ac) 
in normal C57Bl/6 mouse placentas at term (Haeussler et al. 2019). High levels of H3K4me1 
and H3K27ac are generally associated with transcriptionally active genes (Zhang & Reinberg 
2001). To examine the potential sensitivity of the DEGs to changes in histone modifications, 
we evaluated the top 50 downregulated genes (FC<-2.79) and top 50 upregulated genes 
(FC>2.56). We assessed whether placental intragenic or proximal (within 20 kb) H3K4me1 
or H3K27ac enrichment is associated with DEGs under normal circumstances (Figure 5.14). 
We also assessed 50 randomly selected genes as a proxy of the genome. This analysis did not 
determine the existence of histone modifications in the Mtrrgt/gt placentas, but rather it 
highlights the potential for gene dysregulation when abnormal histone modification occurs. 
When the top 50 up- or down-regulated DEGs in placentas of Mtrrgt/gt conceptuses were 
considered, they were equally as likely to be associated with placental H3K4me1 peaks 
compared to the genome. This trend was true of intragenic and proximal peaks (Figure 
5.14A-B, E-F). Up- and down-regulated gene sets also showed a similar level of association 
with H3K4me1 enrichment relative to each other (Figure 5.14A-B, E-F). 
In contrast, downregulated genes were less likely to be associated with placental H3K27ac 
peaks compared to upregulated genes and the genome at large (p<0.05; Figure 5.14C-D, G-
H). The upregulated genes had similar frequencies of H3K27ac peaks compared to the whole 
genome at large (Figure 5.14C-D, G-H). Therefore, genes that were downregulated in 
Mtrrgt/gt placentas are unlikely to be controlled in normal conditions by H3K27ac. In contrast, 
genes that were upregulated are likely similarly sensitive to changes in H3K27ac levels 
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compared to the rest of the genome. From this, we can speculate that histone acetylation may 
not be an important mechanism in the context of Mtrr deficiency. A ChIP-seq experiment 
using antibodies against these and other histone modifications in Mtrrgt/gt placentas is required 
to explore this question further. 
 
Figure 5.14 Frequency of histone modifications associated with genes that were 
misexpressed in Mtrrgt/gt placentas. 
The percentage of the top 50 down-regulated (blue bars) or up-regulated (red bars) genes 
between placentas of phenotypically normal Mtrrgt/gt and C57Bl/6 (A-D), or growth restricted 
Mtrrgt/gt and C57Bl/6 conceptuses (E-H) that display placental H3K4me1 peaks (A-B, E-F) 
localised (A,E) intragenically or (B,F) within 20 kb of the gene, or placental H3K27ac peaks 
(C-D, G-H) localised either (C,G) within the gene or (D,H). The percentage of 50 randomly 
selected genes with similar features is indicated as a proxy for the genome (black bars). 
Statistical analysis: Fisher’s exact test. **p<0.01, ****p<0.001. 
 
 
5.2.11 Analysis of the placental transcriptome in F2 Mtrr+/+ conceptuses at E10.5 
Since we previously showed that Mtrr+/gt maternal grandfathers cause gross placental 
phenotypes in their wildtype grandprogeny (i.e., F2 Mtrr+/+ conceptuses) at E10.5 
(Padmanabhan et al. 2013), we assessed the transcriptome of F2 Mtrr+/+ placentas at E10.5 
and compared the results to similar stage C57Bl/6 control placentas (n=7). The purpose of 
this experiment was to explore potential molecular pathways affected in the placenta over 
multiple generations in this context. Additionally, we previously determined that growth 
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phenotypes were present in the F2 Mtrr+/+ conceptuses (Padmanabhan et al. 2013, 2017). 
Therefore, we analysed the placental transcriptomes of phenotypically normal (n=4) and 
growth enhanced (n=4) F2 Mtrr+/+ conceptuses to explore how growth is affected by 
abnormal folate metabolism in the maternal grandfather. 
We created a PCA plot to determine the transcriptional relationship of the samples (Figure 
5.15A). We observed that there was no clear separation of the samples suggesting that the 
transcriptomes of the C57Bl/6 and F2 Mtrr+/+ placentas were similar, regardless of the 
phenotype. Indeed, there were no genes that were differentially expressed (FC > 2) in 
placentas of C57Bl/6 and phenotypically normal F2 Mtrr+/+ conceptuses (Figure 5.15B). 
When considering genes that were differentially expressed by a fold change greater than 1.5, 
only one gene was up-regulated (Gpnmb, FC= 1.67) in the placentas of phenotypically 
normal F2 Mtrr+/+ conceptuses compared to C57Bl/6. In contrast, only one gene was down-
regulated (Gbp2b, FC= -133.44) in the placentas of growth enhanced F2 Mtrr+/+ conceptuses 
compared to C57Bl/6 (Figure 5.15C). Gbp2b hydrolyses GTP to GMP and protects against 
bacterial infection (Kim et al. 2011). Its expression in the placenta or its role in placenta 
development or function are unknown. A lack of DEGs identified might be due to the small 
sample size of placentas that were sequenced. Lastly, we compared the placental 
transcriptome of phenotypically normal and growth enhanced F2 Mtrr+/+ conceptuses to 
determine whether specific molecular pathways involved in growth were apparent. Only one 
gene was upregulated (Camk2b, FC= 2.06) in the placentas of phenotypically normal F2 
Mtrr+/+ conceptuses compared to growth enhanced F2 Mtrr+/+ conceptuses (Figure 5.15D). 
De novo mutations in Camk2a and Camk2b were shown to cause intellectual disability, 
intrauterine growth restriction, developmental delay, and placental abnormalities (Küry et al. 
2017). These phenotypes were also observed in our model of abnormal folate metabolism 
(Padmanabhan et al. 2013). Placental expression of Camk2b is still unknown. These data 
suggest that, even though placental phenotypes are present (Padmanabhan et al. 2013), the 
Mtrrgt mutation in the maternal grandfather does not affect the placental transcriptome of the 




Figure 5.15 Bioinformatic analysis of the RNA sequencing data from placentas of 
C57Bl/6 and F2 Mtrr+/+ conceptuses. 
(A) PCA plot based on the 500 most variable genes. Blue circles: C57Bl/6, purple triangles: 
growth enhanced F2 Mtrr+/+, red circles: phenotypically normal F2 Mtrr+/+ (B-D) MA plots 
showing DEG between placentas of (B) C57Bl/6 and phenotypically normal 
Mtrr+/+conceptuses, (C) C57Bl/6 and growth enhanced Mtrr+/+conceptuses and (D) 
phenotypically normal and growth enhanced Mtrr+/+ conceptuses. PN: phenotypically normal, 




We have shown that abnormal folate metabolism caused by the Mtrrgt/gt mutation in mice 
results in changes in placental gene expression at E10.5 of gestation in an embryonic 
phenotype-dependent manner. The placental efficiency of C57Bl/6 and phenotypically 
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normal Mtrrgt/gt conceptuses is similar (Padmanabhan et al. 2017), however, we identified 
genes involved in placenta development and embryo growth that were differentially 
expressed in Mtrrgt/gt placentas compared to C57Bl/6. In addition, gene ontology analysis of 
the DEGs in Mtrrgt/gt placentas indicated possible altered placental development and function. 
Human placentas of growth restricted conceptuses have a distinct phenotype, characterised by 
reduced syncytiotrophoblast area, increased apoptosis, and thicker exchange barrier between 
the trophoblast and the fetal capillary endothelium (Ishihara et al. 2002; Levy & Nelson 
2000; Smith, Baker & Symonds 1997). In addition, these placentas have lower villi vascular 
density (Chen, Bajoria & Aplin 2002), fewer capillaries in the stroma, and decreased surface 
area, volume and number of terminal villi (Champlin, Dorr & Gates 1973; Chen, Bajoria & 
Aplin 2002; Jackson et al. 1995; Krebs et al. 1996; Mayhew et al. 2003; Teasdale 1984). The 
placental morphology at E10.5 should be analysed in our model, to determine whether the 
detailed morphology of the placentas of phenotypically normal and growth restricted Mtrrgt/gt 
conceptuses differs compared to the C57Bl/6. Preliminary data on stereological analysis of 
Mtrrgt/gt and C57Bl/6 placentas revealed decreased labyrinth area in the placentas of growth 
restricted Mtrrgt/gt conceptuses compared to the phenotypically normal Mtrrgt/gt, or C57Bl/6 
conceptuses. In addition, the fetal and maternal blood spaces in placentas of growth restricted 
Mtrrgt/gt conceptuses had also a smaller area compared to the phenotypically normal Mtrrgt/gt, 
or C57Bl/6 conceptuses (data by J.Rakoczy). Decreased labyrinth area in placentas of growth 
restricted Mtrrgt/gt conceptuses compared to C57Bl/6 correlates with our RNA-sequencing 
data showing decreased expression of Ctsq, a marker of sinusoidal TGCs in the labyrinth 
(Tunster, Creeth & John 2016) in placentas of growth restricted Mtrrgt/gt conceptuses 
compared to C57Bl/6. The parietal-TGC layer area was increased in placentas of growth 
restricted Mtrrgt/gt conceptuses, while the spongiotrophoblast and decidual areas were not 
affected. Tpbpa, an expression marker of the progenitors of spongiotrophoblast, glycogen 
cells, some P-TGC, spiral artery TGC, and canal TGC (Tunster et al. 2016), was reduced in 
placentas of both phenotypically normal and growth restricted Mtrrgt/gt conceptuses compared 
to C57Bl/6, but not in placentas of phenotypically normal compared to growth restricted 
Mtrrgt/gt conceptuses. This correlates with unpublished in situ hybridisation data by Dr. Nisha 
Padmanabhan showing that Tpbpa mRNA is decreased in Mtrrgt/gt placentas compared to 
C57Bl/6 controls. Considering there are decreased Tpbpa mRNA levels, unaffected 
spongiotrophoblast layer area, and increased parietal-TGC layer area, it is possible that 
decreased Tpbpa expression is due to abnormal differentiation or decreased counts and 
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increased size of spongiotrophoblast cells and glycogen cells. Abnormal function of 
spongiotrophoblast cells might lead to abnormal placental endocrine function, i.e. decreased 
placental prolactin and pregnancy-specific glycoprotein secretion. As mentioned in Chapter 
1, these proteins are essential for protecting the developing fetus from being attacked by the 
maternal immune system, and also to remodel the blood vessels of the placenta and the 
maternal decidua (Kammerer & Zimmermann 2010; Wu et al. 2008). Abnormal remodelling 
of placental and decidual blood vessels causes growth restriction (Arroyo & Winn 2008; 
Barut et al. 2010; Gourvas et al. 2012). 
In addition, we identified several genes with transport function that were misexpressed 
between Mtrrgt/gt and C57Bl/6 placentas. Abnormal development of placenta transport 
systems is a major cause of intrauterine growth restriction in mammals. Placental transport 
occurs by either passive diffusion, or transporter-mediated transport (Sibley, Glazier & 
D’Souza 1997). Unpublished data from our lab showed that placental transport mechanisms 
between phenotypically normal and growth restricted Mtrrgt/gt conceptuses vary. Expression 
of the solute carriers Slc2a1 (glucose) and Slc38a4 (amino acids) was decreased in the 
placentas of growth restricted Mtrrgt/gt conceptuses compared to placentas of both 
phenotypically normal Mtrrgt/gt and C57Bl/6 conceptuses. Slc38a2 was increased in all 
Mtrrgt/gt placentas compared to C57Bl/6 controls. mTORC1 and mTORC2 signalling 
positively regulates placental amino acid transporters and is inhibited by maternal folate 
deficiency, leading to decreased expression of amino acid transporters in the trophoblast 
plasma membrane (Rosario et al. 2017). Studying the uptake of amino acids into plasma 
membrane vesicles will give us information on amino acid transporter activity (Jansson et al. 
2002; Jansson, Scholtbach & Powell 1998; Mahendran et al. 1993; Norberg, Powell & 
Jansson 1998). More recent techniques of assessing placental activity aim to estimate the time 
that the nutrients reside at each placental compartment. FGR is associated with dysregulation 
of placental transporters, such as downregulation of Slc7a7, Slc38a2, Slc19a3, and Slc22a15, 
and upregulation of Slc38a5, Slc2a1, Abca1, and Slc26a2 (Huang et al. 2018). The expression 
of these genes was normal in our study, suggesting an alternative mechanism leading to FGR 
in our model. Analysis of the placental transcriptome of growth restricted F2 Mtrr+/+ 
conceptuses could give us more information about misexpression of placental genes that 
cause growth restriction. More advanced techniques to study placenta transfer mechanisms in 
humans include confocal laser scanning microscopy, transmission electron microscopy, and 
tagged tracers (Sölder et al. 2009). 
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In the Mtrrgt model of abnormal folate metabolism, we observed global DNA 
hypomethylation in the Mtrrgt/gt placentas of phenotypically normal and growth restricted 
conceptuses compared to the C57Bl/6 at E10.5 (Padmanabhan et al. 2013). According to our 
RNA-seq data, we predicted both hypomethylation and hypermethylation of CpG sites. This 
correlates with previous findings that global DNA hypomethylation can be associated with 
locus-specific hypermethylation and hypomethylation in the Mtrrgt/gt placentas (Padmanabhan 
et al. 2013). Further experiments are required to assess the methylation status of the 
differentially expressed genes that are regulated by DNA methylation by bisulfite 
pyrosequencing, or to assess the methylation status of the whole genome by MeDIP-seq 
(Weber et al. 2005). 
We have shown that the DEGs in Mtrrgt/gt placentas are on average less likely to be associated 
with CpG repeats than the rest of the genome. Therefore, we considered histone 
modifications such as methylation and acetylation, as an alternative epigenetic mechanism 
that regulates gene expression. We showed that the DEGs are equally likely to be associated 
with H3K4me1 peaks as the rest of the genome, while the downregulated genes are less likely 
to be associated with H3K27ac peaks than the rest of the genome. We identified two genes, 
Mt3 and Fbp1, which were upregulated in the placentas of Mtrrgt/gt conceptuses compared to 
the C57Bl/6 and are associated with histone modifications. Increased repressive histone 
modification (H3K9me2) and decreased active histone modifications (H3K4me2, H3K9ac) 
are associated with decreased expression of Mt3 (Peng et al. 2011). Additionally, decreased 
H3K27Ac in the Fbp1 enhancer is associated with decreased expression (Yang et al. 2017). 
Based on our RNA-seq data, we predict decreased H3K9me2 and increased H3K4me2, 
H3K9ace in Mt3, and increased H3K27ac in the Fbp1 enhancer in the placentas of both 
phenotypically normal and growth restricted Mtrrgt/gt conceptuses. Interestingly, there were 
no DEGs between phenotypically normal and growth restricted Mtrrgt/gt with known 
regulation by histone modifications. Overall, these data suggest that intrinsic abnormal folate 
metabolism affects only two genes whose expression is regulated by histone modifications. 
Chromatin modifications should be assessed via ChIP-seq (Arrigoni et al. 2016; Furey 2012). 
Interestingly, none of the genes that were upregulated in Mtrrgt/gt placentas as determined via 
RNA-sequencing were validated via RT-qPCR. We observed variation in the expression of 
the upregulated, but not downregulated genes in the Mtrrgt/gt placentas, which could be the 
reason that the upregulated genes did not validate. A possible explanation is that CpG 
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methylation in the regulatory regions of these genes is randomly affected in each individual, 
leading to gene upregulation in some placentas and not others. Finally, differential splicing 
might explain why some genes do not validate. For instance, according to Ensembl, Atp2b2, 
has eight splice variants, Hsd3b6 has three, and Nell1 has five. We performed single-end 
sequencing, however, paired-end sequencing would detect splice variants during RNA 
sequencing (Au et al. 2010; Rossell et al. 2014). 
Finally, we sequenced the RNA of placentas of phenotypically normal and growth enhanced 
F2 Mtrr+/+ conceptuses to assess the effects of maternal grandpaternal Mtrrgt mutation on the 
placental transcriptome. We found that maternal grandpaternal Mtrrgt mutation does not affect 
the placental transcriptome at E10.5. This is interesting since global DNA hypomethylation 
and dysregulation of locus-specific DNA methylation in imprinted genes were previously 
observed in the placentas of phenotypically normal F2 Mtrr+/+ conceptuses at E10.5 
(Padmanabhan et al. 2013). It is possible that changes in DNA methylation detected are not 
directly related to changes in gene expression at E10.5. Additionally, it is possible that 
changes in DNA methylation at E10.5 affect gene expression later during gestation. 
Abnormal DNA methylation was more frequently associated with abnormal gene expression 
in the placentas of growth restricted than phenotypically normal F2 Mtrr+/+ conceptuses at 
E10.5 (Padmanabhan et al. 2013). Therefore, a better experiment would be to sequence RNA 
from placentas of growth restricted F2 Mtrr+/+ conceptuses at E10.5. 
Overall, these data suggest that intrinsic abnormal folate metabolism affects placental 
transcriptome. We identified DEGs between phenotypically normal or growth restricted 
Mtrrgt/gt and C57Bl/6 placentas that are involved in embryo growth, have transport activity, 
and regulate gene expression through epigenetic mechanisms. Specific placental phenotypes 
should be assessed in the future. The RNA-sequencing data will then be used to identify 
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More than seven million babies have been born worldwide using some form of assisted 
reproduction technology (ART) as a treatment approach to infertility (ESHRE 2018). ART 
includes a variety of procedures (e.g., superovulation, in vitro fertilisation (IVF), 
intracytoplasmic sperm injection (ICSI), embryo culture, embryo biopsy, gamete and embryo 
vitrification, and embryo transfer). While ART is generally safe, growing evidence suggests 
that individuals born using these technologies are at an increased risk of FGR, perinatal 
complications (Quinn & Fujimoto 2016), and/or developing diseases later in life, such as 
cardiovascular disease (Guo et al. 2017; Liu et al. 2015; Tararbit et al. 2013; Valenzuela-
Alcaraz et al. 2013). Since optimal placental function is required for normal fetal growth and 
development, it is predicted that placenta pathologies are responsible for some of the adverse 
pregnancy outcomes associated with ART (Choux et al. 2015; Delle Piane et al. 2010; 
Thomopoulos et al. 2012). Indeed, ART pregnancies were overrepresented in the highest 
quartile of placental weight and underrepresented in the highest quartile of birthweight 
(Haavaldsen, Tanbo & Eskild 2012). 
To explore the effects of ART on placental structure and function, animal models (e.g., 
mouse) have been utilised. As in the human, the mouse placenta is composed of three major 
layers: i) the outer maternal layer, which includes decidual cells of the uterus, maternal 
immune cells, and the maternal vasculature that brings blood to and from the implantation 
site; ii) the metabolic ‘junctional’ region, which attaches the placenta to the uterus through 
the invasion of trophoblast cells; and iii) an inner layer composed of highly branched villi 
required for nutrient, gas, and waste exchange between the maternal and fetal circulations 
(Watson & Cross 2005). Defects in mouse placenta development and/or function have 
repercussions for fetal growth and health (Perez-Garcia et al. 2018; Watson & Cross 2005). 
Indeed, IVF and/or superovulation in mice is associated with large placentas with reduced 
vascular density and altered nutrient transport in villi at late gestation to produce normal sized 
or growth restricted fetuses (Bloise et al. 2012; Delle Piane et al. 2010; Weinerman et al. 
2017). Indeed, the sub-optimally formed placenta might undergo counter-balancing 
mechanisms that bring about adaptive placental responses (Choux et al. 2015). How and 
when this dialogue occurs is unclear. 
The mechanism through which ART influences placental formation and function is also not 
well understood. The vast majority of studies have focused on CpG methylation of imprinted 
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loci in the placenta (Bloise et al. 2012; Choux et al. 2015; Delle Piane et al. 2010; Fauque 
2010; Fortier et al. 2008; S Khosla et al. 2001; Mann et al. 2004; Rivera et al. 2008). 
Genomic imprinting is an epigenetic phenomenon in mammals whereby a small number of 
genes are expressed in a parent-of-origin-specific manner, a process that is regulated by DNA 
methylation. Many imprinted genes are expressed in the placenta and are important for its 
development and function (Tunster, Jensen & John 2013). Directed analysis of DNA 
methylation and gene expression at imprinted regions can act as a convenient read-out of 
functional DNA methylation changes across the genome (Messerschmidt et al. 2012; 
Padmanabhan et al. 2013). Therefore, studies showing altered DNA methylation at imprinted 
genes after ART hypothesise that these technologies might influence the establishment of 
DNA methylation genome-wide with consequences for differentiation of cell lineages, 
including those required for the placenta (Choux et al. 2015). Dysregulation of other 
epigenetic mechanisms (e.g., histone methylation or acetylation, non-coding RNA 
expression) have largely been ignored in the context of ART. 
One procedure that all ART have in common is the transfer of the embryo/blastocyst into the 
uterus of the recipient female. However, the precise impact of this procedure alone on the 
placenta growth and transcription is not well understood. Here, we show that blastocyst 
transfer in mice has a stark impact on transcriptional regulation and likely influences 
placental efficiency even as the placenta matures. Furthermore, our unbiased approach 
enabled us to determine that changes in DNA methylation not be the primary cause of gene 
misexpression. Therefore, the study of other epigenetic mechanisms is required. 
Here, we hypothesise that blastocyst transfer alters the placental transcriptome at E10.5. To 
test this hypothesis, we explored the effects of blastocyst transfer on the placental 
transcriptome at E10.5 in mice by RNA-sequencing. Our study does not involve 
superovulation, in vitro fertilisation, ICSI, or vitrification. Additionally, since growth 
phenotypes including growth restriction, growth enhancement, and developmental delay in 
F2 Mtrr+/+ conceptuses are likely caused by an atypical uterine environment in their wildtype 
mothers (F1 Mtrr+/+ females; Padmanabhan et al. 2013), we attempted to determine the 
effects of blastocyst transfer on the placental transcriptomes of F2 Mtrr+/+ conceptuses. 
Specifically, we hypothesise that providing the F2 Mtrr+/+ conceptuses with a normal uterine 
environment alters their placental transcriptome, therefore affects their growth. The F2 
Mtrr+/+ conceptuses developed in the abnormal F1 Mtrr+/+ uteri until E3.0, before being 
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transferred to the normal uterine environment of a BDF1 female (F1 generation derived from 
crossing C57Bl/6 females with DBA/2 males; Padmanabhan et al. 2013). Since the F1 
Mtrr+/+ uterine environment is abnormal (Chapters 3 and 4), it is possible that the blastocysts 
were developmentally programmed such that exposure to a normal uterine environment 
might alter transcription and developmental trajectory. Ongoing work in the Watson lab is 
exploring the specific trophoblast phenotypes of F2 Mtrr+/+ conceptuses, and so the 
transcriptome analysis presented here will complement this analysis. 
 
6.2 Results 
6.2.1 Maternal grandpaternal abnormal folate metabolism affects the placental 
transcriptome in a growth phenotype-dependent manner  
Even though abnormal folate metabolism in the maternal grandfather does not appear to 
affect the placental transcriptome of F2 Mtrr+/+ conceptuses (Chapter 5), we wanted to 
determine whether their epigenomes were metabolically programmed. To do this, the 
placenta transcriptomes of F2 Mtrr+/+ conceptuses that had undergone blastocyst transfer 
were analysed and compared to transferred C57Bl/6 placentas (Figure 6.1A). The RNA from 
the transferred samples was sequenced in the same sequencing experiment as the RNA from 
non-transferred samples, as described in Chapter 5. The blastocyst transfer experiment was 
previously performed and showed that providing a normal uterine environment to the F2 
Mtrr+/+ conceptuses prevented growth restriction and developmental delay (Padmanabhan et 
al. 2013). However, growth enhancement was more frequently observed compared to 
C57Bl/6 conceptuses that were transferred (Padmanabhan et al. 2013). First, we compared 
the placental transcriptome of C57Bl/6 to phenotypically normal and growth enhanced F2 
Mtrr+/+ conceptuses after blastocyst transfer. There were no genes that were differentially 
expressed when comparing placentas of phenotypically normal F2 Mtrr+/+ conceptuses to 
C57Bl/6 or growth enhanced Mtrr+/+ conceptuses after blastocyst transfer (Figure 6.1B, D). 
This might be because the sample size was too small. In contrast, we identified six genes 
(Prl8a8, Prl8a9, Psg19, Fbln7, Zfp964, Phldb3) that are upregulated in the placentas of 
growth enhanced F2 Mtrr+/+ conceptuses compared to C57Bl/6 after blastocyst transfer, with 
at least a two-fold change (Figure 6.1C, E). The placental transcriptomes of phenotypically 




Figure 6.1 Bioinformatic analysis of the RNA sequencing data from C57Bl/6, and 
placentas of F2 Mtrr+/+ conceptuses after blastocyst transfer. 
 (A) PCA plot based on the 500 most variable genes. Blue circles: C57Bl/6 transferred (t), red 
circles: phenotypically normal Mtrr+/+ transferred, green squares: growth enhanced (GE) 
Mtrr+/+ transferred (B-D) MA plots showing DEG between placentas of (B) C57Bl/6 and 
phenotypically normal Mtrr+/+conceptuses after blastocyst transfer, (C) C57Bl/6 and growth 
enhanced Mtrr+/+conceptuses after blastocyst transfer and (D) phenotypically normal and 
growth enhanced Mtrr+/+ conceptuses after blastocyst transfer (E) Heatmap showing the six 
genes that were differentially expressed between placentas of transferred C57Bl/6 and growth 
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enhanced Mtrr+/+ conceptuses. Each column represents an individual placenta. Each row 
represents one gene. 
 
similar phenotype have similar transcriptome. The chromosomal location and placental 
expression of these genes are shown in Table 6.1. Prl8a8 and Prl8a9 are located on 
chromosome 13, however they are not within the Mtrr locus. Prl8a8, Prl8a9, Psg19, and 
Phldb3 are expressed by the trophoblast cells, while the placental expression of Fbln7 and 
Zfp964 is unknown. Prl8a8 and Prl8a9 are prolactin family genes and are expressed in the 
ectoplacental cone lineage and in the maternal decidua (Simmons et al. 2008). Psg19 is a 
pregnancy-specific glycoprotein (Wynne et al. 2006) that can bind to CD9 to initiate TGFβ 
signalling (Ha et al. 2008). Fbln7 is involved in cell adhesion (Whittington et al. 2018) and 
might be required for vasculogenesis (de Vega et al. 2016). Phldb3 plays a role in cell 
proliferation by regulating p53 degradation (Chao et al. 2016). 
 
Table 6.1 Chromosomal location and placental expression of DEGs. 
Gene Function Fold-change Chromosome Expression in placenta 
Prl8a8 Prolactin  9.17 13 TB (SpT) 
Prl8a9 Prolactin 3.88 13 TB (parietal TGC) 
Psg19 Pregnancy-specific 
glycoprotein 
2.93 7 TB (TGC) 
Fbln7 Adhesion molecule 2.8 2 Unknown 
Zfp964 Zinc finger protein 2.3 8 Unknown 
Phldb3 Oncogene, direct target 
of p53 
2.1 7 TB 
TB: trophoblast, SpT: spongiotrophoblast, TGC: trophoblast giant cells, Expression according to Human Protein 
Atlas 
 
6.2.2 Blastocyst transfer leads to possible increase in placental efficiency at E10.5 
Next, we wanted to examine how the uterine environment influences or programmes the 
placental transcriptome of F2 Mtrr+/+ conceptuses. To do this, we mated C57Bl/6 donor 
female mice (n=10) without superovulation to C57Bl/6 male mice (n=10), and F1 Mtrr+/+ 
donor female mice (n=11) without superovulation to C57Bl/6 male mice (n=11). Pre-
implantation embryos were flushed at E3.25 from oviducts and uteri of donor females and 
transferred by embryo injection into the oviducts of pseudopregnant B6D2F1 females at the 
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equivalent of GD2.5. Transferred blastocysts were allowed to implant and were dissected at 
E10.5 (staged according to the recipient female (Ueda et al. 2003)) for phenotyping. C57Bl/6 
and F2 Mtrr+/+ conceptuses were derived from natural matings, did not undergo the 
blastocyst transfer procedure, and were dissected at E10.5 for similar analyses.  
First, we assessed the blastocyst transfer efficiency in C57Bl/6 conceptuses. Prior to transfer, 
litter sizes at E3.25 ranged between 8-10 embryos and included compact morula- and 
blastocyst-staged embryos (Table 6.2). Two litters contained at least one embryo with an 
abnormal appearance (Table 6.2). However, all embryos were transferred regardless of 
appearance. Ten pseudopregnant B6D2F1 females received embryos but only eight were 
pregnant at E10.5 (80% efficiency). The average implantation rate was 47.3% when all 
transferred litters were considered and 58.9% when only considering transfers that resulted in 
pregnancy (Table 6.2).  
Similarly, we assessed the blastocyst transfer efficiency in F2 Mtrr+/+ conceptuses. Prior to 
transfer, litter sizes at E3.25 ranged between 7-11 embryos and included compact morula- 
and blastocyst-staged embryos (Table 6.3). One litter contained two embryos with an 
abnormal appearance (Table 6.3) and another litter contained two unfertilised oocytes (Table 
6.3). However, all embryos and unfertilised oocytes were transferred regardless of 
appearance. Eleven pseudopregnant B6D2F1 females received embryos but only nine were 
pregnant at E10.5 (81.8% efficiency). The average implantation rate was 60% when all 
transferred litters were considered and 73.2% when only considering transfers that resulted in 
pregnancy (Table 6.3).  
C57Bl/6 litter sizes after transfer were smaller (5.4 ± 0.5 implantation sites per litter; 
p<0.001) than control C57Bl/6 litters (9.5 ± 0.4 implantation sites per litter; Table 6.4). No 
congenital malformations were apparent in the control or transferred conceptuses at E10.5 
(Table 6.4). However, one litter was developmentally delayed since the number of somite 
pairs in these embryos ranged between 16-22 pairs (Figure 6.2A) instead of the expected 30-
40 somite pairs. At E10.5, 20.9% of the transferred conceptuses were resorbed compared to 
only 5.3% of control conceptuses (Table 6.4). Although not statistically significant 
(p=0.200), this result suggests that blastocyst transfer might lead to increased post-




Overall, male and female conceptuses were present in a 1:1 ratio at E10.5 in both control and 
transferred C57Bl/6 groups (Table 6.4) indicating that sex was not a selective factor on 
survival after blastocyst transfer. A two-way ANOVA was used to also assess interactions 
between the two factors assessed (i.e. sex and experimental procedure). The blastocyst 
transfer (p=0.5603), the sex (p=0.7642), or the interaction between these two factors 
(p=0.3883) did not have any effect on embryo weight (Figure 6.2B). The blastocyst transfer 
led to a decreased in the placenta weight (p<0.0001) in both sexes, while the sex (p=0.9531) 
had no effect. The interaction between the two factors did not affect placental weight 
(p=0.1302; Figure 6.2C). Indeed, the blastocyst transfer process led to an increase in the 
embryo:placenta weight ratio in the females (p=0.0020), while the sex had no effect on 
embryo:placenta weight ratio (p=0.5421). The interaction between the two factors was not 
different (p=0.7052; Figure 6.2D).  
F2 Mtrr+/+ litter sizes after transfer were similar (6.6 ± 0.6 implantation sites per litter) to 
control F2 Mtrr+/+ litters (8.2 ± 0.4 implantation sites per litter; Table 6.5). No growth 
restriction or developmental delay was observed in the transferred F2 Mtrr+/+ conceptuses 
(Table 6.5). Congenital malformations and resorptions were observed in similar frequencies 
at E10.5 in the non-transferred and transferred F2 Mtrr+/+ conceptuses (11.0% Vs 75%, and 
3.5% Vs 1.9%, respectively; Table 6.5). Overall, male and female conceptuses were present 
in a 1:1 ratio at E10.5 in both control and transferred groups (Table 6.5) indicating that sex 
was not a selective factor on survival after blastocyst transfer. 
The effects of the blastocyst transfer and the sex on the embryo and placenta weight and 
embryo:placenta ratio were assessed by a two-way ANOVA. Both the blastocyst transfer 
(p<0.0001) and the sex (p=0.0099) led to an increase in embryo weight, however the 
interaction between these two factors did not affect embryo weight (p=0.7866; Figure 6.3B). 
The blastocyst transfer led to an increase in the placenta weight (p<0.0001), while the sex 
(p=0.2053) had no effect. The interaction between the two factors did not affect placenta 
weights (p=0.3826; Figure 6.3C). Indeed, the blastocyst transfer process led to an increase in 
the embryo:placenta weight ratio in both males and females (p=0.0001), while the sex had no 
effect on embryo:placenta weight ratio (p=0.0699). The interaction between the two factors 




Table 6.2 Relationship between C57Bl/6 embryos transferred at E3.5 into recipient female and embryonic phenotype at E10.5. 
  Phenotypes of transferred embryos at E3.5   

















N GE GR DD CM R 
C57-T1 10 5 4 1 6 (60.0%) 3 1 0 0 0 2 
C57-T2 9 6 3 0 0 - - - - - - 
C57-T3 10 3 7 0 6 (60.0%) 5 0 0 0 0 1 
C57-T4 8 4 4 0 4 (50.0%) 0 0 0 4 0 0 
C57-T5 10 4 3 3 6 (60.0%) 6 0 0 0 0 0 
C57-T6 9 7 2 0 3 (33.3%) 0 1 1 0 0 1 
C57-T7 8 7 1 0 5 (62.5%) 3 0 1 0 0 1 
C57-T8 9 5 4 0 0 - - - - - - 
C57-T9 8 7 1 0 7 (87.5%) 5 1 0 0 0 1 
C57-T10 10 6 4 0 6 (60.0%) 3 0 0 0 0 3 
Total 91 54 33 4 43 (47.3%) 25 3 2 4   9 
*N, phenotypically normal; GR, growth restricted; GE, growth enhanced; DD, developmentally delayed; CM, congenital malformation; R, resorption. 
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Table 6.3 Relationship between F2 Mtrr+/+ embryos transferred at E3.5 into recipient female and embryonic phenotype at E10.5. 
















N GE GR DD CM R 
F2 Mtrr+/+ - T1 11 9 0 0 2 7 (63.6%) 6 0 0 0 1 0 
F2 Mtrr+/+ - T2 8 5 3 0 0 7 (87.5%) 4 2 0 0 1 0 
F2 Mtrr+/+ - T3 7 4 3 0 0 0 0 0 0 0 0 0 
F2 Mtrr+/+ - T4 10 5 5 0 0 8 (90.0%) 8 0 0 0 1 0 
F2 Mtrr+/+ - T5 11 8 3 0 0 8 (72.7%) 5 1 0 0 2 0 
F2 Mtrr+/+ - T6 11 6 3 2 0 4 (36.4%) 3 1 0 0 0 0 
F2 Mtrr+/+ - T7 11 9 2 0 0 0 0 0 0 0 0 0 
F2 Mtrr+/+ - T8 8 4 4 0 0 7 (87.5%) 4 0 0 0 3 0 
F2 Mtrr+/+ - T9 7 4 3 0 0 7 (100%) 6 0 0 0 0 1 
F2 Mtrr+/+ - T10 7 5 2 0 0 6 (85.7%) 2 4 0 0 0 0 
F2 Mtrr+/+ - T11 9 7 2 0 0 5 (55.36%) 3 2 0 0 0 0 
Total 100 66 30 2 2 60 (60%) 41 10 0 0 8 1 





Table 6.4 Phenotypic comparison of C57Bl/6 control conceptuses and C57Bl/6 transfer 
conceptuses at E10.5. 
Experimental group C57Bl/6 controla C57Bl/6 transfera 












43 (8 litters) 
17 b 
17 b 







9.5 ± 0.4 
4.4 ± 0.5 (46.5%) b 
4.5 ± 0.4 (47.4%) b 
 
 
5.4 ± 0.5*** 
2.1 ± 0.5 (39.5%) b 














8.6 ± 0.5 (90.5%) 
4.2 ± 0.5 (95.5%) 
4.1 ± 0.4 (91.1%) 
 
3.1 ± 0.8*** (58.1%) 
1.3 ± 0.5*** (58.8%) 










0.4 ± 0.2c (7.0%) 







0.4 ± 0.2 (4.2%) 
0.2 ± 0.1 (4.5%) 
0.2 ± 0.1 (4.4%) 
 
0.3 ± 0.2 (4.7%) 
0.1 ± 0.1 (5.9%) 










0.5± 0.5 (9.3%) 
0.4 ± 0.4 (17.6%) 

























1.1 ± 0.4 (20.9%) 
- 
- 
aData presented as average number of conceptuses [± se] per litter unless otherwise indicated. 
Number in brackets indicates the percentage of conceptuses with each phenotype; 




Figure 6.2 Blastocyst transfer results in small placentas with a potential for increased 
efficiency at E10.5. 
(A) Representative images of embryos and placentas from control and transferred 
conceptuses at E10.5. Phenotypes shown include phenotypically normal (PN), growth 
enhanced (GE), growth restricted (GR), and developmentally delayed (DD) as determined by 
crown-rump lengths and somite pair counts. Arrowhead indicates where the allantois (i.e., the 
umbilical cord) was attached. Scale bars: 500 μm. (B-E) Graphs showing (B) embryo 
weights, (C) placenta weights, (D) embryo:placenta (E/P) weight ratios, and (E) embryo 
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crown-rump (CR) lengths in all control (black) and transferred (grey) conceptuses at E10.5. 
Values are shown for male (m) and female (f) conceptuses and data are presented as mean ± 
standard deviation (SD). (F) Frequency distribution curves of crown-rump (CR) lengths as 
determined by sex for control (black solid line) and transferred (grey solid line) embryos. The 
litter that was entirely developmentally delayed was not included in this analysis to ensure 
that only embryos staged to E10.5 were considered. Black dotted lines indicate the mean 
crown-rump length for control embryos. Grey shading indicates the lengths of conceptuses 
that are grossly phenotypically normal (PN). Grey dotted lines indicate crown-rump lengths 
that are two or more SDs from the control mean. Embryos with lengths that were two SDs 
below the control mean were considered growth restricted (GR) and two SDs above the mean 
were considered growth enhanced (GE). (G) Linear regression analysis of litter size versus 
embryo crown-rump (CR) length in control (black) and transferred (grey) conceptuses. (H-K) 
Graphs showing parameters for phenotypically normal (PN) conceptuses only including (H) 
embryo crown-rump (C-R) length, (I) embryo weight, (J) placenta weight, and (K) 
embryo:placenta (E/P) weight ratios in control (black) and transferred (grey) conceptuses. 
Data are presented as mean ± SD and is shown for male (m) and female (f) conceptuses. 
N=10-43 conceptuses per sex per experiment. Statistical analysis in A-D, G-J: Two-way 
ANOVA with Sidak’s multiple comparison tests were performed to assess the effects of 
blastocyst transfer and sex on embryo and placenta weights, and embryo:placenta weight 
ratio. *p<0.05, ***p<0.001.  
 
To further define the growth phenotype of C57Bl/6 conceptuses, crown-rump lengths were 
measured for each sex. While mean lengths were not different between control and 
transferred embryos (Figure 6.2E), frequency distribution curves of crown-rump lengths were 
generated (Figure 6.2F) to detect specific embryos with abnormal growth. Growth restriction 
and growth enhancement in embryos was defined as crown-rump lengths that were at least 
two standard deviations below or above the mean crown-rump length of control embryos, 
respectively. Regardless of sex, a similar frequency of growth restriction was observed in 
control (4.4 – 4.5% of embryos) and transferred conceptuses at E10.5 (5.9% of embryos, 
p=0.687; Figure 6.2A, F, Table 6.4). Interestingly, three out of 17 (17.6%) of the transferred 
male embryos displayed growth enhancement (Figure 6.2A, F, Table 6.4). This frequency 
was not statistically significant (p=0.08), likely due to the small sample size. No transferred 
female embryos were growth enhanced (Figure 6.2F, Table 6.4) suggesting that this 
phenotype might be sexually dimorphic. No correlation between litter size and crown-rump 
length was observed in control or transferred litters at E10.5 (Figure 6.2G). 
When all growth phenotypes (e.g., growth restriction, growth enhancement, developmental 
delay) and resorptions were grouped together, fewer phenotypically normal (PN) conceptuses 
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were observed at E10.5 in the transferred group (55.8%; p<0.001) compared to controls 
(91.6%; Table 6.4). When only PN conceptuses were considered (Figures 6.2A, F), a two-
way ANOVA revealed that the blastocyst transfer (p=0.0176) led to an increase in embryo 
weight, while the sex (p=0.9334) and the interaction between these two factors (p=0.2544) 
did not have any effect on embryo weight (Figure 6.2I). Similarly, the blastocyst transfer led 
to a decrease in the placenta weight in both males and females (p<0.0001), while the sex 
(p=0.2780) had no effect. The interaction between the two factors did not affect placental 
weight (p=0.0597; Figure 6.2J). Despite that the placentas of transferred conceptuses were 
smaller than the controls, we observed an increase in the placenta efficiency, as determined 
by the embryo:placenta weight ratios in PN transferred conceptuses. This reached statistical 
significance only in the female conceptuses (p<0.0001), while the sex had no effect on 
embryo:placenta weight ratio (p=0.4445). The interaction between the two factors was not 
different (p=0.8004; Figure 6.2K). Altogether, these data imply that after blastocyst transfer, 
the normal growth trajectory of the embryo is reliant upon functional compensation by the 
placenta, especially in the females. 
To further define the growth phenotype of F2 Mtrr+/+ conceptuses, crown-rump lengths were 
measured for each sex and frequency distribution curves of crown-rump lengths were 
generated (Figure 6.3E) to detect specific embryos with abnormal growth. As before, 
abnormal growth was defined as crown-rump lengths that were at least two standard 
deviations from the mean length of control embryos. Regardless of sex, growth restriction 
was rescued after the transfer of the E3.0 blastocyst into the recipient uterus (Padmanabhan et 
al. 2013; Figure 6.3E). Two out of 26 transferred females (7.7%) and eight out of 26 males 
(30.8%) were growth enhanced (Figure 6.3E), however this phenotype was not sexually 
dimorphic (p=0.1), possibly because of the small sample size. This suggests that exposure of 
the F2 Mtrr+/+ conceptuses in the abnormal F1 Mtrr+/+ uterus developmentally programmes 
them to adjust to a normal environment after blastocyst transfer. This is in contrast to the 
C57Bl/6 conceptuses, who were never exposed to an abnormal uterine environment, and 
therefore their placentas possibly undergo less adaptations after transfer into the new 
maternal environment. 
When only PN conceptuses were considered (Figure 6.3A, F), a two-way ANOVA revealed 
that the blastocyst transfer (p<0.0001), but not the sex (p=0.1278) led to an increase in 
embryo weight, and the interaction between these two factors also led to an increase in  
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Table 6.5 Phenotypic comparison of non-transferred F2 Mtrr+/+ conceptuses and 
transferred Mtrr+/+ conceptuses at E10.5. 
Experimental group F2 Mtrr+/+ controla F2 Mtrr+/+ transfera 
No. of conceptuses assessed at E10.5      
Total 172 (21 litters) 53 (8 litters) 
Male 80 b 26 b 
Female 80 b 26 b 
Average No. of conceptuses/litter [±se]     
Total 8.2 ± 0.4 6.6 ± 0.6 
Malea 3.81 ± 0.4 (46.5%) b 3.2 ± 0.3 (49.1%) b 









Phenotypically normal     
Total 5.6 ± 0.6 (68.6%) 4.8 ± 0.7 (71.7%) 
Male 2.9 ± 0.4 (51.7%) 2.1 ± 0.4 (44.7%) 
Female 2.7 ± 0.4 (48.3%) 2.6 ± 0.6 (55.3%) 
Growth enhanced     
Total 0.3 ± 0.1 (3.49%) 1.3 ± 0.5 (18.9%) 
Male 0.2 ± 0.1 (3.39%) 1 ± 0.4 (21.1%) 
Female 0.1 ± 0.1 (1.7%) 0.3 ± 0.2 (5.3%) 
Growth restricted     
Total 0.1 ± 0.1 (1.7%) 0 
Male 0.1 ± 0.1 (2.5%) 0 
Female 0.4 ± 0.2 (7.6%) 0* 
Developmental delay     
Total 0.3 ± 0.2 (3.5%) 0 
Male 0.1 ± 0.1 (1.7%) 0 
Female 0.2 ± 0.2 (3.4%) 0 
Congenital malformations     
Total 0.9 ± 0.2 (11.0%) 0.5 ± 0.3 (7.5%) 
Male 0.5 ± 0.2 (8.5%) 0.2 ± 0.1 (2.6%) 
Female 0.4 ± 0.1 (7.6%) 0.4 ± 0.3 (7.9%) 
Resorptionsb     
Total 0.3 ± 0.1 (3.5%) 0.1 ± 0.1 (1.9%) 
Male - - 
Female - - 
aData presented as average number of conceptuses [± se] per litter unless otherwise indicated. 
Number in brackets indicates the percentage of conceptuses with each phenotype; 




Figure 6.3 Blastocyst transfer into the normal BDF1 environment results in bigger 
embryos and placentas with a potential for increased efficiency at E10.5. 
(A) Representative images of embryos and placentas from non-transferred and transferred F2 
Mtrr+/+ conceptuses at E10.5. Phenotypes shown include phenotypically normal (PN) and 
growth enhanced (GE) as determined by crown-rump lengths and somite pair counts. Scale 
bars: 100 μm. (B-D) Graphs showing (B) embryo weights, (C) placenta weights, and (D) 
embryo:placenta (E/P) weight ratios, in all non-transferred (full circle) and transferred 
(hollow circle) F2 Mtrr+/+ conceptuses at E10.5. Values are shown for male (m) and female 
(f) conceptuses and data are presented as mean ± standard deviation (SD). (E) Frequency 
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distribution curves of crown-rump (CR) lengths as determined by sex for non-transferred 
(blue solid line) and transferred (orange solid line) F2 Mtrr+/+ embryos. Black dotted lines 
indicate the mean crown-rump length for non-transferred embryos. Grey shading indicates 
the lengths of conceptuses that are grossly phenotypically normal (PN). Grey dotted lines 
indicate crown-rump lengths that are two or more SDs from the control mean. Embryos with 
lengths that were two SDs below the control mean were considered growth restricted (GR) 
and two SDs above the mean were considered growth enhanced (GE). (F-H) Graphs showing 
parameters for phenotypically normal (PN) conceptuses only including (F) embryo weight, 
(G) placenta weight, and (H) embryo:placenta (E/P) weight ratios in non-transferred (full 
circle) and transferred (hollow circle) F2 Mtrr+/+ conceptuses at E10.. Data are presented as 
mean ± SD and is shown for male (m) and female (f) conceptuses. Statistical analysis in A-D, 
G-J: Two-way ANOVA with Sidak’s multiple comparison tests were performed to assess the 
effects of blastocyst transfer and sex on embryo and placenta weights, and embryo:placenta 
weight ratio. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. 
 
embryo weight (p=0.0314; Figure 6.3F). Similarly, the blastocyst transfer led to decreased 
placenta weight (p<0.0001), while the sex (p=0.4038) had no effect, suggesting that the 
placentas of transferred conceptuses, though small, were more efficient. The interaction 
between the two factors had no effect (p=0.4418; Figure 6.3G). However, neither the 
blastocyst transfer process (p=0.1017) nor the sex affected the embryo:placenta weight ratio 
(p=0.2938). Similarly, the interaction between the two factors had no effects on 
embryo:placenta weight ratio (p=0.1009). However, Sidak's multiple comparisons test 
revealed an increased embryo:placenta weight ratio in the transferred compared to non-
transferred females (p<0.05; Figure 6.3H), reinforcing the hypothesis that placentas of 
transferred conceptuses are more efficient. Altogether, these data imply that after blastocyst 
transfer, the normal growth trajectory of the embryo is reliant upon functional compensation 
by the placenta. 
 
6.2.3 Transferred conceptuses have a different placental transcriptome than non-
transferred 
To examine how the uterine environment influences or programmes the placental 
transcriptome of F2 Mtrr+/+ conceptuses, we assessed the placental transcriptome of non-
transferred and transferred placentas via RNA-sequencing. As mentioned in Chapter 5, we 
observed substantial transcriptional differences between non-transferred and transferred 
placentas. Similar to our previous analysis (Figure 5.3), we created a PCA plot comparing 
178 
 
non-transferred and transferred C57Bl/6 and F2 Mtrr+/+ conceptuses (Figure 6.4A), which 
showed that the samples clustered based on the experimental design: i.e. placentas of non-
transferred conceptuses cluster on the left-hand side of the PCA plot, while placentas of 
transferred conceptuses cluster on the right-hand side. 
Firstly, we wanted to determine whether the blastocyst transfer process itself affects placental 
gene expression. Differential gene expression was determined as a gene that had at least two-
fold change in expression. We identified 189 and 355 genes that were downregulated and 
upregulated, respectively, in the placentas of transferred C57Bl/6 conceptuses compared to 
the non-transferred C57Bl/6 conceptuses. This suggests that the blastocyst transfer process 
itself affects placental gene expression (Figure 6.4B, E, Table 6.6). Next, we compared the 
placental transcriptome of non-transferred and transferred F2 Mtrr+/+ conceptuses in a 
phenotype-dependent manner. When comparing transferred to non-transferred conceptuses, 
we identified 179 and 201 genes that were downregulated and upregulated, respectively, in 
the placentas of phenotypically normal conceptuses (Figure 6.4C, F, Table 6.6). Additionally, 
we identified a further 188 and 174 genes that were downregulated and upregulated, 
respectively, in the placentas of growth enhanced conceptuses that were transferred or non-







Figure 6.4 Bioinformatic analysis of the RNA sequencing data to compare placental 
transcriptome of non-transferred and transferred conceptuses. 
(A) PCA plot based on the 500 most variable genes. Blue circles: C57Bl/6, red circles: 
phenotypically normal Mtrr+/+, purple triangles: growth enhanced Mtrr+/+, orange circles: 
C57Bl/6 transferred, brown circles: phenotypically normal Mtrr+/+ transferred, green 
triangles: growth enhanced Mtrr+/+ transferred (B-D) MA plots showing DEG between 
placentas of (B) non-transferred and transferred C57Bl/6 conceptuses (C) non-transferred and 
transferred phenotypically normal Mtrr+/+conceptuses (D) non-transferred and transferred 
growth enhanced Mtrr+/+conceptuses (E-G) Heatmaps showing DEG between placentas of 
(E) non-transferred and transferred C57Bl/6 (F) non-transferred and transferred 
phenotypically normal Mtrr+/+ conceptuses and (G) non-transferred and transferred and 
growth enhanced Mtrr+/+ conceptuses. Each column represents an individual placenta. Each 





Table 6.6 Number of DEGs in transferred placentas per genotype and phenotype. 
Comparison C57Bl/6 vs 
C57Bl/6 transferred 
F2 Mtrr+/+ PN vs 
F2 Mtrr+/+ PN transferred  
F2 Mtrr+/+ GE vs 














2<fc<3 131 189 111 86 120 66 
3<fc<4 27 64 37 31 29 28 
4<fc<10 28 62 27 44 29 34 
fc>10 3 40 4 40 10 46 
Total 189 355 179 201 188 174 
PN: phenotypically normal, GE: growth enhanced, FC: fold-change 
 
 
Next, we validated the RNA-sequencing experiment using cDNA from C57Bl/6 placentas of 
non-transferred and transferred conceptuses. We analysed 17 genes that were downregulated 
in placentas of transferred conceptuses, out of which 11 validated, giving us a validation rate 
of 64.7% (Figure 6.5).  In addition, we analysed eight genes that were upregulated in 
placentas of transferred conceptuses, out of which five validated, giving us a validation rate 
of 62.5% (Figure 6.6A). Additionally, we confirmed the expression of two genes, Med12 and 
Serf2, that was shown to be similar in the placentas of non-transferred and transferred 
C57Bl/6 conceptuses (Figure 6.6B). Table A.1 shows that all placental cell types are 
represented by the proteins encoded by the DEGs, as will also be discussed in Section 6.2.5.1. 
Therefore, the use of whole placentas for qPCR analysis was essential. Finally, we performed 
gene expression correlation analysis between the RNA sequencing data and the qPCR results 
(Figure 6.7). We observed no relationship in the expression of downregulated genes between 
the RNA-seq and qPCR experiments (r2=0.02289, p=0.5621; Figure 6.7A). In contrast, we 
observed a strong positive correlation in the expression of upregulated genes (r2=0.9308, 
p=0.0001 Figure 6.7B). As mentioned in Chapter 5, the reliability of the RNA-seq data 
increases with higher read counts. The relatively low read counts in combination with the low 
fold change in the expression of Tspan8 and Rem1 compared to the other upregulated genes, 
might suggest a reason why these two genes did not validate. The genes used for validation 
are shown on the MA plot in Figure 6.4B. The specific effects of the embryo transfer process 
itself on the placental transcriptome will be discussed below, by analysing the function of the 




Figure 6.5 Validation of RNA-sequencing data by RT-qPCR analysis of downregulated 
genes. 
Graphs show transcripts that were downregulated in placentas of transferred (grey circles) 
compared to non-transferred (black circles) C57Bl/6 conceptuses. Data are presented as fold 
change compared to controls (normalised to 1). N=4-7 placental samples per group. The 
number below each graph represents the fold change (FC) observed in the RNA-sequencing 
experiment. Mann-Whitney tests were performed to independently compare transferred 
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placentas to control placentas, since the sample size was too small to perform a normality test 
or assume normal Gaussian distribution. *P<0.05, **P<0.01, ***P<0.001.  
 
Figure 6.6 Validation of RNA-sequencing data by RT-qPCR analysis of upregulated 
and non-differentially expressed genes. 
Graphs show transcripts that were upregulated in placentas of transferred (grey circles) 
compared to non-transferred (black circles) C57Bl/6 conceptuses. Data are presented as fold 
change compared to controls (normalised to 1). N=4-7 placental samples per group. The 
number below each graph represents the fold change (FC) observed in the RNA-sequencing 
experiment. Mann-Whitney tests were performed to independently compare transferred 
placentas to control placentas, since the sample size was too small to perform a normality test 





Figure 6.7 Gene expression correlation between the RNA-sequencing data and the 
qPCR results. 
Graphs show the correlation of expression between the RNA sequencing and qPCR data of 
genes that were (A) downregulated and (B) upregulated in C57Bl/6 placentas after embryo 
transfer and used for qPCR validation. Linear regression and correlation analyses were 
performed, and the Pearson correlation coefficient was calculated. 
 
 
6.2.4 Comparison of DEGs between placentas of non-transferred and transferred 
conceptuses at E10.5 
Considering that there were many DEGs identified when comparing placentas of C57Bl/6 
non-transferred and transferred conceptuses, it is likely that a large proportion of DEGs 
identified in the F2 Mtrr+/+ placenta comparisons was the result of the blastocyst transfer 
process. Therefore, we compared the DEGs identified when comparing non-transferred and 
transferred C57Bl/6 placentas to the DEG lists generated when comparing non-transferred 
and transferred F2 Mtrr+/+ conceptuses. Phenotypic comparisons were also kept separate 
(e.g., placentas from phenotypically normal conceptuses; placentas from growth enhanced 
conceptuses). Interestingly, there were 271 genes that were differentially expressed between 
non-transferred and transferred C57Bl/6 placentas only (Figure 6.8). Next, we identified 175 
genes that were common between placentas of (a) non-transferred and transferred C57Bl/6 
conceptuses, (b) non-transferred and transferred phenotypically normal F2 Mtrr+/+ 
conceptuses and (c) non-transferred and transferred growth enhanced F2 Mtrr+/+ conceptuses 
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(Figure 6.8). Another 52 and 46 DEGs from F2 Mtrr+/+ phenotypically normal and growth 
enhanced, respectively, also overlapped with the C57Bl/6 DEG list. Altogether, these genes 
were most likely differentially expressed due to the blastocyst transfer procedure and their 
function will be discussed in Section 6.2.5. Once we removed these genes from the DEG 
lists, we still identified 153 and 141 misexpressed genes in phenotypically normal and growth 
enhanced F2 Mtrr+/+ placentas that underwent blastocyst transfer, respectively, compared to 
non-transferred F2 Mtrr+/+ placentas (Figure 6.8). Of these, 50 genes overlapped between 
phenotypic groups (Figure 6.8), which are likely the result of developmental programming of 
the conceptus that occurred either during oocyte development or during the first three days of 
embryo development in the reproductive tract of their F1 Mtrr+/+ biological mothers.  
 
Figure 6.8 Comparisons between the DEGs of controls and transferred conceptuses. 
Venn diagram comparing the number of DEGs between placentas of non-transferred and 
transferred conceptuses. PN: phenotypically normal; GE: growth enhanced. 
 
 
6.2.5 DEGs caused by the embryo transfer protocol 
We observed a large number of DEGs in transferred C57Bl/6 conceptuses, therefore we 
wanted to assess further the effects of the blastocyst transfer process on the placental 




6.2.5.1 All major placental cell types are represented by DEGs in transferred C57Bl/6 
placentas 
To determine whether blastocyst transfer affected gene expression in specific cell types, we 
performed an extensive literature/database search to resolve the spatial expression of the 
DEGs in the placenta. Expression was classified in terms of major placental cell types (i.e., 
trophoblast, fetal vascular endothelium, and decidua) and was largely based on homolog 
expression in the human placenta due to the availability of data (Uhlen et al. 2015). Of the 
544 DEGs identified, the placental expression of 211 genes is currently unknown in mouse 
and human, and 123 genes are detected in the placenta without information about cell type 
specificity (i.e., general expression; Figure 6.9A, Table A.1). The spatial expression of the 
remaining 210 genes was characterised (Figure 6.9A, Table A.1). In many cases, gene 
expression overlapped in more than one major placental cell populations (Figure 6.9A) 
indicating that blastocyst transfer is unlikely to affect a single placental cell lineage. A similar 
proportion of DEGs were detected in trophoblast cells (50.4%) and decidua layer cells 
(48.6%), though fewer DEGs (27.9%) were detected in the fetal vascular endothelium 
(27.9%; Figure 6.9A). When distinguished as up- or down-regulated, there was a proportional 
representation by each gene set in trophoblast cells, decidual layer cells, and fetal vascular 
endothelial cells (Figure 6.9B). Only a small number of DEGs were exclusively detected in a 
single major cell population: 1.5% (5/333) of genes in fetal vascular endothelium (e.g., Cftr, 
Otoa), 8.1% (27/333) of genes in the decidual layer (e.g., Klrb1c, Cdo1), and 7.5% (25/333) 
of genes in trophoblast cells (e.g., Prl2c2, Prl3d1, Prl7a1, and Prl8a1; Figure 6.9A, Table 
A.1). Overall, this result suggests that blastocyst transfer causes broad transcriptional changes 





Figure 6.9 Spatial analysis of differentially expressed genes identified in placentas of 
transferred conceptuses. 
(A-B) Venn diagrams showing the percentage of differentially expressed genes with general 
(white) or known cell-specific expression in the placenta. Trophoblast (TB, blue); fetal 
endothelial vascular cells (FEV, orange); decidua (Dec, light green). The spatial expression 
pattern of (A) all differentially expressed genes combined and (B) up-regulated or down-
regulated genes separately. 
 
6.2.5.2 DEG are involved in placental development and function 
The primary annotation terms enriched in whole placentas from transferred conceptuses at 
E10.5 included genes important for placental development and function (Figure 6.10). 
Enrichment groups included genes associated with specific mammalian phenotypes (e.g., 
decreased vascular permeability, abnormal visceral yolk sac, abnormal lipid and glucose 
homeostasis, and decreased circulating IGF1 and insulin levels), and genes required for 
specific biological processes (e.g., cell adhesion, response to decreased oxygen levels, and 
negative regulation of cell proliferation and growth; Figure 6.10). At least 13 DEGs identified 
are important for placental labyrinth development and/or function as evidenced by gene 
knockout and over-expression studies (Table 6.7). Furthermore, 31 DEGs encoding for 
proteins with transporter activity were identified (Table 6.8). The majority of these genes 
(24/31 genes, 77.4%) were upregulated, which supports the hypothesis that blastocyst transfer 





Figure 6.10 Functional analysis of differentially expressed genes identified in placentas 
of transferred conceptuses. 
Gene ontology term enrichment analysis for differentially expressed genes in placentas of 
transferred conceptuses. The numbers of genes in each term are also given.  
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Table 6.7 DEGs implicated in growth, placental phenotypes, and/or embryonic lethality at midgestation. 
Gene Gene function Mouse knockout phenotype or clinical characteristics  Reference FC 
Genetic knockout or decreased expression: defective labyrinth, placental insufficiency and/or growth restriction 
Cubn Receptor mediated endocytosis  Defects in chorioallantoic attachment [E10.5] (Smith et al. 2006) 2.9 
Enpp2 Angiogenesis  
 
Defective chorioallantoic attachment [E10.5] (Fotopoulou et al. 
2010) 
2.5 
Zfp36l1 RNA binding protein  Failure of chorioallantoic attachment†, reduced branching 
morphogenesis in labyrinth layer, small spongiotrophoblast layer 
[E10.5†] 
(Bell et al. 2006; 
Stumpo et al. 
2004) 
2.1 
F2 Maintenance of vascular integrity  Reduced or absent branching morphogenesis in labyrinth layer 
[E10.5†] 
(Sun et al. 1998; 
Xue et al. 1998) 
3.4 
Rpgrip1 Regulator of ciliary protein traffic  Abnormal vasculature in labyrinth at E14.5 [‘Pre-weaning’ lethality] DMDD** -2.0 
Slpi Serine protease inhibitor Down-regulated expression in rat model of placental insufficiency 
[ND] 
(Goyal et al. 2010) 2.5 
Igf1 Insulin-like growth factor Severely growth restricted; unknown placental phenotype [Perinatal] (Liu & LeRoith 
1999) 
2.2 
Increased gene expression: trophoblast phenotypes, placental insufficiency, preeclampsia, or FGR 
Aldh3a1 Aldehyde dehydrogenase OE in mouse TS cells prevents differentiation into Tpbpa+ cells 
(EPC lineage) [ND] 
(Nishiyama et al. 
2015) 
-9.3 
Il33 Interleukin  Inhibits trophoblast invasion and adhesion in vitro [ND] (Fang et al. 2017) -4.0 
Tac2 Disintegrin and metalloproteinase Fetal growth restriction in humans associated with increased 
placental expression [ND] 
(Ozler et al. 2016) -3.1 
Crabp2 Retinoic acid signalling pathway OE in endometrial cell line causes decreased proliferation of 
trophoblast spheroids [ND] 
(Lee, Oh & Cho 
2011) 
2.3 
Cp Iron peroxidase  
 
Increased placental expression associated with pre-eclampsia in 
humans [ND] 
(Guller et al. 2008) 2.6 
Slc9a2 Sodium/hydrogen exchanger 
 
Up-regulated in rat model of placental insufficiency; unknown 
placental phenotype [Possible embryonic lethality†] 
(Goyal et al. 2010) 2.9 
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Genetic knockout: embryonic lethality between E10.5-E11.5 suggesting placental phenotype  
Adamts5 Transcriptional co-activator of SRF Developmental delay, cardiovascular insufficiency; unknown 
placental phenotype [E10.5] 
(Li et al. 2003) 2.8 
Myl7 Myoglobin Abnormal heart development, growth restriction and developmental 
delay; unknown placental phenotype [E10.5†] 
(Meeson et al. 
2001) 
-3.7 
Myocd Junctional membrane complex  Abnormal cardiomyocyte development; unknown placental 
phenotype [E10.5] 
(Takeshima et al. 
2000) 
3.6 
Mb Lipoprotein metabolism Pale yolk sac, impaired erythropoiesis, neural tube closure defect; 
unknown placental phenotype [E10.5] 
(Raabe et al. 1998) -2.8 
Jph2 Potassium channel Unknown placental phenotype [E10.5] (Stieber et al. 
2003) 
2.4 
Mttp Lipoprotein metabolism Pale yolk sac, impaired erythropoiesis, neural tube closure defect; 
unknown placental phenotype [E10.5] 
(Raabe et al. 1998) 2.3 
Hcn4 Potassium channel Unknown placental phenotype [E10.5] (Stieber et al. 
2003) 
2.6 
FC, fold change in RNA-sequencing experiment; KO, knockout; OE, overexpression; E, embryonic day; ND, not determined; *Timing of embryonic 
lethality; †Incomplete penetrance; **Deciphering the Mechanisms of Developmental Disorders (https:/dmdd.org.uk) 
 
Table 6.8 DEGs encoding proteins with transporter activity. 
Gene FC Gene Function Expression in placenta 
Down-regulated genes 
Trpm2 -10.11 Calcium channel TB, Dec 
Slc28a2l (Gm14085) -5.15 Purine nucleoside transporter General 
Clca3a1 -3.90 Calcium-activated chloride channel Dec 
Slc17a8 -3.00 L-glutamate transporter Unknown 
Ndufa4l2 -2.93 NADH dehydrogenase [ubiquinone], mitochondria General 
Slc28a2 -2.03 Sodium-coupled purine nucleoside transporter Dec 
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Kcnab2 -2.03 Voltage-gated potassium channel, NADH oxidation Unknown 
Up-regulated genes 
Kcnd2 5.13 Voltage-gated potassium channel Unknown 
Kcne3 3.91 Voltage-gated potassium channel TB, FVE 
Kcnj12 3.07 ATP-sensitive inward rectifier potassium channel General 
Atp6v1c2 2.89 Proton-exporting ATPase, phosphorylative mechanism TB, FVE, Dec 
Slc9a2 2.87 Sodium/hydrogen exchanger TB, FVE, Dec 
Slc13a5 2.87 Sodium-dependent citrate transporter Dec 
Gjb1 2.84 Gap junction protein TB 
Slc7a9 2.72 Sodium-independent L-cystine transporter General 
Abcc6 2.68 ATP-binding cassette transporter General 
Cftr 2.62 ATP-gated chloride channel FVE 
Slc27a2 2.60 Fatty acid transporter TB 
Hcn4 2.58 Cyclic nucleotide-gated potassium channel Unknown 
Slc7a11 2.57 Cysteine/glutamine transporter General 
Cacna1b 2.56 Voltage-gated calcium channel  Unknown 
Jph2 2.42 Calcium channel TB, Dec 
Slc39a8 2.31 Zinc ion transporter TB, Dec 
Trpm3 2.31 Cation channel Unknown 
Mttp 2.30 Microsomal triglyceride transfer protein TB 
Kcnk2 2.21 Potassium channel Unknown 
Asic2 2.14 Voltage-gated sodium channel TB 
Apom 2.09 Lipid transport TB, FE, Dec 
Scnn1g 2.07 Amiloride-sensitive sodium channel General 
Amn 2.04 Cobalamin and lipid transport TB 
Slc4a1 2.03 Chloride/bicarbonate exchanger FBCs 
TB, trophoblast; FC, fetal capillaries; FBCs, fetal blood cells; Dec, maternal decidua; General, expression determined by Mouse ENCODE project via 
RNA-seq of mouse placentas; human placenta expression determined via Human Protein atlas. 
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6.2.5.3 Dysregulation of DNA methylation by blastocyst transfer is unlikely to be the 
primary mechanism of transcriptional disruption  
Studies have shown the effects of ART procedures, such as superovulation, in vitro 
fertilisation, and embryo culture on the expression of imprinted genes in the placenta (Fortier 
et al. 2008; Sanjeev Khosla et al. 2001; Mann et al. 2004), a process which is regulated by 
DNA methylation. The mechanism by which blastocyst transfer alters gene expression is not 
well understood, though epigenetic dysregulation has been implicated (Canovas et al. 2017; 
Choux et al. 2015). For instance, embryo transfer alters the expression of imprinted genes in 
the mouse placenta at E9.5. Monoallelic expression of H19, Snrpn, Igf2, Kcnq1ot1, Cdkn1c, 
Kcnq1, Mknr3, Ascl2, Zim1, Peg3 was observed in the unmanipulated conceptuses, while 
aberrant expression of these genes was observed in placentas and yolk sacs of transferred 
conceptuses. Placentas and yolk sacs derived from embryos that were cultured in vitro prior 
to embryo transfer, showed an even higher degree of aberrant gene expression. IgfII and 
Ascl2 levels in placentas of both manipulated groups (i.e. embryo transfer and in vitro 
culture) were downregulated and upregulated respectively, compared to the unmanipulated 
ones (Rivera et al. 2008). This suggests that embryo transfer might affect DNA methylation, 
leading to misexpression of imprinted genes. To examine the potential sensitivity of the 
DEGs to changes in CpG methylation, we evaluated whether the top 50 down-regulated 
genes (FC>3.1) and top 50 up-regulated genes (FC>6.7) contained intragenic or proximal 
CpG repeats within 20 kb of the gene (Figure 6.11A). This result was compared to 50 
randomly selected genes as a proxy for the genome. While this analysis did not determine 
whether the CpG repeats present were methylated or directly regulate gene expression, it 
highlights the potential for gene dysregulation when methylation patterns are altered. 
Compared to the rest of the genome, both up- and down-regulated gene sets were less likely 
to contain intragenic CpG repeats (24-30% of DEGs compared of 46% of genes genome-
wide; p<0.05, Fisher’s exact test; Figure 6.11A). Moreover, down-regulated DEGs were less 
frequently associated with proximal CpG repeats (26% of DEGs; p<0.05) than both the up-
regulated gene set (40% of DEGs) and the genome (42% of genes; Figure 6.11A). Overall, 
these findings suggest that genes that were differentially expressed after blastocyst transfer 
are less likely to be cis regulated by CpG methylation compared to the genome at large. 
We identified 15 DEGs whose regulation has been directly linked to CpG methylation at 
specific genomic locations in other studies (Table 6.9). Based on the published data and our 
RNA-seq data, we predicted that seven of these DEGs should be associated with CpG 
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hypomethylation and eight DEGs with CpG hypermethylation (Table 6.9). Next, we sought 
to validate CpG methylation in two of these 14 loci (i.e., Prl3d1 and Rasgrf1) via bisulfite 
pyrosequencing (in collaboration with Dr. G. Blake; Figure 6.11B). Whole placentas from 
transferred conceptuses were compared to non-transferred controls (n=5 female placentas per 
group). RT-qPCR analysis revealed a 4.1-fold and 2.3-fold decrease in Prl3d1 mRNA 
expression in male and female transferred placentas, respectively, compared to controls 
(Figure 6.11C). Thus, CpG hypermethylation in the Prl3d1 promoter was expected 
(Hayakawa et al. 2012). Nevertheless, analysis of five CpG sites across the Prl3d1 promoter 
revealed similar levels of methylation in each placenta group (Figure 6.11D). Likewise, we 
assessed CpG methylation in the differentially methylated region (DMR) associated with the 
Rasgrf1 gene. Since RNA-sequencing determined a 2.7-fold decrease in Rasgrf1 mRNA in 
transferred placentas, hypomethylation of the Rasgrf1 DMR was expected (Yoon et al. 2005). 
However, four out of five CpGs assessed showed consistent levels of methylation in 
transferred and control placentas (Figure 6.11E). CpG-5 was hypomethylated in transferred 
placentas (20.7 ± 4.1% methylated compared to 38.6 ± 4.0% in controls; p<0.0001; Figure 
6.11E), but hypomethylation of a single CpG among many is unlikely to be responsible for 
decreased Rasgrf1 mRNA expression. Altogether, these data suggest that disruption of CpG 
methylation by blastocyst transfer is unlikely to be a primary mechanism driving 
transcriptional changes in the mouse placenta at E10.5. 
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Known characteristics of 






DEGs that were downregulated in the placenta (E10.5) after blastocyst transfer 
Trpm2 Cation channel  Methylation of inner CpG island 
associated with gene repression 
-10.11 Hyper (Orfanelli et al. 2008) 
Klra4 Killer cell lectin-like 
receptor; cell 
adhesion  
Promoter hypomethylation associated 
with gene activation 
-8.83 Hyper (Rouhi et al. 2009) 
Dazl 
 
RNA binding protein  Promoter methylation is associated 
with gene repression 
-4.96 Hyper (Hackett et al. 2012) 
Prl8a1 Prolactin hormone 
family 
Placenta-specific DNA 
hypomethylation associated with gene 
activation 
-2.89 Hyper (Hayakawa et al. 2012) 
Prl7a1 Prolactin hormone 
family  
Placenta-specific DNA 
hypomethylation associated with gene 
activation 
-2.85 Hyper (Hayakawa et al. 2012) 
Rasgrf1 Guanine nucleotide-
releasing factor  
Paternally-methylated (imprinted) and 
expressed, methylation leads to gene 
activation 
-2.70 Hypo (Yoon et al. 2005) 
Kazald1 Insulin growth factor 
binding protein 
family 
Promoter hypomethylation associated 
gene activation 
-2.25 Hyper (Wang et al. 2013) 
Prl3d1 Prolactin hormone 
family 
Placenta-specific DNA 
hypomethylation of promoter 
associated with gene activation 
-2.02 Hyper (Hayakawa et al. 2012) 
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DEGs that were upregulated in the placenta (E10.5) after blastocyst transfer 
Edn2 Angiogenesis Hypomethylation of intragenic region 
associated with gene activation 
7.15 Hypo (Wang et al. 2013) 
Cldn11 Gap junction protein Promoter hypermethylation associated 
with gene repression 
5.87 Hypo (Agarwal et al. 2009) 
Eno2 
 
Glycolysis Promoter hypermethylation associated 
with gene repression 
5.65 Hypo (Wang et al. 2014) 
Inhba TGFβ signaling 
pathway 
Promoter hypermethylation in human 
placenta associated with gene 
repression 
4.42 Hypo (Wilson et al. 2015) 
Cfb Complement factor Promoter hypermethylation associated 
with gene repression; in human 
placenta, becomes hypomethylated 
upon CytoT to SynT differentiation 
4.40 Hypo (Yuen et al. 2013) 
Tfpi2 Polycomb repressive 
complex 
Promoter hypomethylation associated 
with gene repression 
3.1 Hypo (Hu et al. 2017; Ribarska et 
al. 2010) 
Cobl Actin interacting 
protein 
Tissue-specific parentally-biased 
expression (Grb10 imprinted DMR); 
maternal methylation at Grb10 DMR 
in yolk sac results in maternal Cobl 
expression  
2.61 Hyper (Shiura et al. 2009) 




Figure 6.11 Unlikely that blastocyst transfer directly alters placental gene expression via 
CpG methylation. 
(A) The percentage of the top 50 down-regulated (blue bars, FC > 3.1) or up-regulated (pink 
bars, FC > 6.7) DEGs after blastocyst transfer that associate with CpG repeats localised 
intragenically or proximally (within 20 kb). The percentage of 50 randomly selected genes is 
indicated as a proxy for the genome (black bars). Statistical analysis: Fisher’s exact test. 
*p<0.05, **p<0.01. (B) Schematic drawings of the Prl3d1 promoter and the Rasgrf1 DMR. 
Open circles represent unmethylated CpG sites and closed circles indicate methylated CpG 
sites in placental tissue. a-d represent regions assessed by bisulfite pyrosequencing in Prl3d1 
promoter. (C) RT-qPCR analysis of Prl3d1 transcripts in male (m) and female (f) placentas 
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of control (black dots) and transferred (grey dots) conceptuses at E10.5. Data are presented as 
fold change compared to controls (normalised to 1; mean ± sd). N = 4-7 placentas per group. 
Statistical analysis: independent t test. *p<0.05. (D-E) CpG site-specific methylation (mean ± 
se) in (D) the promoter region of the Prl3d1 gene and (E) the Rasgrf1 DMR as determined 
via bisulfite pyrosequencing of DNA from control (black) and transferred (grey) female 
placentas at E10.5. N=5 placentas per gene locus. Statistical analysis: independent t test. 
***p<0.001. (F-G) Screen shots of genomic regions of (F) Prl3d1 and (G) Rasgrf1 as 
determined by UCSC mouse genome browser (http://genome.ucsc.edu) gene tracks using 
NCBI37/mm9 genome assembly. The location of the genes, CpG repeats (green), and ChIP-
seq data from normal mouse placentas at term showing enrichment of H3K4me1 and 
H3K27ac histone modifications (from Bing Ren’s laboratory) are shown. Shaded regions 
indicate gene of interest. 
  
 
6.2.5.4 Some DEGs cluster in the genome implying common transcriptional regulation 
Next, we determined the chromosomal location of DEGs (FC>3) including 155 up-regulated 
and 60 down-regulated genes (Figure 6.11A). While the DEGs were distributed throughout 
the genome, we identified 18 genomic regions (<335 kb) with two or more DEGs (Figure 
6.12A). This was unlikely to occur by chance since gene clusters were not identified in a 
group of 60 randomly selected genes (data not shown). This result suggested that clustered 
genes might share common regulatory mechanisms. Therefore, we assessed whether these 
genomic regions included CpG repeats and histone modifications using University of 
California Santa Cruz (UCSC) Mouse Genome Browser (Haeussler et al. 2019; Kent et al. 
2002) and a published ChIP-seq data set that displayed genomic enrichment for H3K4 
monomethylation (me1) and H3K27 acetylation (ac) in normal C57Bl/6 mouse placentas at 
term (Stamatoyannopoulos et al. 2012). High levels of H3K4me1 and H3K27ac at enhancers 
and/or promoters are generally associated with transcriptionally active genes (Zhang & 
Reinberg 2001). While some regions (5/18 regions, 27.8%) lacked CpG repeats and 
enrichment of placental H3K4me1 or H3K27ac peaks (eg. Chr1: Ifi208, Mndal, Ifi202b; 
Figure 6.12D), the majority (13/18 regions, 72.2%) showed potential for a shared regulatory 
region (Figure 6.12B-C). For example, Edn2 and Foxo6 (FC > 5.3) are located within a 
region on chromosome 4 that is enriched in CpG repeats and placental H3K4me1 (Figure 
6.12B). Additionally, Klk8 and Klk9 genes (FC > 3.2) on chromosome 7 share three placental 
H3K4me1 peaks and a CpG repeat region (Figure 6.12C). Furthermore, Prl3d1 and Rasgrf1 
genes, which did not show DNA methylation changes after blastocyst transfer (Figure 6.11D-
197 
 
E), are proximal to histone modification peaks in the placenta (Figure 6.12E-F). Altogether, 
these data support the hypothesis that, after blastocyst transfer, epigenetic marks including 
histone modifications might be dysregulated to alter placenta development and/or function. 
Interestingly, five DEGs (AU022751, Myocd, L3mbtl2, Chd5, and Pygo1) are involved in the 
regulation of histone modifications including methylation and acetylation (Cao et al. 2005; 
Fiedler et al. 2008; Kloet et al. 2016; Maier et al. 2015; Potts et al. 2011; Trojer et al. 2011; 
Zhuang et al. 2014). Indeed, the dysregulation of proteins involved in chromatin remodelling 
has large implications for widespread transcriptional dysregulation. To explore histone 
modifications as a potential mechanism for transcriptional change after blastocyst transfer, 
we used the same published ChIP-seq data set as above (Haeussler et al. 2019). The top 50 
up-regulated genes (FC >6.7) and top 50 down-regulated genes (FC > 3.1) were assessed for 
normal intragenic and proximal placental H3K4me1 and H3K27ac peaks. The frequency of 
association was compared with 50 randomly selected genes representing the genome. DEGs 
showed a similar association to intragenic placental H3K4me1 (62-70% of DEGs; p=0.1764, 
Fisher’s exact test) compared to the genome (74% of genes; Figure 6.11E). Compared to 86% 
of upregulated DEGs and genes in the genome, 68% of down-regulated DEGs were 
associated with proximal placental H3K4me1 (p<0.0001; Figure 6.12E). However, these data 
suggest that the majority of DEGs might be sensitive to changes in histone methylation, 
particularly H3K4me1. Alternatively, the top DEGs were less likely to associate with 
placental H3K27ac peaks under normal conditions compared to the rest of the genome 
(intragenic: 20-26% of DEGs versus 60% of genes in genome, p<0.0001; proximal: 54-56% 
of DEGs versus 72% of genes in genome, p=0.0169; Figure 6.12F). While regulation of some 
DEGs in the placenta might require histone acetylation, it is less likely that this group of 
genes requires it for their regulation under normal conditions. From this, we hypothesise that 
the DEGs might be more sensitive to changes in histone methylation than histone acetylation. 
A ChIP-seq experiment using antibodies against these and other histone modifications in 





Figure 6.12 Clustering of differentially expressed genes in the genome suggests shared 
regulatory regions. 
(A) Schematic representation of mouse chromosomes 1-19 and X indicating the location of 
differentially expressed genes (FC > 3) in whole placentas after embryo transfer as 
determined via RNA-sequencing. Pink lines, up-regulated genes; blue lines, down-regulated 
genes. Arrowheads indicate gene clusters: black arrowhead, two genes within a 75 kb 
window; grey arrowhead, three or more genes that are within a 335 kb window. (B-D) Screen 
shots of examples of clustered gene regions as shown by UCSC genome browser 
(http://genome.ucsc.edu) gene tracks that indicate location of the genes, CpG repeats (green), 
and ChIP-seq data from mouse placentas at term showing enrichment of H3K4me1 and 
H3K27ac histone modifications (from Bing Ren’s laboratory) are shown. Shaded regions 
indicate genes of interest. FC, fold-change determined in the RNA-sequencing experiment. 
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(E-F) The percentage of the top 50 down-regulated (blue bars, FC > 3.1) or up-regulated 
(pink bars, FC > 6.7) DEGs after blastocyst transfer that display (E) placental H3K4me1 
peaks, or (F) placental H3K27ac peaks localised intragenically (Intra) or proximally (Prox; 
within 20 kb). The percentage of 50 randomly selected genes is indicated as a proxy for the 
genome (black bars). Statistical analysis: Fisher’s exact test. *p<0.05, **p<0.01, ***p<0.001.      
 
 
6.2.6 DEGs as a result of developmental programming of F2 Mtrr+/+ conceptuses 
Gene ontology analysis of all the genes that were differentially expressed due to the 
blastocyst transfer process was described in the previous section. Next, we wanted to see 
whether the F2 Mtrr+/+ conceptuses respond differently to the blastocyst transfer into the 
BDF1 uterus compared to the C57Bl/6 conceptuses. Therefore, we performed gene ontology 
analysis on the DEGs in transferred F2 Mtrr+/+ placentas. 
 
6.2.6.1 F2 Mtrr+/+ conceptuses respond differently to the blastocyst transfer into a BDF1 
uterus at E3.0 compared to C57Bl/6 conceptuses 
First, we performed gene ontology analysis on the 271 genes that were differentially 
expressed only in the transferred C57Bl/6 placentas. These genes were not differentially 
expressed in transferred F2 Mtrr+/+ placentas. Enriched biological processes were involved in 
metabolism, such as glucose homeostasis (Prkaa2, Hnf4a, Hkdc1, Igf1, p=0.02) and 
regulation of glycogen metabolism (Igf1, Sorbs1, p=0.02). Other enriched biological 
processes were involved in embryo development, such as somite development (Sfrp2, Meox1, 
p=0.01), cellular response to decreased oxygen levels (Mt3, Hipk2, Aqp1, Zfp36l1, p=0.01), 
and regulation of cell growth (Sfrp2, Hnf4a, Slit3, Inhba, Mt3, p=0.02). Finally, regulation of 
angiogenesis (Sfrp2, Cntn1, Thbs1, Pgf, Hipk2, Aqp1, p=0.003) and regulation of BMP 
signalling (Lrp2, Fbn1, Hipk2, p=0.009) were also enriched (Figure 6.13A). Enriched 
molecular function terms included integrin binding (Sfrp2, Igf1, Thbs1, Fbn1, p=0.04), 
collagen binding (C1qtnf1, Thbs1, Antxr1, p=0.03), insulin receptor binding (Igf1, Sorbs1, 
p=0.03), and ion channel activity (Scnn1g, Trpm2, Trpv6, Cacna1b, Trpm3, p=0.009; Figure 
6.13B). Finally, enriched mammalian phenotypes included absent amnion (Cubn, Amn, 
Hnf4a, p=0.002), weight loss (Galc, Scnn1g, Chrm3, Sftpd, Cntn1, Slc4a1, Ctsf, Cftr, 
p=0.002), cardiac hypertrophy (Gucy2c, Amn, Fxyd1, Slc4a1, Trim55, Fbn1, p=0.002), 
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abnormal circulating insulin levels (Klb, Glp1r, Sorbs1, p=0.002), and decreased IGF levels 
(Galc, Rasgrf1, Foxl2, Igf1, p=0.003; Figure 6.13C). 
 
Figure 6.13 Gene ontology analysis of the DEGs in transferred C57Bl/6 but not F2 
Mtrr+/+ placentas. 
(A) Biological processes, (B) Molecular function, (C) Mammalian phenotypes that are 
enriched according to Enrichr. The number next to each bar shows the number of DEGs that 
fall under that term. 
 
Next, we wanted to see whether similar biological processes and molecular functions are 
affected in the F2 Mtrr+/+ conceptuses after blastocyst transfer. The F2 Mtrr+/+ conceptuses 
had global DNA hypomethylation (Padmanabhan et al. 2013). Additionally, we showed that 
F1 Mtrr+/+ uteri have abnormal structure at estrus, such as increased myometrial thickness, 
increased invaginations in the lumen epithelium, and decreased Pgr mRNA and protein 
expression at estrus (Chapter 3). Implantation sites of F1 Mtrr+/+ females also had decreased 
Bmp2 levels at E6.5 (Chapter 4). Altogether, these data evidence that the uterine environment 
of F1 Mtrr+/+ females is abnormal. The F2 Mtrr+/+ conceptuses developed in the abnormal F1 
Mtrr+/+ uteri until E3.0, before being transferred to the normal uterine environment of a 
BDF1 female (Padmanabhan et al. 2013). The F2 Mtrr+/+ conceptuses were initially 
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developmentally adapted in the environment of the F1 Mtrr+/+ uteri, and after E3.0 they were 
exposed to a different uterine environment. This environmental mismatch (Bateson et al. 
2004) is probably responsible for the rescue of growth restriction and developmental delay 
and increased frequency of growth enhancement of F2 Mtrr+/+ conceptuses after embryo 
transfer (Padmanabhan et al. 2013). Therefore, we performed gene ontology analysis on the 
244 DEGs in transferred F2 Mtrr+/+ placentas. 
Enriched biological processes include vasoconstriction (Ednra, Htr2b, Adra1b, p=0.0005), 
regulation of blood vessel diameter (Ednra, Htr2b, p=0.009), G-protein coupled receptor 
signalling (Htr6, Vipr1, Htr2b, Adra1b, Rxfp1, p=0.019), regulation of MAPK cascade 
(Bmp2, Ccl22, Insrr, Htr2b, Ptpn22, Tnfrsf1a1, Adra1b, Ephb1, p=0.02), regulation of Erbb 
signalling (Mmp9, Art4, p=0.03), and regulation of EGF receptor signalling (Mmp9, Sh3gl2, 
Art4, p=0.03; Figure 6.14A). Enriched molecular function terms include G-protein coupled 
receptor activity (Htr6, Vipr1, Gpr34, Ptger2, Gpr171, Htr2b, Gpr75, Rxfp1, Adgrl3, 
p=0.006), BMP binding (Grem1, Gdf5, p=0.006), CoA hydrolase activity (Acot11, Acot12, 
p=0.02), and ribonuclease activity (Endou, Slfn14, Samhd1, p=0.02; Figure 6.14B). Finally, 
enriched mammalian phenotypes include abnormal heart orientation (Bmp2, Pdlim3, p=0.02), 
abnormal body weight (Pyy, Serpine1, p=0.03), increased angiogenesis (Serpine1, Mmp9, 
p=0.03), abnormal embryo implantation (Dnah11, p=0.03), and delayed allantois 





Figure 6.14 Gene ontology analysis of the DEGs in transferred F2 Mtrr+/+ placentas. 
(A) Biological processes, (B) Molecular function, and (C) Mammalian phenotypes that are 
enriched according to Enrichr. The number next to each bar shows the number of DEGs that 
fall under that term. 
 
We observed that different biological processes, molecular functions, and mammalian 
phenotypes are affected after blastocyst transfer of F2 Mtrr+/+ conceptuses when compared to 
the C57Bl/6 conceptuses. For instance, BMP binding was an enriched molecular function in 
the F2 Mtrr+/+, but not C57Bl/6 conceptuses. This suggests that the placenta might 
compensate in the new uterine environment by improving the decidualisation reaction. 
Additionally, enriched biological processes in the transferred F2 Mtrr+/+ conceptuses suggest 
changes in the signalling pathways in the placenta, while enriched biological processes in the 
transferred C57Bl/6 conceptuses are mostly involved in cell growth and metabolism. 
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Altogether, these data suggest that developmental programming of the F2 Mtrr+/+ 
conceptuses occurred in the F1 Mtrr+/+ uterus during the first three days of development. 
After blastocyst transfer, the F2 Mtrr+/+ conceptuses were exposed to a different 
environment, leading to transcriptional changes in the placenta in order to increase placenta 
efficiency and maintain growth. In contrast, C57Bl/6 conceptuses were exposed to a normal 
uterine environment prior and after the embryo transfer, and therefore they responded 
differently after the blastocyst transfer compared to the F2 Mtrr+/+ conceptuses. 
 
6.2.6.2 Genes involved in transport are misexpressed after transfer of blastocysts into the 
recipient uterine environment 
Enriched gene ontologies such as increased angiogenesis and regulation of blood vessel 
diameter, suggest that the uteroplacental flow might be altered in transferred F2 Mtrr+/+ 
conceptuses. This might affect placental efficiency, considering abnormal body weight was 
an enriched mammalian phenotype. Earlier in this chapter, we showed that E:P weight ratio 
of F2 Mtrr+/+ conceptuses was increased after blastocyst transfer, implying increased 
placental efficiency. Therefore, we investigated whether DEGs with transport activity were 
present (Table 6.10). 
We identified two and nine genes with transport-related activity that were upregulated and 
downregulated respectively in the placentas of transferred compared to non-transferred 
phenotypically normal F2 Mtrr+/+ conceptuses. Only two and five transport-related genes 
were upregulated and downregulated in placentas of transferred compared to non-transferred 
growth enhanced F2 Mtrr+/+ conceptuses, respectively. Slc44a4, which is downregulated in 
placentas of phenotypically normal F2 Mtrr+/+ conceptuses, is known to be expressed both in 
the trophoblast and the decidua. Chrna4, is also expressed by both the trophoblast and the 
decidua, Ednra is expressed by the decidua, and Slc9b2 is expressed by the trophoblast. 
These three genes were differentially expressed in placentas of transferred growth enhanced 
F2 Mtrr+/+ conceptuses compared to non-transferred ones. The expression of the rest of the 
genes in Table 6.10 has not yet been identified in the placenta. These data suggest that the 
provision of a normal uterine environment affects the expression of genes involved in 




Table 6.10 DEGs with transport activity in placentas of transferred compared to non-
transferred F2 Mtrr+/+ conceptuses. 
Transport activity 
Gene FC Function 
DEGs in placentas of transferred PN F2 Mtrr+/+ conceptuses 
Abca13 2.92 ATP-binding cassette (ABC) transporter 
Atp13a4 -3.55 Calcium-transporting ATPase activity 
Atp1a2 -2.2 Sodium/potassium-transporting ATPase activity 
Atp6v0a4 -2.25 Proton-transporting ATPase activity 
Pacsin1 -3.97 Vesicle mediated transport 
Pkd1l2 -2.35 Calcium ion transport 
Slc17a8 -3.63 Amino acid transmembrane transporter 
Slc44a4 -2.1 Organic cation transport 
Slc4a8 -2.05 Bicarbonate transmembrane transport 
Slc8a1 2.33 Solute carrier, calcium ion transport 
Thrsp -3.36 Fatty acid transmembrane transport 
DEGs in placentas of transferred GE F2 Mtrr+/+ conceptuses 
Abcg5 4.11 Cholesterol transport 
Atp1a2 -2.33 Sodium/potassium-transporting ATPase activity 
Atp6v0a4 -2.02 Proton-transporting ATPase activity 
Chrna4 -2.32 Ion transmembrane transport 
Ednra 2.11 Glucose transmembrane transport 
Slc9b2 -2.25 Ion transporter activity 
Thrsp -4.39 Fatty acid transmembrane transport 
FC: fold-change, PN: phenotypically normal, GE: growth enhanced 
 
 
6.2.6.3 The uterine environment of the recipient female might cause changes in 
epigenetic regulation of gene expression 
The uteri of Mtrr+/+ females derived from Mtrr+/gt intercrosses, and placentas of 
phenotypically normal F2 Mtrr+/+ conceptuses at E10.5 had global DNA hypomethylation 
compared to C57Bl/6 (Padmanabhan et al. 2013). Although global DNA methylation levels 
have not yet been assessed in F1 Mtrr+/+ uteri derived from one Mtrr+/gt parent, we showed 
that F1 Mtrr+/+ females had normal homocysteine levels (Padmanabhan et al. 2018). This 
suggests that they have normal folate metabolism and normal availability of methyl groups. It 
is however possible that the uteri of F1 Mtrr+/+ females have altered epigenetic regulation of 
gene expression, that influences the growth and development of F2 Mtrr+/+ conceptuses. 
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We identified Prdm16, which is differentially expressed between placentas of non-transferred 
and transferred phenotypically normal F2 Mtrr+/+ conceptuses (FC= -3.0), to be involved in 
histone modifications. More specifically, Prdm16 has H3K9me1 methyltransferase activity 
and is required for mammalian heterochromatin integrity (Pinheiro et al. 2012). There were 
no genes that were differentially expressed after embryo transfer in growth enhanced F2 
Mtrr+/+ placentas that regulate gene expression by epigenetic modifications. Next, we 
identified DEGs after embryo transfer in F2 Mtrr+/+ placentas whose expression is directly 
regulated by CpG methylation as identified in other studies (Table 6.11). 
 
Table 6.11 Genes whose expression is epigenetically regulated by DNA methylation and 
were differentially expressed in F2 Mtrr+/+ but not C57Bl/6 conceptuses at E10.5 after 
blastocyst transfer. 
Gene name 
(FC in PN, 
FC in GE) 
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Hyper (von dem 





























Hyper (Ulker et al. 2018) 
FC: Fold change; PN: phenotypically normal; GE: growth enhanced 
 
We identified nine genes (Table 6.11) whose expression is directly regulated by DNA 
methylation and were misexpressed between placentas of non-transferred and transferred F2 
Mtrr+/+ conceptuses. Based on the gene expression according to our RNA-seq data, we 
predicted that seven out of the nine genes have increased methylation at the CpG repeats. 
Altogether, these data suggest that the uterine environment of the recipient females might 
cause changes in the epigenetic regulation of placental gene expression. 
 
6.2.6.4 The abnormal uterine environment affects genes implicated in growth, placental 
phenotypes, and/or embryonic lethality at midgestation 
Altered placental gene expression might have adverse effects on fetoplacental development. 
We therefore wanted to identify the DEGs with a role in placenta development and embryo 
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growth. First, we identified two genes, Tfpi and Htr2b, whose expression was altered between 
placentas of non-transferred and transferred F2 Mtrr+/+ conceptuses (Table 6.12). Tfpi mutant 
embryos have abnormal vascularisation in the placenta leading to growth restriction (Huang 
et al. 1997). Htr2b mutant embryos are growth restricted by midgestation and have abnormal 
heart development (Nebigil et al. 2000). Since growth restriction and heart defects are 
associated with abnormal placental function (Barry, Rozance & Anthony 2008; Grivell, Dodd 
& Robinson 2009; Perez-Garcia et al. 2018; Roberts & Post 2008), it is possible that Htr2b 
mutants have altered placental development and function. In addition, Esrrb, which is 
downregulated in placentas of phenotypically normal, but not growth enhanced F2 Mtrr+/+, is 
required for chorion development. Esrrb mutants have abnormal chorion development, 
overabundant TGCs, and severe deficiency of diploid trophoblast, leading to embryonic 
lethality at E10.5 (Luo et al. 1997). Abnormal folate metabolism in mice alters the uterine 
structure and function of their wildtype daughters (Chapters 3 and 4), possibly leading to 
developmental programming of their wildtype grandprogeny. Differential expression of genes 
involved in placental development might be due to the programming of the embryo in the 
abnormal uterine F1 Mtrr+/+ environment, before providing it with a normal uterine 
environment at E3.0. 
Altogether, these data suggest that the F2 Mtrr+/+ conceptuses react differently to the 
blastocyst transfer into a BDF1 uterus compared to the C57Bl/6 conceptuses, based on the 
DEGs identified. It is possible that developmental programming of the F2 Mtrr+/+ 
conceptuses occurs in the abnormal F1 Mtrr+/+ uterus. Alternatively, it is possible that the 
Mtrrgt mutation affects not only the uterine environment, but also the environment of other 
parts of the reproductive system. For instance, the intraovarian or intrafallopian tube 
environments of the F1 Mtrr+/+ females might be altered. Therefore, exposure of the oocytes 
to the adverse intraovarian conditions, or exposure of the zygote to the adverse intrafallopian 
tube environment could also lead to developmental programming of the F2 Mtrr+/+ oocytes or 
zygotes. As a result, once these embryos are transferred into a normal BDF1 uterus, the 
placental transcriptome is altered to compensate for the different intrauterine environment. In 
contrast, C57Bl/6 conceptuses were never exposed to an abnormal uterine environment, and 





Table 6.12 DEGs implicated in growth, placental phenotypes, and/or embryonic 
lethality at midgestation in placentas of transferred F2 Mtrr+/+ conceptuses. 
Gene 
(FC in PN, 
FC in GE) 





Regulator of tissue 
factor-dependent 
pathway of blood 
coagulation 
Placenta vascular abnormalities lead to 
progressive growth retardation and neonatal 
lethality 




Serotonin receptor Growth retardation at E9.5 and E10.5, 
abnormal heart development 








Abnormal chorion development, 
overabundance of trophoblast giant cells, severe 
deficiency of diploid trophoblast, embryonic 
lethality at E10.5 
(Luo et al. 
1997) 




In the third trimester of uncomplicated human pregnancy, the methylation demands increase, 
as shown by an increase in the transmethylation rate (Dasarathy et al. 2010). Abnormal folate 
metabolism affects the transfer of methyl groups by decreasing the rate of homocysteine 
methylation (Cuskelly et al. 2001). In our model of abnormal folate metabolism leading to 
global DNA hypomethylation (Padmanabhan et al. 2013), the placental epigenome is altered, 
possibly affecting placental development and function and ultimately leading to growth 
restriction and developmental delay. 
Here, we assessed the placental transcriptome of the conceptuses that have been transferred at 
the blastocyst stage into a normal BDF1 uterus. First, we assessed the effects of maternal 
grandpaternal Mtrrgt mutation on the placental transcriptome after F2 Mtrr+/+ conceptuses 
were provided with a normal uterine environment. Maternal grandpaternal Mtrrgt mutation 
minimally affects the placental transcriptome at E10.5 after blastocyst transfer, since we 
identified only six genes that were upregulated in growth enhanced F2 Mtrr+/+ compared to 
C57Bl/6 transferred conceptuses. The misexpression of these genes suggests minimal 
alterations in the placental development and function and reinforces the conclusion that 
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maternal grandpaternal abnormal folate metabolism minimally affects the placental 
transcriptome of their wildtype grandprogeny. 
Evidence suggests that ART might influence pregnancy outcome in an adverse manner, yet 
the mechanism is not well understood. Here, we found that the blastocyst transfer process 
affects the placental transcriptome at E10.5. We therefore focused on the blastocyst transfer, 
as part of routine human ART procedures. Evidence suggests that ART might influence 
pregnancy outcome in an adverse manner, yet the mechanism is not well understood. Here we 
show that blastocyst transfer after natural mating of healthy mice is sufficient to restrict 
placental growth at midgestation, even though the associated embryos were larger on 
average. This phenotype corresponds with a placental transcriptome that was enriched for 
genes implicated in labyrinth formation, growth, vascular development, and transport 
function, and implies compensation by the placenta to increase its functional efficiency. 
Therefore, even minimal embryo manipulation has developmental implications for the 
placenta and embryo. Mechanistically, we showed that blastocyst transfer procedure is 
unlikely to alter CpG methylation in a meaningful way. Consequently, efforts should focus 
on other epigenetic mechanisms including dysregulation of histone modifications. 
Fetal growth is contingent upon the placenta since it is the interface between the maternal and 
fetal circulations, facilitating gas and metabolic exchange and hormone production (Watson 
& Cross 2005). After blastocyst transfer, we observed placentas that were small at E10.5 
suggesting delayed development and/or reduced placental growth. Since the associated 
embryos were of normal developmental stage and size, the placentas may have adjusted their 
functional performance to protect the embryo growth trajectory. To achieve this, the placenta 
might respond to fetal requirements by altering its structure and/or nutrient transport capacity. 
In the mouse, the labyrinth layer is the exchange barrier composed of a complex network of 
trophoblastic villi that separate the fetal capillaries from the maternal blood circulation 
(Watson & Cross 2005). We observed several genes associated with labyrinth formation that 
were upregulated after blastocyst transfer including those involved in branching 
morphogenesis and vascularisation as determined by genetic knockout mice (Bell et al. 2006; 
Fotopoulou et al. 2010; Goyal et al. 2010; Liu & LeRoith 1999; Perez-Garcia et al. 2018; 
Smith et al. 2006; Stumpo et al. 2004; Sun et al. 1998; Xue et al. 1998). These transcriptional 
changes might promote branching of additional villi and/or an increase in vascular density of 
existing villi (Wu et al. 2003) to improve the surface area for exchange. In support of this 
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hypothesis, increased placental vascular density is apparent after IVF (and embryo transfer) 
in bovine and ovine conceptuses (Grazul-Bilska et al. 2014; Miles et al. 2005). IVF followed 
by blastocyst transfer in mice might lead to increased branching morphogenesis since an 
initially small placenta at E12.5 develops into a large placenta by late gestation (Bloise et al. 
2012; Delle Piane et al. 2010). To fully understand the effects of blastocyst transfer alone on 
mouse placental villus structure, a morphological analysis is required.  
Alternatively, placentas are capable of stimulating nutrient transport to compensate for poor 
placental growth (Constância et al. 2002). Similar to IVF in mice (Bloise et al. 2012),  we 
observed many upregulated genes in transferred placentas that encode for transport proteins 
(e.g., Gjb1, gap junction protein; Slc7a9, L-cystine transport; Slc27a2, fatty acid transport; 
Slc7a11, cysteine/glutamine transport; Apom, lipid transport, etc.). This implies functional 
compensation by a small placenta in response to fetal requirements (Constância et al. 2002). 
Placental transfer assays will be required to more fully understand the degree to which 
transcriptional upregulation leads to a functional increase in nutrient transport across the 
placenta. Furthermore, whether the placenta is able to continue to compensate in later stages 
of gestation as the demands of the fetus increase remains to be determined. 
Other placental regions (e.g., the junctional zone or decidua) might also be reduced after 
blastocyst transfer. We identified four placenta prolactin cluster genes (i.e., Prl2c2, Prl3d1, 
Prl7a1, and Prl8a1), which are normally expressed in spongiotrophoblast cells and 
trophoblast giant cell (TGC) subtypes (Simmons et al. 2008) and were downregulated in 
transferred placentas. Prl3d1 (also known as Pl1) is a gene regulated by promoter CpG 
methylation (Hayakawa et al. 2012) and its expression is often used as marker to quantify 
parietal-TGCs (Simmons et al. 2008). Since Prl3d1 promoter methylation was normal, 
reduced Prl3d1 mRNA expression might instead indicate that fewer Prl3d1+ parietal-TGCs 
are present in transferred placentas. Similarly, reduced Prl2c2, Prl7a1, and Prl8a1 mRNA 
expression might indicate the presence of fewer spongiotrophoblast cells. In support of this, 
Aldh3a1 and Il33 genes that regulate the differentiation and function of the progenitor cells of 
the junctional zone (i.e., the ectoplacental cone; Fang et al. 2017; Nishiyama et al. 2015). 
were downregulated in transferred placentas. Together, these data suggest that the blastocyst 
transfer procedure might reduce this progenitor pool. This potential morphological change 
has implications for placenta metabolism and hormone production (Woods, Perez-Garcia & 
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Hemberger 2018). Single cell RNA-sequencing would help assess the effects of the 
blastocyst transfer on the transcriptomes of the different cell types present in the placenta. 
Many researchers studying the epigenetic effects of ART have performed directed analysis of 
imprinted regions as a read-out of functional changes in global DNA methylation (Choux et 
al. 2015; Messerschmidt et al. 2012; Padmanabhan et al. 2013). We performed an unbiased 
approach to assess the placental transcriptome and identified only two DEGs associated with 
imprinted control regions (i.e., Rasgrf, Cobl; Shiura et al. 2009; Yoon et al. 2005). Therefore, 
unlike more invasive ART procedures, such as superovulation, IVF, or pronuclear transfer, 
blastocyst transfer might not alter DNA methylation to a great extent. Beyond imprinted 
genes and in support of this hypothesis, fewer misexpressed genes in transferred placentas 
were associated with CpG repeats than the rest of the genome. This result implies that these 
genes do not require cis regulation by DNA methylation. We showed that even DEGs with 
known regulation by CpG methylation (i.e., Prl3d1 and Rasgrf1; Hayakawa et al. 2012; Yoon 
et al. 2005) displayed normal DNA methylation patterns in transferred placentas. 
Alternatively, dysregulation of DNA methylation at the regulatory regions of a few ‘master 
regulator’ genes (e.g., transcription factors) might secondarily cause extensive transcriptional 
changes in placentas after blastocyst transfer. A whole methylome analysis (e.g., whole 
genome bisulfite sequencing) will better address whether blastocyst transfer alters DNA 
methylation to cause the widespread transcriptional changes observed in transferred 
placentas. 
Instead of DNA methylation, blastocyst transfer might disrupt alternative epigenetic 
mechanisms, such as histone modifications. The effects of ART on histone modifications are 
little studied and not well understood. Increased histone acetylation (H3K9ac, H3K14ac) in 
mouse zygotes is associated with superovulation (Huffman, Pak & Rivera 2015). Whether 
these changes are maintained by placenta cell lineages during development to affect gene 
expression is unclear. While we did not assess the effects of blastocyst transfer on histone 
modifications directly, we found that the majority of DEGs in transferred placentas associate 
with placental H3K4me1 peaks but not H3K27ac peaks under normal circumstances. As a 
result, these genes might be sensitive to changes in histone methylation or histone acetylation 
at key stages of development. Further analysis through ChIP-seq experiments is required to 
explore the effects of blastocyst transfer on the regulation of histone modifications. 
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How blastocyst transfer causes placental gene misexpression is still unclear. Since the 
establishment of epigenetic marks is initiated at the blastocyst stage (Hanna, Demond & 
Kelsey 2018) it is possible that the stress of a brief culture period, embryo handling, and/or 
placement into a new uterine environment during this key epigenetic milestone is sufficient to 
alter epigenetic marks and subsequent gene expression required for cells to differentiate. 
Since all technologies associated with ART require blastocyst transfer, it will be important to 
tease apart the transcriptional and developmental effects of the transfer process from the other 
more invasive techniques. Furthermore, the ART field will benefit from unbiased high 
throughput epigenetic analyses of placentas derived from these technologies with the aim of 
stepping away from directed studies on imprinted genes. This will allow for a holistic picture 
of the epigenetic framework that gives rise to transcriptional and functional changes in the 
placenta after ART, and thus the immediate and long-term effects on the fetus. 
Given that some DEGs clustered together in the genome, it is possible that a shared 
epigenetic mechanism is disrupted upon blastocyst transfer as discussed above. However, 
minor differences in the genetic background between the control and transferred placentas 
might also contribute to differential gene expression. For instance, the placentas from control 
conceptuses were entirely of C57Bl/6 genetic background. In contrast, the transferred 
placentas were chimeric since they contained trophoblast and fetal endothelial cells that were 
C57Bl/6 genetic background and maternally-contributed cells (e.g., decidua cells, uNK cells, 
and circulating maternal blood) that were B6D2F1 background (i.e., 50% C57Bl/6 and 50% 
DBA2). F1 hybrids, such as B6D2F1 mice, are often used as recipient females to increase 
blastocyst transfer efficiency (Wakayama, Mizutani & Wakayama 2010). Since whole 
placentas were analysed in the RNA sequencing and validation experiments, maternal cells 
were present. However, only 8.1% of all DEGs were solely expressed within the decidual 
region that comprise a number of different molecular pathways. Whether this sufficiently 
represents a confounding effect of genetic background is unclear. Certainly, there is cross talk 
between maternal decidual and immune cells, and the trophoblast (Pollheimer et al. 2018). 
Given that a mother’s genome is usually only 50% similar to that of her fetus, our study is 
illustrative of human populations. 
In order to eliminate any possible confounding effect of the genetic background on the 
placental transcriptome, there are two experiments that could be done, all with important 
limitations. First, we could mate a BDF1 female with a C57Bl/6 male and collect the 
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embryos at E10.5. We would then compare the expression of decidua-related genes between 
the placentas of these conceptuses, with the placentas of the conceptuses derived from natural 
matings between C57Bl/6 males and females and transferred into a BDF1 female at E3.0. In 
both cases, the maternal environment will be that of a BDF1 female. However, the embryos 
derived from a C57Bl/6 x C57Bl/6 crossing will be 100% C57Bl/6, while the embryos 
derived from a C57Bl/6 (male) x BDF1 (female) will have a 75% C57Bl/6 background, and 
25% DBA genetic background. This genetic heterogeneity of the embryos might affect 
expression of placental genes, not only those expressed by the trophoblast, but possibly those 
expressed by the decidua as well. Alternatively, we would mate C57Bl/6 males and females 
and transfer the blastocysts to a C57Bl/6 recipient. The placental gene expression of the 
E10.5 conceptuses would then be compared to that of the conceptuses transferred into a 
BDF1 female. The genetic background of all the transferred embryos will be identical (100% 
C57Bl/6), and this experiment will account for the different genetic background of the 
recipient female. The limitation of this experiment, however, is that C57Bl/6 females are 
known to be poor recipients, and that is the reason BDF1 females were used as recipients 
initially (Wakayama, Mizutani & Wakayama 2010). Therefore, this experiment will have a 
low success rate, and will be very time and resource consuming. If, however, this could be 
done, any DEGs identified, would be exclusively due to the minimal embryo culture and 
blastocyst transfer process itself, that includes anaesthesia of the recipient female. 
Limitations of these experiments are that the blastocyst transfer procedure is a highly skilled 
one. Previous blastocyst transfers were performed in the laboratory in the University of 
Calgary, by Coleen Gary-Goo, and Dr. Erica Watson. Repeating the experiment in 
Cambridge would mean that different scientists perform the procedure, and the mice will 
have a different after care. This could cause alterations in the methylome of the placentas of 
the developing conceptuses, and therefore alter gene expression. Another limitation is that 
while the blastocyst transfer experiments were performed at the University of Calgary in 
Canada, using C57Bl/6 mice ordered from Canada, the rest of the dissections were performed 
at the University of Cambridge, UK, using C57Bl/6 mice ordered from the Jackson Lab, US. 
The different animal housing conditions and different animal handling might affect gene 
expression.  
Next, we focused on the placental transcriptome of transferred F2 Mtrr+/+ conceptuses to 
assess how exposure to the abnormal uterine environment of F1 Mtrr+/+ females during the 
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first three days of development affects developmental programming of the F2 generation. We 
found that the placental transcriptome of F2 Mtrr+/+ conceptuses is altered after blastocyst 
transfer. We identified a total of 244 genes that were differentially expressed between 
placentas of non-transferred and transferred F2 Mtrr+/+ conceptuses independent of the 
transfer protocol. This suggests that the placentas of F2 Mtrr+/+ conceptuses respond 
differently than the C57Bl/6 placentas after transfer into the recipient uterus. The identified 
enriched biological processes such as vasoconstriction and regulation of blood vessel 
diameter, might affect uteroplacental flow and placental transport, and ultimately alter 
embryo growth. This correlates with the observation that no growth restriction is observed 
after blastocyst transfer, but rather an increase in growth enhancement (Padmanabhan et al. 
2013). Other enriched biological processes such as regulation of Errb signalling, MAPK 
cascade, and EGF receptor signalling, suggest that signalling pathways have been affected. 
Enriched mammalian phenotypes such as increased angiogenesis could be the result of a 
compensatory mechanism to increase fetal growth, once the F2 Mtrr+/+ conceptuses are 
transferred in a normal uterine environment. Alterations in body weight were also expected, 
since we showed an increase in embryo weight and growth enhancement, and absence of 
growth restriction after blastocyst transfer (Padmanabhan et al. 2013). Finally, placental 
defects have been associated with heart defects (Perez-Garcia et al. 2018), and therefore the 
abnormal heart orientation as an enriched mammalian phenotype could be a result of 
abnormal placenta development or function. 
Additionally, we found nine genes whose expression is epigenetically regulated by DNA 
methylation. The differential expression of these genes suggests that the exposure of the F2 
Mtrr+/+conceptuses in the abnormal F1 Mtrr+/+ uterus during the first three days of 
development alters the epigenetic regulation of gene expression. This might be due to 
environmental mismatch, since the donor female had an abnormal uterine environment, while 
the recipient uterus was normal. Further analysis is required to examine the potential 
sensitivity of the DEGs to changes in DNA methylation, by assessing the whole genome 
methylome via MeDIP-seq, or whole genome bisulfite pyrosequencing. 
Two of the genes whose expression is regulated by DNA methylation are Bmp2 and Grem1. 
Bmp2 is involved in decidualisation (Lee et al. 2007) and its expression is decreased in 
placentas of both phenotypically normal and growth enhanced F2 Mtrr+/+conceptuses after 
blastocyst transfer. Even though Bmp2 is known to be a decidua-related gene, end-point RT-
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PCR analysis revealed that Bmp2 is expressed in the peri-implantation bovine conceptuses 
and also the bovine trophectoderm cell line CT1 (Pennington & Ealy 2012). Bmp2 
hypermethylation is associated with decreased gene expression (Fu et al. 2013), suggesting 
that Bmp2 promoter is hypermethylated after blastocyst transfer, leading to downregulation of 
gene expression. However, this is unlikely to have an adverse effect on the decidualisation 
reaction, since the growth restriction and developmental delay are rescued after blastocyst 
transfer, and the frequency of growth enhanced conceptuses is increased (Padmanabhan et al. 
2013). In Chapter 4 we showed that there is abnormal expression of decidual response 
markers, such as Bmp2, in implantation sites of F1 Mtrr+/+ females derived from a Mtrr+/gt 
father and mated with a C57Bl/6 male at GD6.5. Abnormal decidualisation at GD6.5 could 
lead to decreased placental efficiency at E10.5. However, we observed increased placental 
efficiency in transferred female F2 Mtrr+/+ conceptuses, suggesting a compensatory 
mechanism to maintain growth in the new, normal uterine environment. Additionally, we 
observed upregulation of Grem1, which is expressed in the placental labyrinth and is 
involved in branching morphogenesis (O’Connell et al. 2013). Upregulation of Grem1 could 
suggest a role in increased blood vessel formation and ultimately increased placental 
efficiency. 
In summary, we first showed that the blastocyst transfer process affects the placental 
transcriptome at midgestation. This might have important implications in humans, since 
embryo transfer is routinely used as part of ART. Next, we observed that some genes are 
differentially expressed in transferred F2 Mtrr+/+ placentas, and others are differentially 
expressed in transferred C57Bl/6 placentas. One important difference between transferred 
C57Bl/6 and transferred F2 Mtrr+/+ conceptuses, is that the C57Bl/6 have never been exposed 
in an adverse uterine environment. In contrast, the F2 Mtrr+/+ conceptuses were exposed to 
the abnormal uterus of the F1 Mtrr+/+ females before being transferred into the normal uterus 
of a BDF1 female at E3.0 (Padmanabhan et al. 2013). This environmental mismatch 
experienced by the F2 Mtrr+/+ conceptuses has possibly developmentally programmed the 
conceptuses to adjust to the different environment after the blastocyst transfer. Altogether, 
these data suggest that the maternal grandpaternal Mtrrgt mutation minimally affects the 
placental transcriptome of F2 Mtrr+/+ conceptuses. However, the F1 Mtrr+/+ uterus 
developmentally programmes the F2 Mtrr+/+ conceptuses during the first three days of 
development, and their placental transcriptome is altered when they are provided with a 














The environment we are exposed to during development has a profound effect on our health, 
but also on the health of our descendants. For instance, folate deficiency in the mother is 
associated with neural tube defects in the fetus. These effects are sometimes sexually 
dimorphic (Liu et al. 2018; Seller 1987). However, the mechanism by which abnormal folate 
metabolism affects embryo growth and development remains unclear. A mouse model with a 
gene trap mutation in the Mtrr gene (Mtrrgt), which is necessary for the activation of 
methionine synthase and the progression of folate and methionine cycles, was created to 
examine the multigenerational effects of abnormal folate metabolism (Elmore et al. 2007). 
Previous embryo transfer experiments revealed that the abnormal uterine environment of F1 
Mtrr+/+ females causes growth restriction and developmental delay in the F2 Mtrr+/+ 
conceptuses (Padmanabhan et al. 2013). 
However, little is known about how folate affects the uterine structure and function. 
Therefore, in this thesis, we first investigated the effects of Mtrrgt mutation on the uterine 
environment. To do this, we assessed the uterine histological structure and function of estrus-
stage females derived from either Mtrr+/gt intercrosses, or the F1 generation derived from an 
Mtrr+/gt father and a C57Bl/6 mother. We found that a parental Mtrrgt allele is sufficient to 
alter the cell structure of the lumen epithelium and myometrium (Chapter 3). We then mated 
these females with C57Bl/6 males and assessed the decidual histology and gene expression of 
the resulting implantation sites at GD6.5. The implantation sites were histologically normal, 
however the expression of decidual markers was abnormal (Chapter 4). This suggests that 
intrinsic or paternal Mtrr deficiency might alter the decidualisation reaction. Next, to assess 
how Mtrrgt/gt mutation affects the placental transcriptome, we assessed the placental 
transcriptome of Mtrrgt/gt conceptuses at E10.5 and compared it to the transcriptome of 
C57Bl/6 placentas via RNA sequencing. We found that Mtrrgt/gt mutation affects the placental 
transcriptome in a phenotype-dependent manner. We identified DEGs that were involved in 
embryo growth and placental development and function (Chapter 5). To assess the effects of 
maternal grandpaternal Mtrrgt mutation on the placental transcriptome of F2 Mtrr+/+ 
conceptuses, we assessed placentas of phenotypically normal and growth enhanced F2 
Mtrr+/+ and compared them to the transcriptome of C57Bl/6 placentas. We found that 
placentas of phenotypically normal and growth enhanced conceptuses F2 Mtrr+/+ are 
transcriptionally similar to C57Bl/6 placentas, suggesting that abnormal uterine structure and 
function of F1 Mtrr+/+ has minimal consequences on placental transcriptome of F2 at 
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midgestation (Chapter 5). Simultaneously, RNA from placentas of F2 Mtrr+/+ conceptuses 
after blastocyst transfer was sequenced to determine whether the abnormal maternal 
environment of F1 developmentally programmes the F2 and if this programming becomes 
apparent after the F2 offspring is provided with a normal maternal environment (Chapter 6). 
RNA from placentas of transferred C57Bl/6 conceptuses was used as control. One 
remarkable finding was that the blastocyst transfer procedure, itself, affected placental gene 
expression and development, indicating a potential influence of blastocyst transfer, as part of 
assisted reproductive technology procedures in humans, on fetoplacental growth (Chapter 6). 
Placentas of transferred F2 Mtrr+/+ and C57Bl/6 conceptuses were transcriptionally similar, 
with only six genes (Prl8a8, Prl8a9, Psg19, Fbln7, Zfp964, Phldb30) upregulated in 
placentas of transferred growth enhanced, but not phenotypically normal conceptuses. 
Overall, our results indicate that while a parental Mtrrgt mutation is sufficient to impair 
uterine structure and function in their wildtype daughters, this does not substantially alter the 
placental transcriptome of their wildtype grandprogeny. However, Mtrrgt/gt mutation in the 
placenta cells themselves alters the transcriptome. In summary, abnormal folate metabolism 
caused by the Mtrrgt mutation affects the uterine environment and the placental transcriptome 
at midgestation. Normal folate metabolism is required to establish a normal maternal-fetal 
interface. If disrupted, the effects might persist for multiple generations. 
 
7.2 Developmental programming in the Mtrrgt model  
The intrauterine environment where a mammalian fetus develops is important for its health 
later in life, as it regulates the function of its physiological systems (Fowden, Giussani & 
Forhead 2006). Fetal programming occurs when the fetus is exposed to an insult in utero that 
impairs its normal pattern of development (Kwon & Kim 2017; Myatt 2006). Nutrients and 
oxygen are vital for proper embryonic growth and development (Harding & Johnston 1995), 
and studies have shown the effects of nutrient and oxygen deficiencies on fetal programming 
(Brenseke et al. 2013; Wu et al. 2004). For instance, maternal undernutrition during critical 
periods of fetal development can lead to the development of metabolic syndrome later in life 
(Correia-Branco, Keating & Martel 2015; Lopez-Jaramillo et al. 2015). In addition, 
epigenetics influence developmental programming. For instance Rxra promoter methylation 
at birth is associated with increased child’s adiposity (Godfrey et al. 2011) and decreased 
bone mineral content (Harvey et al. 2014). Folate is a methyl donor, and therefore abnormal 
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folate metabolism is also linked to decreased availability of methyl groups necessary for 
cellular methylation (Crider et al. 2012; Niculescu & Zeisel 2002). In our Mtrrgt model of 
abnormal folate metabolism, we observed global DNA hypomethylation in the adult uterine 
tissues, even in Mtrr+/+ females, and in placentas but not embryos at E10.5 (Padmanabhan et 
al. 2013), which correlates with the decreased availability of methyl groups in folate 
deficiency (Crider et al. 2012). 
In our study, we used the appropriate controls. For instance, we compared the uterine 
structure and function of F1 Mtrr+/+ females and placental transcriptome of F2 Mtrr+/+ male 
conceptuses to C57Bl/6 sex-matched controls. This is because the Mtrrgt model is a model of 
transgenerational epigenetic inheritance (Padmanabhan et al. 2013), and therefore the most 
suitable controls would be those who have never been exposed to Mtrr deficiency, such as 
C57Bl/6 mice. We also compared the structure and function of Mtrr+/gt and Mtrrgt/gt uteri and 
implantation sites to the C57Bl/6 control uteri and implantation sites. This is in contrast to 
other studies, which assessed the effects of Mtrrgt mutation on the metabolic phenotype in 
mice by comparing Mtrrgt/gt or Mtrr+/gt conceptuses to Mtrr+/+ littermates instead of C57Bl/6 
controls (Elmore et al. 2007). Others assessed the effects of Mthfr mutation on metabolism 
and embryo development by comparing Mthfr-/- and Mthfr+/- samples to Mthfr+/+ littermates, 
instead of C57Bl/6 controls (Chen et al. 2001). In addition, others assessed the effects of folic 
acid supplementation and Mthfd1-synthetase deficiency in mice by comparing Mthfd1S-/- and 
Mthfd1S-/+ conceptuses to their Mthfd1s+/+ littermates, instead of C57Bl/6 controls 
(Christensen et al. 2016). However, according to our study, Mtrrr+/+ uteri are also abnormal, 
and therefore the use of C57Bl/6 samples as controls is required. 
 
7.2.1 Abnormal uterine morphology and function in Mtrrgt/gt and F1 Mtrr+/+ mice 
Previously, little was known about the effects of abnormal folate metabolism on the uterine 
structure and function. For instance, folate deficiency in monkeys causes decreased cell 
proliferation of the uterine lumen epithelium (Mohanty & Das 1982). Since most of the 
studies in mice focused on the role of folate during pregnancy, we first wanted to assess the 
effects of Mtrrgt/gt mutation on the uterine structure at estrus. Additionally, growth defects 
such as growth restriction, developmental delay, and growth enhancement are observed in F2 
Mtrr+/+ conceptuses derived from an Mtrr+/gt maternal grandparent. Transfer of F2 blastocysts 
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into a normal maternal environment increases the frequency of growth enhancement, while it 
rescues the growth restriction and developmental delay, suggesting a programming effect of 
the F1 environment on the F2 conceptuses. F1 Mtrr+/+ females had normal homocysteine 
levels (Padmanabhan et al. 2018), suggesting that they have normal folate metabolism and 
normal availability of methyl groups. Global DNA methylation levels are yet to be assessed 
in the uteri of these females. However, the epigenetic regulation of gene expression in the F1 
Mtrr+/+ females might have been altered. This can induce a permanent response in the 
developing fetus resulting in diseases later in life, particularly abnormal growth patterns 
(Smith & Ryckman 2015). Therefore, we also assessed the effects of paternal Mtrr+/gt 
mutation on the uterine structure of F1 Mtrr+/+ females at estrus (Chapter 3). We found that 
both Mtrrgt/gt mutation and paternal Mtrr+/gt mutation lead to increased myometrial thickness 
and abnormal cell polarity of the lumen epithelium at estrus. This suggests that abnormal 
folate metabolism might affect cell polarity, a hypothesis that is reinforced by the 
identification of DEGs in Mtrrgt/gt placentas involved in cell adhesion and cytoskeleton 
organisation (see Section 7.5). Abnormal cell polarity in the lumen epithelium might affect 
cell-cell signalling and subsequent uterine function, such as decidualisation. In addition, we 
observed decreased Pgr mRNA and PGR protein levels, which suggests that intrinsic or 
paternal abnormal folate metabolism affects progesterone signalling. It is possible that 
abnormal cell polarity is associated with improper presentation of PGR on the uterine lumen 
epithelium. In our model, abnormal folate metabolism and subsequent alterations in the cell 
polarity of the uterine lumen epithelium does not affect endometrial receptivity, since 
C57Bl/6, Mtrrgt/gt, and F1 Mtrr+/+ mice have similar litter sizes (Padmanabhan et al., 2013 
and Chapter 4). This correlates with the finding that embryo implantation is unaffected by 
folate deficiency (Gao et al. 2012b). 
PGR signalling regulates endometrial decidualisation (Large & DeMayo 2012). Studies 
assessing the effects of folate on the decidualisation reaction, use models of dietary folate 
deficiency (Gao et al. 2012a; Geng et al. 2015; Liao et al. 2015). However, in our study, we 
use a model of abnormal folate metabolism, where both control and study groups are fed the 
same diet. It was shown that folate deficiency causes a decrease in DNA methylation of Esr1 
promoter but does not change the methylation levels of Pgr or Cdh1 promoters at GD4.5 
(Gao et al. 2012a). Methylation levels of these genes are yet to be assessed in our model. In 
contrast to our study, that showed that Mtrr deficiency does not affect Esr1 mRNA levels at 
estrus (Chapter 3), folate deficiency was shown to decrease Esr1 levels in the peri-
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implantation uteri at E4.5 (Gao et al. 2012a). This discrepancy might be because we assessed 
estrus-staged uteri, while they assessed peri-implantation sites at GD4.5. Treatment of GD4.5 
pregnant uteri with a PGR antagonist led to downregulation of Bmp2, which induces stromal 
cell differentiation (Li et al. 2007). We also observed decreased Bmp2 mRNA levels in the 
implantation sites at GD6.5 (Chapter 4), which correlate with the abnormal PGR signalling in 
the uterine tissues and implantation sites at GD6.5 (Chapters 3, 4). Our data also correlate 
with other studies that show decreased Bmp2 levels in folate-deficient mouse uteri that have 
undergone artificial decidualisation through sesame oil infusion (Geng et al. 2015). 
Decreased Bmp2 mRNA levels suggest that the decidualisation reaction might be affected. 
Bmp2 mRNA is expressed in the bovine trophectoderm prior to blastocyst attachment 
(Pennington & Ealy 2012). This suggests that the Mtrrgt mutation and disruption of PGR and 
BMP2 signalling pathways might not only have a local effect in the uterus, but it is possible 
to affect placental physiology. This hypothesis is supported by the observation that Bmp2 
mRNA levels were decreased in the implantation sites of Mtrrgt/gt and F1 Mtrr+/+ females 
derived from an Mtrr+/gt father at GD6.5 (Chapter 4) and increased in the placentas of growth 
restricted Mtrrgt/gt conceptuses (Chapter 5). 
Altogether, we found that intrinsic or paternal Mtrrgt mutation affects the uterine structure and 
function at estrus, and the decidualisation reaction at GD6.5. The hormonal changes during 
the estrous cycles should be assessed in the future by performing ELISA on blood samples 
collected during the different stages of the estrous cycle. In addition, uterine tissues should be 
collected during proestrus, metestrus, and diestrus, to correlate the changes in the uterine 
structure to the changes in blood hormone levels during the estrous cycle, similar to Woods et 
al. (2007). Folate deficiency was previously shown to decrease apoptosis of the decidual cells 
(Liao et al. 2015). Decidual cell apoptosis is essential for decidualisation, as it is involved in 
decidual regression that occurs to provide space for the developing embryo (Gu et al. 1994). 
Flow cytometry and TUNEL assay can be used to assess whether Mtrr deficiency in either 
parent can affect the apoptosis of endometrial decidual cells in the F1 Mtrr+/+ uteri. In 
addition, in vitro experiments are required to assess the decidualisation reaction. For instance, 
treatment of cultured endometrial stroma cells with PGR agonists could possibly increase 





7.2.2 Abnormal placental transcriptome in Mtrrgt/gt and F2 Mtrr+/+ mice 
Placentas but not embryos of phenotypically normal and growth restricted Mtrrgt/gt and F2 
Mtrr+/+ conceptuses exhibited global DNA hypomethylation at E10.5, and locus-specific 
dysregulation of DNA methylation compared to C57Bl/6 (Padmanabhan et al. 2013). 
Therefore, we sequenced RNA from placentas of phenotypically normal and growth 
restricted Mtrrgt/gt conceptuses and phenotypically normal and growth enhanced F2 Mtrr+/+ 
conceptuses. First, we showed that the transcriptome of Mtrrgt/gt placentas was dependent on 
their phenotype and we identified DEGs between placentas of phenotypically normal or 
growth restricted Mtrrgt/gt conceptuses and C57Bl/6 placentas (Chapter 5). More specifically, 
we showed that transport-related genes are misexpressed in the Mtrrgt/gt placentas, most of 
which were upregulated. This suggests that the placentas of Mtrrgt/gt conceptuses adapt to the 
abnormal uterine environment by regulating the expression of channels, solute carriers, and 
transport proteins. Other DEGs are involved in embryonic or post-natal growth, suggesting 
that the Mtrrgt/gt mutation affects the expression of genes that regulate growth. These 
adaptations in placenta transport ensure to meet fetal growth demand and change the fetal 
composition, and might lead to life-long programming (Fowden et al. 2006; Sandovici et al. 
2012; Sibley et al. 2010). 
Our RNA sequencing revealed that DEGs whose expression is regulated by DNA 
methylation are both upregulated and downregulated in Mtrrgt/gt placentas, suggesting both 
hypermethylation and hypomethylation of DNA in our model, confirming the previous results 
(Padmanabhan et al. 2013). By assessing the frequency of the presence of CpG repeats in the 
DEGs, we found that they are less likely to contain intragenic or proximal CpG repeats 
compared to the rest of the genome. This suggests that an epigenetic mechanism other than 
DNA methylation might be involved. Further analysis of locus-specific DNA methylation of 
these DEGs using bisulfite pyrosequencing is required to confirm this hypothesis. 
Mass spectrometry experiments have shown that mice fed a folate deficient diet have 
increased H3K4me2 levels in their livers, compared to mice fed the same diet supplemented 
with 1mg of folic acid per kg of diet (Garcia et al. 2016). Methylation of Lysine 4 is often 
associated with transcriptional activation (Schneider et al. 2004). Indeed, decreased 
H3K4me2 is associated with decreased expression of Mt3 (Peng et al. 2011). Mt3 was 
upregulated in Mtrrgt/gt placentas, suggesting that H3K4me2 was increased in these placentas 
(Chapter 5). This correlates with increased H3K4me2 levels in the livers of folate-deficient 
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mice (Garcia et al. 2016), suggesting that folate deficiency and abnormal folate metabolism 
might have similar effects on histone modifications. To assess whether histone modification 
changes occur in the Mtrrgt/gt placentas, ChIP-sequencing using antibodies against specific 
histone modifications would be performed (Lin & Garcia 2012). 
Next, we found that the placental transcriptomes of C57Bl/6 and phenotypically normal F2 
Mtrr+/+ conceptuses were similar (Chapter 5). This suggests that placentas of conceptuses 
with the same genotype and phenotype have similar transcriptomes. A future direction is to 
assess the placental transcriptome of growth restricted F2 Mtrr+/+ conceptuses and compare it 
to the placental transcriptome of either phenotypically normal F2 Mtrr+/+ or C57Bl/6 
conceptuses. This would give us information about the changes in gene expression that cause 
growth restriction. For instance, it is possible that abnormal vascular changes, such as 
abnormal spiral artery remodelling, and inadequate angiogenesis occurs (Plaisier 2011). 
These changes will impair uteroplacental flow and lead to growth defects. 
Overall, these data suggest that Mtrrgt/gt mutation affects fetoplacental development at E10.5. 
This might have an implication in human embryo development. For instance, pregnant 
women with dietary folate deficiency, or those who have genetic mutations in genes involved 
in folate metabolism, might have abnormal uterus structure during the menstrual cycle and 
carry fetuses that are growth restricted or have decreased birth weight. Such a phenotype is 
yet to be assessed. 
Abnormal fetoplacental development can lead to uteroplacental insufficiency and FGR 
(Krishna & Bhalerao 2011). Cases of FGR in humans with unknown aetiology might be due 
to abnormal folate metabolism or dietary folate deficiency in their maternal grandparents. 
Although there might be no effects on their placental transcriptome, exposure to a uterine 
environment with altered epigenetic marks might developmentally programme the embryos 
and increase the risk of disease later in life. This highlights the importance of folate 
supplementation in pregnant women or women who are thinking of becoming pregnant, 
independently of their folate status, since folate deficiency in their parents can also cause 
FGR in their children. In addition, since it was shown that paternal Mtrrgt mutation also 
affects the uterine structure and function of their wildtype daughters (Chapter 3), folate 
supplementation in men might also be beneficial for the growth of their grandchildren. 
However, folate supplementation should be controlled, since studies have shown that high 
folate levels during pregnancy were associated with insulin resistance and adiposity in 
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children at 5 years of age (Krishnaveni et al. 2014). Additionally, moderate folic acid 
supplementation and Mthfd1S deficiency resulted in congenital abnormalities, developmental 
delay and abnormal placental development, such as abnormal labyrinth formation 
(Christensen et al. 2016). However, a limitation of this study is that they used Mthfd1s+/+, 
instead of C57Bl/6 as controls. 
 
7.2.3 Associations between abnormal uterine and placental phenotypes 
Altogether, we have shown that Mtrrgt/gt and F1 Mtrr+/+ mice have abnormal uterine structure 
and function at estrus, and abnormal expression of decidual markers at GD6.5 (Chapter 3 and 
4). In addition, Mtrrgt/gt conceptuses have abnormal placental transcriptome at midgestation 
(Chapter 5). It is possible that the abnormal uterine environment of Mtrrgt/gt females leads to 
poor placenta development of Mtrrgt/gt conceptuses. In contrast, the placental transcriptome of 
F2 Mtrr+/+ conceptuses was minimally affected at E10.5 compared to C57Bl/6 controls. 
However, the lack of DEGs might be because we have sequenced phenotypically normal F2 
Mtrr+/+ conceptuses. It is possible that the placenta transcriptome of growth restricted F2 
Mtrr+/+ conceptuses has been altered due to the abnormal uterine structure and function of F1 
Mtrr+/+ females. Additionally, the observation that the F2 Mtrr+/+ samples are scattered on 
the PCA plot (Figure 5.14A), after being in an Mtrr+/+ uterine environment, might suggest 
that these conceptuses are able to adapt to an abnormal uterine environment in different ways. 
This makes it difficult to detect subtle changes in their transcriptome that are, for instance, 
due to epigenetic factors. 
Studies have shown that abnormal uterine gene expression can impair placenta development. 
For instance, a conditional knockout of Alk5 in the mouse uterus leads to implantation 
defects, such as defective lumen closure and increased lumen epithelial folding at E4.5, as a 
result of increased uterine E2 response, as indicated by increased Esr1 mRNA levels, and 
increased epithelial cell proliferation (Peng et al. 2015). In our Mtrrgt model, we observed 
increased lumen epithelial folding in non-pregnant, estrus-staged uteri, but normal Esr1 
receptor expression and normal epithelial cell proliferation (Chapter 3). The increased lumen 
epithelial folding in our model possibly results from the abnormal apicobasal polarity. This 
hypothesis is supported by a theoretical model proposing that epithelial folding is driven by 
apical and baso-lateral modulation (Wen, Wang & Shibata 2017). We observed normal 
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morphology of implantation sites at GD6.5 (Chapter 4) which correlates with the Alk5 uterine 
conditional knockout model (Peng et al. 2015). Despite normal morphology at GD6.5, 
abnormal placenta development was observed in both models. Placenta defects such as off-
centred chorioallantoic attachment and placenta haemorrhage were observed at E10.5 in the 
Mtrrgt model (Padmanabhan et al. 2013). Similarly, the Alk5 uterine conditional knockout 
model is characterised by placenta defects, such as disorganisation of trophoblast cells, 
decreased uNK cell numbers, and impaired spiral artery remodelling (Peng et al. 2015). 
Future studies should assess the uNK cells and spiral artery remodelling in our model. 
Additionally, uterine Nodal knockout leads to abnormal trophoblast giant cell layer, and 
malformation of the decidua basalis due to decreased cell proliferation and increased cell 
apoptosis at E10.5 (Park et al. 2012). Furthermore, a retrospective study involving singleton 
ART births revealed that endometrial thickness is directly correlated to placenta praevia 
(Rombauts et al. 2014). Placenta praevia is a condition where the placenta attaches to the 
uterine wall in a position that covers partly or fully the cervical opening. This causes bleeding 
during pregnancy and has implications during birth (Alouini et al. 2019). Therefore, it is 
possible that abnormal E2 and P4 levels affect the endometrial thickness and ultimately lead 
to placenta praevia during gestation. Finally, deletion of the PI3K antagonist Pten leads to 
decreased decidual cell apoptosis and ultimately an increase in the decidual thickness. As a 
result, trophoblast invasion and spiral artery remodelling are impaired (Lague et al. 2010). 
Altogether, these studies show how abnormalities in the uterus can affect placenta 
development and function. 
Alternatively, it is possible that abnormal placenta function of Mtrrgt/gt conceptuses, as 
indicated by abnormal gene expression, can affect the decidualisation reaction. One of the 
functions of the trophoblast during pregnancy is to invade the uterine epithelium. During 
implantation and early placentation, the trophoblast penetrates the uterine decidua and 
replaces the vascular endothelial cells in the spiral arteries. Absence of trophoblast results in 
reduced SAR (Whitley & Cartwright 2010). At E13.5, Tpbpa+ glycogen trophoblast cells 
invade the decidua basalis (Adamson et al. 2002; Cross et al. 2002; Silva & Serakides 2016), 
a process that requires extracellular matrix degradation (Favaro, Abrahamsohn & Zorn 2014). 
This is achieved by the secretion of proteases, such as MMPs by the trophoblast (Aplin 2000; 
Lala & Graham 1990). Expression of tissue inhibitor metalloproteinase (TIMP) 3 by decidual 
cells prevents excessive extracellular matrix degradation and excessive trophoblast invasion 
(Moore & Crocker 2012). Abnormal decidual extracellular matrix remodelling can impair 
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decidualisation (White, Robb & Salamonsen 2004). Finally, extravillous trophoblast 
secretions such as Profilin 1 induce human endometrial stromal cell decidualisation, and 
decidualised human endometrial stromal cell adhesion, proliferation, and migration 
(Menkhorst et al. 2017). Altogether, these studies suggest that abnormal placental gene 
expression and trophoblast function in Mtrrgt/gt mice can impair decidualisation. 
 
7.2.4 The blastocyst transfer process affects feto-placental growth, suggesting 
ART might affect the adult health of ART-born children 
RNA sequencing revealed a large number of DEGs between non-transferred and transferred 
F2 Mtrr+/+ conceptuses. However, most of the DEGs were also misexpressed between non-
transferred and transferred C57Bl/6 conceptuses, suggesting a possible effect of the 
blastocyst transfer process on feto-placental growth, rather than a programming effect of F1 
Mtrr+/+ intrauterine environment on F2 Mtrr+/+ conceptuses. 
These results might have significant importance for assisted reproductive technologies. 
Blastocyst transfer is routinely used in ART. Here, we assessed the effects of blastocyst 
transfer and surrogacy on mouse placental transcriptome and showed that the blastocyst 
transfer process alters the expression of genes that are involved in feto-placental development 
and function (Chapter 6). As highlighted in Chapter 6, the recipient female, BDF1, has 50% 
similar genetic background to C57Bl/6, therefore differences in gene expression between 
transferred and non-transferred conceptuses that are expressed solely by the decidua might be 
attributed to the different genetic background of the decidual tissue. This shows the effects 
that surrogacy possibly has on feto-placental growth. Our study is different from most 
studies, which also involve superovulation, in vitro fertilisation, in vitro culture, gamete or 
embryo freezing, or blastomere biopsy (Chen et al. 2015; Delle Piane et al. 2010; Fortier et 
al. 2008; Rivera et al. 2008; Yao et al. 2016). In addition, while other studies focus on the 
effects of ART on the expression of imprinted genes specifically (Fortier et al. 2008; Nelissen 
et al. 2013; Rivera et al. 2008), we performed an unbiased RNA sequencing analysis to assess 
the effects of blastocyst transfer on the placental transcriptome. 
First, we observed genes with transport function to be differentially expressed after blastocyst 
transfer. The placental expression of most of the genes is yet to be determined, therefore we 
cannot speculate whether these genes are due to the different genetic background of the 
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recipient female, that contributed to the decidua, or due to the blastocyst transfer itself. If 
these genes are expressed in the trophoblast, their differential expression is most probably 
due to the blastocyst transfer procedure and not due to the difference in genetic background 
of the mothers. Additionally, we identified DEGs that regulate gene expression by epigenetic 
mechanisms including DNA methylation, histone modifications, and RNA-mediated 
mechanisms. Therefore, misexpression of these genes might alter the epigenome of the 
placenta, leading to misexpression of genes important for normal feto-placental growth. We 
also identified DEGs that when knocked out, developmental phenotypes are observed. 
Finally, our study highlights the importance of following up the ART-born babies, since we 
showed that even the simplest ART technique, the blastocyst transfer, affects the placental 
transcriptome. 
Next, we identified DEGs in transferred F2 Mtrr+/+ placentas and found that F2 Mtrr+/+ 
conceptuses respond differently to the blastocyst transfer into a BDF1 uterus at E3.0 
compared to C57Bl/6 conceptuses. The adverse intrauterine conditions that the F2 Mtrr+/+ 
conceptuses were exposed to during the first three days of development, i.e. the uterus of F1 
Mtrr+/+, were sufficient to developmentally programme the embryos. This is supported by the 
fact that growth restriction and developmental delay are rescued after blastocyst transfer, 
while the frequency of growth enhancement was increased (Padmanabhan et al. 2013). DEGs 
were involved in transport, or their expression is regulated by DNA methylation. This 
suggests that the uterine environment of the recipient female might cause changes in the 
epigenetic regulation of gene expression (Chapter 6).  
In summary, while the C57Bl/6 conceptuses were transferred from a normal C57Bl/6 uterine 
environment to another normal BDF1 uterine environment, the F2 Mtrr+/+ conceptuses were 
transferred from an abnormal F1 Mtrr+/+ uterus into a normal BDF1 uterus. It is therefore 
possible that the F2 Mtrr+/+ conceptuses were developmentally programmed during the first 
three days of development in the abnormal F1 Mtrr+/+ uterine environment. This hypothesis 
is reinforced by the number of DEGs which are misexpressed independently of the blastocyst 
transfer. It is possible that the abnormal uterine environment of F1 Mtrr+/+ females prevents 
or alters the establishment of the epigenetic marks in the pre-implantation embryo. 
Additionally, it is possible that the epigenetic marks established in the F2 Mtrr+/+ embryos 
during the first three days of development are important for embryo survival in the abnormal 
F1 Mtrr+/+ uterine environment, while different epigenetic marks are required for embryo 
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survival in the normal BDF1 uterus. Abnormal establishment of epigenetic marks might 
affect cell differentiation during development and might ultimately influence placenta 
development. The long-term effects of developmental programming on the F2 Mtrr+/+ 
generation are yet to be assessed. A future experiment would be to assess the reproductive 
function of the adult transferred mice, by performing sperm analysis and fertility checks, to 
see whether the blastocyst transfer process, or a developmental programming mechanism 
affects their reproductive function, by assessing C57Bl/6 and F2 Mtrr+/+ transferred 
conceptuses respectively, compared to non-transferred conceptuses of the same pedigrees. 
 
7.3 Sexual dimorphism in the Mtrrgt model 
Sexual dimorphism has previously been observed in placental transcriptomes (Gabory et al. 
2013; Gallou-Kabani et al. 2010). For instance, the expression of the placental housekeeping 
genes Ubc, Top1,and Ywhaz was higher in males than females, suggesting the necessity of 
comparing the transcriptome between same-sex placentas (Cleal et al. 2010). In utero 
exposures also have a sex-specific impact on the developing fetus (Gallou-Kabani et al. 2010; 
Kundakovic et al. 2013; Mao et al. 2010; Mckay et al. 2011; Rosenfeld 2015; Tarrade et al. 
2013), highlighting the importance of studying the effects of in utero exposures in both sexes. 
Sexual dimorphism has been observed in the Mtrrgt model. Firstly, the developmental 
phenotypes observed in our model, only occur through the maternal lineage (Padmanabhan et 
al. 2013). More specifically, the developmental phenotypes are due to abnormal folate 
metabolism in either the maternal grandparent. These phenotypes are not observed in the F2 
generation of an Mtrr+/gt paternal grandparent (Padmanabhan et al. 2013). Additionally, we 
have previously showed that there is no sexual dimorphism of the developmental phenotypes 
in the Mtrrgt model at E10.5 (Padmanabhan et al. 2017). However, we observed an increase 
in the placenta efficiency of the female conceptuses in each subsequent generation, up to the 
F4, when the phenotypically normal Mtrr+/+ conceptuses derived from an Mtrr+/gt maternal 
grandparent were considered (Padmanabhan et al. 2017). Finally, we showed that abnormal 
folate metabolism causes sex-specific haematological defects in mice (Appendix B;  
Padmanabhan et al. 2018). 
In this thesis, we sequenced placental RNA from male conceptuses at E10.5. However, 
considering the sexually dimorphic effects of abnormal folate metabolism observed in the 
Mtrrgt model, analysis of the placental transcriptome of female C57Bl/6, Mtrrgt/gt, and F2 
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Mtrr+/+ conceptuses at E10.5 by RNA sequencing is required. This will give us information 
on how the female placentas adapt differently than the male ones to the abnormal uterine 
environment caused by intrinsic or ancestral Mtrrgt mutation. 
 
7.4 MTRR polymorphisms in the human population 
The effects of folate on embryo growth and development have been determined through 
studies looking at folate deficiency, or polymorphisms in genes involved in folate 
metabolism. Hyperhomocysteinemia is a clinical indicator of folate deficiency in humans 
(Mcmullin et al. 2001; Ni et al. 2017). This correlates with the Mtrrgt model, where we 
observed increased plasma homocysteine in Mtrrgt/gt mice, and also in the F0 Mtrr+/gt male 
mice (Padmanabhan et al. 2013). 
MTRR A66G polymorphism was found to be associated with increased risk of congenital 
abnormalities, such as neural tube defects (Wang et al. 2015) and heart defects (Cai et al. 
2014). These phenotypes were also observed in the Mtrrgt mouse model (Padmanabhan et al. 
2013), suggesting that the Mtrrgt mouse model can be representative of the human population. 
The MTR A2756G and MTHFR C677T polymorphisms were also independently associated 
with increased risk of neural tube defects (Wang et al. 2015; Zhang et al. 2019), but not heart 
defects (Cai et al. 2014; Zhang et al. 2019). 
Folate metabolism has also been shown to affect the embryonic growth trajectory. For 
instance, the MTR A2756G polymorphism in either the fetus or the mother is associated with 
increased risk of uteroplacental insufficiency (Furness et al. 2008). Additionally, the 
MTHFD1 G1958A polymorphism in the mother is associated with increased risk of FGR 
(Furness et al. 2008). In contrast, the MTRR A66G polymorphism is not associated with FGR 
or uteroplacental insufficiency in humans (Furness et al. 2008). This does not correlate with 
our Mtrrgt model, where FGR is observed. Additionally, the MTRR A66G polymorphism, but 
not the MTR A2756G or MTHFR C677T polymorphisms, increases the risk of preeclampsia 
(Seremak-Mrozikiewicz et al. 2017; Zhang et al. 2019). Preeclampsia is often associated with 
FGR (Milosevic-Stevanovic et al. 2016). The risk of preeclampsia in the Mtrrgt model has to 
be determined by assessing clinical features of preeclampsia, such as elevated systolic blood 
pressure, proteinuria, and renal glomerular endotheliosis (Sandgren et al. 2018). Altogether, 
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these studies highlight the effects of abnormal folate metabolism on embryo growth and 
development in humans. 
 
7.5 Further analysis of placental phenotype and function in the Mtrrgt 
model 
The abnormal uterine environment of F1 Mtrr+/+ females in the Mtrrgt model, characterised 
by abnormal cellular structure of the lumen epithelium and myometrium at estrus (Chapter 3), 
and abnormal expression of decidual markers at GD6.5 (Chapter 4), may be responsible for 
the growth phenotypes observed in the F2 Mtrr+/+ conceptuses (Padmanabhan et al. 2013). 
Further experiments in our lab (J. Rakoczy, P. Laouris, L. White, K. Tan, N. Padmanabhan, 
S. Tunster, E.D. Watson, unpublished) aimed to assess the placental phenotype, since 
abnormal decidualisation might lead to abnormal interaction between the trophoblast and the 
decidua (Adamson et al. 2002; Aplin 2000), and ultimately abnormal placenta development 
and function. First, trophoblast populations were altered in Mtrrgt/gt conceptuses including 
absent or disorganised labyrinth progenitor cells in the chorion at E8.5 (J. Rakoczy, K. Tan, 
E.D. Watson, unpublished), and fewer ectoplacental cone cells at E8.5 associated with fewer 
glycogen trophoblast cells at E14.5 (P. Laouris, S. Tunster, E.D. Watson, unpublished). In 
addition, Prl3d1 mRNA expression was decreased in phenotypically normal and abnormal 
Mtrrgt/gt conceptuses compared to C57Bl/6, suggesting abnormal differentiation of 
spongiotrophoblast and TGCs. Mtrrgt/gt females mated to Mtrrgt/gt males were injected with 
Rhodamine 123 dye to assess placental diffusion in their Mtrrgt/gt conceptuses at E10.5 when 
epigenetic instability was observed associated with large scale transcriptional changes. 
Placenta diffusion was determined to be reduced in Mtrrgt/gt conceptuses and became more 
severe as the phenotype worsened (J. Rakoczy, unpublished). Misexpression of transporter 
genes in the placenta, as identified by the RNA sequencing (Chapter 5), suggests that active 
transport mechanisms are influenced by the Mtrrgt mutation. The expression of three solute 
carriers was assessed via RT-qPCR. As mentioned in Chapter 5, further experiments in our 
lab showed that the expression of Slc38a4 mRNA levels were decreased in the growth 
restricted and abnormal Mtrrgt/gt conceptuses compared to C57Bl/6 (N. Padmanabhan, 
unpublished data). Methylation analysis of Slc38a4 DMRs revealed no difference in DNA 
methylation in any of the CpG sites assessed, suggesting the expression of Slc38a might be 
due to abnormal placental development and abnormal differentiation of the cell types that 
231 
 
express this solute carrier. To further assess the active transport capacity of the placentas of 
Mtrrgt/gt and F2 Mtrr+/+ conceptuses, we could label nutrients, such as amino acids, with a 
radioactive label and trace their transport through the placenta (Sferruzzi-Perri 2018). 
Trophoblast stem (TS) cells cultured in folate-depleted media do not interact properly with 
each other, appear more rounded, and exhibit abnormal adhesion (J. Rakoczy, unpublished). 
Additionally, chorions of Mtrrgt/gt placentas appear disorganised. Together, these observations 
suggest that cell adhesion and tissue polarity might be altered. We previously showed 
abnormal E-Cadherin mRNA and protein expression and defective cell polarity in the uterine 
tissues of non-pregnant females (Chapter 3). These data suggest a possible mechanism of 
folate metabolism in regulating the expression of genes important for adhesion and cellular 
organisation. We identified DEGs with cell adhesion function in placentas of growth 
restricted Mtrrgt/gt, but not phenotypically normal Mtrrgt/gt conceptuses (Chapter 5). For 
instance, Plxna1 (FC = 2.15) and Bmp2 (FC = 2.15) are involved in negative regulation of 
cell adhesion. Micall2 (FC = 2.26) is involved in substrate adhesion-dependent cell 
spreading, and Ceacam5 (FC = -7.6) is involved in the cell adhesion of cells of identical type. 
Since the cytoskeleton regulates cell adhesion (Fuhrmann & Engler 2015), we also looked for 
genes involved in cytoskeleton organisation. Three DEGs, Pacsin1 (FC = 2.43), Micall2 (FC 
= 2.26), and Trpm2 (FC = -8.24 in PN Mtrrgt/gt placentas) are involved in cytoskeleton 
organisation. Altogether, these data suggest that folate metabolism affects the expression of 
genes involved in cell adhesion and cellular organisation. 
Finally, expression of the methylation machinery enzymes was analysed in embryos and 
placentas. While Dnmt1, Dnmt3a, and Dnmt3b mRNA expression was normal in embryos 
and placentas of phenotypically normal and growth restricted Mtrrgt/gt conceptuses at E10.5, 
expression of Tet2 mRNA was upregulated in placentas, but not embryos of Mtrrgt/gt 
conceptuses, independently of the phenotype, compared to C57Bl/6. Interestingly, Tet2 
expression in Mtrrgt/gt estrus-staged uteri was similar to C57Bl/6 (Chapter 3), suggesting its 
misexpression occurs during pregnancy. Tet2 continues to be upregulated at E14.5 and E18.5, 
while Tet1 and Tet3 mRNA is decreased in Mtrrgt/gt placentas at E14.5 only. Tet2 
upregulation in Mtrrgt/gt placentas at E10.5 is due to abnormal methylation of Tet2 proximal 
promoter (unpublished data). These data suggest that Tet2 expression might play a role on the 




7.6 Future directions 
Overall, we showed the importance of folate metabolism in the establishment of a normal 
maternal-fetal interface, by assessing the effects of the Mtrrgt mutation that causes abnormal 
folate metabolism, on the uterine structure at estrus, the decidual reaction at GD6.5, and the 
placental transcriptome at E10.5. The effects of the abnormal uterine environment on the 
placenta development should be further assessed. A future direction is to derive endometrial 
organoids from C57Bl/6, Mtrrgt/gt, and F1 Mtrr+/+ endometrial tissues (Boretto et al. 2017; 
Deane, Cousins & Gargett 2017; Turco et al. 2018), to study the mechanisms underlying 
uterine function. By deriving Mtrrgt/gt trophoblast stem cell lines, and co-culturing them with 
the uterine organoids, we could study the maternal-fetal interactions during placentation in 
our model (Turco et al. 2018). 
Further blastocyst transfer experiments should be performed in the Mtrrgt/gt pedigree, i.e. 
Mtrrgt/gt embryos to be transferred at E3.0 into a E2.5 pseudopregnant BDF1 females. This is 
to assess the developmental phenotypes of the transferred conceptuses and see whether the 
growth phenotypes are rescued even when the conceptus has intrinsic abnormal folate 
metabolism, and it is provided with a normal uterine environment. Additionally, the Mtrrgt/gt 
blastocyst transfer experiment will allow to assess the placental transcriptome of the 
transferred Mtrrgt/gt conceptuses and compare it with both the transcriptome of non-
transferred Mtrrgt/gt and transferred C57Bl/6 conceptuses. In addition, assessment of the gross 
placenta phenotype of transferred F2 Mtrr+/+ and Mtrrgt/gt conceptuses via histology and 
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Region of known placental expression Ref.* 
Human homolog Mouse  
Trophoblast, fetal endothelial vascular cell and decidua expression 
Ang2 799.25 Ribonuclease SynT, FVE, Dec S-TGCs, FVE (Geva et al. 2005) 
Adam28 57.59 Metalloprotease disintegrin SynT, CytoT, EVT, Dec  Unknown (De Luca et al. 2017) 
Actn3 8.40 Actin binding protein SynT, CytoT, FVE, Dec Unknown  
Adgrf2 7.79 G-protein coupled receptor activity SynT, Dec Unknown  
Tnfsf11 7.78 Cytokine SynT, Dec Unknown  
Rnf150 7.53 Ubiquitin protein ligase activity SynT, CytoT, Dec General  
Edn2 7.15 Angiogenesis SynT, Dec General  
Prokr2 5.32 Angiogenesis SynT, CytoT, FVE, Dec Unknown  
Colgalt2 5.27 Extracellular matrix; PPARγ pathway SynT, CytoT, FVE, Dec General  
Ptafr 4.85 G-protein coupled receptor activity SynT, FVE, Dec General  
Eno1b 4.73 Glycolysis (Human ortholog: ENO1) 
CytoT, FVE, Dec 
General  
Csdc2 4.62 RNA-binding factor; histone synthesis SynT, CytoT, FVE, Dec  General  
C3 4.60 Complement system; ERK1/2 cascade SynT, FVE, Dec General  
Adcy2 4.01 Adenylate cyclase SynT, CytoT, FVE, Dec General  
Fbln2 3.84 Extracellular matrix SynT, FVE, Dec General  
Gldn -3.77 Extracellular matrix CytoT, FVE, Dec Unknown  
Myocd 3.61 Transcriptional co-activator SynT, CytoT, FVE, Dec General  
Tspan8 3.46 Integrin binding SynT, FVE, Dec General  
F2 3.37 Vascular integrity SynT, FVE, Dec General  
Klrb1b -3.27 Killer cell lectin-like receptor SynT, CytoT, Dec General  
Rasl11a 3.25 GTPase SynT, CytoT, FVE, Dec Unknown  
Fam189a2 3.20 Unknown SynT, CytoT, FVE, Dec General  
Kank4 3.13 Cytoskeleton SynT, CytoT, FVE, Dec General  
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Fermt1 3.12 Cell adhesion SynT, CytoT, FVE, Dec General  
Ptprz1 3.09 FGF binding SynT, CytoT, FVE, Dec Unknown  
Gpr176 3.04 G protein coupled receptor activity SynT, CytoT, FVE, Dec Unknown  
Unc93a 2.95 Unknown SynT, CytoT, FVE, Dec General  
Robo1 2.90 Slit receptor, cell migration SynT, CytoT, EVT, FVE, 
Dec 
S-TGCs at E13.5 and 
E15.5 
(P. Li et al. 2015) 
Atp6v1c2 2.89 Ion transport SynT, CytoT, FVE, Dec Unknown  
Rasgrf1 -2.70 Ras protein signal transduction pathway SynT, CytoT, Dec General  
Thbs2 2.69 Thrombospondin SynT, CytoT, FVE, Dec General  
Wdfy1 2.67 Phosphatidylinositol 3-phosphate binding 
protein 
SynT, FVE, Dec General (Sferruzzi-Perri et al. 
2009) 
Cp 2.63 Iron homeostasis  SynT, FVE, Dec General  
Il15ra -2.63 Interleukin SynT, CytoT, FVE, Dec, 
uNK  
General  
Fam13c 2.60 Unknown SynT, CytoT, FVE, Dec Unknown  
Tfpi -2.57 Tissue factor pathway inhibitor SynT, CytoT, FVE, Dec General (Pedersen et al. 2005) 
B3gat2 -2.55 Carbohydrate metabolism SynT, CytoT, Dec, uNK  General  
Pcdhga1 2.52 Protocadherin SynT, CytoT, FVE, Dec General  
Sema3a 2.51 Chemokine SynT, CytoT, FVE, Dec Unknown  
Zfp30 2.46 Zinc finger protein SynT, FVE, Dec Unknown  
Axin2 2.42 Wnt signaling pathway SynT, CytoT, FVE, Dec Unknown  
Jph2 2.42 Junctional membrane complex protein SynT, FVE, Dec General  
Draxin -2.40 Chemokine SynT, CytoT, FVE, Dec Unknown  
Fbn1 2.38 Fibrillin SynT, CytoT, FVE, Dec General  
Trim55 -2.37 Cytoskeleton SynT, FE, Dec General  
Efcab7 2.36 Hedgehog signalling SynT, CytoT, FVE, Dec General  
Dpp4 2.32 Adenosine deaminase CytoT, FVE, Dec General  
Kng2 2.32 Kininogenin (Human ortholog: KNG1) 
SynT, FVE, Dec 
General  
Grap2 2.32 GRB2-related adaptor protein SynT, CytoT, FVE, Dec General  
Slit3 2.32 Slit/Robo pathway SynT, FVE, Dec General  
Sorbs1 2.28 Insulin signalling SynT, CytoT, FVE, Dec General  
Fam135b 2.28 Unknown SynT, CytoT, FVE, Dec Unknown  
Pde7b 2.26 Phosphodiesterase SynT, CytoT, FVE, Dec Unknown  
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Tnip3 -2.25 NF-κB inhibitor SynT, CytoT, FVE, Dec Unknown  
Hddc3 2.24 Purine metabolism SynT, CytoT, FVE, Dec Unknown  
C1qtnf1 2.21 MAPK pathway SynT, CytoT, FVE, Dec General  
Hipk2 2.19 Negative regulator of BMP pathway SynT, CytoT, FVE, Dec General  
Thbs1 2.15 Thrombospondin SynT, CytoT, FVE, Dec General  
Cd53 -2.17 Integrin binding, involved in cell growth SynT, CytoT, FVE, Dec General  
Adcy1 2.09 Adenylate cyclase SynT, CytoT, FVE, Dec Unknown  
Apom 2.09 Apoplipoprotein SynT, CytoT, FVE, Dec General  
Ms4a6c 2.09 Membrane protein (Human ortholog: 
MS4A6A) SynT, CytoT, 
FVE, Dec  
Unknown  
Ntn4 2.07 ECM protein SynT, CytoT, FVE, Dec Unknown (Dakouane-Giudicelli 
et al. 2012) 
Pygo1 2.06 Wnt signalling pathway SynT, CytoT, FVE, Dec Unknown  
Zfp36l1 2.06 Zinc finger protein SynT, CytoT, FVE, Dec Allantois, chorionic plate, 
yolk sac 
(Deng et al. 2006; 
Stumpo et al. 2004) 
Svip 2.04 Inhibitor of ER-associated degradation SynT, CytoT, FVE, Dec Unknown  
Far2 -2.03 fatty-acyl-CoA reductase activity SynT, CytoT, FVE, Dec General  
Tcp11l1 2.03 T-complex 11 like 1 CytoT, FVE, Dec Unknown  
Ctsf 2.02 Cathepsin SynT, CytoT, FVE, Dec General  
Trim5 -2.01 E3 ubiquitin-ligase SynT, CytoT, FVE, Dec General  
Trophoblast and fetal endothelial vascular cell expression 
Calcoco2 -5.19 Actin cytoskeleton reorganization SynT, FVE Unknown  
Cfb 4.40 Cell proliferation SynT, CytoT, FVE General  
Kcne3 3.91 Potassium channel activity SynT, FVE General  
Chmp4c 3.89 Chromatin modifying protein, mitosis SynT, CytoT, FVE General  
P2ry10 -3.55 G-protein coupled receptor SynT, FVE General  
Cobl 2.61 Actin nucleator SynT, CytoT, FVE Unknown  
Enpp2 2.48 Ectonucleotide pyrophosphatase/ 
phosphodiesterase 
SynT, CytoT, FVE,  General  
Golga7b 2.41 S-palmitoyltransferase SynT, CytoT, FVE Unknown  
Mttp 2.30 Lipoprotein assembly SynT, FVE General  
Pcdhgb7 2.29 Protocadherin SynT, CytoT, FVE General  
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Nipal4 2.24 Magnesium ion transmembrane 
transporter 
SynT, FVE Unknown  
Igfbpl1 -2.13 Insulin-like growth factor binding  SynT, FVE Unknown  
Tmem151a 2.13 Transmembrane protein SynT, CytoT, FVE Unknown  
Sytl1 2.13 Intracellular protein transport SynT, CytoT, FVE Unknown  
Schip1 2.13 Estrogen metabolism SynT, FVE General  
Trophoblast and decidua expression 
Adamdec1 1194.78 Metalloprotease General GlyT, SpT, Dec  (Baran, Kelly & 
Binart 2003) 
Itmcln1 246.27 Lectin, glucose transport SynT, CytoT, Dec Unknown  
Sorcs1 10.26 Growth factor receptor SynT, CytoT, Dec Unknown  
Trpm2 -10.10 Cation channel  SynT, Dec  General  
Aldh3a1 -9.29 Aldehyde dehydrogenase Unknown TS cells, SpT, Dec (McConaha et al. 
2011; Nishiyama et 
al. 2015) 
Ccl1 -6.81 Chemokine SynT, Dec, uNK  Unknown  
Kynu 4.64 NAD cofactor biosynthesis SynT, CytoT, Dec General  
Duoxa1 4.34 Thyroid hormone synthesis SynT, Dec Unknown  
Klb 3.97 FGF signaling pathway SynT, CytoT, Dec General  
Dyrk4 -3.93 Protein kinase SynT, Dec Unknown  
Gpr183 -3.60 G protein-coupled receptor SynT, Dec General  
Cntn1 3.41 Cell adhesion SynT, Dec Unknown  
Robo2 3.41 Cell migration SynT, Dec General  
Pak7 3.17 Cytoskeleton SynT, CytoT, Dec Unknown  
Meox1 3.17 Transcription factor SynT, CytoT, Dec  Unknown  
Wscd1 3.07 Sulfotransferase activity SynT, Dec General  
Gxylt2 3.03 EGF pathway SynT, Dec General  
Slc8a1 3.01 Na+-Ca2+ exchanger SynT, Dec General  
Nkd2 3.00 Wnt signaling SynT, CytoT, Dec General  
Arsk 3.00 Sulfatase, hormone biosynthesis SynT, Dec General  
Galnt2 2.95 Glycosyltransferase SynT, CytoT, Dec General  
Mt3 2.93 Metallothionein SynT, Dec Unknown  
Slc9a2 2.87 Na+/H+ transporter SynT, CytoT, Dec General  
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Gjb1 2.84 Gap junction protein SynT, CytoT, Dec General  
Miat 2.78 lncRNA Cyto, Dec Unknown  
Klrd1 -2.71 Killer cell lectin-like receptor SynT, Dec General  
Lonrf2 2.71 Ubiquitin protein ligase SynT, Dec Unknown  
Cd3g 2.71 T-cell receptor-CD3 complex protein SynT, Dec General  
Hnf4a 2.66 Transcription factor SynT, Dec General  
Tshr -2.66 Thyroid stimulating hormone receptor SynT, Dec Unknown  
Mfsd6l -2.65 Unknown SynT, CytoT, Dec Unknown  
Hkdc1 2.57 Glucose metabolism SynT, CytoT, Dec General  
Sytl3 -2.53 Exocytosis SynT, CytoT, Dec General  
Aff2 2.51 Transcriptional activator SynT, Dec General  
St8sia6 2.40 Sialyltransferase CytoT, Dec Unknown  
Pllp 2.37 Ion transport SynT, Dec General  
Gucy2c -2.34 cGMP biosynthesis SynT, CytoT, Dec General  
Ntrk1 -2.32 Kinase in MAPK pathway SynT, Dec General  
Slc39a8 2.31 Zinc ion transporter SynT, CytoT, Dec General  
Fndc1 2.29 Fibronectin SynT, Dec Unknown  
Mid1 -2.27 Cytoskeleton SynT, Dec General (Sferruzzi-Perri et al. 
2009) 
Enox1 2.26 Electron transport SynT, CytoT, Dec Unknown  
Kazald1 -2.25 Insulin-like growth factor binding  SynT, CytoT, Dec General  
Ptgs2 -2.25 Prostaglandin synthesis SynT, Dec General  
Galc 2.24 Galactosylceramidase SynT, CytoT, Dec Unknown  
Galnt17 2.23 Mucin type O-glycan biosynthesis SynT, Dec Unknown  
Aldh1l2 -2.21 One-carbon metabolism (mitochondria) SynT, Dec General  
Krt23 2.19 Intermediate filament SynT, CytoT, Dec General  
Apbb1ip -2.13 Ras signaling pathway SynT, Dec General  
Fam20a 2.13 Unknown SynT, CytoT, Dec General  
Stom 2.12 Membrane protein SynT, CytoT, Dec General  
Fam84a 2.09 Unknown SynT, CytoT, Dec Unknown  
Rps23 -2.06 Ribosomal protein SynT, CytoT, Dec General  
Cdh13 2.03 Cadherin CytoT, Dec Unknown  
Tgm6 2.02 Transglutaminase SynT, CytoT, Dec Unknown  
Atp1a3 2.02 Potassium ion transport SynT, Dec Unknown  
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Cmc4 -2.00 Mitochondrial protein import SynT, Dec General  
Fetal endothelial vascular and decidual expression 
Pianp 50.79 Cell adhesion FVE, villus stroma, Dec General  
Il33 4.04 Interleukin FVE, Dec General  
Rem1 3.94 Ras-like GTPase FVE, Dec Unknown  
Trpv6 3.68 Calcium transport FVE, Dec S-TGCs, GlyT at E17.5  (Yang, Ahn & Jeung 
2015) 
Chrm3 2.85 Cholinergic receptor FVE, Dec Unknown (Huh et al. 2009) 
Adamts5 2.76 Disintegrin and metalloproteinase FVE, Dec General  
Gpr19 2.46 G protein coupled receptor FVE, Dec General  
Arhgef26 2.37 Rho-guanine nucleotide exchange factor FVE, Dec General  
Rasgef1a 2.21 Ras guanyl-nucelotide exchange factor 
activity 
FVE, Dec Unknown  
Fabp4 2.15 Fatty acid binding protein FVE, Dec FVE, Dec (Makkar et al. 2014) 
Trophoblast expression  
Fmo3 21.47 Flavin-containing monooxygenase SynT Unknown  
A2ml1 6.63 Peptidase inhibitor SynT General  
Pigr 5.93 EGF pathway SynT 
 
General  
Cldn11 5.87 Tight junction SynT, CytoT General  
Inhba 4.42 TGFβ signaling pathway General EPC, P-TGCs at E7.5 (Albano et al. 1994) 
Fam196a 3.89 Unknown SynT, CytoT General  
Cldn1 
 
3.30 Tight junction SynT General  




Cubn 2.89 Receptor mediating endocytosis SynT, CytoT General (Burke et al. 2013) 
Prl8a1 -2.89 Prolactin cluster No orthologs EPC, SpT, P-TGCs (Simmons et al. 
2008) 
mt-Tp 2.87 Mitochondrially encoded tRNA proline SynT Unknown  




Hsd17b1 -2.85 17β-hydroxysteroid dehydrogenase  SynT Unknown  
Slc27a2 2.60 Fatty acid transport CytoT General  
Spon1 2.39 Cell adhesion CytoT General  
Crabp2 2.32 Retinoic acid signaling pathway CytoT General  
Prl2c2 -2.27 Prolactin cluster (proliferin) No orthologs EPC, SpT, P-TGCs (Simmons et al. 
2008) 
Chst10 2.27 Sulfotransferase SynT, CytoT Unknown  
Rcan2 2.27 Serine/threonine phosphatase regulator SynT Unknown  
Enpep 2.20 Aminopeptidase CytoT General  
Naip6 -2.17 Apoptosis inhibitory protein (Human ortholog: NAIP) 
SynT, CytoT 
General  
Asic2 2.14 Cation channel SynT, CytoT Unknown  
Foxs1 2.05 Transcription factor SynT Unknown  
Amn 2.04 Cobalamin transport CytoT General  
Prl3d1 -2.02 Prolactin cluster  No orthologs P-TGCs (Simmons et al. 
2008) 
Fetal endothelial vascular cell expression  
Otoa -2.63 Predicted adhesion protein FVE General  
Cftr 2.62 Chloride channel FVE Unknown  
Napsa 
 
-2.36 Aspartic protease FVE General  
Zfand4 -2.19 Zinc finger protein FVE General  
Ifi205 -2.15 Transcription factor FVE General  
Decidua expression  
Hspb7 16.67 Chaperone Dec General  
Pdgfrl 14.46 PDGF receptor-like protein General Dec at E7.5, unknown in 
trophoblast 
(Ashley et al. 2010) 
Klrb1c -9.71 Killer cell lectin-like receptor Dec, uNK uNK  
Fcgbp 9.67 Fc fragment of IgG binding protein General Dec at E7.5, unknown in 
trophoblast 
(McConaha et al. 
2011) 
Klra4 -8.83 Killer cell lectin-like receptor Dec, uNK General  
Clip4 6.38 Microtubule associating protein Dec Unknown  
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Ctla4 -5.52 Cytotoxic T-lymphocyte-associated 
protein 
Dec, CD8+ T cells General (van der Zwan et al. 
2018) 
Guca2b 4.67 cGMP biosynthesis Unknown Dec at E7.5, unknown in 
trophoblast 
(McConaha et al. 
2011) 
Cldn10 4.16 Tight junction protein Dec Unknown  
Cdo1 4.08 SHH co-receptor Unknown Dec at E10.5 (Rakoczy et al. 2015) 
Clca3a1 -3.90 Calcium-activated chloride channel Dec General  
Prap1 3.35 Proline rich acidic protein Dec General  
Lcn2 3.34 Lipocalin 2 Unknown Dec at E7.5 (McConaha et al. 
2011) 
Erv3 3.27 Endogenous retrovial sequence Unknown Dec at E7.5 (McConaha et al. 
2011) 
Fbp2 3.25 Fructose bisphosphotase Dec General  
Hdg 3.16 Amino acid catabolism Dec Unknown  
Ear2 3.04 Ribonuclease General Dec at E7.5 (McConaha et al. 
2011) 
Btg3 -2.86 Transcription factor binding protein Dec General  
Slc13a5 2.86 Sodium-dependent citrate transporter Dec Unknown  
Duox1 2.56 NADPH oxidase family Dec Unknown  
Slpi 2.47 Serine protease inhibitor Dec General  
Ltf 2.28 Lactotransferrin General Dec at E7.5 (McConaha et al. 
2011) 
Styk1 -2.19 Serine-threonine kinase Dec Unknown  
Gzmb -2.18 Hydrolyase Dec uNK cells (Tachibana et al. 
2013) 
Arhgef40 2.13 Rho guanine nucleotide exchange factor Dec Unknown  
Slc28a2 -2.03 Sodium-coupled purine nucleoside 
transporter 
Dec General  
*Human protein expression data was obtained from the Human Protein Atlas (Uhlen et al. 2015). Mouse protein expression data obtained from Mouse 
Encode (Yue et al. 2014) and Mouse Cell Atlas (Han et al. 2018) transcriptomic data. Further references were provided if specific expression data are 
published. SynT, syncytiotrophoblast; CytoT, cytotrophoblast; FVE, fetal vascular endothelium; Dec, maternal decidua; uNK, uterine natural killer; EVT, 




The data included in this appendix have been published in Padmanabhan et al. (2018). 
B1 Abnormal maternal physiology caused by the Mtrrgt mutation 
B1.1 Introduction 
Dietary folate deficiency in humans is associated with megaloblastic anaemia (Castellanos-
Sinco et al. 2015). Megaloblastic anaemia is a type of macrocytic anaemia characterised by 
fewer in number but enlarged erythrocytes (red blood cells, RBC), fewer reticulocytes, and 
fewer platelets (thrombocytopenia) (Koury & Ponka 2004). Folate metabolism is required for 
the synthesis of purines and pyrimidines, therefore is important for DNA replication (Palmer 
et al. 2017). Erythropoiesis is characterised by high proliferation rates, and therefore folate 
deficiency or abnormal folate metabolism can making erythrocyte progenitors (reticulocytes) 
susceptible to genomic instability during erythropoiesis (Wickramasinghe, Cooper & 
Chalmers 1968; Yoshida et al. 1968). Additionally, folate is essential for the release of 
methyl groups essential for the methylation of cellular substances (Ghandour et al. 2002; 
Jacob et al. 1998). Hematopoietic stem cell commitment and differentiation into the erythroid 
lineage is characterised by dynamic changes in DNA methylation patterns (Madzo et al. 
2014). For instance, the binding sides of transcription factors that regulate erythroid 
differentiation, such as GATA2 and RUNX1, gain 5-hydroxymethylxytosine during 
differentiation (Madzo et al. 2014). Abnormal regulation of DNA methylation in mice has 
been associated with blood phenotypes (Ko et al. 2010; Kunimoto et al. 2017; Sasaki et al. 
2012). For instance, a loss of function mutation of Aid, which is an enzyme that regulates 
active DNA demethylation, leads to DNA hypermethylation, expansion of myeloid cells, 
decreased erythroid progenitors, and ultimately, anaemia (Kunimoto et al. 2017). Epigenetic 
instability caused by global DNA hypomethylation in the Mtrrgt mouse model of abnormal 
folate metabolism (Padmanabhan et al. 2013) could possibly lead to misexpression of genes 
essential for erythropoiesis. Mtrr deficiency can also possibly cause abnormal DNA 
methylation in the erythroid lineage affecting its differentiation, maturation, and/ or potential 
for survival. 
We identified an age- and sex- dependent hematopoietic phenotype in Mtrrgt/gt mice 
(Padmanabhan et al. 2018). Specifically, we showed that Mtrrgt/gt female mice at 5 months of 
age display macrocytic anaemia, since they have decreased RBC numbers compared to 
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C57Bl/6 age-matched females (Padmanabhan et al. 2018). We also analysed females at 7 
weeks of age, and found that they have normal RBC counts, suggesting that anaemia emerged 
with age (Padmanabhan et al. 2018). In contrast, Mtrrgt/gt male mice of either age group were 
not anaemic. Sex-specific lymphopenia was also observed, since Mtrrgt/gt females had normal 
lymphocyte and white blood cell numbers compared to C57Bl/6 controls. Mtrrgt/gt males and 
females had normal levels of basophils, eosinophils, and monocytes, which come from the 
myeloid lineage (Padmanabhan et al. 2018). Erythrocytic macrocytosis and lymphopenia was 
observed in Mtrrgt/gt males at 5 months of age, but not at 7 weeks of age, suggesting that these 
haematological effects emerged with age (Padmanabhan et al. 2018). Altogether these data 
showed that the haematological phenotypes not only emerged with age, but also in a sex-
specific manner. 
We have previously shown that abnormal phenotypes in the Mtrrgt model occur in several 
wildtype generations later and that these multigenerational effects occur through the maternal 
lineage (Padmanabhan et al. 2013). Therefore, we analysed the blood profile of F1 Mtrr+/+ 
females derived from an Mtrr+/gt to assess any generational effects of Mtrrgt mutation in 
haematopoiesis. F1 Mtrr+/+ females have normal folate metabolism, as indicated by normal 
homocysteine levels. F1 females derived from Mtrr+/gt mothers exhibited anaemia, as 
indicated by reduced RBC counts and haematocrit. In contrast, F1 females derived from 
Mtrr+/gt fathers had normal RBC counts, and therefore were not anaemic, suggesting a parent-
of-origin specific effect (Padmanabhan et al. 2018).  
Next, we wanted to identify the mechanism behind the macrocytic anaemia observed in aged 
Mtrrgt/gt females and F1 Mtrr+/+ females. Haemolysis was ruled out, since there was no 
difference in iron deposition in spleens of male and female Mtrrgt/gt mice compared to 
C57Bl/6. In addition, Ftl1 mRNA, which mediates iron uptake, and Hamp1 mRNA, a 
hormone that regulates iron storage expression was similar in Mtrrgt/gt and C57Bl/6 mice 
(Padmanabhan et al. 2018). These results excluded the hypothesis that anaemia is due to 
haemolysis of RBCs. Then, we explored the hypothesis that defective differentiation of 
erythroid precursor occurs (Padmanabhan et al. 2018), by assessing Epo mRNA levels in 
kidneys of adult Mtrrgt/gt and F1 Mtrr+/+ females. Increased Epo mRNA levels would suggest 





Kidneys were collected from two age groups of Mtrrgt/gt mice: females and male mice at 7 
weeks of age, and female and male mice at 5 months of age (n=3-5 per sex per age group). 
Kidneys were also collected from the same age groups of female and male Mtrr+/+ mice 
derived from either an Mtrr+/gt father and a C57Bl/6 mother (paternal), or an Mtrr+/gt mother 
and a C57Bl/6 father (maternal). Kidney samples were homogenised at 6000x for 20 sec for 
RNA extraction, as described in Section 2.8.  
Epo mRNA expression in kidneys was analysed via RT-qPCR as described in Section 2.12, 
with the following primers: Epo F: TCTGCGACAGTCGAGTTCTG, Epo R: 
CTTCTGCACAACCCATCGT, Hprt F: TCCTCCTCAGACCGCTTTT, Hprt R: 
CCTGGTTCATCATCGCTAATC at a concentration of 150nM. Epo probe #16 
(4686896001, Roche) and Hprt probe #45 (4692128001, Roche) were also used. 
The following modified RT-qPCR reaction was used: FastStart TaqMan Probe master mix 
(4673409001, Roche) was used under the following protocol: The enzyme was activated at 
95oC for 15 minutes and the cDNA was amplified for 40 cycles under the following 
conditions: denaturation at 95oC for 30 seconds, annealing at 59.8oC for 30 seconds, and 
extension at 72oC for 30 seconds.  
Statistical analysis was performed using GraphPad Prism 6 software. Data were analysed 
using independent t-tests or ordinary one-way ANOVA with Tukey multiple comparison 
tests. P values less than 0.05 were considered significant. 
 
B1.3 Results 
To assess whether there is increased differentiation of hematopoietic stem cells into 
erythrocytes, as a response to anaemia, we assessed the levels of Epo (Erythropoietin) mRNA 
expression in adult kidneys. Epo is a hormone that regulates erythropoiesis. It is synthesised 
in the kidneys and stimulates differentiation of erythroid precursors in the bone marrow into 
red blood cells. Increased Epo levels are associated with anaemia (Koury & Ponka 2004). As 
expected, since male mice were not anaemic, both young and aged Mtrrgt/gt male mice 
showed normal Epo mRNA expression compared to C57Bl/6 age-matched males (Figure 
B1A). In contrast, we observed a 3.0- and an 8.3-fold increase in Epo mRNA expression in 
kidneys of young and old Mtrrgt/gt females, respectively, compared to C57Bl/6 age-matched 
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females (p<0.001, Figure B1A). The increase of Epo mRNA expression in kidneys of young 
Mtrrgt/gt female mice in the absence of anaemia, could suggest an early, symptom-free 
anaemia that progresses with age. 
Remarkably, haematological defects were also observed in F1 Mtrr+/+ females derived from 
an Mtrr+/gt parent (F0). These defects were parent-of-origin-specific, since Mtrr+/+ females 
derived from an Mtrr+/gt mother displayed normocytic anaemia, while Mtrr+/+ females 
derived from an Mtrr+/gt father displayed erythrocytic microcytosis not associated with 
anaemia (Padmanabhan et al. 2018). However, reticulocyte counts, and reticulocyte 
production indices were normal in both cases. As before, we wanted to assess whether 
anaemia observed in the F1 Mtrr+/+ females derived from an Mtrr+/gt mother was due to 
abnormal haematopoiesis. Renal Epo mRNA expression was increased in Mtrr+/+ females 
derived from an either Mtrr+/gt mother or father (3.0-fold increase caused by Mtrr+/gt mother, 
p=0.066, 4.4-fold increase caused by Mtrr+/gt father, p=0.033; Figure B1B), although only the 
latter was statistically significant (Padmanabhan et al. 2018). These data suggest that the 
erythroid precursors of F1 females are more sensitive to a maternal, rather than a paternal 
Mtrrgt allele. Transcriptional compensation of Epo was sufficient to prevent anemia in F1 








Figure B1 Abnormal erythroid differentiation, not haemolysis is likely the cause of 
anaemia in mice. 
(A) RT-qPCR analysis of Epo mRNA expression in kidneys of 7-week old (younger) and 5-
month old (older) female (f) and male (m) C57Bl/6 (grey) and Mtrrgt/gt (black) mice. n = 3-5 
mice were analysed per group. Data are presented as fold change compared to same sex 
C57Bl/6 controls (normalised to 1) (B) RT-qPCR analysis of Epo mRNA expression in 
kidneys. n = 3-5 mice were analysed per group. Data are presented as fold change compared 
to C57Bl/6 controls (normalised to 1). 
 
B1.4 Discussion 
Megaloblastic anaemia is associated with dietary folate deficiency and defective folate uptake 
in humans. Abnormal folate metabolism due to the Mtrrgt mutation results in an age- and sex- 
dependent hematopoietic phenotype in Mtrrgt/gt mice. More specifically, both young and aged 
Mtrrgt/gt male mice were not anaemic and had normal Epo mRNA expression compared to 
C57Bl/6 age-matched males. In contrast, only aged, but not young Mtrrgt/gt females displayed 
anaemia, although both age groups have increased Epo mRNA expression in kidneys 
compared to C57Bl/6 age-matched females. The increase of Epo mRNA expression in 
kidneys of young Mtrrgt/gt female mice in the absence of anaemia, could suggest an early, 
symptom-free anaemia that progresses with age. Increased Epo in our model correlates with 
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other models of folate deficiency or defective folate uptake (Bills et al. 1992; Koury et al. 
1997; Salojin et al. 2011). Anaemia in the Mtrrgt model is due to a potential erythrocyte 
precursor differentiation defect, as indicated by increased Epo levels. Normal Ftl1 and 
Hamp1 expression indicated that haemolysis is unlikely to happen. This is in contrast to 
Slc46a1 mutants where anaemia is likely to be associated with increased haemolysis of the 
differentiating erythrocytes (Koury et al. 1997; Salojin et al. 2011). 
F1 Mtrr+/+ females derived from Mtrr+/gt mothers were anaemic with normal levels of Epo 
mRNA, while F1 Mtrr+/+ females derived from Mtrr+/gt fathers were not anaemic, but 
increased Epo mRNA levels. In both instances, this suggests an abnormal maternal 
environment. In our Mtrrgt model of abnormal folate metabolism, the growth phenotypes 
observed, such as growth restriction and developmental delay, are due to an abnormal 
maternal environment. A systematic review of the literature and meta-analysis concluded that  
moderate to severe, but not mild, anaemia in the mother increases the risk of small for 
gestational age outcomes (Kozuki, Lee & Katz 2012). In these studies, anaemia was defined 
as low levels of haemoglobin in the blood, associated with reduced quality or quantity of 
erythrocytes. The cause of anaemia in the studies included in this review is either not stated 
(Gonzales, Steenland & Tapia 2009; Scanlon et al. 2000), or iron deficiency (Hamalainen, 
Hakkarainen & Heinonen 2003; Ren et al. 2007; Zhou et al. 1998). This is in contrast to our 
model, where anaemia is likely due to erythrocyte precursor differentiation defect. 
Altogether, these data suggest that the Mtrrgt heterozygosity of the parent is sufficient to 
cause an abnormal environment in their Mtrr+/+ daughter, characterised by anaemia or 
abnormal Epo levels. 
The abnormal maternal environment of F1 Mtrr+/+ females, characterised by anaemia or 
abnormal Epo levels, can be responsible for the growth defects observed in F2 generation. 
Although FGR is a multifactorial condition, in most cases, fetal growth is constrained by 
hypoxia and impaired nutrient transport (Hutter, Kingdom & Jaeggi 2010; Marsal 2002). 
Hypoxia can be caused by anaemia. Even though the levels of haemoglobin, which carries 
oxygen to the cells, were normal in F1 Mtrr+/+ females (Padmanabhan et al. 2018), it is 
possible that the haemoglobin has decreased affinity to oxygen, and therefore lead to 
hypoxia. Hypoxia leads to increased Epo expression (Stockmann & Fandrey 2006). Increased 
Epo levels in F1 Mtrr+/+ females could suggest that their environment might be hypoxic. This 
can impair oxygen transport to the placenta or the fetus and impair fetal growth. 
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Erythropoietic responses to hypoxia, such as increased Epo production, are regulated by HIF 
(Kapitsinou et al. 2010; Stockmann & Fandrey 2006). HIF is a heterodimer, composed of 
HIFα and HIFβ (ARNT) subunits. Defective placental vascularisation was observed in 
placentas from Arnt-/- and Hif1a-/- Hif2a-/- conceptuses. In addition, trophoblast stem cells 
lacking Hifα and Arnt are unable to differentiate into trophoblast giant cells, or 
spongiotrophoblast, and differentiate into labyrinth trophoblast instead, suggesting placental 
development is regulated by hypoxia (Cowden Dahl et al. 2005). Altogether, these studies 
suggest that the F1 Mtrr+/+ females might have a hypoxic environment, which might lead to 









Table C.1 DEGs in placentas of phenotypically normal Mtrrgt/gt conceptuses compared to C57Bl/6 at E10.5. 
C57Bl/6 Vs Mtrrgt/gt PN 
Gene ID Fold 
change 
Gene abbreviation Gene name 
ENSMUSG00000040264 -219.19 Gbp2b guanylate binding protein 2b 
ENSMUSG00000078994 -63.96 Zfp429 zinc finger protein 429 
ENSMUSG00000065922 -11.67 n-R5-8s1 nuclear encoded rRNA 5.8S 1 
ENSMUSG00000088088 -10.73 Rmrp RNA component of mitochondrial RNAase P 
ENSMUSG00000073177 -9.64 Gm773 predicted gene 773 
ENSMUSG00000042386 -8.69 Tex13b testis expressed 13B 
ENSMUSG00000074871 -8.60 Ctsm cathepsin M 
ENSMUSG00000009292 -8.24 Trpm2 Transient receptor potential cation channel subfamily M member 2  
ENSMUSG00000091273 -6.88 Gm6673 predicted gene 6673 
ENSMUSG00000067750 -5.78 Khdc1a KH homology domain-containing protein 1A  
ENSMUSG00000100865 -5.36 Gm9320 predicted gene 9320 
ENSMUSG00000092837 -4.68 Rpph1 ribonuclease P RNA component H1 
ENSMUSG00000023185 -4.53 Ceacam14 carcinoembryonic antigen-related cell adhesion molecule 14 
ENSMUSG00000091562 -4.33 Crybg3 beta-gamma crystallin domain containing 3 
ENSMUSG00000070798 -4.33 Psg25 pregnancy-specific glycoprotein 25 
ENSMUSG00000074359 -4.29 Psg23 pregnancy-specific glycoprotein 23 
ENSMUSG00000070797 -4.08 Psg27 pregnancy-specific glycoprotein 27 
ENSMUSG00000086695 -4.03 Gm15247 predicted gene 15247 
ENSMUSG00000044285 -4.02 Gm1821 predicted gene 1821 
ENSMUSG00000065037 -3.83 Rn7sk RNA, 7SK, nuclear 
ENSMUSG00000078793 -3.75 Gm5155 predicted gene 5155 
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ENSMUSG00000070796 -3.60 Psg21 pregnancy-specific glycoprotein 21 
ENSMUSG00000045928 -3.53 4933440M02Rik RIKEN cDNA 4933440M02 gene 
ENSMUSG00000034617 -3.49 Mtrr 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 
ENSMUSG00000003505 -3.37 Psg18 pregnancy specific glycoprotein 18 
ENSMUSG00000062705 -3.24 Tpbpb trophoblast specific protein beta 
ENSMUSG00000030373 -3.23 Psg28 pregnancy-specific glycoprotein 28 
ENSMUSG00000023087 -3.19 Noct Nocturnin  
ENSMUSG00000004540 -3.06 Psg17 pregnancy-specific glycoprotein 17 
ENSMUSG00000006154 -3.02 Eps8l1 Epidermal growth factor receptor kinase substrate 8-like protein 1  
ENSMUSG00000079476 -2.99 1700011M02Rik RIKEN cDNA 1700011M02 gene 
ENSMUSG00000001901 -2.95 Kcnh6 potassium voltage-gated channel, subfamily H (eag-related), member 6 
ENSMUSG00000030368 -2.90 Ceacam11 carcinoembryonic antigen-related cell adhesion molecule 11 
ENSMUSG00000103034 -2.89 Gm8797 predicted gene, 8797 
ENSMUSG00000097971 -2.87 Gm26917 predicted gene, 26917 
ENSMUSG00000098973 -2.84 Mir6236 microRNA 6236 
ENSMUSG00000066760 -2.77 Psg16 pregnancy-specific glycoprotein 16 
ENSMUSG00000086324 -2.76 Gm15564 predicted gene 15564 
ENSMUSG00000061684 -2.72 Rpl21-ps8 ribosomal protein L21, pseudogene 8 
ENSMUSG00000026358 -2.71 Rgs1 regulator of G-protein signaling 1 
ENSMUSG00000060377 -2.70 Rpl36a-ps1 ribosomal protein L36A, pseudogene 1 
ENSMUSG00000094334 -2.62 Fabp5l2 fatty acid binding protein 5-like 2 
ENSMUSG00000046899 -2.61 Prl7a2 prolactin family 7, subfamily a, member 2 
ENSMUSG00000025789 -2.55 St8sia2 Alpha-2,8-sialyltransferase 8B  
ENSMUSG00000040013 -2.54 Fkbp6 Inactive peptidyl-prolyl cis-trans isomerase FKBP6  
ENSMUSG00000021439 -2.52 Ctsq cathepsin Q 
ENSMUSG00000029437 -2.50 Il31 Interleukin-31  
ENSMUSG00000097276 -2.50 4930525G20Rik RIKEN cDNA 4930525G20 gene 
ENSMUSG00000026390 -2.49 Marco Macrophage receptor MARCO  
ENSMUSG00000053228 -2.48 Ceacam3 carcinoembryonic antigen-related cell adhesion molecule 3 
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ENSMUSG00000073422 -2.47 H2-Ke6 H2-K region expressed gene 6 
ENSMUSG00000075245 -2.46 Gm6043 predicted gene 6043 
ENSMUSG00000009596 -2.45 Taf7l Transcription initiation factor TFIID subunit 7-like  
ENSMUSG00000091730 -2.40 Gm17230 predicted gene 17230 
ENSMUSG00000080811 -2.39 Gm14513 predicted gene 14513 
ENSMUSG00000053411 -2.36 Cbx7 Chromobox protein homolog 7  
ENSMUSG00000035202 -2.35 Lars2 Probable leucine--tRNA ligase, mitochondrial  
ENSMUSG00000028825 -2.34 Rhd Rh blood group, D antigen 
ENSMUSG00000015224 -2.34 Cyp2j9 cytochrome P450, family 2, subfamily j, polypeptide 9 
ENSMUSG00000097368 -2.33 Gm10390 predicted gene, 10390 
ENSMUSG00000107810 -2.33 Gm18609 predicted gene, 18609 
ENSMUSG00000079017 -2.32 Ifi27l2a Interferon alpha-inducible protein 27-like protein 2A  
ENSMUSG00000029369 -2.31 Afm Afamin  
ENSMUSG00000092447 -2.31 Gm7696 predicted gene 7696 
ENSMUSG00000027794 -2.30 Sohlh2 Spermatosis- and oosis-specific basic helix-loop-helix-containing protein 2  
ENSMUSG00000033834 -2.29 Tpbpa trophoblast specific protein alpha 
ENSMUSG00000086740 -2.28 Gm17029 predicted gene 17029 
ENSMUSG00000025932 -2.27 Eya1 Eyes absent homolog 1  
ENSMUSG00000062480 -2.27 Acat3 acetyl-Coenzyme A acetyltransferase 3 
ENSMUSG00000072940 -2.26 Gm10443 predicted pseudogene 10443 
ENSMUSG00000086552 -2.23 Dlx4os distal-less homeobox 4, opposite strand 
ENSMUSG00000020871 -2.23 Dlx4 Homeobox protein DLX-4  
ENSMUSG00000034645 -2.23 Zyg11a zyg-11 family member A, cell cycle regulator 
ENSMUSG00000031144 -2.22 Syp Synaptophysin  
ENSMUSG00000069939 -2.21 Gm12070 predicted gene 12070 
ENSMUSG00000060727 -2.21 Gm12571 predicted gene 12571 
ENSMUSG00000004035 -2.21 Gstm7 Glutathione S-transferase Mu 7  
ENSMUSG00000108446 -2.20 Gm44997 predicted gene 44997 
ENSMUSG00000081929 -2.19 Rps11-ps2 ribosomal protein S11, pseudogene 2 
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ENSMUSG00000031994 -2.17 Adamts8 A disintegrin and metalloproteinase with thrombospondin motifs 8 isoform 2  
ENSMUSG00000020279 -2.16 Il9r Interleukin-9 receptor  
ENSMUSG00000085465 -2.15 Gm15347 predicted gene 15347 
ENSMUSG00000108207 -2.15 1810059H22Rik RIKEN cDNA 1810059H22 gene 
ENSMUSG00000097536 -2.15 2610037D02Rik RIKEN cDNA 2610037D02 gene 
ENSMUSG00000018486 -2.14 Wnt9b wingless-type MMTV integration site family, member 9B 
ENSMUSG00000104443 -2.13 4932442E05Rik RIKEN cDNA 4932442E05 gene 
ENSMUSG00000028137 -2.12 Celf3 CUGBP, Elav-like family member 3 
ENSMUSG00000072721 -2.12 Klra14-ps killer cell lectin-like receptor subfamily A, member 14, pseudogene 
ENSMUSG00000031849 -2.11 Comp Cartilage oligomeric matrix protein  
ENSMUSG00000081087 -2.10 Rps15a-ps7 ribosomal protein S15A, pseudogene 7 
ENSMUSG00000081231 -2.10 Tcp1-ps1 t-complex protein 1, pseudogene 1 
ENSMUSG00000104781 -2.09 Gm43303 predicted gene 43303 
ENSMUSG00000097242 -2.07 Gm16907 predicted gene, 16907 
ENSMUSG00000095419 -2.07 Gm14328 predicted gene 14328 
ENSMUSG00000039079 -2.06 Trhr2 thyrotropin releasing hormone receptor 2 
ENSMUSG00000058152 -2.06 Chsy3 Chondroitin sulfate synthase 3  
ENSMUSG00000083305 -2.05 Gm13315 predicted gene 13315 
ENSMUSG00000086631 -2.05 Gm12784 predicted gene 12784 
ENSMUSG00000073530 -2.05 Pappa2 pappalysin 2 
ENSMUSG00000105632 -2.04 Gm43272 predicted gene 43272 
ENSMUSG00000026919 -2.04 Lcn4 lipocalin 4 
ENSMUSG00000104864 -2.04 Gm43655 predicted gene 43655 
ENSMUSG00000108402 -2.04 9430064I24Rik RIKEN cDNA 9430064I24 gene 
ENSMUSG00000060938 -2.04 Rpl26 60S ribosomal protein L26  
ENSMUSG00000085415 -2.03 Selenok-ps1 selenoprotein K, pseudogene 1 
ENSMUSG00000084790 -2.03 Gm15879 predicted gene 15879 
ENSMUSG00000026443 -2.02 Lrrn2 leucine rich repeat protein 2, neuronal 
ENSMUSG00000086331 -2.02 Gm16310 predicted gene 16310 
335 
 
ENSMUSG00000107428 -2.02 Gm44154 predicted gene, 44154 
ENSMUSG00000028730 -2.01 Cfap57 Cilia- and flagella-associated protein 57  
ENSMUSG00000097399 -2.01 Gm26555 predicted gene, 26555 
ENSMUSG00000040065 2.01 Pfpl pore forming protein-like 
ENSMUSG00000042684 2.01 Npl N-acetylneuraminate lyase  
ENSMUSG00000089704 2.01 Galnt2 Polypeptide N-acetylgalactosaminyltransferase 2 soluble form 
ENSMUSG00000000560 2.01 Gabra2 Gamma-aminobutyric acid receptor subunit alpha-2  
ENSMUSG00000072437 2.01 Nanos1 Nanos homolog 1  
ENSMUSG00000074345 2.02 Tnfaip8l3 Tumor necrosis factor alpha-induced protein 8-like protein 3  
ENSMUSG00000054069 2.02 6030452D12Rik RIKEN cDNA 6030452D12 gene 
ENSMUSG00000028158 2.03 Mttp Microsomal triglyceride transfer protein large subunit  
ENSMUSG00000034810 2.03 Scn7a sodium voltage-gated channel alpha subunit 7 
ENSMUSG00000038732 2.04 Mboat1 membrane bound O-acyltransferase domain containing 1 
ENSMUSG00000022468 2.04 Endou Poly(U)-specific endoribonuclease  
ENSMUSG00000024354 2.04 Slc23a1 Solute carrier family 23 member 1  
ENSMUSG00000062310 2.04 Glrp1 glutamine repeat protein 1 
ENSMUSG00000020953 2.04 Coch Cochlin  
ENSMUSG00000026227 2.05 2810459M11Rik Uncharacterized   
ENSMUSG00000046167 2.06 Gldn Gliomedin Gliomedin shedded ectodomain 
ENSMUSG00000026870 2.06 Cutal cutA divalent cation tolerance homolog-like 
ENSMUSG00000029055 2.06 Plch2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2  
ENSMUSG00000006221 2.07 Hspb7 Heat shock protein beta-7  
ENSMUSG00000024912 2.07 Fosl1 Fos-related antigen 1  
ENSMUSG00000098021 2.08 Gm9522 predicted gene 9522 
ENSMUSG00000020193 2.08 Zpbp zona pellucida binding protein 
ENSMUSG00000024990 2.09 Rbp4 Retinol-binding protein 4  
ENSMUSG00000022755 2.09 Adgrg7 Adhesion G-protein coupled receptor G7  
ENSMUSG00000049999 2.09 Ppp1r3d protein phosphatase 1 regulatory subunit 3D 
ENSMUSG00000029380 2.10 Cxcl1 Growth-regulated alpha protein KC(5-72) 
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ENSMUSG00000045915 2.10 Ccdc42 Coiled-coil domain-containing protein 42  
ENSMUSG00000026204 2.11 Ptprn protein tyrosine phosphatase, receptor type, N 
ENSMUSG00000040276 2.12 Pacsin1 Protein kinase C and casein kinase substrate in neurons protein 1  
ENSMUSG00000029154 2.13 Cwh43 PGAP2-interacting protein  
ENSMUSG00000021477 2.13 Ctsl cathepsin L 
ENSMUSG00000043448 2.14 Gjc2 gap junction protein, gamma 2 
ENSMUSG00000059040 2.14 Eno1b enolase 1B, retrotransposed 
ENSMUSG00000103427 2.15 Gm37534 predicted gene, 37534 
ENSMUSG00000076612 2.15 Ighg2c immunoglobulin heavy constant gamma 2C 
ENSMUSG00000042734 2.16 Ttc9 tetratricopeptide repeat domain 9 
ENSMUSG00000031952 2.16 Chst5 Carbohydrate sulfotransferase 5  
ENSMUSG00000026304 2.17 Rab17 Ras-related protein Rab-17  
ENSMUSG00000041193 2.18 Pla2g5 phospholipase A2, group V 
ENSMUSG00000039313 2.20 AF529169 UPF0258 protein KIAA1024  
ENSMUSG00000047797 2.21 Gjb1 gap junction protein, beta 1 
ENSMUSG00000040891 2.21 Foxa3 Hepatocyte nuclear factor 3-gamma  
ENSMUSG00000108367 2.24 Gm4881 predicted gene, 4881 
ENSMUSG00000102189 2.24 Gm37194 predicted gene, 37194 
ENSMUSG00000027832 2.24 Ptx3 Pentraxin-related protein PTX3  
ENSMUSG00000041577 2.24 Prelp proline arginine-rich end leucine-rich repeat 
ENSMUSG00000045775 2.25 Slc16a5 solute carrier family 16 (monocarboxylic acid transporters), member 5 
ENSMUSG00000027376 2.25 Prom2 Prominin-2  
ENSMUSG00000052143 2.25 Gm9869 predicted gene, 9869 
ENSMUSG00000006205 2.25 Htra1 Serine protease HTRA1  
ENSMUSG00000037936 2.26 Scarb1 Scavenger receptor class B member 1  
ENSMUSG00000019756 2.28 Prl8a1 prolactin family 8, subfamily a, member 1 
ENSMUSG00000031936 2.29 Hephl1 Hephaestin-like protein 1  
ENSMUSG00000027249 2.31 F2 coagulation factor II 
ENSMUSG00000033102 2.33 Cdc14b Dual specificity protein phosphatase CDC14B  
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ENSMUSG00000032496 2.34 Ltf Lactotransferrin  
ENSMUSG00000021364 2.35 Elovl2 Elongation of very long chain fatty acids protein 2  
ENSMUSG00000073293 2.36 Nudt10 Diphosphoinositol polyphosphate phosphohydrolase 3-alpha  
ENSMUSG00000027870 2.40 Hao2 Hydroxyacid oxidase 2  
ENSMUSG00000064372 2.40 mt-Tp mitochondrially encoded tRNA proline 
ENSMUSG00000097017 2.41 Gm26707 predicted gene, 26707 
ENSMUSG00000032023 2.42 Jhy junctional cadherin complex regulator 
ENSMUSG00000022949 2.42 Clic6 Chloride intracellular channel protein 6  
ENSMUSG00000072978 2.43 Gm5830 predicted pseudogene 5830 
ENSMUSG00000056457 2.44 Prl2c3 Mus musculus prolactin family 2, subfamily c, member 4 (Prl2c4), mRNA. 
ENSMUSG00000087362 2.49 Gm13710 predicted gene 13710 
ENSMUSG00000031760 2.53 Mt3 Metallothionein-3  
ENSMUSG00000057170 2.53 Prl3d1 prolactin family 3, subfamily d, member 1 
ENSMUSG00000033082 2.53 Clec1a C-type lectin domain family 1 member A  
ENSMUSG00000040600 2.61 Eps8l3 Epidermal growth factor receptor kinase substrate 8-like protein 3  
ENSMUSG00000057228 2.61 Aadat aminoadipate aminotransferase 
ENSMUSG00000021850 2.63 1700011H14Rik RIKEN cDNA 1700011H14 gene 
ENSMUSG00000060985 2.65 Tdrd5 Tudor domain-containing protein 5  
ENSMUSG00000058626 2.66 Capn11 Calpain-11  
ENSMUSG00000073988 2.66 Ttpa tocopherol (alpha) transfer protein 
ENSMUSG00000049556 2.66 Lingo1 Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-
interacting protein 1  
ENSMUSG00000028989 2.67 Angptl7 Angiopoietin-related protein 7  
ENSMUSG00000035699 2.68 Slc51a solute carrier family 51, alpha subunit 
ENSMUSG00000072849 2.70 Serpina1e serine (or cysteine) peptidase inhibitor, clade A, member 1E 
ENSMUSG00000032257 2.70 Ankk1 Ankyrin repeat and protein kinase domain-containing protein 1  
ENSMUSG00000021536 2.70 Adcy2 adenylate cyclase 2 
ENSMUSG00000050097 2.72 Ces2b carboxyesterase 2B 
ENSMUSG00000065418 2.72 Mir322 microRNA 322 
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ENSMUSG00000078995 2.74 Zfp456 zinc finger protein 456 
ENSMUSG00000009246 2.75 Trpm5 Transient receptor potential cation channel subfamily M member 5  
ENSMUSG00000039037 2.78 St6galnac5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 5 
ENSMUSG00000031574 2.82 Star Steroidogenic acute regulatory protein, mitochondrial  
ENSMUSG00000076140 2.84 Mir542 microRNA 542 
ENSMUSG00000053930 2.84 Shisa6 shisa family member 6 
ENSMUSG00000062201 2.84 Prl3d3 prolactin family 3, subfamily d, member 3 
ENSMUSG00000019359 2.86 Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2, transcript variant 3 
ENSMUSG00000052981 2.89 Ube2ql1 ubiquitin-conjugating enzyme E2Q family-like 1 
ENSMUSG00000028544 2.90 Slc5a9 Sodium/glucose cotransporter 4  
ENSMUSG00000067081 2.91 Asb18 Ankyrin repeat and SOCS box protein 18  
ENSMUSG00000046844 2.93 Vat1l vesicle amine transport protein 1 like 
ENSMUSG00000031883 2.96 Car7 Carbonic anhydrase 7  
ENSMUSG00000046203 2.98 Sprr2g Small proline-rich protein 2G  
ENSMUSG00000035226 2.98 Rims4 Regulating synaptic membrane exocytosis protein 4  
ENSMUSG00000105703 3.02 Gm43305 predicted gene 43305 
ENSMUSG00000032495 3.02 Lrrc2 leucine rich repeat containing 2 
ENSMUSG00000029260 3.05 Ugt2b34 UDP glucuronosyltransferase 2 family, polypeptide B34 
ENSMUSG00000020226 3.06 Slc5a4b solute carrier family 5 (neutral amino acid transporters, system A), member 4b 
ENSMUSG00000094590 3.06 Gm10251 predicted gene 10251 
ENSMUSG00000021795 3.07 Sftpd Pulmonary surfactant-associated protein D  
ENSMUSG00000029273 3.12 Sult1d1 Sulfotransferase 1 family member D1  
ENSMUSG00000062737 3.13 Prl3d2 prolactin family 3, subfamily d, member 1 
ENSMUSG00000027690 3.13 Slc2a2 solute carrier family 2 (facilitated glucose transporter), member 2 
ENSMUSG00000038239 3.27 Hrc histidine rich calcium binding protein 
ENSMUSG00000065503 3.31 Mir351 microRNA 351 
ENSMUSG00000049799 3.45 Lrrc19 Leucine-rich repeat-containing protein 19  
ENSMUSG00000047990 3.45 C2cd4a C2 calcium-dependent domain containing 4A 
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ENSMUSG00000027869 3.52 Hsd3b6 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 6 
ENSMUSG00000055341 3.55 Zfp457 zinc finger protein 457 
ENSMUSG00000011632 3.60 Pinlyp phospholipase A2 inhibitor and LY6/PLAUR domain containing 
ENSMUSG00000101026 3.68 D730001G18Rik lymphocyte antigen 6 complex, locus G6G (Ly6g6g) 
ENSMUSG00000067149 3.70 Jchain Immunoglobulin J chain  
ENSMUSG00000058147 3.76 Xlr3c X-linked lymphocyte-regulated 3C 
ENSMUSG00000035551 3.79 Igfbpl1 Insulin-like growth factor-binding protein-like 1  
ENSMUSG00000095079 3.86 Igha immunoglobulin heavy constant alpha 
ENSMUSG00000055409 3.99 Nell1 Protein kinase C-binding protein NELL1  
ENSMUSG00000021456 4.18 Fbp2 Fructose-1,6-bisphosphatase isozyme 2  
ENSMUSG00000030302 4.33 Atp2b2 Plasma membrane calcium-transporting ATPase 2  
ENSMUSG00000105155 4.55 Gm42910 predicted gene 42910 
ENSMUSG00000062168 4.89 Ppef1 Serine/threonine-protein phosphatase with EF-hands 1  
ENSMUSG00000037334 5.52 H2-M1 histocompatibility 2, M region locus 1 
ENSMUSG00000069805 10.46 Fbp1 Fructose-1,6-bisphosphatase 1  
ENSMUSG00000031620 13.69 Iqcm IQ motif containing M 
 
Table C.2 DEGs in placentas of growth restricted Mtrrgt/gt conceptuses compared to C57Bl/6 at E10.5. 
C57Bl/6 Vs Mtrrgt/gt GR 





ENSMUSG00000040264 -341.28 Gbp2b guanylate binding protein 2b 
ENSMUSG00000078994 -51.38 Zfp429 zinc finger protein 429 
ENSMUSG00000073177 -36.76 Gm773 predicted gene 773 
ENSMUSG00000108558 -29.98 Psg-ps1 pregnancy specific glycoprotein, pseudogene 1 
ENSMUSG00000074871 -19.49 Ctsm cathepsin M 
ENSMUSG00000030366 -13.64 Ceacam12 carcinoembryonic antigen-related cell adhesion molecule 12 
ENSMUSG00000023185 -12.57 Ceacam14 carcinoembryonic antigen-related cell adhesion molecule 14 
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ENSMUSG00000070798 -10.89 Psg25 pregnancy-specific glycoprotein 25 
ENSMUSG00000074359 -10.52 Psg23 pregnancy-specific glycoprotein 23 
ENSMUSG00000070797 -9.74 Psg27 pregnancy-specific glycoprotein 27 
ENSMUSG00000078793 -9.33 Gm5155 predicted gene 5155 
ENSMUSG00000070796 -9.28 Psg21 pregnancy-specific glycoprotein 21 
ENSMUSG00000030373 -8.34 Psg28 pregnancy-specific glycoprotein 28 
ENSMUSG00000003505 -7.60 Psg18 pregnancy specific glycoprotein 18 
ENSMUSG00000008789 -7.55 Ceacam5 Carcinoembryonic antigen-related cell adhesion molecule 5  
ENSMUSG00000046899 -7.13 Prl7a2 prolactin family 7, subfamily a, member 2 
ENSMUSG00000062705 -6.42 Tpbpb trophoblast specific protein beta 
ENSMUSG00000030368 -6.34 Ceacam11 carcinoembryonic antigen-related cell adhesion molecule 11 
ENSMUSG00000091273 -6.26 Gm6673 predicted gene 6673 
ENSMUSG00000057195 -6.18 Ceacam13 carcinoembryonic antigen-related cell adhesion molecule 13 
ENSMUSG00000067750 -5.88 Khdc1a KH homology domain-containing protein 1A  
ENSMUSG00000004540 -5.57 Psg17 pregnancy specific glycoprotein 17 
ENSMUSG00000074870 -5.54 Cts3 cathepsin 3 
ENSMUSG00000021345 -4.88 Prl8a6 prolactin family 8, subfamily a, member 6 
ENSMUSG00000009596 -4.79 Taf7l Transcription initiation factor TFIID subunit 7-like  
ENSMUSG00000053228 -4.60 Ceacam3 carcinoembryonic antigen-related cell adhesion molecule 3 
ENSMUSG00000102700 -3.97 Gm38312 predicted gene, 38312 
ENSMUSG00000086050 -3.80 Gm16045 predicted gene 16045 
ENSMUSG00000109116 -3.67 Sycp1-ps1 synaptonemal complex protein 1, pseudogene 1 
ENSMUSG00000074206 -3.66 Adh6b alcohol dehydrogenase 6B (class V) 
ENSMUSG00000031027 -3.66 Stk33 Serine/threonine-protein kinase 33  
ENSMUSG00000034617 -3.64 Mtrr 5-methyltetrahydrofolate-homocysteine methyltransferase reductase 
ENSMUSG00000066760 -3.55 Psg16 pregnancy specific glycoprotein 16 
ENSMUSG00000021439 -3.51 Ctsq cathepsin Q 
ENSMUSG00000073530 -3.44 Pappa2 pappalysin 2 
ENSMUSG00000092624 -3.43 Gm3654 predicted gene 3654 
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ENSMUSG00000047661 -3.42 1600012P17Rik RIKEN cDNA 1600012P17 gene 
ENSMUSG00000033834 -3.36 Tpbpa trophoblast specific protein alpha 
ENSMUSG00000023087 -3.36 Noct Nocturnin  
ENSMUSG00000019775 -3.26 Rgs17 regulator of G-protein signaling 17 
ENSMUSG00000097203 -3.25 4732419C18Rik RIKEN cDNA 4732419C18 gene 
ENSMUSG00000020871 -3.17 Dlx4 Homeobox protein DLX-4  
ENSMUSG00000058152 -3.17 Chsy3 Chondroitin sulfate synthase 3  
ENSMUSG00000035694 -3.16 Caps2 Calcyphosin-2  
ENSMUSG00000058022 -3.14 Adtrp Androgen-dependent TFPI-regulating protein  
ENSMUSG00000034690 -3.04 Nlrp4c NACHT, LRR and PYD domains-containing protein 4C  
ENSMUSG00000027560 -2.96 Dok5 Docking protein 5  
ENSMUSG00000045928 -2.92 4933440M02Rik RIKEN cDNA 4933440M02 gene 
ENSMUSG00000031994 -2.92 Adamts8 A disintegrin and metalloproteinase with thrombospondin motifs 8 isoform 2  
ENSMUSG00000097276 -2.89 4930525G20Rik RIKEN cDNA 4930525G20 gene 
ENSMUSG00000099812 -2.88 Gm28515 predicted gene 28515 
ENSMUSG00000041523 -2.87 Upk2 uroplakin 2 
ENSMUSG00000079476 -2.84 1700011M02Rik RIKEN cDNA 1700011M02 gene 
ENSMUSG00000072721 -2.82 Klra14-ps killer cell lectin-like receptor subfamily A, member 14, pseudogene 
ENSMUSG00000073722 -2.80 4931408C20Rik RIKEN cDNA 4931408C20 gene 
ENSMUSG00000000861 -2.80 Bcl11a B-cell lymphoma/leukemia 11A  
ENSMUSG00000025789 -2.79 St8sia2 Alpha-2,8-sialyltransferase 8B  
ENSMUSG00000103050 -2.75 Gm38273 predicted gene, 38273 
ENSMUSG00000020698 -2.74 Cct6b chaperonin containing Tcp1, subunit 6b (zeta) 
ENSMUSG00000030523 -2.73 Trpm1 Transient receptor potential cation channel subfamily M member 1  
ENSMUSG00000006154 -2.72 Eps8l1 Epidermal growth factor receptor kinase substrate 8-like protein 1  
ENSMUSG00000034645 -2.69 Zyg11a zyg-11 family member A, cell cycle regulator 
ENSMUSG00000030657 -2.64 Xylt1 xylosyltransferase 1 
ENSMUSG00000059898 -2.62 Dsc3 Desmocollin-3  
ENSMUSG00000041794 -2.61 Myrip Rab effector MyRIP  
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ENSMUSG00000072419 -2.60 Dppa2 Developmental pluripotency-associated protein 2  
ENSMUSG00000031972 -2.59 Acta1 Actin, alpha skeletal muscle  
ENSMUSG00000067860 -2.59 Zic3 zinc finger protein of the cerebellum 3 
ENSMUSG00000086552 -2.58 Dlx4os distal-less homeobox 4, opposite strand 
ENSMUSG00000033453 -2.57 Adamts15 A disintegrin and metalloproteinase with thrombospondin motifs 15  
ENSMUSG00000037568 -2.57 Vash2 vasohibin 2 
ENSMUSG00000103840 -2.57 1700040K01Rik RIKEN cDNA 1700040K01 gene 
ENSMUSG00000030607 -2.56 Acan Aggrecan core protein  
ENSMUSG00000092225 -2.55 Gm2381 predicted gene 2381 
ENSMUSG00000073012 -2.55 Fnd3c2 fibronectin type III domain containing 3C2 
ENSMUSG00000022053 -2.50 Ebf2 early B cell factor 2 
ENSMUSG00000034450 -2.49 Gulo gulonolactone (L-) oxidase 
ENSMUSG00000024134 -2.47 Six2 Homeobox protein SIX2  
ENSMUSG00000022900 -2.44 Ildr1 Immunoglobulin-like domain-containing receptor 1  
ENSMUSG00000086631 -2.44 Gm12784 predicted gene 12784 
ENSMUSG00000029878 -2.44 Dbpht2 DNA binding protein with his-thr domain 
ENSMUSG00000056300 -2.43 Zfp981 zinc finger protein 981 
ENSMUSG00000097747 -2.43 Gm26534 predicted gene, 26534 
ENSMUSG00000024935 -2.41 Slc1a1 solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system 
Xag), member 1 
ENSMUSG00000000730 -2.39 Dnmt3l DNA (cytosine-5)-methyltransferase 3-like  
ENSMUSG00000053411 -2.37 Cbx7 Chromobox protein homolog 7  
ENSMUSG00000021347 -2.37 Prl7b1 Prolactin-7B1  
ENSMUSG00000021348 -2.36 Prl7d1 prolactin family 7, subfamily d, member 1 
ENSMUSG00000036168 -2.36 Ccdc38 Coiled-coil domain-containing protein 38  
ENSMUSG00000028354 -2.35 Fmn2 Formin-2  
ENSMUSG00000039079 -2.34 Trhr2 thyrotropin releasing hormone receptor 2 
ENSMUSG00000040569 -2.33 Slc26a7 Anion exchange transporter  
ENSMUSG00000000794 -2.32 Kcnn3 Small conductance calcium-activated potassium channel protein 3  
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ENSMUSG00000022483 -2.29 Col2a1 Collagen alpha-1(II) chain Collagen alpha-1(II) chain Chondrocalcin 
ENSMUSG00000020701 -2.29 Tmem132e transmembrane protein 132E 
ENSMUSG00000005947 -2.28 Itgae integrin alpha E, epithelial-associated 
ENSMUSG00000087651 -2.28 1500009L16Rik RIKEN cDNA 1500009L16 gene 
ENSMUSG00000029648 -2.28 Flt1 fms related tyrosine kinase 1 
ENSMUSG00000001661 -2.26 Hoxc6 Homeobox protein Hox-C6  
ENSMUSG00000042340 -2.25 Ctf1 Cardiotrophin-1  
ENSMUSG00000026357 -2.25 Rgs18 regulator of G-protein signaling 18 
ENSMUSG00000068614 -2.24 Actc1 Actin, alpha cardiac muscle 1  
ENSMUSG00000031849 -2.24 Comp Cartilage oligomeric matrix protein  
ENSMUSG00000103685 -2.23 Gm37074 predicted gene, 37074 
ENSMUSG00000069259 -2.22 Prl6a1 prolactin family 6, subfamily a, member 1 
ENSMUSG00000047115 -2.22 Fam221a Protein FAM221A  
ENSMUSG00000030402 -2.21 Ppm1n Probable protein phosphatase 1N  
ENSMUSG00000032224 -2.21 Fam81a Protein FAM81A  
ENSMUSG00000060402 -2.21 Chst8 Carbohydrate sulfotransferase 8  
ENSMUSG00000029369 -2.19 Afm Afamin  
ENSMUSG00000025081 -2.19 Tdrd1 Tudor domain-containing protein 1  
ENSMUSG00000032908 -2.18 Sgpp2 Sphingosine-1-phosphate phosphatase 2  
ENSMUSG00000064194 -2.17 Zfp936 zinc finger protein 936 
ENSMUSG00000029372 -2.17 Ppbp pro-platelet basic protein 
ENSMUSG00000064294 -2.17 Aox3 Aldehyde oxidase 3  
ENSMUSG00000046854 -2.15 Pip5kl1 Phosphatidylinositol 4-phosphate 5-kinase-like protein 1  
ENSMUSG00000028519 -2.15 Dab1 Disabled homolog 1  
ENSMUSG00000102555 -2.15 6430511E19Rik RIKEN cDNA 6430511E19 gene 
ENSMUSG00000070331 -2.14 Qrich2 glutamine rich 2 
ENSMUSG00000092335 -2.13 Zfp977 zinc finger protein 977 
ENSMUSG00000027716 -2.13 Trpc3 transient receptor potential cation channel, subfamily C, member 3 
ENSMUSG00000026443 -2.12 Lrrn2 leucine rich repeat protein 2, neuronal 
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ENSMUSG00000070719 -2.12 Pla2g4d cytosolic phospholipase A2 delta  
ENSMUSG00000069258 -2.11 Prl2b1 prolactin family 2, subfamily b, member 1 
ENSMUSG00000027562 -2.10 Car2 Mus musculus carbonic anhydrase 2 (Car2), transcript variant 2, mRNA. 
ENSMUSG00000019876 -2.10 Pkib cAMP-dependent protein kinase inhibitor beta 
ENSMUSG00000043549 -2.10 Fam90a1b family with sequence similarity 90, member A1B 
ENSMUSG00000066607 -2.10 6030419C18Rik UPF0583   
ENSMUSG00000086924 -2.10 Gm11766 predicted gene 11766 
ENSMUSG00000032015 -2.09 Pou2f3 POU domain, class 2, transcription factor 3 
ENSMUSG00000031790 -2.08 Mmp15 matrix metalloproteinase-15  
ENSMUSG00000062444 -2.07 Ap3b2 AP-3 complex subunit beta-2  
ENSMUSG00000033590 -2.07 Myo5c myosin VC 
ENSMUSG00000033882 -2.07 Rbm46 probable RNA-binding protein 46  
ENSMUSG00000031144 -2.05 Syp Synaptophysin  
ENSMUSG00000056972 -2.05 Magel2 MAGE-like protein 2  
ENSMUSG00000035104 -2.05 Eva1a eva1 homolog A 
ENSMUSG00000043924 -2.05 Ncmap noncompact myelin-associated protein  
ENSMUSG00000038319 -2.04 Kcnh2 potassium voltage-gated channel subfamily H member 2 
ENSMUSG00000021363 -2.04 Mak serine/threonine-protein kinase MAK  
ENSMUSG00000041287 -2.03 Sox15 SRY (sex determining region Y)-box 15 
ENSMUSG00000020908 -2.03 Myh3 myosin-3  
ENSMUSG00000007989 -2.02 Fzd3 frizzled-3  
ENSMUSG00000032034 -2.02 Kcnj5 G protein-activated inward rectifier potassium channel 4  
ENSMUSG00000055679 -2.02 Ctsr cathepsin R 
ENSMUSG00000002266 -2.02 Zim1 zinc finger, imprinted 1 
ENSMUSG00000029452 -2.02 Tmem116 transmembrane protein 116 
ENSMUSG00000045004 -2.01 Spata21 spermatogenesis-associated protein 21  
ENSMUSG00000007594 -2.01 Hapln4 hyaluronan and proteoglycan link protein 4  
ENSMUSG00000028626 -2.01 Col9a2 collagen type IX alpha 2 chain 
ENSMUSG00000027765 -2.01 P2ry1 purinergic receptor P2Y, G-protein coupled 1 
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ENSMUSG00000004542 -2.01 Psg19 pregnancy specific glycoprotein 19 
ENSMUSG00000029646 -2.00 Cdx2 Homeobox protein CDX-2  
ENSMUSG00000021482 2.00 Aaed1 AhpC/TSA antioxidant enzyme domain containing 1 
ENSMUSG00000087168 2.00 Gm15983 predicted gene 15983 
ENSMUSG00000040065 2.01 Pfpl pore forming protein-like 
ENSMUSG00000074575 2.01 Kcng1 potassium voltage-gated channel subfamily G member 1  
ENSMUSG00000053930 2.02 Shisa6 shisa family member 6 
ENSMUSG00000063704 2.02 Mapk15 mitogen-activated protein kinase 15  
ENSMUSG00000039004 2.03 Bmp6 bone morphogenetic protein 6  
ENSMUSG00000079598 2.03 Clec2l C-type lectin domain family 2 member L  
ENSMUSG00000109446 2.04 Gm9195 predicted gene 9195 
ENSMUSG00000058454 2.04 Dhcr7 7-dehydrocholesterol reductase  
ENSMUSG00000049999 2.04 Ppp1r3d protein phosphatase 1 regulatory subunit 3D 
ENSMUSG00000031952 2.04 Chst5 carbohydrate sulfotransferase 5  
ENSMUSG00000021319 2.05 Sfrp4 secreted frizzled-related protein 4 
ENSMUSG00000041577 2.06 Prelp proline arginine-rich end leucine-rich repeat 
ENSMUSG00000002885 2.06 Adgre5 adhesion G protein-coupled receptor E5 
ENSMUSG00000034570 2.06 Inpp5j phosphatidylinositol 4,5-bisphosphate 5-phosphatase A  
ENSMUSG00000055629 2.06 B4galnt4 N-acetyl-beta-glucosaminyl-glycoprotein 4-beta-N-acetylgalactosaminyltransferase 1  
ENSMUSG00000022840 2.06 Adcy5 adenylate cyclase type 5  
ENSMUSG00000035916 2.07 Ptprq phosphatidylinositol phosphatase PTPRQ  
ENSMUSG00000032323 2.07 Cyp11a1 cholesterol side-chain cleavage enzyme, mitochondrial  
ENSMUSG00000034159 2.07 2310007B03Rik Uncharacterized   
ENSMUSG00000044748 2.07 Defb1 beta-defensin 1  
ENSMUSG00000071984 2.08 Fndc1 fibronectin type III domain containing 1 
ENSMUSG00000032023 2.09 Jhy junctional cadherin complex regulator 
ENSMUSG00000036560 2.10 Lgi4 leucine-rich repeat LGI family member 4  
ENSMUSG00000087033 2.10 Gm14155 predicted gene 14155 
ENSMUSG00000026259 2.11 Ngef ephexin-1  
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ENSMUSG00000033595 2.11 Lgi3 leucine-rich repeat LGI family member 3  
ENSMUSG00000020654 2.11 Adcy3 adenylate cyclase type 3  
ENSMUSG00000004558 2.11 Ndrg2 protein NDRG2 Protein NDRG2, N-terminally processed 
ENSMUSG00000034652 2.11 Cd300a Mus musculus CD300A molecule (Cd300a), transcript variant 2, mRNA 
ENSMUSG00000046623 2.11 Gjb4 gap junction protein, beta 4 
ENSMUSG00000079012 2.13 Serpina3m serine protease inhibitor A3M  
ENSMUSG00000035735 2.14 Dagla Sn1-specific diacylglycerol lipase alpha  
ENSMUSG00000032548 2.14 Slco2a1 solute carrier organic anion transporter family, member 2a1 
ENSMUSG00000030084 2.15 Plxna1 plexin-A1  
ENSMUSG00000020017 2.15 Hal histidine ammonia-lyase  
ENSMUSG00000027358 2.15 Bmp2 bone morphotic protein 2  
ENSMUSG00000027513 2.15 Pck1 phosphoenolpyruvate carboxykinase, cytosolic [GTP]  
ENSMUSG00000020953 2.16 Coch cochlin  
ENSMUSG00000039037 2.16 St6galnac5 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide 
alpha-2,6-sialyltransferase 5 
ENSMUSG00000043448 2.18 Gjc2 gap junction protein, gamma 2 
ENSMUSG00000099429 2.18 1600019K03Rik RIKEN cDNA 1600019K03 gene 
ENSMUSG00000028976 2.20 Slc2a5 solute carrier family 2 (facilitated glucose transporter), member 5 
ENSMUSG00000062310 2.21 Glrp1 glutamine repeat protein 1 
ENSMUSG00000019756 2.21 Prl8a1 prolactin family 8, subfamily a, member 1 
ENSMUSG00000056073 2.22 Grik2 glutamate receptor ionotropic, kainate 2  
ENSMUSG00000044177 2.22 Wfikkn2 WAP, follistatin/kazal, immunoglobulin, kunitz and netrin domain containing 2 
ENSMUSG00000076613 2.22 Ighg2b immunoglobulin heavy constant gamma 2B 
ENSMUSG00000015451 2.25 C4a complement component 4A (Rodgers blood group) 
ENSMUSG00000036718 2.26 Micall2 MICAL-like protein 2  
ENSMUSG00000018819 2.31 Lsp1 lymphocyte-specific protein 1  
ENSMUSG00000051243 2.32 Islr2 immunoglobulin superfamily containing leucine-rich repeat protein 2  
ENSMUSG00000029055 2.34 Plch2 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase eta-2  
ENSMUSG00000024912 2.34 Fosl1 Fos-related antigen 1  
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ENSMUSG00000027978 2.34 Prss12 protease, serine 12 neurotrypsin (motopsin) 
ENSMUSG00000054069 2.35 6030452D12Rik RIKEN cDNA 6030452D12 gene 
ENSMUSG00000042734 2.36 Ttc9 tetratricopeptide repeat domain 9 
ENSMUSG00000026420 2.38 Il24 interleukin 24 
ENSMUSG00000090291 2.39 Lrrc10b leucine rich repeat containing 10B 
ENSMUSG00000023885 2.40 Thbs2 thrombospondin-2  
ENSMUSG00000032051 2.41 Fdx1 ferredoxin 1 
ENSMUSG00000040276 2.43 Pacsin1 protein kinase C and casein kinase substrate in neurons protein 1  
ENSMUSG00000090588 2.43 Gm9573 predicted gene 9573 
ENSMUSG00000072601 2.45 Ear1 eosinophil cationic protein 1  
ENSMUSG00000079092 2.45 Prl2c2 prolactin-2C2  
ENSMUSG00000033102 2.47 Cdc14b dual specificity protein phosphatase CDC14B  
ENSMUSG00000050635 2.47 Sprr2f small proline-rich protein 2F 
ENSMUSG00000033765 2.48 Calm4 calmodulin-4  
ENSMUSG00000025475 2.51 Adgra1 adhesion G protein-coupled receptor A1  
ENSMUSG00000031936 2.54 Hephl1 hephaestin-like protein 1  
ENSMUSG00000026204 2.55 Ptprn protein tyrosine phosphatase, receptor type, N 
ENSMUSG00000078995 2.56 Zfp456 zinc finger protein 456 
ENSMUSG00000061540 2.57 Orm2 orosomucoid 2 
ENSMUSG00000033082 2.60 Clec1a C-type lectin domain family 1 member A  
ENSMUSG00000098021 2.62 Gm9522 predicted gene 9522 
ENSMUSG00000022468 2.63 Endou Poly(U)-specific endoribonuclease  
ENSMUSG00000097017 2.64 Gm26707 predicted gene, 26707 
ENSMUSG00000032495 2.66 Lrrc2 leucine rich repeat containing 2 
ENSMUSG00000058755 2.67 Osm oncostatin-M  
ENSMUSG00000021477 2.67 Ctsl cathepsin L 
ENSMUSG00000041193 2.68 Pla2g5 phospholipase A2, group V 
ENSMUSG00000068536 2.68 Doxl2 diamine oxidase-like protein 2 
ENSMUSG00000027376 2.69 Prom2 prominin-2  
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ENSMUSG00000045915 2.72 Ccdc42 coiled-coil domain-containing protein 42  
ENSMUSG00000094590 2.73 Gm10251 predicted gene 10251 
ENSMUSG00000037936 2.74 Scarb1 scavenger receptor class B member 1  
ENSMUSG00000067081 2.76 Asb18 ankyrin repeat and SOCS box protein 18  
ENSMUSG00000108367 2.78 Gm4881 predicted gene 4881 
ENSMUSG00000060985 2.81 Tdrd5 tudor domain-containing protein 5  
ENSMUSG00000027603 2.81 Ggt7 glutathione hydrolase 7 
ENSMUSG00000085651 2.87 Gm11695 predicted gene 11695 
ENSMUSG00000006205 2.89 Htra1 serine protease HTRA1  
ENSMUSG00000026241 2.90 Nppc natriuretic peptide type C 
ENSMUSG00000046203 2.92 Sprr2g small proline-rich protein 2G  
ENSMUSG00000058147 2.95 Xlr3c X-linked lymphocyte-regulated 3C 
ENSMUSG00000095079 2.97 Igha immunoglobulin heavy constant alpha 
ENSMUSG00000045775 2.97 Slc16a5 solute carrier family 16 (monocarboxylic acid transporters), member 5 
ENSMUSG00000021536 2.98 Adcy2 adenylate cyclase 2 
ENSMUSG00000049556 2.99 Lingo1 leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-
interacting protein 1  
ENSMUSG00000031760 3.03 Mt3 metallothionein-3  
ENSMUSG00000032257 3.09 Ankk1 ankyrin repeat and protein kinase domain-containing protein 1  
ENSMUSG00000000049 3.10 Apoh beta-2-glycoprotein 1  
ENSMUSG00000057170 3.16 Prl3d1 prolactin family 3, subfamily d, member 1 
ENSMUSG00000076612 3.25 Ighg2c immunoglobulin heavy constant gamma 2C 
ENSMUSG00000035226 3.28 Rims4 regulating synaptic membrane exocytosis protein 4  
ENSMUSG00000031574 3.30 Star steroidogenic acute regulatory protein, mitochondrial  
ENSMUSG00000046844 3.30 Vat1l vesicle amine transport protein 1 like 
ENSMUSG00000021795 3.33 Sftpd pulmonary surfactant-associated protein D  
ENSMUSG00000038239 3.43 Hrc histidine rich calcium binding protein 
ENSMUSG00000020226 3.46 Slc5a4b solute carrier family 5 (neutral amino acid transporters, system A), member 4b 
ENSMUSG00000021456 3.49 Fbp2 fructose-1,6-bisphosphatase isozyme 2  
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ENSMUSG00000062201 3.74 Prl3d3 prolactin family 3, subfamily d, member 3 
ENSMUSG00000009246 3.78 Trpm5 transient receptor potential cation channel subfamily M member 5  
ENSMUSG00000019359 3.79 Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2, transcript variant 3 
ENSMUSG00000062737 3.91 Prl3d2 prolactin family 3, subfamily d, member 1 
ENSMUSG00000035551 4.48 Igfbpl1 insulin-like growth factor-binding protein-like 1  
ENSMUSG00000055409 4.66 Nell1 protein kinase C-binding protein NELL1  
ENSMUSG00000027869 4.87 Hsd3b6 hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 6 
ENSMUSG00000037334 4.91 H2-M1 histocompatibility 2, M region locus 1 
ENSMUSG00000101026 5.07 D730001G18Rik lymphocyte antigen 6 complex, locus G6G (Ly6g6g) 
ENSMUSG00000062168 5.16 Ppef1 serine/threonine-protein phosphatase with EF-hands 1  
ENSMUSG00000030302 5.53 Atp2b2 plasma membrane calcium-transporting ATPase 2  
ENSMUSG00000105703 5.83 Gm43305 predicted gene 43305 
ENSMUSG00000069805 12.30 Fbp1 fructose-1,6-bisphosphatase 1  
ENSMUSG00000031620 12.59 Iqcm IQ motif containing M 
 
Table C.3 DEGs in placentas of phenotypically normal Mtrrgt/gt conceptuses compared to growth restricted Mtrrgt/gt conceptuses at 
E10.5. 
Mtrrgt/gt PN Vs Mtrrgt/gt GR 





ENSMUSG00000065922 -16.62 n-R5-8s1 nuclear encoded rRNA 5.8S 1 
ENSMUSG00000088088 -7.19 Rmrp RNA component of mitochondrial RNAase P 
ENSMUSG00000092837 -3.85 Rpph1 ribonuclease P RNA component H1 
ENSMUSG00000097971 -3.09 Gm26917 predicted gene, 26917 
ENSMUSG00000069939 -2.97 Gm12070 predicted gene 12070 
ENSMUSG00000085415 -2.86 Selenok-ps1 selenoprotein K, pseudogene 1 
ENSMUSG00000091562 -2.73 Crybg3 beta-gamma crystallin domain containing 3 
ENSMUSG00000098973 -2.42 Mir6236 microRNA 6236 
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ENSMUSG00000060727 -2.39 Gm12571 predicted gene 12571 
ENSMUSG00000094334 -2.36 Fabp5l2 fatty acid binding protein 5-like 2 
ENSMUSG00000082566 -2.35 Gm11485 predicted gene 11485 
ENSMUSG00000003477 -2.29 Inmt indolethylamine N-methyltransferase  
ENSMUSG00000026919 -2.28 Lcn4 lipocalin 4 
ENSMUSG00000095419 -2.27 Gm14328 predicted gene 14328 
ENSMUSG00000072612 -2.25 Gm10382 predicted gene 10382 
ENSMUSG00000081087 -2.19 Rps15a-ps7 ribosomal protein S15A, pseudogene 7 
ENSMUSG00000109408 -2.16 A930037H05Rik RIKEN cDNA A930037H05 gene 
ENSMUSG00000101567 -2.14 Txn-ps1 thioredoxin, pseudogene 1 
ENSMUSG00000092116 -2.12 Gm10320 predicted gene 10320 
ENSMUSG00000104864 -2.11 Gm43655 predicted gene 43655 
ENSMUSG00000020018 -2.08 Snrpf small nuclear ribonucleoprotein polypeptide F 
ENSMUSG00000072940 -2.05 Gm10443 predicted pseudogene 10443 
ENSMUSG00000106926 -2.05 Rpl7-ps7 ribosomal protein L7, pseudogene 7 
ENSMUSG00000027716 2.00 Trpc3 transient receptor potential cation channel, subfamily C, member 3 
ENSMUSG00000021347 2.03 Prl7b1 prolactin-7B1  
ENSMUSG00000073293 2.06 Nudt10 diphosphoinositol polyphosphate phosphohydrolase 3-alpha  
ENSMUSG00000001657 2.08 Hoxc8 homeobox protein Hox-C8  
ENSMUSG00000074817 2.09 Papolb poly(A) polymerase beta 
ENSMUSG00000029878 2.09 Dbpht2 DNA binding protein with his-thr domain 
ENSMUSG00000100826 2.10 Snhg14 small nucleolar RNA host gene 14 
ENSMUSG00000010592 2.15 Dazl deleted in azoospermia-like  
ENSMUSG00000067860 2.18 Zic3 zinc finger protein of the cerebellum 3 
ENSMUSG00000091955 2.19 Gm9844 predicted pseudogene 9844 
ENSMUSG00000096929 2.22 A330023F24Rik RIKEN cDNA A330023F24 gene 
ENSMUSG00000036168 2.24 Ccdc38 coiled-coil domain-containing protein 38  
ENSMUSG00000031027 2.36 Stk33 serine/threonine-protein kinase 33  
ENSMUSG00000075324 2.49 Fign fidgetin  
ENSMUSG00000040167 2.60 Ikzf5 zinc finger protein Pegasus  
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ENSMUSG00000099812 2.64 Gm28515 predicted gene 28515 
ENSMUSG00000046899 2.73 Prl7a2 prolactin family 7, subfamily a, member 2 
ENSMUSG00000046942 2.74 Mageb16 melanoma-associated antigen B16  
ENSMUSG00000021345 2.75 Prl8a6 prolactin family 8, subfamily a, member 6 
ENSMUSG00000072978 2.96 Gm5830 predicted pseudogene 5830 
ENSMUSG00000109116 3.17 Sycp1-ps1 synaptonemal complex protein 1, pseudogene 1 
 
Table C.4 DEGs in placentas of growth enhanced F2 Mtrr+/+ conceptuses compared to C57Bl/6 placentas at E10.5. 
C57Bl/6 Vs F2 Mtrr+/+ GE 
Gene ID Fold change Gene abbreviation Gene name 
ENSMUSG00000040264 -7.06 Gbp2b guanylate binding protein 2b 
 
Table C.5 DEGs in placentas of growth enhanced F2 Mtrr+/+ conceptuses compared to placentas of phenotypically normal F2 Mtrr+/+ 
conceptuses E10.5. 
F2 Mtrr+/+ PN Vs F2 Mtrr+/+ GE 
Gene ID Fold change Gene abbreviation Gene name 
ENSMUSG00000057897 2.06 Camk2b calcium/calmodulin-dependent protein kinase II, beta 
 
Table C.6 DEGs in placentas of growth enhanced F2 Mtrr+/+ conceptuses compared to C57Bl/6 placentas at E10.5 after embryo 
transfer. 
C57Bl/6 transferred Vs F2 Mtrr+/+ GE transferred 
Gene ID Fold change Gene abbreviation Gene name 
ENSMUSG00000021346 9.17 Prl8a8 prolactin family 8, subfamily a, member 81 
ENSMUSG00000006490 3.88 Prl8a9 prolactin family8, subfamily a, member 9 
ENSMUSG00000004542 2.93 Psg19 pregnancy specific glycoprotein 19 
ENSMUSG00000027386 2.80 Fbln7 fibulin 7 
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ENSMUSG00000091764 2.30 Zfp964 zinc finger protein 964 
ENSMUSG00000074277 2.10 Phldb3 pleckstrin homology like domain, family B, member 3 
 
Table C.7 DEGs in placentas of C57Bl/6 conceptuses at E10.5 after embryo transfer. 
C57Bl/6 Vs C57Bl/6 transferred 
Gene ID Fold 
change 
Gene abbreviation Gene name 
ENSMUSG00000073177 -40.97 Gm773 predicted gene 773 
ENSMUSG00000072844 -14.49 G530011O06Rik RIKEN cDNA G530011O06 gene 
ENSMUSG00000009292 -10.10 Trpm2 transient receptor potential cation channel, subfamily M, member 2 
ENSMUSG00000030325 -9.71 Klrb1c killer cell lectin-like receptor subfamily B member 1C 
ENSMUSG00000019102 -9.29 Aldh3a1 aldehyde dehydrogenase family 3, subfamily A1 
ENSMUSG00000090015 -9.00 Gm15446 predicted gene 15446 
ENSMUSG00000079852 -8.83 Klra4 killer cell lectin-like receptor, subfamily A, member 4 
ENSMUSG00000072721 -8.07 Klra14-ps killer cell lectin-like receptor subfamily A, member 14, pseudogene 
ENSMUSG00000090710 -7.90 Gm9513 predicted gene 9513 
ENSMUSG00000023093 -7.67 Gm7257 predicted gene 7257 
ENSMUSG00000062310 -7.40 Glrp1 glutamine repeat protein 1 
ENSMUSG00000090709 -7.09 Gm17173 predicted gene 17173 
ENSMUSG00000089727 -6.82 Klra8 killer cell lectin-like receptor, subfamily A, member 8 
ENSMUSG00000020702 -6.81 Ccl1 chemokine (C-C motif) ligand 1 
ENSMUSG00000071489 -6.18 Ptgdr prostaglandin D receptor 
ENSMUSG00000067750 -5.97 Khdc1a KH domain containing 1A 
ENSMUSG00000085391 -5.95 Gm16150 predicted gene 16150 
ENSMUSG00000073294 -5.63 AU022751 expressed sequence AU022751 
ENSMUSG00000067599 -5.59 Klra7 killer cell lectin-like receptor, subfamily A, member 7 
ENSMUSG00000026011 -5.52 Ctla4 cytotoxic T-lymphocyte-associated protein 4 
ENSMUSG00000006056 -5.19 Calcoco2 calcium binding and coiled-coil domain 2 
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ENSMUSG00000079071 -5.15 Gm14085 predicted gene 14085 
ENSMUSG00000010592 -4.96 Dazl deleted in azoospermia-like 
ENSMUSG00000087263 -4.86 Gm15726 predicted gene 15726 
ENSMUSG00000073010 -4.69 Gm5127 predicted gene 5127 
ENSMUSG00000086695 -4.63 Gm15247 predicted gene 15247 
ENSMUSG00000026358 -4.34 Rgs1 regulator of G-protein signalling 1 
ENSMUSG00000079105 -4.09 C7 complement component 7 
ENSMUSG00000024155 -4.07 Meiob meiosis specific with OB domains 
ENSMUSG00000047884 -4.07 Klk9 kallikrein related-peptidase 9 
ENSMUSG00000024810 -4.04 Il33 interleukin 33 
ENSMUSG00000031654 -3.95 Cbln1 cerebellin 1 precursor protein 
ENSMUSG00000066677 -3.95 Ifi208 interferon activated gene 208 
ENSMUSG00000030345 -3.93 Dyrk4 dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 4 
ENSMUSG00000042816 -3.90 Gpr151 G protein-coupled receptor 151 
ENSMUSG00000056025 -3.90 Clca3a1 chloride channel accessory 3A1 
ENSMUSG00000046167 -3.77 Gldn gliomedin 
ENSMUSG00000020469 -3.71 Myl7 myosin, light polypeptide 7, regulatory 
ENSMUSG00000056290 -3.71 Ms4a4b membrane-spanning 4-domains, subfamily A, member 4B 
ENSMUSG00000051212 -3.60 Gpr183 G protein-coupled receptor 183 
ENSMUSG00000068536 -3.59 Doxl2 diamine oxidase-like protein 2 
ENSMUSG00000050921 -3.55 P2ry10 purinergic receptor P2Y, G-protein coupled 10 
ENSMUSG00000087066 -3.52 Gm15518 predicted gene 15518 
ENSMUSG00000040950 -3.49 Mgl2 macrophage galactose N-acetyl-galactosamine specific lectin 2 
ENSMUSG00000107985 -3.33 Gm35037 predicted gene, 35037 
ENSMUSG00000041309 -3.29 Nkx6-2 NK6 homeobox 2 
ENSMUSG00000079298 -3.27 Klrb1b killer cell lectin-like receptor subfamily B member 1B 
ENSMUSG00000064023 -3.25 Klk8 kallikrein related-peptidase 8 
ENSMUSG00000103899 -3.22 Gm37940 predicted gene, 37940 
ENSMUSG00000042671 -3.10 Rgs8 regulator of G-protein signalling 8 
354 
 
ENSMUSG00000025400 -3.09 Tac2 tachykinin 2 
ENSMUSG00000093446 -3.07 Gm20694 predicted gene 20694 
ENSMUSG00000084826 -3.05 AI847159 expressed sequence AI847159 
ENSMUSG00000030365 -3.02 Clec2i C-type lectin domain family 2, member i 
ENSMUSG00000020599 -3.01 Rgs9 regulator of G-protein signalling 9 
ENSMUSG00000074635 -3.01 3110070M22Rik RIKEN cDNA 3110070M22 gene 
ENSMUSG00000060445 -3.00 Sycp2 synaptonemal complex protein 2 
ENSMUSG00000019935 -3.00 Slc17a8 solute carrier family 17 (sodium-dependent inorganic phosphate cotransporter), 
member 8 
ENSMUSG00000064137 -2.97 Rhox8 reproductive homeobox 8 
ENSMUSG00000076867 -2.96 Trdv4 T cell receptor delta variable 4 
ENSMUSG00000090272 -2.96 Mndal myeloid nuclear differentiation antigen like 
ENSMUSG00000040065 -2.95 Pfpl pore forming protein-like 
ENSMUSG00000040280 -2.93 Ndufa4l2 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 
ENSMUSG00000019756 -2.89 Prl8a1 prolactin family 8, subfamily a, member 1 
ENSMUSG00000080783 -2.89 Gm8250 predicted gene 8250 
ENSMUSG00000030178 -2.87 Klra13-ps killer cell lectin-like receptor subfamily A, member 13, pseudogene 
ENSMUSG00000070063 -2.87 Snora33 small nucleolar RNA, H/ACA box 33 
ENSMUSG00000022863 -2.86 Btg3 B cell translocation gene 3 
ENSMUSG00000006488 -2.85 Prl7a1 prolactin family 7, subfamily a, member 1 
ENSMUSG00000010796 -2.85 Asz1 ankyrin repeat, SAM and basic leucine zipper domain containing 1 
ENSMUSG00000019301 -2.85 Hsd17b1 hydroxysteroid (17-beta) dehydrogenase 1 
ENSMUSG00000025491 -2.83 Ifitm1 interferon induced transmembrane protein 1 
ENSMUSG00000032021 -2.83 Crtam cytotoxic and regulatory T cell molecule 
ENSMUSG00000103175 -2.83 Gm37169 predicted gene, 37169 
ENSMUSG00000044117 -2.82 2900011O08Rik RIKEN cDNA 2900011O08 gene 
ENSMUSG00000070111 -2.81 Gm10286 predicted gene 10286 
ENSMUSG00000109293 -2.81 Dcst2 DC-STAMP domain containing 2 
ENSMUSG00000107385 -2.80 C330024D21Rik RIKEN cDNA C330024D21 gene 
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ENSMUSG00000054951 -2.76 9130008F23Rik RIKEN cDNA 9130008F23 gene 
ENSMUSG00000018893 -2.75 Mb myoglobin 
ENSMUSG00000024032 -2.75 Tff1 trefoil factor 1 
ENSMUSG00000020279 -2.73 Il9r interleukin 9 receptor 
ENSMUSG00000046908 -2.71 Ltb4r1 leukotriene B4 receptor 1 
ENSMUSG00000079355 -2.71 Ackr4 atypical chemokine receptor 4 
ENSMUSG00000030165 -2.71 Klrd1 killer cell lectin-like receptor, subfamily D, member 1 
ENSMUSG00000032356 -2.70 Rasgrf1 RAS protein-specific guanine nucleotide-releasing factor 1 
ENSMUSG00000103731 -2.70 Gm17530 predicted gene, 17530 
ENSMUSG00000073491 -2.70 Ifi213 interferon activated gene 213 
ENSMUSG00000020963 -2.66 Tshr thyroid stimulating hormone receptor 
ENSMUSG00000048329 -2.65 Mfsd6l major facilitator superfamily domain containing 6-like 
ENSMUSG00000079652 -2.65 Fam71f2 family with sequence similarity 71, member F2 
ENSMUSG00000034990 -2.63 Otoa otoancorin 
ENSMUSG00000050241 -2.63 Klre1 killer cell lectin-like receptor family E member 1 
ENSMUSG00000005045 -2.63 Chd5 chromodomain helicase DNA binding protein 5 
ENSMUSG00000023206 -2.63 Il15ra interleukin 15 receptor, alpha chain 
ENSMUSG00000015476 -2.62 Prrt1 proline-rich transmembrane protein 1 
ENSMUSG00000075042 -2.59 4930431P03Rik RIKEN cDNA 4930431P03 gene 
ENSMUSG00000027082 -2.57 Tfpi tissue factor pathway inhibitor 
ENSMUSG00000002500 -2.57 Rpl3l ribosomal protein L3-like 
ENSMUSG00000026156 -2.55 B3gat2 beta-1,3-glucuronyltransferase 2 (glucuronosyltransferase S) 
ENSMUSG00000031845 -2.55 Bco1 beta-carotene oxygenase 1 
ENSMUSG00000026919 -2.54 Lcn4 lipocalin 4 
ENSMUSG00000041831 -2.53 Sytl3 synaptotagmin-like 3 
ENSMUSG00000021594 -2.52 Srd5a1 steroid 5 alpha-reductase 1 
ENSMUSG00000063458 -2.45 Lrmda leucine rich melanocyte differentiation associated 
ENSMUSG00000066684 -2.45 Pilrb1 paired immunoglobin-like type 2 receptor beta 1 
ENSMUSG00000035105 -2.45 Egln3 egl-9 family hypoxia-inducible factor 3 
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ENSMUSG00000077734 -2.43 Snord83b small nucleolar RNA, C/D box 83B 
ENSMUSG00000005883 -2.42 Spo11 SPO11 meiotic protein covalently bound to DSB 
ENSMUSG00000029005 -2.40 Draxin dorsal inhibitory axon guidance protein 
ENSMUSG00000078795 -2.39 Ceacam15 carcinoembryonic antigen-related cell adhesion molecule 15 
ENSMUSG00000060913 -2.37 Trim55 tripartite motif-containing 55 
ENSMUSG00000002204 -2.36 Napsa napsin A aspartic peptidase 
ENSMUSG00000097433 -2.36 Gm26781 predicted gene, 26781 
ENSMUSG00000103034 -2.36 Gm8797 predicted pseudogene 8797 
ENSMUSG00000042638 -2.34 Gucy2c guanylate cyclase 2c 
ENSMUSG00000028072 -2.32 Ntrk1 neurotrophic tyrosine kinase, receptor, type 1 
ENSMUSG00000044285 -2.31 Gm1821 predicted gene 1821 
ENSMUSG00000001520 -2.31 Nrip2 nuclear receptor interacting protein 2 
ENSMUSG00000087259 -2.30 2610035D17Rik RIKEN cDNA 2610035D17 gene 
ENSMUSG00000051499 -2.30 Zfp786 zinc finger protein 786 
ENSMUSG00000022818 -2.30 Cyp2ab1 cytochrome P450, family 2, subfamily ab, polypeptide 1 
ENSMUSG00000039492 -2.29 Ccdc27 coiled-coil domain containing 27 
ENSMUSG00000027238 -2.28 Frmd5 FERM domain containing 5 
ENSMUSG00000053101 -2.27 Gpr141 G protein-coupled receptor 141 
ENSMUSG00000035299 -2.27 Mid1 midline 1 
ENSMUSG00000079092 -2.27 Prl2c2 prolactin family 2, subfamily c, member 2 
ENSMUSG00000010021 -2.25 Kif19a kinesin family member 19A 
ENSMUSG00000044162 -2.25 Tnip3 TNFAIP3 interacting protein 3 
ENSMUSG00000025213 -2.25 Kazald1 Kazal-type serine peptidase inhibitor domain 1 
ENSMUSG00000032487 -2.25 Ptgs2 prostaglandin-endoperoxide synthase 2 
ENSMUSG00000015443 -2.23 Gzmn granzyme N 
ENSMUSG00000020256 -2.21 Aldh1l2 aldehyde dehydrogenase 1 family, member L2 
ENSMUSG00000092187 -2.21 Gm20457 predicted gene 20457 
ENSMUSG00000098024 -2.21 Gm27003 predicted gene, 27003 
ENSMUSG00000107458 -2.20 Gm44040 predicted gene, 44040 
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ENSMUSG00000054003 -2.19 Tdrd9 tudor domain containing 9 
ENSMUSG00000032899 -2.19 Styk1 serine/threonine/tyrosine kinase 1 
ENSMUSG00000020310 -2.19 Madcam1 mucosal vascular addressin cell adhesion molecule 1 
ENSMUSG00000042213 -2.19 Zfand4 zinc finger, AN1-type domain 4 
ENSMUSG00000015437 -2.18 Gzmb granzyme B 
ENSMUSG00000078942 -2.17 Naip6 NLR family, apoptosis inhibitory protein 6 
ENSMUSG00000040747 -2.17 Cd53 CD53 antigen 
ENSMUSG00000086938 -2.16 4930481A15Rik RIKEN cDNA 4930481A15 gene 
ENSMUSG00000086652 -2.15 Gm14029 predicted gene 14029 
ENSMUSG00000054203 -2.15 Ifi205 interferon activated gene 205 
ENSMUSG00000066258 -2.14 Trim12a tripartite motif-containing 12A 
ENSMUSG00000107227 -2.14 Gm42559 predicted gene 42559 
ENSMUSG00000030156 -2.13 Cd69 CD69 antigen 
ENSMUSG00000026786 -2.13 Apbb1ip amyloid beta (A4) precursor protein-binding, family B, member 1 interacting protein 
ENSMUSG00000035551 -2.13 Igfbpl1 insulin-like growth factor binding protein-like 1 
ENSMUSG00000079056 -2.11 Kcnip3 Kv channel interacting protein 3, calsenilin 
ENSMUSG00000074264 -2.11 Amy1 amylase 1, salivary 
ENSMUSG00000054293 -2.10 A630033H20Rik RIKEN cDNA A630033H20 gene 
ENSMUSG00000000223 -2.10 Drp2 dystrophin related protein 2 
ENSMUSG00000083226 -2.10 Gm7831 predicted gene 7831 
ENSMUSG00000094845 -2.10 Tmem95 transmembrane protein 95 
ENSMUSG00000086474 -2.10 9130204K15Rik RIKEN cDNA 9130204K15 gene 
ENSMUSG00000102609 -2.10 Gm18432 predicted gene, 18432 
ENSMUSG00000029026 -2.09 Trp73 transformation related protein 73 
ENSMUSG00000091575 -2.07 2010016I18Rik RIKEN cDNA 2010016I18 gene 
ENSMUSG00000049517 -2.06 Rps23 ribosomal protein S23 
ENSMUSG00000086264 -2.06 Gm15850 predicted gene 15850 
ENSMUSG00000071716 -2.05 Apol7e apolipoprotein L 7e 
ENSMUSG00000007216 -2.05 Zfp775 zinc finger protein 775 
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ENSMUSG00000105814 -2.05 Mir703 microRNA 703 
ENSMUSG00000076434 -2.05 Wfdc3 WAP four-disulfide core domain 3 
ENSMUSG00000057596 -2.04 Trim30d tripartite motif-containing 30D 
ENSMUSG00000004707 -2.04 Ly9 lymphocyte antigen 9 
ENSMUSG00000058755 -2.04 Osm oncostatin M 
ENSMUSG00000030098 -2.04 Grip2 glutamate receptor interacting protein 2 
ENSMUSG00000057132 -2.04 Rpgrip1 retinitis pigmentosa GTPase regulator interacting protein 1 
ENSMUSG00000075334 -2.03 Rprm reprimo, TP53 dependent G2 arrest mediator candidate 
ENSMUSG00000030303 -2.03 Far2 fatty acyl CoA reductase 2 
ENSMUSG00000027219 -2.03 Slc28a2 solute carrier family 28 (sodium-coupled nucleoside transporter), member 2 
ENSMUSG00000101970 -2.03 1810026B05Rik RIKEN cDNA 1810026B05 gene 
ENSMUSG00000029055 -2.03 Plch2 phospholipase C, eta 2 
ENSMUSG00000027794 -2.03 Sohlh2 spermatogenesis and oogenesis specific basic helix-loop-helix 2 
ENSMUSG00000028931 -2.02 Kcnab2 potassium voltage-gated channel, shaker-related subfamily, beta member 2 
ENSMUSG00000057170 -2.02 Prl3d1 prolactin family 3, subfamily d, member 1 
ENSMUSG00000004791 -2.02 Pgf placental growth factor 
ENSMUSG00000063383 -2.02 Zfp947 zinc finger protein 947 
ENSMUSG00000036570 -2.02 Fxyd1 FXYD domain-containing ion transport regulator 1 
ENSMUSG00000084899 -2.02 Gm15344 predicted gene 15344 
ENSMUSG00000042345 -2.01 Ubash3a ubiquitin associated and SH3 domain containing, A 
ENSMUSG00000038094 -2.01 Atp13a4 ATPase type 13A4 
ENSMUSG00000060441 -2.01 Trim5 tripartite motif-containing 5 
ENSMUSG00000090110 -2.00 Cmc4 C-x(9)-C motif containing 4 
ENSMUSG00000076490 -2.00 Trbc1 T cell receptor beta, constant region 1 
ENSMUSG00000043518 2.00 Rai2 retinoic acid induced 2 
ENSMUSG00000028518 2.00 Prkaa2 protein kinase, AMP-activated, alpha 2 catalytic subunit 
ENSMUSG00000042115 2.00 Klhdc8a kelch domain containing 8A 
ENSMUSG00000056133 2.00 Gm9992 predicted gene 9992 
ENSMUSG00000023000 2.00 Dhh desert hedgehog 
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ENSMUSG00000022949 2.00 Clic6 chloride intracellular channel 6 
ENSMUSG00000069814 2.01 Ccdc92b coiled-coil domain containing 92B 
ENSMUSG00000030020 2.01 Prickle2 prickle planar cell polarity protein 2 
ENSMUSG00000040907 2.02 Atp1a3 ATPase, Na+/K+ transporting, alpha 3 polypeptide 
ENSMUSG00000083282 2.02 Ctsf cathepsin F 
ENSMUSG00000091269 2.02 Gm6682 predicted gene 6682 
ENSMUSG00000027403 2.02 Tgm6 transglutaminase 6 
ENSMUSG00000031841 2.03 Cdh13 cadherin 13 
ENSMUSG00000006574 2.03 Slc4a1 solute carrier family 4 (anion exchanger), member 1 
ENSMUSG00000033207 2.03 Mamdc2 MAM domain containing 2 
ENSMUSG00000004730 2.03 Adgre1 adhesion G protein-coupled receptor E1 
ENSMUSG00000027175 2.03 Tcp11l1 t-complex 11 like 1 
ENSMUSG00000021278 2.04 Amn amnionless 
ENSMUSG00000074093 2.04 Svip small VCP/p97-interacting protein 
ENSMUSG00000084304 2.05 Gm6142 predicted pseudogene 6142 
ENSMUSG00000074676 2.05 Foxs1 forkhead box S1 
ENSMUSG00000107810 2.05 Gm18609 predicted gene, 18609 
ENSMUSG00000046844 2.06 Vat1l vesicle amine transport protein 1 like 
ENSMUSG00000021127 2.06 Zfp36l1 zinc finger protein 36, C3H type-like 1 
ENSMUSG00000034910 2.06 Pygo1 pygopus 1 
ENSMUSG00000055413 2.06 H2-Q5 histocompatibility 2, Q region locus 5 
ENSMUSG00000020019 2.07 Ntn4 netrin 4 
ENSMUSG00000105461 2.07 Gm4742 predicted gene 4742 
ENSMUSG00000033420 2.07 Antxr1 anthrax toxin receptor 1 
ENSMUSG00000000216 2.08 Scnn1g sodium channel, nonvoltage-gated 1 gamma 
ENSMUSG00000107317 2.08 Gm19719 predicted gene, 19719 
ENSMUSG00000072941 2.08 Sod3 superoxide dismutase 3, extracellular 
ENSMUSG00000079419 2.09 Ms4a6c membrane-spanning 4-domains, subfamily A, member 6C 
ENSMUSG00000073412 2.09 Lst1 leukocyte specific transcript 1 
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ENSMUSG00000024391 2.09 Apom apolipoprotein M 
ENSMUSG00000020431 2.09 Adcy1 adenylate cyclase 1 
ENSMUSG00000090622 2.09 A930033H14Rik RIKEN cDNA A930033H14 gene 
ENSMUSG00000020607 2.09 Fam84a family with sequence similarity 84, member A 
ENSMUSG00000082292 2.10 Gm12250 predicted gene 12250 
ENSMUSG00000076258 2.11 Gm23935 predicted gene, 23935 
ENSMUSG00000012428 2.11 Steap4 STEAP family member 4 
ENSMUSG00000028834 2.11 Trim63 tripartite motif-containing 63 
ENSMUSG00000099375 2.12 Gm28187 predicted gene 28187 
ENSMUSG00000036040 2.12 Adamtsl2 ADAMTS-like 2 
ENSMUSG00000026880 2.12 Stom stomatin 
ENSMUSG00000004562 2.13 Arhgef40 Rho guanine nucleotide exchange factor (GEF) 40 
ENSMUSG00000027777 2.13 Schip1 schwannomin interacting protein 1 
ENSMUSG00000028860 2.13 Sytl1 synaptotagmin-like 1 
ENSMUSG00000062588 2.13 Gm6104 predicted gene 6104 
ENSMUSG00000061451 2.13 Tmem151a transmembrane protein 151A 
ENSMUSG00000020614 2.13 Fam20a family with sequence similarity 20, member A 
ENSMUSG00000020704 2.14 Asic2 acid-sensing (proton-gated) ion channel 2 
ENSMUSG00000023064 2.14 Sncg synuclein, gamma 
ENSMUSG00000022763 2.14 Aifm3 apoptosis-inducing factor, mitochondrion-associated 3 
ENSMUSG00000062515 2.15 Fabp4 fatty acid binding protein 4, adipocyte 
ENSMUSG00000040152 2.15 Thbs1 thrombospondin 1 
ENSMUSG00000063727 2.17 Tnfrsf11b tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 
ENSMUSG00000027908 2.18 Tchhl1 trichohyalin-like 1 
ENSMUSG00000074071 2.18 Fam169b family with sequence similarity 169, member B 
ENSMUSG00000061436 2.19 Hipk2 homeodomain interacting protein kinase 2 
ENSMUSG00000028825 2.19 Rhd Rh blood group, D antigen 
ENSMUSG00000006777 2.19 Krt23 keratin 23 
ENSMUSG00000096780 2.19 Tmem181b-ps transmembrane protein 181B, pseudogene 
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ENSMUSG00000003273 2.20 Car11 carbonic anhydrase 11 
ENSMUSG00000028024 2.20 Enpep glutamyl aminopeptidase 
ENSMUSG00000030208 2.20 Emp1 epithelial membrane protein 1 
ENSMUSG00000037624 2.21 Kcnk2 potassium channel, subfamily K, member 2 
ENSMUSG00000072115 2.21 Ang angiogenin, ribonuclease, RNase A family, 5 
ENSMUSG00000030134 2.21 Rasgef1a RasGEF domain family, member 1A 
ENSMUSG00000025867 2.21 Cplx2 complexin 2 
ENSMUSG00000017446 2.21 C1qtnf1 C1q and tumor necrosis factor related protein 1 
ENSMUSG00000020053 2.23 Igf1 insulin-like growth factor 1 
ENSMUSG00000034040 2.23 Galnt17 polypeptide N-acetylgalactosaminyltransferase 17 
ENSMUSG00000030532 2.24 Hddc3 HD domain containing 3 
ENSMUSG00000020411 2.24 Nipal4 NIPA-like domain containing 4 
ENSMUSG00000021003 2.24 Galc galactosylceramidase 
ENSMUSG00000019990 2.26 Pde7b phosphodiesterase 7B 
ENSMUSG00000022012 2.26 Enox1 ecto-NOX disulfide-thiol exchanger 1 
ENSMUSG00000063696 2.26 Gm8730 predicted pseudogene 8730 
ENSMUSG00000039601 2.27 Rcan2 regulator of calcineurin 2 
ENSMUSG00000026080 2.27 Chst10 carbohydrate sulfotransferase 10 
ENSMUSG00000032496 2.28 Ltf lactotransferrin 
ENSMUSG00000050397 2.28 Foxl2 forkhead box L2 
ENSMUSG00000036800 2.28 Fam135b family with sequence similarity 135, member B 
ENSMUSG00000025006 2.28 Sorbs1 sorbin and SH3 domain containing 1 
ENSMUSG00000029123 2.28 Stk32b serine/threonine kinase 32B 
ENSMUSG00000071984 2.29 Fndc1 fibronectin type III domain containing 1 
ENSMUSG00000047230 2.29 Cldn2 claudin 2 
ENSMUSG00000104063 2.29 Pcdhgb7 protocadherin gamma subfamily B, 7 
ENSMUSG00000026676 2.29 Ccdc3 coiled-coil domain containing 3 
ENSMUSG00000028158 2.30 Mttp microsomal triglyceride transfer protein 
ENSMUSG00000052387 2.31 Trpm3 transient receptor potential cation channel, subfamily M, member 3 
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ENSMUSG00000031530 2.31 Dusp4 dual specificity phosphatase 4 
ENSMUSG00000053897 2.31 Slc39a8 solute carrier family 39 (metal ion transporter), member 8 
ENSMUSG00000074217 2.31 2210011C24Rik RIKEN cDNA 2210011C24 gene 
ENSMUSG00000056427 2.32 Slit3 slit homolog 3 (Drosophila) 
ENSMUSG00000004655 2.32 Aqp1 aquaporin 1 
ENSMUSG00000004885 2.32 Crabp2 cellular retinoic acid binding protein II 
ENSMUSG00000060459 2.32 Kng2 kininogen 2 
ENSMUSG00000042351 2.32 Grap2 GRB2-related adaptor protein 2 
ENSMUSG00000035000 2.32 Dpp4 dipeptidylpeptidase 4 
ENSMUSG00000001281 2.34 Itgb7 integrin beta 7 
ENSMUSG00000014602 2.34 Kif1a kinesin family member 1A 
ENSMUSG00000032262 2.34 Elovl4 elongation of very long chain fatty acids (FEN1/Elo2, SUR4/Elo3, yeast)-like 4 
ENSMUSG00000081126 2.36 Gm15784 predicted gene 15784 
ENSMUSG00000073791 2.36 Efcab7 EF-hand calcium binding domain 7 
ENSMUSG00000087150 2.37 BC064078 cDNA sequence BC064078 
ENSMUSG00000031775 2.37 Pllp plasma membrane proteolipid 
ENSMUSG00000036885 2.37 Arhgef26 Rho guanine nucleotide exchange factor (GEF) 26 
ENSMUSG00000027204 2.38 Fbn1 fibrillin 1 
ENSMUSG00000038156 2.39 Spon1 spondin 1, (f-spondin) extracellular matrix protein 
ENSMUSG00000003418 2.40 St8sia6 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 6 
ENSMUSG00000042532 2.41 Golga7b golgi autoantigen, golgin subfamily a, 7B 
ENSMUSG00000017817 2.42 Jph2 junctophilin 2 
ENSMUSG00000000142 2.43 Axin2 axin 2 
ENSMUSG00000066553 2.43 Gm6969 predicted pseudogene 6969 
ENSMUSG00000053957 2.44 Gm12474 predicted gene 12474 
ENSMUSG00000036446 2.45 Lum lumican 
ENSMUSG00000047473 2.46 Zfp30 zinc finger protein 30 
ENSMUSG00000032641 2.46 Gpr19 G protein-coupled receptor 19 
ENSMUSG00000017002 2.47 Slpi secretory leukocyte peptidase inhibitor 
363 
 
ENSMUSG00000022425 2.48 Enpp2 ectonucleotide pyrophosphatase/phosphodiesterase 2 
ENSMUSG00000003477 2.48 Inmt indolethylamine N-methyltransferase 
ENSMUSG00000072571 2.48 Tmem253 transmembrane protein 253 
ENSMUSG00000056771 2.48 Gm10010 predicted gene 10010 
ENSMUSG00000106664 2.49 Gm17936 predicted gene, 17936 
ENSMUSG00000052504 2.49 Epha3 Eph receptor A3 
ENSMUSG00000082566 2.49 Gm11485 predicted gene 11485 
ENSMUSG00000032889 2.50 Gm6685 predicted pseudogene 6685 
ENSMUSG00000031189 2.51 Aff2 AF4/FMR2 family, member 2 
ENSMUSG00000028883 2.51 Sema3a sema domain, immunoglobulin domain (Ig), short basic domain, secreted, 
(semaphorin) 3A 
ENSMUSG00000078605 2.52 E030025P04Rik RIKEN cDNA E030025P04 gene 
ENSMUSG00000103144 2.52 Pcdhga1 protocadherin gamma subfamily A, 1 
ENSMUSG00000097993 2.53 Ptprv protein tyrosine phosphatase, receptor type, V 
ENSMUSG00000065503 2.55 Mir351 microRNA 351 
ENSMUSG00000004113 2.56 Cacna1b calcium channel, voltage-dependent, N type, alpha 1B subunit 
ENSMUSG00000033268 2.56 Duox1 dual oxidase 1 
ENSMUSG00000027737 2.57 Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 
ENSMUSG00000020080 2.57 Hkdc1 hexokinase domain containing 1 
ENSMUSG00000040613 2.58 Apobec1 apolipoprotein B mRNA editing enzyme, catalytic polypeptide 1 
ENSMUSG00000032338 2.58 Hcn4 hyperpolarization-activated, cyclic nucleotide-gated K+ 4 
ENSMUSG00000090394 2.59 4930523C07Rik RIKEN cDNA 4930523C07 gene 
ENSMUSG00000043259 2.60 Fam13c family with sequence similarity 13, member C 
ENSMUSG00000015957 2.60 Wnt11 wingless-type MMTV integration site family, member 11 
ENSMUSG00000027359 2.60 Slc27a2 solute carrier family 27 (fatty acid transporter), member 2 
ENSMUSG00000020173 2.61 Cobl cordon-bleu WH2 repeat 
ENSMUSG00000041301 2.62 Cftr cystic fibrosis transmembrane conductance regulator 
ENSMUSG00000003617 2.63 Cp ceruloplasmin 
ENSMUSG00000083186 2.65 Gm11805 predicted gene 11805 
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ENSMUSG00000032425 2.65 Zfp949 zinc finger protein 949 
ENSMUSG00000017950 2.66 Hnf4a hepatic nuclear factor 4, alpha 
ENSMUSG00000085666 2.67 Gm9855 predicted pseudogene 9855 
ENSMUSG00000073643 2.67 Wdfy1 WD repeat and FYVE domain containing 1 
ENSMUSG00000030834 2.68 Abcc6 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 
ENSMUSG00000023885 2.69 Thbs2 thrombospondin 2 
ENSMUSG00000053835 2.69 H2-T24 histocompatibility 2, T region locus 24 
ENSMUSG00000002033 2.71 Cd3g CD3 antigen, gamma polypeptide 
ENSMUSG00000048814 2.71 Lonrf2 LON peptidase N-terminal domain and ring finger 2 
ENSMUSG00000030492 2.72 Slc7a9 solute carrier family 7 (cationic amino acid transporter, y+ system), member 9 
ENSMUSG00000057228 2.73 Aadat aminoadipate aminotransferase 
ENSMUSG00000044748 2.74 Defb1 defensin beta 1 
ENSMUSG00000086043 2.74 Gm12473 predicted gene 12473 
ENSMUSG00000055926 2.75 Gm14137 predicted gene 14137 
ENSMUSG00000043556 2.76 Fbxl7 F-box and leucine-rich repeat protein 7 
ENSMUSG00000022894 2.76 Adamts5 a disintegrin-like and metallopeptidase (reprolysin type) with thrombospondin type 1 
motif, 5 (aggrecanase-2) 
ENSMUSG00000052353 2.77 Cemip cell migration inducing protein, hyaluronan binding 
ENSMUSG00000097767 2.78 Miat myocardial infarction associated transcript (non-protein coding) 
ENSMUSG00000103428 2.80 Gm20754 predicted gene, 20754 
ENSMUSG00000105331 2.81 Gm29865 predicted gene, 29865 
ENSMUSG00000086108 2.83 Gm5602 predicted gene 5602 
ENSMUSG00000027996 2.84 Sfrp2 secreted frizzled-related protein 2 
ENSMUSG00000037362 2.84 Nov nephroblastoma overexpressed gene 
ENSMUSG00000090124 2.84 Ugt1a7c UDP glucuronosyltransferase 1 family, polypeptide A7C 
ENSMUSG00000047797 2.84 Gjb1 gap junction protein, beta 1 
ENSMUSG00000046159 2.85 Chrm3 cholinergic receptor, muscarinic 3, cardiac 
ENSMUSG00000080811 2.85 Gm14513 predicted gene 14513 
ENSMUSG00000020805 2.87 Slc13a5 solute carrier family 13 (sodium-dependent citrate transporter), member 5 
365 
 
ENSMUSG00000064372 2.87 mt-Tp mitochondrially encoded tRNA proline 
ENSMUSG00000026062 2.87 Slc9a2 solute carrier family 9 (sodium/hydrogen exchanger), member 2 
ENSMUSG00000060068 2.87 Gm12222 predicted gene 12222 
ENSMUSG00000020566 2.89 Atp6v1c2 ATPase, H+ transporting, lysosomal V1 subunit C2 
ENSMUSG00000019359 2.89 Gdpd2 glycerophosphodiester phosphodiesterase domain containing 2 
ENSMUSG00000026726 2.89 Cubn cubilin (intrinsic factor-cobalamin receptor) 
ENSMUSG00000022883 2.90 Robo1 roundabout guidance receptor 1 
ENSMUSG00000046372 2.92 Gm5590 predicted gene 5590 
ENSMUSG00000031760 2.93 Mt3 metallothionein 3 
ENSMUSG00000089704 2.95 Galnt2 polypeptide N-acetylgalactosaminyltransferase 2 
ENSMUSG00000067049 2.95 Unc93a unc-93 homolog A (C. elegans) 
ENSMUSG00000091345 2.97 Col6a5 collagen, type VI, alpha 5 
ENSMUSG00000050010 3.00 Shisa3 shisa family member 3 
ENSMUSG00000021592 3.00 Arsk arylsulfatase K 
ENSMUSG00000021567 3.00 Nkd2 naked cuticle 2 homolog (Drosophila) 
ENSMUSG00000054640 3.01 Slc8a1 solute carrier family 8 (sodium/calcium exchanger), member 1 
ENSMUSG00000030074 3.03 Gxylt2 glucoside xylosyltransferase 2 
ENSMUSG00000032023 3.04 Jhy junctional cadherin complex regulator 
ENSMUSG00000044468 3.04 Fam46c family with sequence similarity 46, member C 
ENSMUSG00000040133 3.04 Gpr176 G protein-coupled receptor 176 
ENSMUSG00000072596 3.05 Ear2 eosinophil-associated, ribonuclease A family, member 2 
ENSMUSG00000039518 3.06 Cdsn corneodesmosin 
ENSMUSG00000042529 3.07 Kcnj12 potassium inwardly-rectifying channel, subfamily J, member 12 
ENSMUSG00000022766 3.07 Serpind1 serine (or cysteine) peptidase inhibitor, clade D, member 1 
ENSMUSG00000020811 3.07 Wscd1 WSC domain containing 1 
ENSMUSG00000068748 3.09 Ptprz1 protein tyrosine phosphatase, receptor type Z, polypeptide 1 
ENSMUSG00000079012 3.09 Serpina3m serine (or cysteine) peptidase inhibitor, clade A, member 3M 
ENSMUSG00000099342 3.11 Gm18180 predicted gene, 18180 
ENSMUSG00000063296 3.11 Tmem117 transmembrane protein 117 
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ENSMUSG00000029664 3.12 Tfpi2 tissue factor pathway inhibitor 2 
ENSMUSG00000027356 3.12 Fermt1 fermitin family member 1 
ENSMUSG00000075217 3.12 4833423E24Rik RIKEN cDNA 4833423E24 gene 
ENSMUSG00000005628 3.13 Tmod4 tropomodulin 4 
ENSMUSG00000035407 3.13 Kank4 KN motif and ankyrin repeat domains 4 
ENSMUSG00000022821 3.16 Hgd homogentisate 1, 2-dioxygenase 
ENSMUSG00000001493 3.17 Meox1 mesenchyme homeobox 1 
ENSMUSG00000057715 3.19 A830018L16Rik RIKEN cDNA A830018L16 gene 
ENSMUSG00000039913 3.19 Pak7 p21 protein (Cdc42/Rac)-activated kinase 7 
ENSMUSG00000060044 3.20 Tmem26 transmembrane protein 26 
ENSMUSG00000071604 3.20 Fam189a2 family with sequence similarity 189, member A2 
ENSMUSG00000041577 3.24 Prelp proline arginine-rich end leucine-rich repeat 
ENSMUSG00000029641 3.25 Rasl11a RAS-like, family 11, member A 
ENSMUSG00000021456 3.25 Fbp2 fructose bisphosphatase 2 
ENSMUSG00000054150 3.26 Syne3 spectrin repeat containing, nuclear envelope family member 3 
ENSMUSG00000037482 3.27 Erv3 endogenous retroviral sequence 3 
ENSMUSG00000022512 3.30 Cldn1 claudin 1 
ENSMUSG00000042429 3.30 Adora1 adenosine A1 receptor 
ENSMUSG00000081434 3.30 Gm14165 predicted gene 14165 
ENSMUSG00000007682 3.30 Dio2 deiodinase, iodothyronine, type II 
ENSMUSG00000026185 3.33 Igfbp5 insulin-like growth factor binding protein 5 
ENSMUSG00000026822 3.34 Lcn2 lipocalin 2 
ENSMUSG00000025467 3.35 Prap1 proline-rich acidic protein 1 
ENSMUSG00000027249 3.37 F2 coagulation factor II 
ENSMUSG00000052516 3.41 Robo2 roundabout guidance receptor 2 
ENSMUSG00000055022 3.41 Cntn1 contactin 1 
ENSMUSG00000027070 3.43 Lrp2 low density lipoprotein receptor-related protein 2 
ENSMUSG00000034127 3.46 Tspan8 tetraspanin 8 
ENSMUSG00000078183 3.56 Gm15610 predicted gene 15610 
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ENSMUSG00000020542 3.61 Myocd myocardin 
ENSMUSG00000045322 3.67 Tlr9 toll-like receptor 9 
ENSMUSG00000029868 3.68 Trpv6 transient receptor potential cation channel, subfamily V, member 6 
ENSMUSG00000070866 3.69 Zfp804a zinc finger protein 804A 
ENSMUSG00000020609 3.74 Apob apolipoprotein B 
ENSMUSG00000050860 3.76 Phospho1 phosphatase, orphan 1 
ENSMUSG00000041986 3.82 Elmod1 ELMO/CED-12 domain containing 1 
ENSMUSG00000064080 3.84 Fbln2 fibulin 2 
ENSMUSG00000028116 3.87 Myoz2 myozenin 2 
ENSMUSG00000027536 3.89 Chmp4c charged multivesicular body protein 4C 
ENSMUSG00000073805 3.89 Fam196a family with sequence similarity 196, member A 
ENSMUSG00000021795 3.91 Sftpd surfactant associated protein D 
ENSMUSG00000027188 3.91 Pamr1 peptidase domain containing associated with muscle regeneration 1 
ENSMUSG00000035165 3.91 Kcne3 potassium voltage-gated channel, Isk-related subfamily, gene 3 
ENSMUSG00000000359 3.94 Rem1 rad and gem related GTP binding protein 1 
ENSMUSG00000029195 3.97 Klb klotho beta 
ENSMUSG00000028989 3.99 Angptl7 angiopoietin-like 7 
ENSMUSG00000006205 3.99 Htra1 HtrA serine peptidase 1 
ENSMUSG00000044320 4.01 1700001O22Rik RIKEN cDNA 1700001O22 gene 
ENSMUSG00000028356 4.01 Ambp alpha 1 microglobulin/bikunin 
ENSMUSG00000021536 4.01 Adcy2 adenylate cyclase 2 
ENSMUSG00000034918 4.01 Cdhr2 cadherin-related family member 2 
ENSMUSG00000037254 4.03 Itih2 inter-alpha trypsin inhibitor, heavy chain 2 
ENSMUSG00000033022 4.08 Cdo1 cysteine dioxygenase 1, cytosolic 
ENSMUSG00000050635 4.09 Sprr2f small proline-rich protein 2F 
ENSMUSG00000031517 4.09 Gpm6a glycoprotein m6a 
ENSMUSG00000018822 4.15 Sfrp5 secreted frizzled-related sequence protein 5 
ENSMUSG00000026725 4.15 Tnn tenascin N 
ENSMUSG00000022132 4.16 Cldn10 claudin 10 
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ENSMUSG00000107349 4.18 Gm6655 predicted gene 6655 
ENSMUSG00000040412 4.28 5330417C22Rik RIKEN cDNA 5330417C22 gene 
ENSMUSG00000027224 4.34 Duoxa1 dual oxidase maturation factor 1 
ENSMUSG00000030935 4.34 Acsm3 acyl-CoA synthetase medium-chain family member 3 
ENSMUSG00000090231 4.40 Cfb complement factor B 
ENSMUSG00000041324 4.42 Inhba inhibin beta-A 
ENSMUSG00000021876 4.43 Rnase4 ribonuclease, RNase A family 4 
ENSMUSG00000105233 4.46 Gm20568 predicted gene, 20568 
ENSMUSG00000028359 4.55 Orm3 orosomucoid 3 
ENSMUSG00000024164 4.60 C3 complement component 3 
ENSMUSG00000042109 4.62 Csdc2 cold shock domain containing C2, RNA binding 
ENSMUSG00000026866 4.64 Kynu kynureninase (L-kynurenine hydrolase) 
ENSMUSG00000074280 4.65 Gm6166 predicted gene 6166 
ENSMUSG00000032978 4.67 Guca2b guanylate cyclase activator 2b (retina) 
ENSMUSG00000029260 4.71 Ugt2b34 UDP glucuronosyltransferase 2 family, polypeptide B34 
ENSMUSG00000059040 4.73 Eno1b enolase 1B, retrotransposed 
ENSMUSG00000102189 4.73 Gm37194 predicted gene, 37194 
ENSMUSG00000024027 4.81 Glp1r glucagon-like peptide 1 receptor 
ENSMUSG00000056529 4.85 Ptafr platelet-activating factor receptor 
ENSMUSG00000060882 5.13 Kcnd2 potassium voltage-gated channel, Shal-related family, member 2 
ENSMUSG00000082809 5.15 Gm14150 predicted gene 14150 
ENSMUSG00000046203 5.19 Sprr2g small proline-rich protein 2G 
ENSMUSG00000032649 5.27 Colgalt2 collagen beta(1-O)galactosyltransferase 2 
ENSMUSG00000050558 5.32 Prokr2 prokineticin receptor 2 
ENSMUSG00000052135 5.33 Foxo6 forkhead box O6 
ENSMUSG00000024114 5.36 Prss41 protease, serine 41 
ENSMUSG00000097929 5.55 Tunar Tcl1 upstream neural differentiation associated RNA 
ENSMUSG00000010651 5.56 Acaa1b acetyl-Coenzyme A acyltransferase 1B 
ENSMUSG00000004267 5.65 Eno2 enolase 2, gamma neuronal 
369 
 
ENSMUSG00000042751 5.68 Nmnat2 nicotinamide nucleotide adenylyltransferase 2 
ENSMUSG00000037625 5.87 Cldn11 claudin 11 
ENSMUSG00000026417 5.93 Pigr polymeric immunoglobulin receptor 
ENSMUSG00000036377 6.08 C530008M17Rik RIKEN cDNA C530008M17 gene 
ENSMUSG00000041750 6.10 Cd1d2 CD1d2 antigen 
ENSMUSG00000097554 6.25 Gm26825 predicted gene, 26825 
ENSMUSG00000024059 6.38 Clip4 CAP-GLY domain containing linker protein family, member 4 
ENSMUSG00000047228 6.63 A2ml1 alpha-2-macroglobulin like 1 
ENSMUSG00000074206 6.70 Adh6b alcohol dehydrogenase 6B (class V) 
ENSMUSG00000040627 6.72 Aicda activation-induced cytidine deaminase 
ENSMUSG00000105300 6.97 Gm30613 predicted gene, 30613 
ENSMUSG00000028635 7.15 Edn2 endothelin 2 
ENSMUSG00000070533 7.34 Wfdc8 WAP four-disulfide core domain 8 
ENSMUSG00000047747 7.53 Rnf150 ring finger protein 150 
ENSMUSG00000081329 7.55 Gm12492 predicted gene 12492 
ENSMUSG00000022015 7.78 Tnfsf11 tumor necrosis factor (ligand) superfamily, member 11 
ENSMUSG00000057899 7.79 Adgrf2 adhesion G protein-coupled receptor F2 
ENSMUSG00000102474 7.90 2610012C04Rik RIKEN cDNA 2610012C04 gene 
ENSMUSG00000006457 8.40 Actn3 actinin alpha 3 
ENSMUSG00000020953 9.07 Coch cochlin 
ENSMUSG00000004552 9.27 Ctse cathepsin E 
ENSMUSG00000047730 9.67 Fcgbp Fc fragment of IgG binding protein 
ENSMUSG00000025930 10.02 Msc musculin 
ENSMUSG00000043531 10.26 Sorcs1 sortilin-related VPS10 domain containing receptor 1 
ENSMUSG00000018451 11.02 6330403K07Rik RIKEN cDNA 6330403K07 gene 
ENSMUSG00000081355 11.02 Gm15264 predicted gene 15264 
ENSMUSG00000068877 11.23 Selenbp2 selenium binding protein 2 
ENSMUSG00000095026 12.64 Gm3336 predicted gene 3336 
ENSMUSG00000067235 13.01 H2-Q10 histocompatibility 2, Q region locus 10 
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ENSMUSG00000076757 13.82 Tcrg-C4 T cell receptor gamma, constant 4 
ENSMUSG00000031595 14.46 Pdgfrl platelet-derived growth factor receptor-like 
ENSMUSG00000079507 16.56 H2-Q1 histocompatibility 2, Q region locus 1 
ENSMUSG00000006221 16.67 Hspb7 heat shock protein family, member 7 (cardiovascular) 
ENSMUSG00000100837 18.33 1700063D05Rik RIKEN cDNA 1700063D05 gene 
ENSMUSG00000097644 18.44 Gm26862 predicted gene, 26862 
ENSMUSG00000020890 18.70 Gucy2e guanylate cyclase 2e 
ENSMUSG00000084403 20.49 Rps15a-ps8 ribosomal protein S15A, pseudogene 8 
ENSMUSG00000026691 21.47 Fmo3 flavin containing monooxygenase 3 
ENSMUSG00000033182 24.30 Kbtbd12 kelch repeat and BTB (POZ) domain containing 12 
ENSMUSG00000091705 29.40 H2-Q2 histocompatibility 2, Q region locus 2 
ENSMUSG00000093880 33.35 Tmem181c-ps transmembrane protein 181C, pseudogene 
ENSMUSG00000108608 35.38 Gm6916 predicted pseudogene 6916 
ENSMUSG00000026535 40.50 Ifi202b interferon activated gene 202B 
ENSMUSG00000026535 40.50 Ifi202b interferon activated gene 202B 
ENSMUSG00000059565 44.17 Gm5292 predicted gene 5292 
ENSMUSG00000070661 44.32 Rnf186 ring finger protein 186 
ENSMUSG00000030329 50.79 Pianp PILR alpha associated neural protein 
ENSMUSG00000097891 55.21 Gm3650 predicted gene 3650 
ENSMUSG00000041735 57.50 Gm13178 predicted gene 13178 
ENSMUSG00000014725 57.59 Adam28 a disintegrin and metallopeptidase domain 28 
ENSMUSG00000101639 68.84 Gm8597 predicted gene 8597 
ENSMUSG00000073402 70.98 Gm8909 predicted gene 8909 
ENSMUSG00000072324 72.56 Gm8420 predicted gene 8420 
ENSMUSG00000006216 75.48 Clcnkb chloride channel, voltage-sensitive Kb 
ENSMUSG00000083773 161.82 Gm13394 predicted gene 13394 
ENSMUSG00000079492 164.59 Gm11127 predicted gene 11127 
ENSMUSG00000036322 231.87 H2-Ea-ps histocompatibility 2, class II antigen E alpha, pseudogene 
ENSMUSG00000038209 246.27 Itln1 intelectin 1 (galactofuranose binding) 
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ENSMUSG00000091373 537.65 Gm8810 predicted gene 8810 
ENSMUSG00000073403 573.81 Gm10499 predicted gene 10499 
ENSMUSG00000047894 799.25 Ang2 angiogenin, ribonuclease A family, member 2 
ENSMUSG00000022057 1194.78 Adamdec1 ADAM-like, decysin 1 
ENSMUSG00000047222 17313.54 Rnase2a ribonuclease, RNase A family, 2A (liver, eosinophil-derived neurotoxin) 
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ENSMUSG00000066362 -69933.60 Rps13-ps1 ribosomal protein S13, pseudogene 1  
ENSMUSG00000089229 -21.97 Gm25043 predicted gene, 25043 
ENSMUSG00000060416 -13.41 Gm839 predicted gene 839  
ENSMUSG00000105440 -11.11 Gm31693 predicted gene, 31693  
ENSMUSG00000067081 -9.67 Asb18 ankyrin repeat and SOCS box-containing 18  
ENSMUSG00000031738 -7.88 Irx6 Iroquois homeobox 6  
ENSMUSG00000086164 -7.76 Gm13029 predicted gene 13029  
ENSMUSG00000049571 -7.29 Cfap46 cilia and flagella associated protein 46  
ENSMUSG00000095079 -5.99 Igha immunoglobulin heavy constant alpha  
ENSMUSG00000061633 -5.96 1700029P11Rik RIKEN cDNA 1700029P11 gene  
ENSMUSG00000109485 -5.58 Gm45016 predicted gene 45016  
ENSMUSG00000060985 -4.65 Tdrd5 tudor domain containing 5  
ENSMUSG00000029597 -4.64 Sds serine dehydratase  
ENSMUSG00000040276 -3.97 Pacsin1 protein kinase C and casein kinase substrate in neurons 1 
ENSMUSG00000079853 -3.89 Klra1 killer cell lectin-like receptor, subfamily A, member 1  
ENSMUSG00000002769 -3.79 Gnmt glycine N-methyltransferase 
ENSMUSG00000028362 -3.66 Tnfsf8 tumor necrosis factor (ligand) superfamily, member 8  
ENSMUSG00000043448 -3.61 Gjc2 gap junction protein, gamma 2  
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ENSMUSG00000033327 -3.45 Tnxb tenascin XB  
ENSMUSG00000044294 -3.42 Krt84 keratin 84  
ENSMUSG00000022468 -3.39 Endou endonuclease, polyU-specific  
ENSMUSG00000035686 -3.36 Thrsp thyroid hormone responsive  
ENSMUSG00000049556 -3.33 Lingo1 leucine rich repeat and Ig domain containing 1  
ENSMUSG00000039209 -3.16 Rpl39l ribosomal protein L39-like  
ENSMUSG00000096035 -3.16 Odaph odontogenesis associated phosphoprotein  
ENSMUSG00000050541 -3.10 Adra1b adrenergic receptor, alpha 1b  
ENSMUSG00000070880 -3.03 Gad1 glutamate decarboxylase 1  
ENSMUSG00000079357 -3.00 Gm11100 predicted gene 11100  
ENSMUSG00000039410 -2.96 Prdm16 PR domain containing 16  
ENSMUSG00000027978 -2.76 Prss12 protease, serine 12 neurotrypsin (motopsin)  
ENSMUSG00000028747 -2.76 Htr6 5-hydroxytryptamine (serotonin) receptor 6  
ENSMUSG00000026204 -2.74 Ptprn protein tyrosine phosphatase, receptor type, N  
ENSMUSG00000004558 -2.74 Ndrg2 N-myc downstream regulated gene 2  
ENSMUSG00000005640 -2.73 Insrr insulin receptor-related receptor  
ENSMUSG00000027376 -2.69 Prom2 prominin 2  
ENSMUSG00000029369 -2.69 Afm afamin  
ENSMUSG00000027358 -2.65 Bmp2 bone morphogenetic protein 2  
ENSMUSG00000025776 -2.64 Crispld1 cysteine-rich secretory protein LCCL domain containing 1  
ENSMUSG00000049719 -2.63 Prss46 protease, serine 46  
ENSMUSG00000026321 -2.59 Tnfrsf11a tumor necrosis factor receptor superfamily, member 11a, NFKB activator  
ENSMUSG00000046807 -2.57 Lrrc75b leucine rich repeat containing 75B  
ENSMUSG00000046731 -2.49 Kctd11 potassium channel tetramerisation domain containing 11  
ENSMUSG00000090273 -2.49 Prr22 proline rich 22 
ENSMUSG00000071047 -2.45 Ces1a carboxylesterase 1A  
ENSMUSG00000018581 -2.44 Dnah11 dynein, axonemal, heavy chain 11  
ENSMUSG00000042414 -2.43 Prdm14 PR domain containing 14  
ENSMUSG00000031958 -2.42 Ldhd lactate dehydrogenase D  
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ENSMUSG00000028573 -2.41 Fggy FGGY carbohydrate kinase domain containing  
ENSMUSG00000018819 -2.40 Lsp1 lymphocyte specific 1  
ENSMUSG00000030732 -2.39 Chrdl2 chordin-like 2  
ENSMUSG00000025265 -2.39 Fgd1 FYVE, RhoGEF and PH domain containing 1  
ENSMUSG00000053963 -2.37 Stum mechanosensory transduction mediator  
ENSMUSG00000027636 -2.37 Sla2 Src-like-adaptor 2  
ENSMUSG00000038179 -2.36 Slamf7 SLAM family member 7  
ENSMUSG00000034416 -2.35 Pkd1l2 polycystic kidney disease 1 like 2  
ENSMUSG00000041479 -2.35 Syt15 synaptotagmin XV  
ENSMUSG00000012819 -2.26 Cdh23 cadherin 23 (otocadherin)  
ENSMUSG00000046999 -2.26 1110032F04Rik RIKEN cDNA 1110032F04 gene  
ENSMUSG00000038600 -2.25 Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4  
ENSMUSG00000085683 -2.25 Tmem238l transmembrane protein 238 like  
ENSMUSG00000076617 -2.24 Ighm immunoglobulin heavy constant mu  
ENSMUSG00000009633 -2.24 G0s2 G0/G1 switch gene 2  
ENSMUSG00000007097 -2.23 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  
ENSMUSG00000037411 -2.23 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1 
ENSMUSG00000025064 -2.22 Col17a1 collagen, type XVII, alpha 1  
ENSMUSG00000027316 -2.22 Gfra4 glial cell line derived neurotrophic factor family receptor alpha 4  
ENSMUSG00000031636 -2.19 Pdlim3 PDZ and LIM domain 3  
ENSMUSG00000054065 -2.19 Pkp3 plakophilin 3  
ENSMUSG00000107761 -2.19 2010008C14Rik RIKEN cDNA 2010008C14 gene  
ENSMUSG00000003545 -2.18 Fosb FBJ osteosarcoma oncogene B  
ENSMUSG00000031990 -2.16 Jam3 junction adhesion molecule 3 
ENSMUSG00000028071 -2.15 Sh2d2a SH2 domain containing 2A  
ENSMUSG00000025017 -2.14 Pik3ap1 phosphoinositide-3-kinase adaptor protein 1  
ENSMUSG00000006529 -2.13 Itih1 inter-alpha trypsin inhibitor, heavy chain 1  
ENSMUSG00000075604 -2.13 Cyp11b1 cytochrome P450, family 11, subfamily b, polypeptide 1  
ENSMUSG00000079547 -2.13 H2-DMb1 histocompatibility 2, class II, locus Mb1  
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ENSMUSG00000007034 -2.11 Slc44a4 solute carrier family 44, member 4 
ENSMUSG00000021200 -2.11 Asb2 ankyrin repeat and SOCS box-containing 2  
ENSMUSG00000074006 -2.10 Omp olfactory marker protein  
ENSMUSG00000030217 -2.10 Art4 ADP-ribosyltransferase 4  
ENSMUSG00000037940 -2.10 Inpp4b inositol polyphosphate-4-phosphatase, type II  
ENSMUSG00000036718 -2.10 Micall2 MICAL-like 2  
ENSMUSG00000046080 -2.10 Clec9a C-type lectin domain family 9, member a  
ENSMUSG00000043789 -2.09 Vwce von Willebrand factor C and EGF domains  
ENSMUSG00000028749 -2.08 Pla2g2f phospholipase A2, group IIF  
ENSMUSG00000027460 -2.08 Angpt4 angiopoietin 4  
ENSMUSG00000037469 -2.08 Acp7 acid phosphatase 7, tartrate resistant  
ENSMUSG00000073418 -2.06 C4b complement component 4B (Chido blood group)  
ENSMUSG00000023032 -2.05 Slc4a8 solute carrier family 4 (anion exchanger), member 8  
ENSMUSG00000045725 -2.05 Prr15 proline rich 15  
ENSMUSG00000022032 -2.05 Scara5 scavenger receptor class A, member 5  
ENSMUSG00000026259 -2.05 Ngef neuronal guanine nucleotide exchange factor  
ENSMUSG00000034438 -2.04 Gbp8 guanylate-binding protein 8  
ENSMUSG00000021322 -2.03 Aoah acyloxyacyl hydrolase  
ENSMUSG00000021255 -2.02 Esrrb estrogen related receptor, beta  
ENSMUSG00000026890 -2.01 Lhx6 LIM homeobox protein 6  
ENSMUSG00000028751 -2.01 Pla2g2e phospholipase A2, group IIE  
ENSMUSG00000019876 2.01 Pkib protein kinase inhibitor beta, cAMP dependent, testis specific  
ENSMUSG00000024253 2.02 Dync2li1 dynein cytoplasmic 2 light intermediate chain 1  
ENSMUSG00000038354 2.04 Ankrd35 ankyrin repeat domain 35  
ENSMUSG00000027254 2.07 Map1a microtubule-associated protein 1 A  
ENSMUSG00000096942 2.08 Rps19-ps6 ribosomal protein S19, pseudogene 6  
ENSMUSG00000026228 2.08 Htr2b 5-hydroxytryptamine (serotonin) receptor 2B  
ENSMUSG00000096950 2.13 Gm9530 predicted gene 9530  
ENSMUSG00000059058 2.13 Tma7-ps translational machinery associated 7 homolog (S. cerevisiae), pseudogene  
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ENSMUSG00000038415 2.20 Foxq1 forkhead box Q1  
ENSMUSG00000104943 2.21 Gm42868 predicted gene 42868  
ENSMUSG00000032226 2.22 Gcnt3 glucosaminyl (N-acetyl) transferase 3, mucin type  
ENSMUSG00000037605 2.22 Adgrl3 adhesion G protein-coupled receptor L3  
ENSMUSG00000058927 2.23 Gm10053 predicted gene 10053  
ENSMUSG00000026579 2.27 F5 coagulation factor V  
ENSMUSG00000081975 2.27 Gm12482 predicted gene 12482  
ENSMUSG00000090247 2.28 Bloc1s1 biogenesis of lysosomal organelles complex-1, subunit 1  
ENSMUSG00000041984 2.33 Rptn repetin  
ENSMUSG00000096557 2.34 Gm7258 predicted gene 7258  
ENSMUSG00000086477 2.36 Gm15506 predicted gene 15506  
ENSMUSG00000091764 2.36 Zfp964 zinc finger protein 964  
ENSMUSG00000094320 2.40 Chchd2-ps coiled-coil-helix-coiled-coil-helix domain containing 2, pseudogene  
ENSMUSG00000064317 2.40 Gm10146 predicted gene 10146  
ENSMUSG00000051149 2.48 Adnp activity-dependent neuroprotective protein  
ENSMUSG00000044468 2.49 Tent5c terminal nucleotidyltransferase 5C  
ENSMUSG00000032246 2.49 Calml4 calmodulin-like 4  
ENSMUSG00000093483 2.49 AA465934 expressed sequence AA465934  
ENSMUSG00000074766 2.55 Ism1 isthmin 1, angiogenesis inhibitor  
ENSMUSG00000041794 2.58 Myrip myosin VIIA and Rab interacting protein  
ENSMUSG00000079173 2.59 Zan zonadhesin  
ENSMUSG00000043633 2.59 Fam221b family with sequence similarity 221, member B  
ENSMUSG00000081700 2.67 Atp5k-ps2 ATP synthase, H+ transporting, mitochondrial F1F0 complex, subunit E, pseudogene 
2  
ENSMUSG00000034009 2.82 Rxfp1 relaxin/insulin-like family peptide receptor 1  
ENSMUSG00000057897 2.82 Camk2b calcium/calmodulin-dependent protein kinase II, beta  
ENSMUSG00000078190 2.86 Dnm3os dynamin 3, opposite strand  
ENSMUSG00000004668 2.92 Abca13 ATP-binding cassette, sub-family A (ABC1), member 13  
ENSMUSG00000091955 3.06 Gm9844 predicted pseudogene 9844  
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ENSMUSG00000090136 3.22 Gm10177 predicted gene 10177  
ENSMUSG00000071141 3.35 Rpl36a-ps3 ribosomal protein L36A, pseudogene 3  
ENSMUSG00000082456 3.38 Gm11598 predicted gene 11598  
ENSMUSG00000104765 3.41 Gm43058 predicted gene 43058  
ENSMUSG00000100174 3.78 Gm28719 predicted gene 28719  
ENSMUSG00000038259 3.78 Gdf5 growth differentiation factor 5  
ENSMUSG00000105703 4.92 Gm43305 predicted gene 43305  
ENSMUSG00000063628 6.77 Gm7665 predicted pseudogene 7665  
ENSMUSG00000051590 7.10 Map3k19 mitogen-activated protein kinase kinase kinase 19  
ENSMUSG00000096878 8.73 Gm21083 predicted gene, 21083  
ENSMUSG00000060161 9.21 Klk1b7-ps kallikrein 1-related peptidase b7, pseudogene 
ENSMUSG00000021620 9.65 Acot12 acyl-CoA thioesterase 12  
ENSMUSG00000021852 9.72 Slc35f4 solute carrier family 35, member F4 
ENSMUSG00000043999 9.89 Gpr75 G protein-coupled receptor 75  
ENSMUSG00000109186 11.46 Gm34821 predicted gene, 34821  
ENSMUSG00000100744 11.81 Gm17764 predicted gene, 17764  
ENSMUSG00000017311 17.82 Pyy peptide YY  
ENSMUSG00000074934 22.09 Grem1 gremlin 1, DAN family BMP antagonist  
ENSMUSG00000024747 54.70 Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7  
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ENSMUSG00000109482 -19.08 Gm4756 predicted gene 4756  
ENSMUSG00000085020 -17.68 2310081O03Rik RIKEN cDNA 2310081O03 gene  
ENSMUSG00000031779 -16.59 Ccl22 chemokine (C-C motif) ligand 22  
ENSMUSG00000067081 -15.92 Asb18 ankyrin repeat and SOCS box-containing 18  
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ENSMUSG00000089757 -15.55 Gm16334 predicted gene 16334  
ENSMUSG00000024678 -9.15 Ms4a4d membrane-spanning 4-domains, subfamily A, member 4D  
ENSMUSG00000044294 -7.79 Krt84 keratin 84  
ENSMUSG00000079853 -7.60 Klra1 killer cell lectin-like receptor, subfamily A, member 1  
ENSMUSG00000028362 -7.52 Tnfsf8 tumor necrosis factor (ligand) superfamily, member 8  
ENSMUSG00000095079 -6.24 Igha immunoglobulin heavy constant alpha  
ENSMUSG00000031738 -5.82 Irx6 Iroquois homeobox 6  
ENSMUSG00000059213 -5.05 Ddn dendrin  
ENSMUSG00000021440 -4.99 Cts7 cathepsin 7  
ENSMUSG00000050541 -4.84 Adra1b adrenergic receptor, alpha 1b  
ENSMUSG00000096035 -4.70 Odaph odontogenesis associated phosphoprotein  
ENSMUSG00000035686 -4.39 Thrsp thyroid hormone responsive  
ENSMUSG00000033327 -3.99 Tnxb tenascin XB  
ENSMUSG00000027875 -3.93 Hmgcs2 3-hydroxy-3-methylglutaryl-Coenzyme A synthase 2  
ENSMUSG00000050075 -3.91 Gpr171 G protein-coupled receptor 171  
ENSMUSG00000005338 -3.82 Cadm3 cell adhesion molecule 3  
ENSMUSG00000028488 -3.64 Sh3gl2 SH3-domain GRB2-like 2  
ENSMUSG00000036062 -3.53 Phf24 PHD finger protein 24  
ENSMUSG00000030173 -3.41 Klra5 killer cell lectin-like receptor, subfamily A, member 5  
ENSMUSG00000074199 -3.26 Krtdap keratinocyte differentiation associated protein  
ENSMUSG00000039313 -3.18 AF529169 cDNA sequence AF529169  
ENSMUSG00000043448 -3.11 Gjc2 gap junction protein, gamma 2  
ENSMUSG00000040229 -2.93 Gpr34 G protein-coupled receptor 34  
ENSMUSG00000027457 -2.91 Snph syntaphilin  
ENSMUSG00000057446 -2.89 Cts8 cathepsin 8  
ENSMUSG00000073418 -2.87 C4b complement component 4B (Chido blood group)  
ENSMUSG00000046807 -2.86 Lrrc75b leucine rich repeat containing 75B  
ENSMUSG00000032172 -2.81 Olfm2 olfactomedin 2  
ENSMUSG00000053963 -2.76 Stum mechanosensory transduction mediator  
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ENSMUSG00000047793 -2.76 Sned1 sushi, nidogen and EGF-like domains 1  
ENSMUSG00000104802 -2.71 Gm5869 predicted gene 5869  
ENSMUSG00000046999 -2.70 1110032F04Rik RIKEN cDNA 1110032F04 gene  
ENSMUSG00000005973 -2.70 Rcn1 reticulocalbin 1  
ENSMUSG00000028713 -2.70 Cyp4b1 cytochrome P450, family 4, subfamily b, polypeptide 1  
ENSMUSG00000054978 -2.67 Kbtbd13 kelch repeat and BTB (POZ) domain containing 13  
ENSMUSG00000029675 -2.66 Eln elastin  
ENSMUSG00000027358 -2.59 Bmp2 bone morphogenetic protein 2  
ENSMUSG00000029334 -2.58 Prkg2 protein kinase, cGMP-dependent, type II  
ENSMUSG00000041479 -2.58 Syt15 synaptotagmin XV  
ENSMUSG00000075707 -2.55 Dio3 deiodinase, iodothyronine type III  
ENSMUSG00000026321 -2.53 Tnfrsf11a tumor necrosis factor receptor superfamily, member 11a, NFKB activator  
ENSMUSG00000045725 -2.53 Prr15 proline rich 15  
ENSMUSG00000087698 -2.52 Gm13031 predicted gene 13031  
ENSMUSG00000104350 -2.52 Gm38244 predicted gene, 38244  
ENSMUSG00000005640 -2.52 Insrr insulin receptor-related receptor  
ENSMUSG00000020926 -2.47 Adam11 a disintegrin and metallopeptidase domain 11  
ENSMUSG00000026365 -2.44 Cfh complement component factor h  
ENSMUSG00000038179 -2.43 Slamf7 SLAM family member 7  
ENSMUSG00000037759 -2.42 Ptger2 prostaglandin E receptor 2 (subtype EP2)  
ENSMUSG00000025742 -2.37 Prps2 phosphoribosyl pyrophosphate synthetase 2  
ENSMUSG00000032528 -2.35 Vipr1 vasoactive intestinal peptide receptor 1  
ENSMUSG00000022468 -2.35 Endou endonuclease, polyU-specific  
ENSMUSG00000027376 -2.34 Prom2 prominin 2  
ENSMUSG00000022032 -2.34 Scara5 scavenger receptor class A, member 5  
ENSMUSG00000032537 -2.33 Ephb1 Eph receptor B1  
ENSMUSG00000007097 -2.33 Atp1a2 ATPase, Na+/K+ transporting, alpha 2 polypeptide  
ENSMUSG00000035948 -2.33 Acss3 acyl-CoA synthetase short-chain family member 3  
ENSMUSG00000027577 -2.33 Chrna4 cholinergic receptor, nicotinic, alpha polypeptide 4  
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ENSMUSG00000002831 -2.30 Plin4 perilipin 4  
ENSMUSG00000027639 -2.28 Samhd1 SAM domain and HD domain, 1  
ENSMUSG00000017737 -2.27 Mmp9 matrix metallopeptidase 9  
ENSMUSG00000031958 -2.26 Ldhd lactate dehydrogenase D  
ENSMUSG00000067220 -2.26 Cnga1 cyclic nucleotide gated channel alpha 1  
ENSMUSG00000037994 -2.25 Slc9b2 solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2  
ENSMUSG00000027377 -2.24 Mall mal, T cell differentiation protein-like  
ENSMUSG00000028749 -2.24 Pla2g2f phospholipase A2, group IIF  
ENSMUSG00000021508 -2.22 Cxcl14 chemokine (C-X-C motif) ligand 14  
ENSMUSG00000037846 -2.22 Rtkn2 rhotekin 2  
ENSMUSG00000027848 -2.20 Olfml3 olfactomedin-like 3  
ENSMUSG00000034853 -2.20 Acot11 acyl-CoA thioesterase 11  
ENSMUSG00000049744 -2.19 Arhgap15 Rho GTPase activating protein 15  
ENSMUSG00000079547 -2.18 H2-DMb1 histocompatibility 2, class II, locus Mb1  
ENSMUSG00000029082 -2.18 Bst1 bone marrow stromal cell antigen 1  
ENSMUSG00000027796 -2.17 Smad9 SMAD family member 9  
ENSMUSG00000006642 -2.15 Tcf23 transcription factor 23  
ENSMUSG00000006342 -2.15 Susd2 sushi domain containing 2  
ENSMUSG00000026204 -2.12 Ptprn protein tyrosine phosphatase, receptor type, N  
ENSMUSG00000046731 -2.10 Kctd11 potassium channel tetramerisation domain containing 11  
ENSMUSG00000051431 -2.09 Gpr87 G protein-coupled receptor 87  
ENSMUSG00000027460 -2.09 Angpt4 angiopoietin 4  
ENSMUSG00000052861 -2.07 Dnah6 dynein, axonemal, heavy chain 6  
ENSMUSG00000041608 -2.07 Entpd3 ectonucleoside triphosphate diphosphohydrolase 3  
ENSMUSG00000104713 -2.05 Gbp6 guanylate binding protein 6  
ENSMUSG00000043789 -2.05 Vwce von Willebrand factor C and EGF domains  
ENSMUSG00000037411 -2.05 Serpine1 serine (or cysteine) peptidase inhibitor, clade E, member 1  
ENSMUSG00000027843 -2.04 Ptpn22 protein tyrosine phosphatase, non-receptor type 22 (lymphoid)  
ENSMUSG00000026259 -2.04 Ngef neuronal guanine nucleotide exchange factor  
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ENSMUSG00000073678 -2.04 Pgap1 post-GPI attachment to proteins 1  
ENSMUSG00000020848 -2.03 Doc2b double C2, beta  
ENSMUSG00000038600 -2.02 Atp6v0a4 ATPase, H+ transporting, lysosomal V0 subunit A4  
ENSMUSG00000086591 -2.02 Dnah2os dynein, axonemal, heavy chain 2, opposite strand 
ENSMUSG00000024912 -2.02 Fosl1 fos-like antigen 1  
ENSMUSG00000021322 -2.02 Aoah acyloxyacyl hydrolase  
ENSMUSG00000031990 -2.01 Jam3 junction adhesion molecule 3  
ENSMUSG00000026832 -2.01 Cytip cytohesin 1 interacting protein  
ENSMUSG00000004709 -2.00 Cd244a CD244 molecule A  
ENSMUSG00000057880 -2.00 Abat 4-aminobutyrate aminotransferase  
ENSMUSG00000039114 -2.00 Nrn1 neuritin 1  
ENSMUSG00000107355 2.05 AI839979 expressed sequence AI839979  
ENSMUSG00000031616 2.11 Ednra endothelin receptor type A  
ENSMUSG00000038354 2.12 Ankrd35 ankyrin repeat domain 35  
ENSMUSG00000038415 2.12 Foxq1 forkhead box Q1  
ENSMUSG00000103472 2.12 Pcdhga7 protocadherin gamma subfamily A, 7  
ENSMUSG00000038555 2.18 Reep2 receptor accessory protein 2  
ENSMUSG00000067158 2.19 Col4a4 collagen, type IV, alpha 4  
ENSMUSG00000026228 2.27 Htr2b 5-hydroxytryptamine (serotonin) receptor 2B  
ENSMUSG00000104943 2.32 Gm42868 predicted gene 42868  
ENSMUSG00000045555 2.34 Mettl24 methyltransferase like 24  
ENSMUSG00000069072 2.42 Slc7a14 solute carrier family 7 (cationic amino acid transporter, y+ system), member 14  
ENSMUSG00000041984 2.42 Rptn repetin  
ENSMUSG00000033491 2.46 Prss35 protease, serine 35  
ENSMUSG00000040666 2.47 Sh3bgr SH3-binding domain glutamic acid-rich protein  
ENSMUSG00000091764 2.48 Zfp964 zinc finger protein 964  
ENSMUSG00000044468 2.52 Tent5c terminal nucleotidyltransferase 5C  
ENSMUSG00000078190 2.64 Dnm3os dynamin 3, opposite strand  
ENSMUSG00000106554 2.66 Gm33474 predicted gene, 33474  
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ENSMUSG00000034226 2.67 Rhov ras homolog family member V  
ENSMUSG00000040653 3.05 Ppp1r14c protein phosphatase 1, regulatory inhibitor subunit 14C  
ENSMUSG00000046748 3.25 Tmem45a2 transmembrane protein 45A2  
ENSMUSG00000054013 3.29 Tmem179 transmembrane protein 179  
ENSMUSG00000097495 3.72 Gm26651 predicted gene, 26651  
ENSMUSG00000026023 3.99 Cdk15 cyclin-dependent kinase 15  
ENSMUSG00000082101 4.39 Slfn14 schlafen 14  
ENSMUSG00000015090 5.13 Ptgds prostaglandin D2 synthase (brain)  
ENSMUSG00000024747 10.44 Aldh1a7 aldehyde dehydrogenase family 1, subfamily A7  
ENSMUSG00000096878 11.70 Gm21083 predicted gene, 21083  
ENSMUSG00000086820 16.22 Gm11465 predicted gene 11465  
ENSMUSG00000040505 17.25 Abcg5 ATP binding cassette subfamily G member 5  
ENSMUSG00000046160 17.89 Olig1 oligodendrocyte transcription factor 1  
ENSMUSG00000083623 22.86 Gm7224 predicted gene 7224  
ENSMUSG00000091553 22.89 Serpina3e-ps serine (or cysteine) peptidase inhibitor, clade A, member 3E, pseudogene  
ENSMUSG00000027209 29.55 Fam227b family with sequence similarity 227, member B  
ENSMUSG00000062148 32.03 Ear6 eosinophil-associated, ribonuclease A family, member 6  
ENSMUSG00000074934 35.81 Grem1 gremlin 1, DAN family BMP antagonist  
ENSMUSG00000101939 81.30 Gm28438 predicted gene 28438  
ENSMUSG00000066362 40479.63 Rps13-ps1 ribosomal protein S13, pseudogene 1  
 
 
